var title_f38_5_38992="Survival by diagnosis";
var content_f38_5_38992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Kaplan-Meier survival by diagnosis for adult lung transplants performed between January 1990 and June 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 437px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AT Def: &alpha;1-anti-trypsin deficiency emphysema; COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis; IPAH: idiopathic pulmonary arterial hypertension; CF: cystic fibrosis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Reproduced with permission from: Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth Official Adult Lung and Heart/Lung Transplantation Report-2008. J Heart Lung Transplant 2008; 27:957. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2008 Elsevier Inc.",
"       </li>",
"       <li>",
"        For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled&nbsp;\"Adult lung transplantation: Kaplan-Meier survival by diagnosis\" at:",
"        <a href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"         file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"        </a>",
"        .",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38992=[""].join("\n");
var outline_f38_5_38992=null;
var title_f38_5_38993="Yellow fever Americas PI";
var content_f38_5_38993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Areas in Central and South America where yellow fever is present",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38993=[""].join("\n");
var outline_f38_5_38993=null;
var title_f38_5_38994="Sacrocervicopexy";
var content_f38_5_38994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sacrocervicopexy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An alternative procedure for uterine suspension involves suturing the posterior vagina and cervix to the sacrum using an intervening graft, which may be either synthetic (eg, polypropylene, polyester) or natural (eg, fascia, dermis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter L Rosenblatt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38994=[""].join("\n");
var outline_f38_5_38994=null;
var title_f38_5_38995="Monobenzone: Patient drug information";
var content_f38_5_38995=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Monobenzone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21122?source=see_link\">",
"     see \"Monobenzone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the color of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to monobenzone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Practice good skin care and avoid the sun.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12083 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38995=[""].join("\n");
var outline_f38_5_38995=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031380\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031379\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031384\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031385\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031387\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031382\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031383\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031388\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031389\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21122?source=related_link\">",
"      Monobenzone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_5_38996="Trimethoprim and polymyxin B: Pediatric drug information";
var content_f38_5_38996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethoprim and polymyxin B: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?5/19/5429?source=see_link\">",
"    see \"Trimethoprim and polymyxin B: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/23/40307?source=see_link\">",
"    see \"Trimethoprim and polymyxin B: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Polytrim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Polytrimethoprim;",
"     </li>",
"     <li>",
"      Polytrim&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1040845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1040857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/19/5429?source=see_link\">",
"      see \"Trimethoprim and polymyxin B: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants &ge;2 months, Children, Adolescents, and Adults: Ophthalmic: Instill 1 drop in eye(s) every 3 hours (maximum: 6 doses/day) for 7-10 days (manufacturer&rsquo;s recommendation for mild to moderate infection)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic: Trimethoprim 1 mg and polymyxin B sulfate 10,000 units per 1 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Polytrim&reg;: Trimethoprim 1 mg and polymyxin B sulfate 10,000 units per 1 mL (10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1040860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use in eye only; avoid contamination of the applicator tip. Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10831044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1040846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of surface ocular conjunctivitis and blepharoconjunctivitis caused by susceptible",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. epidermidis",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      S. viridans",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     , and",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     (FDA approved in ages &ge;2 months and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F231552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocular: Burning, itching, edema, rash, redness increased, stinging, tearing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1040848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trimethoprim, polymyxin B, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10483867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in overgrowth of nonsusceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10483866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for prophylaxis or treatment of ophthalmia neonatorum.",
"     <b>",
"      Not for injection into the eye.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Trimethoprim may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Trimethoprim may decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): May increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Trimethoprim may decrease the excretion of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Trimethoprim may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: Trimethoprim may decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Memantine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F231527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8771688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events have been observed with trimethoprim in animal studies; animal reproduction studies have not been conducted with polymyxin B. Trimethoprim/polymyxin B is classified as pregnancy category C. Due to trimethoprim&rsquo;s potential effect on folic acid metabolism, trimethoprim should only be used during pregnancy if the benefit justifies the potential risk. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10483868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by reversibly inhibiting dihydrofolate reductase interfering with bacterial nucleic acid and protein synthesis. Polymyxin B increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1040862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/23/40307?source=see_link\">",
"      see \"Trimethoprim and polymyxin B: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contamination of the applicator tip; contact physician and discontinue use if redness, swelling, pain, or irritation persists. Discontinue wearing contact lenses if signs and symptoms of ocular bacterial infection are present.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10882125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Polytrim&reg;: pH 4-6.2; osmolality: 270-310 mOsm/kg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16063 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38996=[""].join("\n");
var outline_f38_5_38996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231539\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040845\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040857\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231530\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231520\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040860\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10831044\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040846\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231552\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040848\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483867\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483866\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231546\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231526\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231527\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771688\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483868\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040862\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10882125\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16063|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/19/5429?source=related_link\">",
"      Trimethoprim and polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/23/40307?source=related_link\">",
"      Trimethoprim and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_5_38997="Interferon beta-1a: Patient drug information";
var content_f38_5_38997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Interferon beta-1a: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     see \"Interferon beta-1a: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avonex&reg;;",
"     </li>",
"     <li>",
"      Avonex&reg; Pen&trade;;",
"     </li>",
"     <li>",
"      Rebif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avonex&reg;;",
"     </li>",
"     <li>",
"      Rebif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat MS (multiple sclerosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702309",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to interferon beta-1a or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor. The flu-like side effects of interferon may be stressful to heart patients.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3795884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle 1 to 3 times a week.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime to help with flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to give closely if you or a family member is giving the shot at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699652",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store unopened Avonex&reg; vials or Rebif&reg; at room temperature. Throw away after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3795902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store Avonex&reg; syringes or pens at room temperature. Throw away after 7 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10766 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38997=[""].join("\n");
var outline_f38_5_38997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183458\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183459\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027666\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027668\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027667\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027672\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027673\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027675\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027670\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027671\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027676\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027677\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=related_link\">",
"      Interferon beta-1a: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_5_38998="Amphotericin B nephrotoxicity";
var content_f38_5_38998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amphotericin B nephrotoxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/38998/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/38998/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/38998/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/38998/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/38998/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/38998/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/5/38998/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is used in the treatment of often life-threatening fungal infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .) Impaired renal function is a relatively common complication of amphotericin B, as are other renal manifestations, including urinary potassium wasting and hypokalemia, urinary magnesium wasting and hypomagnesemia, metabolic acidosis due to type 1 (or distal) renal tubular acidosis, and polyuria due to nephrogenic diabetes insipidus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    nephrotoxicity is presented here. The management of hypokalemia, hypomagnesemia, distal renal tubular acidosis, and nephrogenic diabetes insipidus is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link&amp;anchor=H3820122#H3820122\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation and treatment of hypomagnesemia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Distal (type 1) RTA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE KIDNEY INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence with conventional amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (ie, not the lipid formulations) causes renal vasoconstriction and can reduce the glomerular filtration rate (GFR) by more than half [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1-4,6,7\">",
"     1-4,6,7",
"    </a>",
"    ]. In the two largest reviews, a 50 percent or greater increase in serum creatinine was observed in 138 of 494 and 174 of 643 patients (28 and 27 percent), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of amphotericin-induced renal injury is influenced by other factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent therapy with other nephrotoxins, such as an aminoglycoside,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , increases the risk of acute kidney injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/4,6-8\">",
"       4,6-8",
"      </a>",
"      ]. In one report, the incidence of a twofold or greater increase in serum creatinine was 15 percent in patients taking no or one concurrent nephrotoxic drug and 41 percent in those taking two or more concurrent nephrotoxic drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic kidney disease at baseline and the severity of the underlying illness also increase the risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/4,6\">",
"       4,6",
"      </a>",
"      ]. In one series, the incidence of moderate to severe nephrotoxicity (defined as a doubling of the serum creatinine to a level greater than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      was 4 percent in patients with no risk factors for acute kidney injury, and 8 to 29 percent in those with chronic kidney disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The likelihood of renal disease is also dose-dependent, with the risk of renal dysfunction being low at doses of less than 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and a cumulative dose of less than 600 mg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/4,6,8\">",
"       4,6,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prediction rule risk stratified patients based upon the following clinical data available during the course of therapy: location of care (general medical unit versus intensive care unit); concurrent use of cyclosporin; and maximum daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    dose (&lt;60 mg versus &ge;60 mg daily). In the lowest risk group (12 percent of patients), the risk of nephrotoxicity was 4 percent, while in the highest risk group (10 percent of patients), the risk of acute kidney injury was 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the serum creatinine increases by no more than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (220",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    above baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1,4,6,9\">",
"     1,4,6,9",
"    </a>",
"    ]. More severe kidney injury due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    alone is uncommon, but can occur with diuretic-induced volume depletion or the concurrent administration of another nephrotoxin.",
"   </p>",
"   <p>",
"    Issues related to prevention of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    nephrotoxicity, including the use of lipid-based formulations, are discussed below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Lipid-based formulations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of amphotericin-induced nephrotoxicity is incompletely understood. It has been proposed that both tubular injury and renal vasoconstriction play an important role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    inserts into cell membranes, resulting in the creation of pores that increase membrane permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition to this direct effect, in vitro studies suggest that approximately one-half of the tubular toxicity of amphotericin B may be mediated by deoxycholate, a detergent used as a solubilizing agent for amphotericin B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction in GFR associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    -induced tubular toxicity may be mediated in part by the tubuloglomerular feedback (TGF) system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Normally, when sodium chloride (NaCl) delivery to the distal tubule increases, a greater quantity of NaCl enters the macula densa cells located in the early portion of the distal tubule. This results in a feedback loop (TGF), which triggers afferent arteriolar vasoconstriction and a fall in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Under most circumstances, this TGF response is physiologically appropriate: high rates of NaCl delivery out of the proximal tubule are restored to near normal levels by the appropriate reduction in GFR, and this prevents excessive NaCl losses in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    nephrotoxicity increases the permeability of the macula densa cells. This may inappropriately activate the TGF system and lead to excessive afferent arteriolar vasoconstriction and a fall in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1,9\">",
"     1,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, the renal vasoconstriction and fall in GFR may reflect a direct action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    on blood vessels, rather than TGF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/13\">",
"     13",
"    </a>",
"    ]. In experimental animals, administration of a calcium channel blocker prevents amphotericin-induced vasoconstriction and the resultant decline in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/14\">",
"     14",
"    </a>",
"    ]. The possible applicability of this observation to humans remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of nephrotoxicity can be reduced by using lower doses of amphotericin and by avoiding concurrent therapy with other nephrotoxins, such as an aminoglycoside or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Two other preventive measures are salt loading and the use of lipid formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . In addition, for some fungal infections, non-amphotericin B agents are now available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Salt loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proposed importance of TGF in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    nephrotoxicity has led to the use of salt loading, since volume expansion has been shown to reduce the sensitivity of the TGF system. Studies in both humans and animals have shown that saline administration can protect against or ameliorate the amphotericin B-induced decline in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1,2,9,15\">",
"     1,2,9,15",
"    </a>",
"    ] but",
"    <strong>",
"     not",
"    </strong>",
"    the signs of tubular dysfunction described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The beneficial effect of salt loading was best shown in a controlled study of patients with mucocutaneous leishmaniasis who received a 10-week course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (average dose 50 mg per day, given three times per week) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/15\">",
"     15",
"    </a>",
"    ]. The serum creatinine concentration was stable with salt loading (1 liter of isotonic saline over the 60 minutes prior to amphotericin B administration) but rose from 0.6 to 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (53 to 88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in patients given only water. The minor degree of renal insufficiency in the relatively healthy control group probably reflects in part the absence of potentiating factors, such as volume depletion or concurrent aminoglycoside therapy.",
"   </p>",
"   <p>",
"    However, this benefit of salt loading does not prove that TGF, rather than vasoconstriction, is the major mechanism underlying the reduced GFR. Increases in the secretion of vasoconstrictors (angiotensin II and norepinephrine) and decreases in the secretion of the vasodilator atrial natriuretic peptide might modulate the constrictive effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/13\">",
"     13",
"    </a>",
"    ]; volume expansion could prevent these hormonal changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lipid-based formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/16\">",
"     16",
"    </a>",
"    ] and human studies (including both observational [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/17-20\">",
"     17-20",
"    </a>",
"    ] and randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/21\">",
"     21",
"    </a>",
"    ]) suggest that the incidence and severity of nephrotoxicity can be minimized, though not eliminated, by administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in a lipid-based formulation. Several lipid-based amphotericin B products exist. Lipid complex (Abelcet&reg;) and liposomal (AmBisome&reg;) are available in the USA. Colloidal dispersion (Amphocil&reg;) is not currently widely available. &nbsp;",
"   </p>",
"   <p>",
"    The best comparative data are reported in a meta-analysis of randomized trials which compared conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (five trials, 1233 patients) and lipid emulsion amphotericin B (nine trials, 459 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared with conventional amphotericin B, the incidence of nephrotoxicity was significantly reduced with the use of liposomal amphotericin B (14.5 versus 32.5 percent) or lipid emulsion amphotericin B (12.2 versus 30.6 percent).",
"   </p>",
"   <p>",
"    The reduced risk of nephrotoxicity found in this meta-analysis is consistent with a large retrospective series of 3514 patients treated with lipid-based formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/19\">",
"     19",
"    </a>",
"    ]. A doubling of the serum creatinine concentration occurred in 13 percent of patients, and 3 percent required dialysis.",
"   </p>",
"   <p>",
"    The reason why lipid-based formulations are associated with less acute kidney injury is incompletely understood. However, two possibilities have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The liposomal preparation does not contain deoxycholate, which (as noted above) has direct tubular toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The liposomes may be preferentially distributed to the reticuloendothelial system, where",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      can be transferred directly to trapped fungi with less delivery to other cholesterol-containing cells, such as those in the kidney.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the lipid preparations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    may be less nephrotoxic than the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , the risk of nephrotoxicity with lipid-based formulations is higher among patients concurrently treated with other nephrotoxic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/7,19\">",
"     7,19",
"    </a>",
"    ]. In one randomized trial, for example, the incidence of nephrotoxicity, defined as a twofold or greater increase in serum creatinine, was significantly lower in patients who were given the liposomal preparation (19 versus 34 percent). However, the incidence of nephrotoxicity varied according to whether patients were taking additional nephrotoxic drugs (an aminoglycoside,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ). In those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , the incidence of nephrotoxicity was 6 percent if no or one concurrent nephrotoxic drug was administered and 22 percent if two or more concurrent nephrotoxic drugs were used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ELECTROLYTE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in membrane permeability caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is also thought to contribute to the electrolyte abnormalities that often occur. This defect results in the reduction of ion concentration gradients, which normally exist between the cytoplasm of distal tubule cells and the tubule lumen. In these cases, potassium leaks from the cytoplasm down a favorable concentration gradient into the lumen. Similarly, hydrogen ions diffuse down their gradient from the lumen into the cytoplasm of distal tubule cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, an increase in tubular permeability will promote the back-diffusion of secreted hydrogen ions (or of H2CO3 formed by the combination of hydrogen with filtered bicarbonate), thereby limiting acid excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Hypomagnesaemia and renal magnesium wasting also occur as a result of amphotericin renal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Amphotericin B is one of three drugs (the other two are cyclosporin and cis-platinum) associated with major renal magnesium loss and magnesium depletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The loss of magnesium and potassium may also be related in part to the systemic toxicity of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    that causes these intracellular ions to leak into the extracellular fluid space and then be lost into the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of these changes is that both hypokalemia due to potassium loss and a normal anion gap metabolic acidosis (ie, a distal renal tubular acidosis) due to hydrogen retention are commonly seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/2,7,23,25\">",
"     2,7,23,25",
"    </a>",
"    ]. Hypomagnesemia, though somewhat less common, is also reported. The distal renal tubular acidosis (RTA) generated by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , unlike most other forms of distal RTA, is associated with a normal urine-blood PCO2 after alkaline loading [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This likely results from the previously mentioned back-diffusion of secreted hydrogen ions, but a loss of polarity of the chloride-bicarbonate exchanger is also consistent with this finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/28\">",
"     28",
"    </a>",
"    ]. Treatment of the hypokalemia and renal tubular acidosis consists of administering alkali with potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Distal (type 1) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    may also cause resistance to antidiuretic hormone, leading to polyuria and polydipsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/2,5,7,29\">",
"     2,5,7,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with acute kidney injury, electrolyte abnormalities and nephrogenic diabetes insipidus may be less common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/7,30\">",
"     7,30",
"    </a>",
"    ]. In the randomized trial cited above, liposomal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    was associated with a significantly lower rate of hypokalemia (serum potassium concentration &le;2.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    but no significant change in the rate of hypomagnesemia (serum magnesium concentration &le;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to acute kidney injury, the manifestations of tubular dysfunction do not appear to be ameliorated by volume expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/15\">",
"     15",
"    </a>",
"    ]. Treatment of the magnesium-wasting consists of the administration of magnesium supplements. However, the efficacy of this regimen is limited by the urinary excretion of most of the supplemental magnesium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=see_link\">",
"     \"Evaluation and treatment of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is usually reversible with discontinuation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/9,31\">",
"     9,31",
"    </a>",
"    ]. However, recurrent renal dysfunction can occur if treatment is reinstituted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38998/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4653582\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      commonly causes renal functional impairment, including decreased glomerular filtration rate (GFR), urinary potassium wasting and hypokalemia, urinary magnesium wasting and hypomagnesemia, metabolic acidosis due to distal (or type 1) renal tubular acidosis (RTA), and polyuria due to nephrogenic diabetes insipidus.",
"     </li>",
"     <li>",
"      Possible mechanisms for decreased GFR include: 1) renal vasoconstriction, due to a direct effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      on the vasculature or to tubular glomerular feedback mediated by the drug&rsquo;s effect on sodium entry into juxtaglomerular cells; and 2) tubular toxicity, which alters ion permeability. This is probably mediated in part by binding of the drug to cholesterol in mammalian cell membranes and in part by deoxycholate, a detergent used as a solubilizing agent for the original formulation of amphotericin B. Deoxycholate is not contained in the liposomal preparation.",
"     </li>",
"     <li>",
"      The risk of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      nephrotoxicity is increased by higher daily doses and concurrent therapy with other nephrotoxins, such as an aminoglycoside or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The decline in GFR caused by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , but not the manifestations of tubular dysfunction, is ameliorated by volume expansion with saline.",
"     </li>",
"     <li>",
"      The incidence and severity of nephrotoxicity can be minimized by administering",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in lipid-based formulations;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      may be less nephrotoxic than the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      An increase in membrane permeability induced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      is thought to account for the electrolyte abnormalities that often occur: 1) back-diffusion of secreted hydrogen ion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      H2CO3 from the tubular lumen to the plasma best explains renal tubular acidosis; and 2) enhanced diffusion of potassium from the renal tubular cell to the tubular lumen down a favorable concentration gradient explains renal potassium wasting and hypokalemia. Renal magnesium wasting and hypomagnesemia may develop.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      may also cause resistance to antidiuretic hormone (nephrogenic diabetes insipidus), leading to polyuria and polydipsia.",
"     </li>",
"     <li>",
"      Liposomal preparations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      are associated with a lower incidence of acute kidney injury and electrolyte abnormalities. The nephrotoxicity associated with amphotericin B is usually reversible with discontinuation of therapy. However, recurrent renal dysfunction can occur if treatment is reinstituted.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/1\">",
"      Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/2\">",
"      Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/3\">",
"      BUTLER WT, BENNETT JE, ALLING DW, et al. NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS. Ann Intern Med 1964; 61:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/4\">",
"      Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001; 60:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/5\">",
"      Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984; 77:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/6\">",
"      Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/7\">",
"      Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/8\">",
"      Fisher MA, Talbot GH, Maislin G, et al. Risk factors for Amphotericin B-associated nephrotoxicity. Am J Med 1989; 87:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/9\">",
"      Heidemann HT, Gerkens JF, Spickard WA, et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/10\">",
"      Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int 1992; 41:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/11\">",
"      Heyman SN, Stillman IE, Brezis M, et al. Chronic amphotericin nephropathy: morphometric, electron microscopic, and functional studies. J Am Soc Nephrol 1993; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/12\">",
"      Blantz RC, Pelayo JC. A functional role for the tubuloglomerular feedback mechanism. Kidney Int 1984; 25:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/13\">",
"      Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991; 87:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/14\">",
"      Tolins JP, Raij L. Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade. J Am Soc Nephrol 1991; 2:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/15\">",
"      Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/16\">",
"      D&oacute;rea EL, Yu L, De Castro I, et al. Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion. J Am Soc Nephrol 1997; 8:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/17\">",
"      Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs Today (Barc) 2004; 40:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/18\">",
"      Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/19\">",
"      Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40 Suppl 6:S414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/20\">",
"      White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/21\">",
"      Mistro S, Maciel Ide M, de Menezes RG, et al. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 2012; 54:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/22\">",
"      Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/23\">",
"      Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969; 46:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/24\">",
"      Gil FZ, Malnic G. Effect of amphotericin B on renal tubular acidification in the rat. Pflugers Arch 1989; 413:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/25\">",
"      Batlle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986; 30:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/26\">",
"      Atsmon J, Dolev E. Drug-induced hypomagnesaemia : scope and management. Drug Saf 2005; 28:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/27\">",
"      Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 2000; 34:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/28\">",
"      Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004; 38:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/29\">",
"      Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 2009; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/30\">",
"      Canada TW, Weavind LM, Augustin KM. Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus. Ann Pharmacother 2003; 37:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38998/abstract/31\">",
"      Sacks P, Fellner SK. Recurrent reversible acute renal failure from amphotericin. Arch Intern Med 1987; 147:593.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2364 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38998=[""].join("\n");
var outline_f38_5_38998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4653582\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence with conventional amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Salt loading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lipid-based formulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ELECTROLYTE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4653582\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_5_38999="Counseling parents after stillbirth";
var content_f38_5_38999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Counseling parents after stillbirth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/38999/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/38999/contributors\">",
"     Amos Grunebaum, MD, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/38999/contributors\">",
"     Frank A Chervenak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/38999/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/38999/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/38999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/38999/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/5/38999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost one-half of stillbirths occur in apparently uncomplicated pregnancies, usually before labor begins; therefore, most parents are unprepared when told that the fetus has died. The family's anticipation of a joyous event is supplanted by despair and confusion. Even when the loss is not unexpected or occurs early in pregnancy, the death of offspring is a severe emotional stress. Limited observational studies describe psychological sequelae, such as depression, posttraumatic stress disorder, and anxiety, as well as deleterious effects on maternal-child attachment, in pregnancies subsequent to a stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, it is important for all care providers to be knowledgeable about these issues when they approach parents during the stressful situation of a stillbirth or fetal demise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care of parents who experience stillbirth will be reviewed here. A general discussion of the normal and dysfunctional grieving processes can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link\">",
"     \"Grief and bereavement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PURPOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of perinatal loss is felt in terms of loss of a desired child, loss of self-esteem in the role of parent, and loss of confidence in the ability to produce a healthy child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/4\">",
"     4",
"    </a>",
"    ]. Counseling parents can serve many different emotional purposes, for the couple as well as for the provider. Counseling:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Helps parents in both connecting to and separating from the baby. It makes the loss of a baby real and helps prevent emotional withdrawal from the loss.",
"     </li>",
"     <li>",
"      Helps the individuals involved identify and express their feelings of anger, guilt, blame, fear, anxiety, sorrow, grief, and failure.",
"     </li>",
"     <li>",
"      Explores defenses and coping mechanisms.",
"     </li>",
"     <li>",
"      Is used to evaluate the need for professional referral if needed.",
"     </li>",
"     <li>",
"      Allows for individual behavior.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supporting parents and creating a trusting relationship with them can affect how they respond to bereavement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, there is no information available from randomized trials to indicate the benefits of providing specific psychological support or counseling after perinatal death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, grieving parents want staff to appreciate the severity of their loss, offer understanding and support, and allow them to talk about the death. An appropriate approach consists of empathetic, honest communication between parents and hospital staff that acknowledges the specific needs and cultural practices of individual couples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/8\">",
"     8",
"    </a>",
"    ] and the differing needs of the mother and father [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The process of grief often does not occur in a linear fashion, is cyclical, and often manifests itself in many different ways. No two people grieve or express their grief in the same way or for the same time period. Gender and cultural differences need to be considered.",
"   </p>",
"   <p>",
"    Bereaved parents should be provided with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical care, as appropriate",
"     </li>",
"     <li>",
"      Support in viewing, holding, and then separating from the baby",
"     </li>",
"     <li>",
"      Emotional support in what may be a chaotic environment",
"     </li>",
"     <li>",
"      Grief assessment and counseling",
"     </li>",
"     <li>",
"      An opportunity to obtain as complete information as possible about the course of events, cause of death, risk of recurrence in a future pregnancy, and potential interventions, such as prenatal",
"      <span class=\"nowrap\">",
"       diagnosis/therapy",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings have been confirmed in observational studies, three representative examples are illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, one or both parents of 31 stillborn infants were interviewed twice regarding their views and experiences in the transitional process after the birth of a stillborn child [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/11\">",
"       11",
"      </a>",
"      ]. The interviewees described six \"qualities\" that summarized what they wanted from their caregivers: support in chaos, support in meeting with and separation from the baby, support in bereavement, explanation of the stillbirth, organization of their care, and understanding the nature of grief.",
"     </li>",
"     <li>",
"      A prospective study over 12 years described the choices parents made regarding contact with their baby following stillbirth or immediate neonatal death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/12\">",
"       12",
"      </a>",
"      ]. Most parents wanted contact with their baby to personalize the event, information about the death and follow-up from their health care providers. Many parents chose different options and no single option was chosen by all parents.",
"     </li>",
"     <li>",
"      Another study concluded that behaviors that promoted rather than offered contact with the stillborn infant were associated with worse outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/13\">",
"       13",
"      </a>",
"      ]. Women who had held their stillborn infant were more depressed than those who only saw the infant, while those who did not see the infant were least likely to be depressed (13 of 33 versus three of 14 versus one of 17, respectively). Women who had seen their stillborn infant had more symptoms of posttraumatic stress disorder than those who had not and their next-born infants were more likely to show disorganized attachment behavior. Having a funeral and keeping mementos were not associated with further adverse outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies support offering choices to all parents, and indicate that providers should neither bias parents nor make presumptions that would limit parental choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PERSONNEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the patient's caregivers need to be supportive during their interactions with the patient and family and cognizant of the nature of grief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/11\">",
"     11",
"    </a>",
"    ]. Usually the patient's primary provider (eg, obstetrician-gynecologist, midwife) is responsible for coordination of counseling efforts, but may not be the primary person providing counseling. The counselor may be one person or part of a team with specific expertise: obstetrician, maternal-fetal medicine specialist, neonatologist, pathologist, genetics counselor, nurse practitioner, or social worker. Social workers often assist the family in making arrangements for burial or disposition of the body. Referral for genetics consultation is particularly appropriate when malformations have been identified in the baby.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COUNSELING ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stillbirth counseling process has several chronologically distinct stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At the time of diagnosis",
"     </li>",
"     <li>",
"      When making plans for delivery",
"     </li>",
"     <li>",
"      At delivery and immediately postpartum",
"     </li>",
"     <li>",
"      During the weeks after discharge and at the first post-partum visit",
"     </li>",
"     <li>",
"      At a \"wrap-up\" meeting when all laboratory and pathology results are available",
"     </li>",
"     <li>",
"      When the patient is considering another pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     At diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the introduction of ultrasonography and electronic fetal heart rate monitoring, the diagnosis of a stillbirth was often not made until delivery. Today, an intrauterine fetal demise can sometimes be anticipated from prenatal evaluations and is rarely diagnosed at delivery, unless the demise occurs just before birth.",
"   </p>",
"   <p>",
"    The initial approach to the couple with a fetal demise is crucial in mapping out the counseling process. Once the demise has been confirmed, the couple should be informed in an expeditious and straightforward manner, but with empathy and in surroundings in which parents can feel they are allowed to react. The moment of diagnosis is often a very painful event for the prospective parents, as well as for the person conveying the information.",
"   </p>",
"   <p>",
"    Parents may go through the traditional \"stages of grief\" beginning at the time of diagnosis. According to the K&uuml;bler-Ross model, there are five stages that a dying person goes through when they are told that they have a terminal illness. Parents who lose a baby may similarly experience the five stages: denial, anger, bargaining, depression, and acceptance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link&amp;anchor=H2#H2\">",
"     \"Grief and bereavement\", section on 'Normal bereavement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis of fetal demise has been made, parents usually ask: why did it happen?, what do we do now? and will it happen again?. Unless it is clear why the fetus has died, the answers to \"why\" and \"will it happen again\" cannot be given. The patient should be told at the time of initial diagnosis that the provider will attempt to answer these questions when the necessary examinations have been completed and when all relevant information has been reviewed, but that this will take time, possibly weeks or even months, depending upon the studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Delivery decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It often takes time to fully accept the death of a baby, and parents need not be rushed into making any decisions about delivery during a chaotic period in the absence of maternal medical concerns (eg, disseminated coagulopathy, severe preeclampsia, infection). Clinical and social issues, gestational age, cervical findings, and parity also play a significant role in making decisions about delivery timing.",
"   </p>",
"   <p>",
"    Some women may want to be admitted to the hospital, but it is also medically acceptable, and possibly psychologically desirable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/14\">",
"     14",
"    </a>",
"    ], for parents to go home and take their time in deciding upon the next step. This is a controversial area as some studies have suggested that women who were induced after 24 hours of the diagnosis of stillbirth had an increased risk of anxiety years after the loss compared to women whose labors were induced within six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/1\">",
"     1",
"    </a>",
"    ]. Once the parents have accepted the diagnosis and are ready to discuss it further, a discussion of the timing and procedure for delivery can ensue.",
"   </p>",
"   <p>",
"    Parents should be told that spontaneous labor usually begins within one to two weeks of fetal death in the majority of cases. It is not unreasonable to offer patients the opportunity to wait for spontaneous labor and to inform them that waiting may decrease medical complications from induction. However, there is a risk of developing coagulation abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/15\">",
"     15",
"    </a>",
"    ]. If active intervention is desired or indicated, prostaglandins and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    have been used for cervical ripening and labor induction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cesarean delivery can often be avoided in women with a previous cesarean delivery because there is no benefit to the fetus of performing a cesarean delivery in the presence of fetal demise. Management of patients with a history of prior classical cesarean delivery or hysterotomy should be managed on an individual basis and depends upon the size of the fetus, cervical findings, and whether the patient previously had a vaginal delivery or not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autopsy and disposition of the stillborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predelivery counseling should also include a discussion of whether an autopsy is requested and disposition of the fetal remains. Many hospitals have specially trained bereavement counselors who can help the parents through this decision process.",
"   </p>",
"   <p>",
"    The postmortem examination is a useful and necessary tool in helping to discover the reasons why the baby died. The medical staff involved in consent for postmortem examination should be fully trained in how to ask for parental consent, the postmortem examination procedure, what is gained by this examination, cost, and how to explain the findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/16\">",
"     16",
"    </a>",
"    ]. Simplifying the language used to explain findings may further raise parents' understanding of the value of the postmortem examination and ensure that they are satisfied with it. Randomized trials have not determined the optimum approach for helping parents decide whether to have post-mortem investigations, including an autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38839?source=see_link\">",
"     \"Evaluation of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some parents may elect to have a full burial, while others may choose to dispose of the body through the hospital's usual mechanisms. State law governs the process of burial and disposition, which vary from state to state.",
"   </p>",
"   <p>",
"    Many parents are upset that a birth certificate is not generated for stillborns. For this reason, some states issue a \"Birth certificate resulting in stillbirth\" to parents of stillborn children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the delivery room, parents should be offered support in viewing, holding, and then separating from the baby (who should be referred to by name, if one has been given). Contact between the parents and stillborn is thought to be important because the quality of the attachment (ie, the process that establishes an emotional bond) to a deceased person can affect how the living deal with their loss. The help of caregivers with attachment to the stillborn can be considered an important phase in the transition to parenthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/11\">",
"     11",
"    </a>",
"    ]. Although most parents want contact with their baby [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/12,18\">",
"     12,18",
"    </a>",
"    ] and it is commonly assumed that seeing and holding the stillborn infant is conducive to the mourning process, the value of this practice has been questioned, as discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/13\">",
"     13",
"    </a>",
"    ]. Parents should not be told that they must hold the baby if it is not their wish. Some parents appreciate receiving \"keepsakes\" such as a lock of hair or footprint, if possible.",
"   </p>",
"   <p>",
"    A gross examination of the fetus and placenta should be performed at the time of delivery and the parents should be informed of the findings. If there is a clear finding, such as a tight knot in the umbilical cord, this should be communicated. Otherwise, the parents are advised to wait until all tests and examinations have been completed before trying to determine the cause of death.",
"   </p>",
"   <p>",
"    Some women want to be on a postpartum floor and receive similar care to that which they would receive if they delivered a live born. Others do not want to be on a postpartum floor because they do not want to be around patients with healthy newborns. Discussing these issues with the woman is useful before her transfer off of labor and delivery.",
"   </p>",
"   <p>",
"    Another issue concerns parents who have a multiple gestation with delivery of both healthy and stillborn infants. These couples experience both joy and grief, and may experience difficulty with attachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/19\">",
"     19",
"    </a>",
"    ]. They also need support and guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     After discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The weeks after discharge are usually very difficult for the parents. They have just experienced a major traumatic event; they need to accept the fact that they do not have a live baby; they need to inform others of their loss; they may have to address preparations they may have made in expectation of bringing the baby home; and they need to cope with their grief in relation to the people in their surroundings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, couples with other children will need to discuss the stillbirth with them. A study exploring this issue found that parents could support their children by recognizing and acknowledging the child's grief, including the child in family rituals, and keeping the baby alive in the family memory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that the physician contact patients regularly after delivery and schedule the first postpartum visit earlier than the usual six weeks. Talking regularly with patients during this time, and especially at the first postpartum visit, helps the provider find out about their emotional status, whether there are signs of depression, and whether professional referral is indicated. This is the time of the 4th stage according to the K&uuml;bler-Ross model and often involves depression. The evaluation of postpartum women for depression is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=see_link\">",
"     \"Postpartum blues and depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complicated or traumatic grief describes a syndrome in which the individual does not return to the level of function and well-being at which he or she lived before the loss. It involves the persistence of reactions (eg, difficulty accepting the death, denial of the death, absence of grief, searching, preoccupation with thoughts of the deceased, avoidance of reminders of the deceased, auditory and visual hallucinations of the person who has died, symptoms of identification with the deceased) that are normal in the immediate period after a loss. Complicated grief can lead to prolonged dysfunction; these patients should be referred to a psychiatrist for evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link&amp;anchor=H6#H6\">",
"     \"Grief and bereavement\", section on 'Abnormal bereavement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support groups may be helpful for some parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/22\">",
"     22",
"    </a>",
"    ]. In one study, participants in such groups stated the group helped members recognize their commonalities, remember their earlier babies who died, develop caring relationships, and learn new coping skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/23\">",
"     23",
"    </a>",
"    ]. Support groups for parents who have lost a fetus or child exist in many hospitals and communities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sites of organizations supporting families after pregnancy loss include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.compassionatefriends.org/\">",
"       www.compassionatefriends.org",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nationalshare.org/\">",
"       www.nationalshare.org",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Discussion of test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"wrap-up\" meeting is scheduled when all results of testing and the autopsy are available, which may take several months. However, parents can be informed as progress is made along the way.",
"   </p>",
"   <p>",
"    Some couples prefer to meet with their physician alone, while others prefer to bring along some family members or friends. At the wrap-up meeting, information about the events leading up to the fetal demise and stillbirth, as well as the laboratory results and the autopsy report (if an autopsy was performed), should be reviewed with ample opportunity for the couple to ask questions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recurrence risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a prior stillbirth are at higher risk of stillbirth in future pregnancies than women with prior live births; the magnitude of risk (two- to ten-fold) is affected by multiple factors, including characteristics of the stillbirth and race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. It is important to discuss possible causes and risks for recurrence and a plan for the next pregnancy. We suggest a periconception visit to review the circumstances of the prior stillbirth and the interval medical history, as well as discuss risks and management of future pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Etiology not determined",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 25 to 50 percent of cases, despite all evaluative efforts, no cause for the fetal demise can be found, and parents should be informed that the cause remains unidentified. In low-risk women with unexplained stillbirth, the risk of recurrence is 7.8 to 10.5 per 1000 births and most of these deaths occur before 37 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of recurrent stillbirth at term is only 1.8 per 1000 births. However, the patient is at risk of abruption, preterm birth, and low birthweight in the subsequent pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Etiology known or suspected",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a specific cause for the fetal demise or stillbirth is identified, then an estimate of the recurrence risk can be provided based upon review of the literature. The recurrence risk of specific disorders and risk reduction interventions are discussed separately in individual topic reviews on each subject (eg, see topic reviews on abruptio placentae, inherited thrombophilia, preeclampsia, antiphospholipid syndrome, nonimmune hydrops, etc).",
"   </p>",
"   <p>",
"    Two findings are of particular importance: congenital anomalies and fetal growth restriction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of women whose first infant had a birth defect, the risk of the same defect in the second infant was substantially increased and the risk of a different defect in the second infant was slightly increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The association between the birth of a small for gestational age (SGA) infant in a first pregnancy and stillbirth in a subsequent pregnancy was illustrated by analysis of data from the Swedish Birth Register (",
"      <a class=\"graphic graphic_table graphicRef56032 \" href=\"mobipreview.htm?18/19/18747\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/31\">",
"       31",
"      </a>",
"      ]. This and other studies have shown that the highest risk of stillbirth is in women who deliver a preterm SGA infant in the previous pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"       \"Fetal growth restriction: Evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An active area of investigation is the hypothesis that placental abruption, intrauterine growth restriction, preeclampsia, and stillbirth are different manifestations of ischemic placental disease and predispose to preterm birth. There is evidence that these disorders often co-exist in a pregnancy or one may occur in one pregnancy while another occurs in a subsequent pregnancy (eg, stillbirth in the first pregnancy, growth restriction in the second pregnancy). Thus, women with these pregnancy complications comprise a high risk group in their subsequent pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See individual topic reviews on abruption, fetal growth restriction, preeclampsia, and stillbirth).",
"   </p>",
"   <p>",
"    The gestational age at loss of the index pregnancy is also an important factor. In a study of 95 women with pregnancy loss at 13 to 24 weeks, the next pregnancy in these women was characterized by increased risks of preterm delivery (40 percent), stillbirth (5 percent), and neonatal death (6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Planning future pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data from large studies on the optimum interpregnancy interval after stillbirth. Observational series suggest that women are more vulnerable to post traumatic stress in the pregnancy subsequent to stillbirth when conception occurs soon after the loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/36\">",
"     36",
"    </a>",
"    ] and that mothers who bear their next baby around the anniversary of their first baby's death are particularly vulnerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/37\">",
"     37",
"    </a>",
"    ]. Others have shown that most women recover psychologically by 12 months after a pregnancy loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, it is reasonable to advise patients to delay conception until they feel they have achieved psychological closure of the previous pregnancy loss and that this typically takes at least six months to one year. In addition, the risk of adverse pregnancy outcome may be lower when the interpregnancy interval is more than six months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/63/13302?source=see_link\">",
"     \"Interpregnancy interval and pregnancy outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that intensive monitoring in future pregnancies will make a significant difference in preventing stillbirth, especially when the cause was unknown. Nevertheless, many practitioners offer frequent prenatal visits and frequent testing, such as nonstress tests and ultrasound examinations, as well as early delivery (eg, 38 weeks) to provide the couple with some psychological reassurance and a measure of control over the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Management of future pregnancies is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31306?source=see_link&amp;anchor=H30#H30\">",
"     \"Incidence, etiology, and prevention of stillbirth\", section on 'Prevention strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of eight couples who had a healthy infant subsequent to a stillborn noted that half of the mothers did not make preparations for their babies until after delivery and seven of the eight wanted the hospital staff to recognize their previous loss and give them special understanding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/38999/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/3/29745?source=see_link\">",
"       \"Patient information: Stillbirth (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stillbirth is a severe emotional stress. Limited observational studies describe psychological sequelae in pregnancies subsequent to a stillbirth; therefore, it is important for all care providers to be knowledgeable about these issues when they approach parents. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Counseling helps parents in both connecting to and separating from the baby; helps them to identify and express their feelings; and is used to evaluate the need for professional referral. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Purpose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When performed in an empathetic and honest way, counseling offers understanding and support, allows parents to talk about the death, and provides information. We suggest that providers offer the parents choices about seeing and holding their stillborn and not bias parents nor make presumptions that would limit parental choices. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Components'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The counselor may be one person or part of a team with specific expertise: obstetrician, maternal-fetal medicine specialist, neonatologist, pathologist, genetics counselor, nurse practitioner, or social worker. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Personnel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parents need not be rushed into making any decisions about delivery in the absence of maternal medical concerns. Some women may want to be admitted to the hospital, but it is also medically acceptable to delay induction of labor. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Counseling issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Let the patient decide whether she wishes to be given postpartum care on a maternity floor or elsewhere in the hospital. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Postpartum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest talking regularly with patients postpartum to find out about their emotional status, whether there are signs of depression, and whether professional referral is indicated. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'After discharge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a postmortem examination to help discover the reasons for the stillbirth and to provide information for planning future pregnancies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Autopsy and disposition of the stillborn'",
"      </a>",
"      above.) If no specific etiology for a late stillbirth is determined, the probability of recurrence, is probably no greater than approximately 3 percent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recurrence risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest delaying the next pregnancy until the parents feel they have achieved psychological closure of the previous pregnancy loss. This typically takes six months to one year. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Planning future pregnancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that women with a history of a stillbirth receive preconception counseling prior to the next pregnancy to review findings of the prior stillbirth and to help plan care and management of future pregnancies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recurrence risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the presence of fetal growth restriction, placental abruption, and other recurring conditions, we suggest development of risk assessment and management strategies to potentially reduce the number of fetal deaths in future pregnancies. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Planning future pregnancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/1\">",
"      Hughes PM, Turton P, Evans CD. Stillbirth as risk factor for depression and anxiety in the subsequent pregnancy: cohort study. BMJ 1999; 318:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/2\">",
"      Gold KJ, Dalton VK, Schwenk TL. Hospital care for parents after perinatal death. Obstet Gynecol 2007; 109:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/3\">",
"      Committee on Genetics. ACOG Committee Opinion No. 383: Evaluation of stillbirths and neonatal deaths. Obstet Gynecol 2007; 110:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/4\">",
"      Weiss L, Frischer L, Richman J. Parental adjustment to intrapartum and delivery room loss. The role of a hospital-based support program. Clin Perinatol 1989; 16:1009.",
"     </a>",
"    </li>",
"    <li>",
"     Lasker ,J, Borg, S, Toedter, L. Report of new research on pregnancy loss. In: Borg S, Lasker J, eds. When Pregnancy Fails: Families Coping With Miscarriage, Ectopic Pregnancy, Stillbirth and Infant Death. New York: Bantam, 1989: 211.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/6\">",
"      Robinson M, Baker L, Nackerud L. The relationship of attachment theory and perinatal loss. Death Stud 1999; 23:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/7\">",
"      Parkes, CM. Bereavement as a psychosocial transition: Processes of adaptation to change. J Soc Issues 1988; 3:53.",
"     </a>",
"    </li>",
"    <li>",
"     National Fetal and Infant Mortality Review Program, Third National Conference, Washington, DC, July 1998. (full text available at www.acog.org/from_home/departments/dept_notice.cfm?recno=10&amp;bulletin=797#top).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/9\">",
"      McCreight BS. A grief ignored: narratives of pregnancy loss from a male perspective. Sociol Health Illn 2004; 26:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/10\">",
"      Vance JC, Boyle FM, Najman JM, Thearle MJ. Couple distress after sudden infant or perinatal death: a 30-month follow up. J Paediatr Child Health 2002; 38:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/11\">",
"      S&auml;flund K, Sj&ouml;gren B, Wredling R. The role of caregivers after a stillbirth: views and experiences of parents. Birth 2004; 31:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/12\">",
"      Rand CS, Kellner KR, Revak-Lutz R, Massey JK. Parental behavior after perinatal death: twelve years of observations. J Psychosom Obstet Gynaecol 1998; 19:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/13\">",
"      Hughes P, Turton P, Hopper E, Evans CD. Assessment of guidelines for good practice in psychosocial care of mothers after stillbirth: a cohort study. Lancet 2002; 360:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/14\">",
"      Trulsson O, R&aring;destad I. The silent child--mothers' experiences before, during, and after stillbirth. Birth 2004; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/15\">",
"      Maslow AD, Breen TW, Sarna MC, et al. Prevalence of coagulation abnormalities associated with intrauterine fetal death. Can J Anaesth 1996; 43:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/16\">",
"      Rankin J, Wright C, Lind T. Cross sectional survey of parents' experience and views of the postmortem examination. BMJ 2002; 324:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/17\">",
"      Horey D, Flenady V, Heazell AE, Khong TY. Interventions for supporting parents' decisions about autopsy after stillbirth. Cochrane Database Syst Rev 2013; 2:CD009932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/18\">",
"      Surkan PJ, R&aring;destad I, Cnattingius S, et al. Events after stillbirth in relation to maternal depressive symptoms: a brief report. Birth 2008; 35:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/19\">",
"      Pector EA. How bereaved multiple-birth parents cope with hospitalization, homecoming, disposition for deceased, and attachment to survivors. J Perinatol 2004; 24:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/20\">",
"      Geerinck-Vercammen CR, Duijvestijn MJ. [Coping with grief following perinatal death: a multifaceted and natural process]. Ned Tijdschr Geneeskd 2004; 148:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/21\">",
"      Wilson RE. Parents' support of their other children after a miscarriage or perinatal death. Early Hum Dev 2001; 61:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/22\">",
"      Heazell AE, Leisher S, Cregan M, et al. Sharing experiences to improve bereavement support and clinical care after stillbirth: report of the 7th annual meeting of the international stillbirth alliance. Acta Obstet Gynecol Scand 2013; 92:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/23\">",
"      C&ocirc;t&eacute;-Arsenault D, Freije MM. Support groups helping women through pregnancies after loss. West J Nurs Res 2004; 26:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/24\">",
"      Reddy UM. Prediction and prevention of recurrent stillbirth. Obstet Gynecol 2007; 110:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/25\">",
"      Sharma PP, Salihu HM, Kirby RS. Stillbirth recurrence in a population of relatively low-risk mothers. Paediatr Perinat Epidemiol 2007; 21 Suppl 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/26\">",
"      Bhattacharya S, Prescott GJ, Black M, Shetty A. Recurrence risk of stillbirth in a second pregnancy. BJOG 2010; 117:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/27\">",
"      Stubblefield PG, Coonrod DV, Reddy UM, et al. The clinical content of preconception care: reproductive history. Am J Obstet Gynecol 2008; 199:S373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/28\">",
"      ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol 2009; 113:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/29\">",
"      Heinonen S, Kirkinen P. Pregnancy outcome after previous stillbirth resulting from causes other than maternal conditions and fetal abnormalities. Birth 2000; 27:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/30\">",
"      Lie RT, Wilcox AJ, Skjaerven R. A population-based study of the risk of recurrence of birth defects. N Engl J Med 1994; 331:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/31\">",
"      Surkan PJ, Stephansson O, Dickman PW, Cnattingius S. Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth. N Engl J Med 2004; 350:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/32\">",
"      Gordon A, Raynes-Greenow C, McGeechan K, et al. Stillbirth risk in a second pregnancy. Obstet Gynecol 2012; 119:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/33\">",
"      Black M, Shetty A, Bhattacharya S. Obstetric outcomes subsequent to intrauterine death in the first pregnancy. BJOG 2008; 115:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/34\">",
"      Getahun D, Lawrence JM, Fassett MJ, et al. The association between stillbirth in the first pregnancy and subsequent adverse perinatal outcomes. Am J Obstet Gynecol 2009; 201:378.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/35\">",
"      Goldenberg RL, Mayberry SK, Copper RL, et al. Pregnancy outcome following a second-trimester loss. Obstet Gynecol 1993; 81:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/36\">",
"      Turton P, Hughes P, Evans CD, Fainman D. Incidence, correlates and predictors of post-traumatic stress disorder in the pregnancy after stillbirth. Br J Psychiatry 2001; 178:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/37\">",
"      Thomas J. The effects on the family of miscarriage, termination for abnormality, stillbirth and neonatal death. Child Care Health Dev 1995; 21:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/38\">",
"      Janssen HJ, Cuisinier MC, Hoogduin KA, de Graauw KP. Controlled prospective study on the mental health of women following pregnancy loss. Am J Psychiatry 1996; 153:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/39\">",
"      Eller AG, Branch DW, Byrne JL. Stillbirth at term. Obstet Gynecol 2006; 108:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/40\">",
"      Weeks JW, Asrat T, Morgan MA, et al. Antepartum surveillance for a history of stillbirth: when to begin? Am J Obstet Gynecol 1995; 172:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/41\">",
"      Spong CY. Add stillbirth to the list of outcomes to worry about in a pregnant woman with a history of preterm birth or fetal growth restriction. Obstet Gynecol 2012; 119:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/38999/abstract/42\">",
"      Wilson AL, Soule DJ, Fenton LJ. The next baby: parents' responses to perinatal experiences subsequent to a stillbirth. J Perinatol 1988; 8:188.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6740 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_38999=[""].join("\n");
var outline_f38_5_38999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PURPOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PERSONNEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COUNSELING ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      At diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Delivery decisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autopsy and disposition of the stillborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postpartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      After discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Discussion of test results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recurrence risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Etiology not determined",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Etiology known or suspected",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Planning future pregnancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6740|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/19/18747\" title=\"table 1\">",
"      SGA stillbirth association",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38839?source=related_link\">",
"      Evaluation of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/63/13302?source=related_link\">",
"      Interpregnancy interval and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/3/29745?source=related_link\">",
"      Patient information: Stillbirth (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=related_link\">",
"      Postpartum blues and depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_5_39000="Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring";
var content_f38_5_39000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/39000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/39000/contributors\">",
"     David F Graft, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/39000/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/39000/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/5/39000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/5/39000/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/5/39000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hymenoptera stings can result in life-threatening anaphylaxis, and the most severe reactions can be refractory to single or multiple doses of epinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Venom immunotherapy (VIT) is highly effective and well tolerated by most patients.",
"   </p>",
"   <p>",
"    VIT for patients with allergies to honeybee, yellow jacket, yellow hornet, white-faced hornet, and wasp is administered using purified venoms, whereas whole body extracts are used in immunotherapy for fire ant allergy. The techniques, adverse effects, and safety of VIT will be reviewed here. Efficacy, indications, and mechanism of action of VIT, as well as immunotherapy for fire ant allergy, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7994?source=see_link&amp;anchor=H22#H22\">",
"     \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues in the administration of venom immunotherapy (VIT) include venom selection, dosing, injection protocol, premedications, and adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Venom selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venoms used for immunotherapy are the same as those used for skin testing. In the United States, there are two companies that supply venom extracts for skin testing and treatment: Hollister-Stier Labs (Spokane, Washington) and ALK-Abello Labs (Round Rock, Texas). Depot preparations are available in some countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/3\">",
"     3",
"    </a>",
"    ], although not in the United States; the discussion herein does NOT apply to depot products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Multiple versus single venom",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, patients are usually treated with all the venoms to which they had a positive skin test, with the goal of providing maximal coverage for future sting events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2\">",
"     2",
"    </a>",
"    ]. This approach ensures that a patient who has reacted to a yellow jacket sting, for example, is not left with doubts about the expected outcome of a sting from a different Hymenoptera insect (to which he had a positive venom skin test but had never been stung, such as honeybee). Thus, skin testing should be performed with venoms from each of the insects relevant to the geographic area, and treatment should include all the venoms to which the patient showed skin test sensitivity.",
"   </p>",
"   <p>",
"    Skin testing is the preferred method of determining sensitivity to venoms, but sometimes measurement of venom-specific IgE may provide additional information. It is most often recommended when all of the venom skin tests are negative.",
"   </p>",
"   <p>",
"    Single venom immunotherapy is used at some centers, and available data indicate that the effectiveness of this approach is also high at 75 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. No head-to-head comparative studies are available.",
"   </p>",
"   <p>",
"    In North America, the most common flying Hymenoptera insect to cause allergy is the yellow jacket (YJ), except for some areas of the south central and southwestern United States, where wasps and honeybees are predominant, respectively.",
"   </p>",
"   <p>",
"    The vast majority of yellow jacket allergic patients also have positive skin tests to yellow hornet (YH) and white-faced hornet (WFH) venoms, because these insects are in the same Hymenoptera subfamily (",
"    <a class=\"graphic graphic_algorithm graphicRef80397 \" href=\"mobipreview.htm?24/14/24815\">",
"     algorithm 1",
"    </a>",
"    ). These patients are usually treated with a mixed vespid extract containing the full dose of each venom. About 50 percent of yellow jacket allergic patients are also sensitized to Polistes wasp (same family) and should receive this venom as a separate injection.",
"   </p>",
"   <p>",
"    Venoms should not be mixed, with the exception of the commercially-prepared mixed vespid products. Mixing of other venoms can result in proteolytic degradation of venom proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment with the H1 antihistamine terfenadine reduced VIT reactions (local and systemic) in randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Although this drug is no longer available, it is our practice to advise the patient to take a minimally-sedating H1 antihistamine each day that an injection is to be administered. Some experts advise patients to take premedications throughout the duration of VIT, while others discontinue it over time if the patient has not had local reactions. A preliminary report suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    may also reduce local reactions, but we have not found this necessary in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H947131\">",
"    <span class=\"h2\">",
"     Measurement of baseline tryptase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline tryptase measurements are helpful in assessing a patient&rsquo;s risk for systemic reactions in response to the dose escalation phase of VIT. Baseline levels should be measured after the sting reaction has fully resolved and the patient is in their usual state of health. Baseline serum levels above 11.4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    should prompt an evaluation for a mast cell disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective, observational study of 680 patients receiving honeybee or vespid VIT, serum tryptase values correlated with the risk of adverse systemic reactions to therapy, such that an increase in baseline tryptase from 4.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    to 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    increased the risk for a systemic reaction by a factor of approximately 3.8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/8\">",
"     8",
"    </a>",
"    ]. Of note, this study defined an adverse systemic reaction as systemic symptoms requiring any measure or medication for treatment, as determined by the supervising clinician.",
"   </p>",
"   <p>",
"    The measurement of baseline tryptase is also useful in assessing other aspects of a patient&rsquo;s risk. Specifically, elevated baseline tryptase is associated with more severe reactions to stings in general, more frequent treatment failure (ie, failure to achieve protection), and a greater risk of relapse after stopping VIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should wait 30 minutes after each injection, as systemic allergic reactions to the injections are most likely to occur in the half hour after administration. In addition, VIT should be administered by staff who are trained to recognize and treat systemic allergic reactions, and in a setting equipped to manage anaphylaxis. In most cases, VIT is given in the prescribing allergist's office, although exceptions are sometimes made. The risks associated with administration of immunotherapy in remote locations are reviewed elsewhere. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Systemic reactions to VIT'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=see_link\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Alterations in venom extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;One should be cautious if a switch is necessary from the venom of one company to another once a patient has begun VIT, because source materials may vary and the venom products may not be equivalent. Changing venom manufacturers should be avoided if at all possible. Methods for changing venom extracts in a patient already undergoing VIT have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Initial",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIT is traditionally initiated with a dose between 0.001 and 0.05 mcg of venom (",
"    <a class=\"graphic graphic_table graphicRef51030 \" href=\"mobipreview.htm?36/46/37612\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64856 \" href=\"mobipreview.htm?9/30/9709\">",
"     table 2",
"    </a>",
"    ). However, a higher initial dose of 1 mcg is also well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/11\">",
"     11",
"    </a>",
"    ]. This relatively wide range of starting doses necessitates that clinicians use judgment in choosing a starting point for an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dose of 100 mcg per injection (or 300 mcg for the mixed vespid preparation that contains three venoms) was initially chosen for both adults and children because it represented approximately twice the venom content of a honeybee sting, or three to four times that of a vespid sting. This dose has been used as maintenance in the majority of published protocols, and is recommended in the Hollister-Stier Labs and ALK-Abello Labs prescribing information. Studies of lower or higher maintenance doses in adults and children are more limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One center reported a ten-year experience with a maintenance dose of 50 mcg, in which most patients received treatment with a single venom (the majority received yellow jacket venom) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/4\">",
"       4",
"      </a>",
"      ]. There were 258 subsequent stings, of which only 3 resulted in systemic reactions. However, a smaller prospective study compared the outcomes in patients treated with 50 mcg to patients treated with 100 mcg, and found that the lower dose protected 79 percent of subjects from systemic reactions on challenge, while the higher dose protected 96 to 100 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/12\">",
"       12",
"      </a>",
"      ]. Therefore, we suggest a maintenance dose of 100 mcg for adults.",
"     </li>",
"     <li>",
"      Doses higher than 100 mcg per injection are occasionally needed to achieve protection. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment failure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Lower venom doses may provide adequate protection in children. A small study found that children produced a more vigorous IgG response to VIT (approximately twice that of adults), suggesting that one-half the dose of venom might be protective in this age group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. A retrospective study found that 50 mcg of honeybee venom (single venom VIT) protected children from recurrent systemic reactions in 94 percent of field stings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/15\">",
"       15",
"      </a>",
"      ]. In another report of 54 children treated with 50 mcg maintenance doses of various venoms, 21 were stung during or after a five-year course of VIT and none had a systemic reaction, including several with initially severe reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/16\">",
"       16",
"      </a>",
"      ]. Thus, both 50 and 100 mcg appear to be effective maintenance doses in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choice of protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various schedules of injections may be used, and each manufacturer provides a suggested injection schedule in the package insert. The choice of schedule is based upon the urgency of the patient's need for treatment, convenience, and the clinician's experience and comfort with specific protocols:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Traditional protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional protocols involve one to three injections per week and reach maintenance doses in two to four months. Traditional protocols are widely used in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The schedule provided by Hollister-Stier Labs in their packing insert involves once weekly injections. Maintenance is reached in 15 weeks (",
"      <a class=\"graphic graphic_table graphicRef51030 \" href=\"mobipreview.htm?36/46/37612\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The schedule provided by ALK-Abello Labs is more rapid, requiring three injections per week and reaching the maintenance dose in 8 weeks (",
"      <a class=\"graphic graphic_table graphicRef64856 \" href=\"mobipreview.htm?9/30/9709\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two approaches above are equally effective and the frequency of systemic reactions is equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2\">",
"     2",
"    </a>",
"    ]. However, at least one study found that there were more systemic reactions overall in patients following the slower regimen, presumably because they received more injections during the build-up phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Accelerated protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated protocols include \"rush\" and \"ultra-rush\" schedules, although these terms are not strictly defined. Accelerated protocols are popular in some European centers and US military hospitals, and offer certain advantages, such as the rapid achievement of clinical protection for the patient at very high risk for recurrent sting (eg, a beekeeper) who suffered a severe initial reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Rush schedules also require fewer visits, which is helpful for patients who do not live near a medical facility.",
"   </p>",
"   <p>",
"    Rush protocols are generally effective and safe. Systemic reactions do not appear to be more common with most rush protocols for VIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. As an example, a two- to five-hour regimen of VIT was described in which 10 gradually increasing doses were administered at 10 to 15 minute intervals to achieve a total dose of about 55 mcg per venom by the end of day one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/19\">",
"     19",
"    </a>",
"    ]. This was followed by an accelerated build-up over three weeks to a maintenance dose of 100 mcg. Patients were not routinely premedicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/21\">",
"     21",
"    </a>",
"    ]. Among 77 patients treated with this protocol, 5 percent developed diffuse urticaria on day one, but treatment was otherwise uncomplicated and all completed the procedure. In fact, several studies have found that rates of systemic reactions are actually lower with accelerated compared with conventional schedules for VIT, and accelerated protocols are sometimes used for patients who cannot tolerate conventional schedules because of frequent systemic reactions. Thus, most rush VIT can be performed in a properly staffed and equipped outpatient clinic.",
"   </p>",
"   <p>",
"    Ultra-rush protocols, in which the maintenance dose is reached in one or two days, may carry an increased risk of systemic reactions and are usually performed in the hospital setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/8,22\">",
"     8,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Interval between maintenance injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance dose of 100 mcg is given every four weeks initially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2,23,24\">",
"     2,23,24",
"    </a>",
"    ]. In most patients, the interval between maintenance injections can be lengthened further without impacting the efficacy of VIT. There is no specific test to identify patients in whom this is appropriate. Rather, it has been safely accomplished in patients who have not experienced systemic reactions to either the injections or to subsequent stings.",
"   </p>",
"   <p>",
"    Several approaches to lengthening the period between maintenance injections have been described, although these have not been compared directly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2011 update to the practice parameter published by the Joint Council of Allergy, Asthma and Immunology (a group representing the leading American allergy societies) notes that a maintenance interval of four weeks is recommended for indefinite treatment in the US Food and Drug Administration approved product package inserts. However, it states that &ldquo;experts in the field support the regimen of a four-week maintenance interval for 12 to 18 months followed by a six-week interval for 12 to 18 months and then eight-week intervals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/23\">",
"       23",
"      </a>",
"      ].&rdquo; As examples, the author of this topic has the following approach: every four weeks for one year, then every six weeks for one year, then every eight weeks for one year, then extend some patients at 10 to 12 week intervals. The section editor&rsquo;s approach is similar, but progresses every 18 months, instead of yearly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least two studies support longer maintenance intervals and advancing to those intervals more rapidly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One observational study started with either conventional build-up (weekly over three to four months) or a three-day rush protocol, then lengthened the interval between maintenance injections as follows: once at one month, once at six weeks, once at two months, and three-month intervals thereafter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/25\">",
"       25",
"      </a>",
"      ]. While on three-month intervals, 36 patients experienced 49 field stings, 47 of which were tolerated without a systemic reaction. The other two stings resulted in mild systemic reactions that resolved without treatment.",
"     </li>",
"     <li>",
"      In another observational study, 186 patients receiving single venom VIT were built-up to maintenance over three weeks, then given the choice of conventional intervals of four to six weeks between injections or extended intervals. In the latter group (76 patients, one half of which were allergic to honeybee), the intervals between maintenance injections were lengthened in a stepwise manner until an interval of three months was reached after 4.5 months of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/26\">",
"       26",
"      </a>",
"      ]. Three-month intervals were continued until the start of the fifth year of VIT, at which point the interval was extended to four months. While receiving every three-month maintenance injections, patients in this cohort sustained 205 stings, 7 of which resulted in a systemic reaction. After four years of VIT, the patients getting injections at four-month intervals sustained 39 stings, 1 of which resulted in a systemic reaction. In the conventional group, there were 167 stings, 11 of which resulted in a systemic reaction. Thus, the three-month interval was as effective as the four to six-week interval at maintaining protection from recurrent systemic reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intervals of longer than three to four months have not been determined to be safe. Specifically, the authors of one of the above studies determined that a six-month interval was not adequate to maintain protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In light of the above studies, it is reasonable to extend the interval between maintenance injections in those patients who have not had systemic reactions to stings, using one of the approaches above. We suggest extending this interval to six to eight weeks in most cases, and up to 12 weeks at the discretion of the allergist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS AND SAFETY OF VIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom immunotherapy (VIT) is well tolerated by most patients. The most significant adverse effect of VIT is a systemic allergic reaction to the venom injections. Local reactions at the site of administration are far more common, although these are not dangerous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Systemic reactions to VIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 3 to 12 percent of patients have treatment-induced systemic reactions; the majority of these reactions are mild and easily treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/12,28\">",
"     12,28",
"    </a>",
"    ]. This systemic reaction rate is similar to that seen in conventional pollen immunotherapy when effective immunizing doses are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients receiving honeybee VIT and those with elevated baseline tryptase measurements are at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/8\">",
"     8",
"    </a>",
"    ]. Systemic reactions do not appear to be more common with most rush protocols.",
"   </p>",
"   <p>",
"    The majority of systemic reactions to VIT occur in the dose-escalation phase of treatment. For this reason, VIT is best administered in an allergist's office until the maintenance dose is reached.",
"   </p>",
"   <p>",
"    If a systemic reaction occurs, the patient should be evaluated by a clinician as soon as possible after the event, to determine if there were any patient-related or external factors that may have contributed to the reaction, such as a dosing error, failure to premedicate, or an increase in the patient's baseline asthma or allergy symptoms.",
"   </p>",
"   <p>",
"    A baseline serum total tryptase should be measured, if not done in the past. If tryptase is persistently elevated and the patient is found to have an underlying mast cell disorder, then VIT should be continued because the patient is at high risk for severe reactions to stings. In this situation, pretreatment with one or more doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    (ie, anti-IgE therapy) can help the patient tolerate continued treatment. The use of omalizumab in patients with mastocytosis and venom allergy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39817?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prognosis of systemic mastocytosis\", section on 'Venom immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients will not have elevated tryptase. In this setting, the schedule should be interrupted and adjusted when a systemic reaction occurs. We typically ask the patient to return one week later and administer one-half of the problematic dose as the next injection. If tolerated, the dose is increased on a weekly basis until the patient again reaches maintenance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1288269\">",
"    <span class=\"h2\">",
"     Recurrent systemic reactions to VIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients experience repeated systemic reactions to the venom injections. In this situation, the nature of the patient&rsquo;s symptoms should be carefully evaluated and a serum tryptase should be obtained after the reaction (ideally 30 minutes to 3 hours from the onset of symptoms) if there is doubt about whether these symptoms are anaphylaxis. In the experience of the author and section editor, a large proportion of these patients have constitutional symptoms that are not anaphylaxis and may be related to release of inflammatory mediators or cytokines at the local injection site. Most of these reactions will resolve spontaneously with further escalation of the dose. However, other explanations for recurrent reactions to VIT are extreme sensitivity to venom or the presence of an underlying mast cell disorder (as discussed previously).",
"   </p>",
"   <p>",
"    When recurrent systemic reactions to VIT occur in a patient (with",
"    <strong>",
"     no",
"    </strong>",
"    evidence of an underlying mast cell disorder) who has not yet reached the full maintenance dose, we suggest attempting to get the patient to tolerate a full maintenance dose. This can usually be achieved either by performing a two-day rush protocol to reach maintenance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/30\">",
"     30",
"    </a>",
"    ], during which the patient is hospitalized, or by administering one or more doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    (ie, anti-IgE therapy) and then continuing dose escalation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A less serious, but more frequent problem with VIT is the large local reactions that occur in 25 percent of children and 50 percent of adults, usually at doses of 20 to 30 mcg of venom. Although bothersome, local reactions do not predict an increased risk of future systemic reactions to treatment. The best way to manage these is to reassure the patient and proceed with the injection schedule, as these reactions generally do not continue to occur at the higher doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a patient is experiencing significant discomfort",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inconvenience because of large local reactions to the injections, one or more of the following may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply cold packs to the site of the injection(s) immediately after administration.",
"     </li>",
"     <li>",
"      Make sure that the patient is taking an antihistamine several hours before the injections are administered.",
"     </li>",
"     <li>",
"      Divide the problematic dose(s) between the patient's arms, such that half the volume is delivered to each site. As the dose increases, it should be again given as a single injection.",
"     </li>",
"     <li>",
"      Consider adding premedication with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      , 10 mg orally, several hours before the injections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We have also had some anecdotal success in reducing large local reactions at a specific step in VIT by giving the same venom dose using a smaller volume of a higher concentration venom solution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Long-term safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;No long-term toxicity or side effects have been associated with VIT thus far.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MONITORING VENOM IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We usually assess patients after the initial four to six weeks of VIT and then again at six months. Patients who are tolerating VIT without difficulty can generally be reassessed annually after the first year of treatment. At these visits, the patient's injection schedule should be reviewed, noting that dose and frequency of injections have reached the desired parameters. The patient should be questioned about any stings that may have occurred since the last visit and the symptoms that resulted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Assessing effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no simple test to determine with certainty how well VIT is protecting a given patient from a future sting reaction. One study using sting challenges suggested that most patients are protected from recurrent systemic reactions after six weeks of conventional (non-rush) VIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/34\">",
"     34",
"    </a>",
"    ]. The following tests provide some information about how well VIT is working, but none of them is conclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Venom-specific IgG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom-specific IgG may be measured, and a serum level of &gt;3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is characteristic of patients who are protected from repeat stings in the first three years of venom immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/35\">",
"     35",
"    </a>",
"    ]. However, values &lt;3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    may also be seen in patients with adequate protection, and after four years of VIT, most patients are protected from recurrent systemic reactions regardless of their venom-specific IgG level. Thus, venom-specific IgG must be interpreted in the context of the patient's other clinical and laboratory data. The utility and cost effectiveness of measuring venom-specific IgG routinely is unclear, since there are so few treatment failures with venom immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/36\">",
"     36",
"    </a>",
"    ]. We do not measure venom-specific IgG in all patients in our practice, but rather use this determination to assess patients with apparent treatment failures. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Venom-specific IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom specific IgE is used in research, but is NOT routinely used in clinical practice to monitor the progress or success of VIT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Venom skin tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over time, venom skin tests tend to become smaller and will revert to negative in a significant proportion of patients. In children, 45 percent of those who had received three to six years of VIT developed negative venom skin tests to one or more venoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/37\">",
"     37",
"    </a>",
"    ]. In adults, 20 percent had negative venom skin tests after five years of VIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts repeat skin testing when deciding whether or not to stop VIT after five years of treatment, although this practice is not based on controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2\">",
"     2",
"    </a>",
"    ]. If the patient is interested in discontinuing VIT and skin test reactivity is clearly diminished, then most clinicians will stop treatment after consideration of the other criteria and risk factor described below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Duration of therapy'",
"    </a>",
"    below.) If skin reactivity has not decreased or has increased, the patient is generally treated for an additional year or two and then reassessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Sting challenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sting challenges are frequently used in research, but are not recommended for routine clinical practice. These procedures are associated with some risk, and the lack of response on a single sting challenge does not guarantee that the patient will not react to a subsequent sting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure (ie, recurrent systemic reactions to stings despite VIT) may be seen in patients with indolent systemic mastocytosis or other mast cell disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. A serum tryptase level should be obtained as an initial screen for an underlying mast cell disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing the maintenance dose up to 200 mcg is effective in most individuals who experienced sting reactions while receiving the 100 mcg maintenance dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians measure venom-specific IgG in such patients, since a level &lt;3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is consistent with incomplete protection. However, aside from observing the response to a subsequent sting, there is no entirely reliable way to identify patients who are not adequately protected by standard doses of VIT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients remain sufficiently protected after completing five years of immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/38,43-45\">",
"     38,43-45",
"    </a>",
"    ]. After discontinuation, recurrent reactions are rare for a year or two, after which there is approximately a 10 percent chance of a systemic reaction with each subsequent sting. Indefinite VIT is considered for patients with any of the following characteristics, which may account for more than one-third of all those receiving VIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/5/39000/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reactions to past stings were life-threatening",
"     </li>",
"     <li>",
"      Honeybee venom allergy",
"     </li>",
"     <li>",
"      Systemic reactions to the venom injections",
"     </li>",
"     <li>",
"      Anxiety concerning the residual risk of a repeat reaction",
"     </li>",
"     <li>",
"      Those requiring higher venom doses for adequate protection",
"     </li>",
"     <li>",
"      Patients with elevated baseline serum tryptase or systemic mastocytosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39817?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment and prognosis of systemic mastocytosis\", section on 'Venom immunotherapy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients on indefinite VIT, the risk of recurrent systemic reactions is believed to remain low (ie, less than 5 percent per sting).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom immunotherapy (VIT) is administered to patients with past systemic allergic reactions to stings of honeybees, yellow jackets, yellow hornets, white-faced hornets, and wasps, for the purpose of prevent recurrent reactions. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most commonly, the patient is treated with all the venoms relevant to a geographic location to which that individual tested positive. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Venom selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest premedicating all patients with an H1 antihistamine prior to each venom injection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Premedication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Schedules of injections vary, but may be divided into traditional and accelerated (rush and ultra-rush). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiating VIT, we recommend measurement of baseline tryptase values in all patients with severe reactions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reactions involving hypotension. The utility of measuring tryptase in patients with mild systemic reactions is less clear. (See",
"      <a class=\"local\" href=\"#H947131\">",
"       'Measurement of baseline tryptase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 3 to 12 percent of patients have treatment-induced systemic reactions with both traditional and rush schedules; the majority of these reactions are mild and easily treated. Doses should be reduced temporarily following a systemic reaction. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Systemic reactions to VIT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local reactions to the injections occur in 25 to 50 percent of patients and are not associated with an increased risk of a systemic reaction. Local reactions do not require dose adjustment. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Local reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no one accepted approach to monitoring VIT, and no simple test to determine with certainty how well VIT is protecting a given patient from a future sting reaction. However, most patients do not experience recurrent systemic reactions to stings once receiving VIT, so this is not a common clinical problem. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Monitoring venom immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have not experienced systemic reactions to either the VIT injections or to subsequent stings, we suggest lengthening the interval between maintenance injections to six to eight weeks in most cases, and as long as 12 weeks at the discretion of the allergist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There are several approaches for doing this. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Interval between maintenance injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients are protected after five years of VIT, but up to one-third may have factors which lead the patient and clinician to prefer continuing treatment indefinitely. Candidates for lifelong VIT include those with life-threatening past reactions, honeybee venom allergy, reactions to the injections or a recurrent sting during therapy, mastocytosis or elevated baseline serum tryptase, or the desire to reduce the risk to the lowest possible level. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/1\">",
"      Graft DF. Insect sting allergy. Med Clin North Am 2006; 90:211.",
"     </a>",
"    </li>",
"    <li>",
"     Golden DBK. Insect allergy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et aL (Eds), Mosby, Philadelphia 2009. p.1005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/3\">",
"      Finegold I. Issues in stinging insect allergy immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008; 8:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/4\">",
"      Reisman RE, Livingston A. Venom immunotherapy: 10 years of experience with administration of single venoms and 50 micrograms maintenance doses. J Allergy Clin Immunol 1992; 89:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/5\">",
"      Brockow K, Kiehn M, Riethm&uuml;ller C, et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997; 100:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/6\">",
"      M&uuml;ller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/7\">",
"      W&ouml;hrl S, Gamper S, Hemmer W, et al. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007; 144:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/8\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/9\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/10\">",
"      Haeberli G, Br&ouml;nnimann M, Hunziker T, M&uuml;ller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/11\">",
"      Roumana A, Pitsios C, Vartholomaios S, et al. The safety of initiating Hymenoptera immunotherapy at 1 microg of venom extract. J Allergy Clin Immunol 2009; 124:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/12\">",
"      Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980; 92:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/13\">",
"      Golden DBK, Kagey-Sobotka A, Hamilton RG. Human immune response to Hymenoptera venoms. J Allergy Clin Immunol 1983; 71:140 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/14\">",
"      Graft DF, Schuberth KC, Kagey-Sobotka A. Immunologic effects of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1983; 71:140 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/15\">",
"      Houliston L, Nolan R, Noble V, et al. Honeybee venom immunotherapy in children using a 50-&mu;g maintenance dose. J Allergy Clin Immunol 2011; 127:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/16\">",
"      Konstantinou GN, Manoussakis E, Douladiris N, et al. A 5-year venom immunotherapy protocol with 50 &mu;g maintenance dose: safety and efficacy in school children. Pediatr Allergy Immunol 2011; 22:393.",
"     </a>",
"    </li>",
"    <li>",
"     Muller UR. Insect sting allergy: Clinical picture, diagnosis, and treatment, Gustav Fischer Verlag, Germany 1990. p.130.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/18\">",
"      Goldberg A, Yogev A, Confino-Cohen R. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int Arch Allergy Immunol 2011; 156:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/19\">",
"      Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994; 73:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/20\">",
"      Thurnheer U, M&uuml;ller U, Stoller R, et al. Venom immunotherapy in hymenoptera sting allergy. Comparison of rush and conventional hyposensitization and observations during long-term treatment. Allergy 1983; 38:465.",
"     </a>",
"    </li>",
"    <li>",
"     Bernstein J, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/22\">",
"      Brehler R, Wolf H, K&uuml;tting B, et al. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/23\">",
"      Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/24\">",
"      Bonifazi F, Jutel M, Bil&oacute; BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/25\">",
"      Goldberg A, Confino-Cohen R. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J Allergy Clin Immunol 2001; 107:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/26\">",
"      Simioni L, Vianello A, Bonadonna P, et al. Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimen. Ann Allergy Asthma Immunol 2013; 110:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/27\">",
"      Goldberg A, Confino-Cohen R. Effectiveness of maintenance bee venom immunotherapy administered at 6-month intervals. Ann Allergy Asthma Immunol 2007; 99:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/28\">",
"      Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/29\">",
"      Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982; 69:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/30\">",
"      Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 2003; 91:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/31\">",
"      Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/32\">",
"      Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62:963.",
"     </a>",
"    </li>",
"    <li>",
"     Golden D, Graft D, unpublished observations from personal practice experience.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/34\">",
"      Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/35\">",
"      Golden DB, Lawrence ID, Hamilton RH, et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992; 90:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/36\">",
"      Reisman RE. Should routine measurements of serum venom-specific IgG be a standard of practice in patients receiving venom immunotherapy? J Allergy Clin Immunol 1992; 90:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/37\">",
"      Graft DF, Schuberth KC, Kagey-Sobotka A, et al. The development of negative skin tests in children treated with venom immunotherapy. J Allergy Clin Immunol 1984; 73:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/38\">",
"      Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/39\">",
"      Franken HH, Dubois AE, Minkema HJ, et al. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol 1994; 93:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/40\">",
"      Fricker M, Helbling A, Schwartz L, M&uuml;ller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/41\">",
"      Gonz&aacute;lez de Olano D, Alvarez-Twose I, Esteban-L&oacute;pez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/42\">",
"      Ru&euml;ff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/43\">",
"      Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/44\">",
"      The discontinuation of Hymenoptera venom immunotherapy. Report from the Committee on Insects. J Allergy Clin Immunol 1998; 101:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/5/39000/abstract/45\">",
"      Lerch E, M&uuml;ller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101:606.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4096 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-29E1B55F6D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39000=[""].join("\n");
var outline_f38_5_39000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Venom selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Multiple versus single venom",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H947131\">",
"      Measurement of baseline tryptase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Alterations in venom extracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Initial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choice of protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Traditional protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Accelerated protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Interval between maintenance injections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADVERSE EFFECTS AND SAFETY OF VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Systemic reactions to VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1288269\">",
"      Recurrent systemic reactions to VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Local reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Long-term safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MONITORING VENOM IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Assessing effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Venom-specific IgG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Venom-specific IgE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Venom skin tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Sting challenges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4096|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/14/24815\" title=\"algorithm 1\">",
"      Hymenoptera taxonomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/46/37612\" title=\"table 1\">",
"      VIT schedules 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/30/9709\" title=\"table 2\">",
"      VIT schedules 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=related_link\">",
"      Anaphylaxis induced by subcutaneous allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_5_39001="Tenaculum apple extraction";
var content_f38_5_39001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60758%7EGAST%2F72834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60758%7EGAST%2F72834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tenaculum use for apple extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transanal extraction of a rectal foreign body. Note use of a Richardson retractor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Steele, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal foreign body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An apple has been divided so that it can be removed using a transanal approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Steele, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39001=[""].join("\n");
var outline_f38_5_39001=null;
var title_f38_5_39002="Dermoscopic structures 3";
var content_f38_5_39002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Non-melanocytic lesions: Dermoscopic structures and histopathological correlation",
"    <sup>",
"     [1-4]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 775px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAMHAlQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2v4Wf8kx8If8AYHs//RKV1Fcv8LP+SY+EP+wPZ/8AolK39Rna20+6njALxRM6humQCeaALNFeJ+HPih4iPhTwj4n16LSJdK12+/s+SCzt5IpbVy7ojhmkcOuYySMKR2zXRaV8Z/CmqeJbbR7SSd2ubh7aC5DRGOR1/wBgSGVQTwGZAD2NAHpVFeUWPxx0K90aHVYtD8SrYTTR28c8lmio8juyBVcybWIK5OCcA+uQLy/F/RBM0dzpusW3laqNHuWljhK21w2docrIcqcHld3TnHGQD0miuAHxV0E6iYRBqH9njUv7IOqeWn2YXWP9Xnfv/wCBbNvvSaP8V9B1b+1JraK6XTdNEpub2R4AqCP7x8rzPOweg/d85oA9AorgpvibYWvhqLXtQ0XWrPT7rylsWlSAvetJ9xY0WUsCRz84UY71VvPi9ollGUudO1dNRTVItJl0/wAuIzRTSKzISRJsKsFOCrGgD0eivMrj4qWU02mw2sV3Y3T69Hol3a3dmsskcjdspMFUHs4Mg/2TXQ+FvG1v4puZDoul6nPpaTyW51Q+StuWTrgGTzCM8AhMZ9smgDrK5fUP+SnaB/2B9R/9HWNdRXL6h/yU7QP+wPqP/o6xoA6iisTxtq91oPhPVNU06wfUbu1gaSO1TOZCPpzgdTjsK878KfF+wuNIv9U1rXtGntrC0E13b2tlcW1zbylkUR+XIzeYNzbd4IG4jjqaAPX6K8j8fePNetJfBcun6ZqmkR6hrVvbTQXSWryXULjJRcSPsJ6clCCfrWg/xn8MxaQt5PHe2851CXTPsU5hilE0YBfLNIIgoDL8xfHI70AemUV5nZ/GXQL+LR20yx1a9l1NboxQwpDuQ267pFYtIFzjkYJB9at+G/itoniDUNGtbOz1OP8Ati2lubGWaONUm8rPmJ98kMpVhyAOOCRzQB6DRXkuq/GjThZ6/baVYznXdP06a+igkltp422ZzuaGdgNuNzKWVtoOATgF+gfFCa5TwW+uQf2YdZsbi8nBtleNlihEjSJIs5MadcBkdjjBC9aAPV65f4jf8i/af9hjSv8A04W9P8HeLF8V2sd7ZaPqlvpc0Zkt7268lY5gGwNqrIZBnkjcg4H0yz4jf8i/af8AYY0r/wBOFvQB1FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcv8LP8AkmPhD/sD2f8A6JSuorl/hZ/yTHwh/wBgez/9EpXUUAFFFcL8V/GN34NtvDk9nBFMmoazb2FwHhklYQuGLGNUO4v8vAwfoaAO6orxnU/i5cW914+kEX2fTdAisXtnm0yb7QTMVDeZDJJETyeOU45+bv1dt8S9Mu/FFx4f06yvr/ULXy1nMb28KqzDPCyzK7YHXaGA9TQB3dFeP+D/AIwyXHhe51TxRpM8Mp1VtMs47JEP2mUthYlUyk+YOck7U9Ca2rv4uaJaWoafT9WF6urJo0tj5cRmiuHBK7v3mwqQpwysaAPRqK8/HxS0r+yr+9fT76F9PvWsLy3uZrS3e3kAz8zSTrGQe21zmucv/jI97eeCpfCmlTX2na5cTQzLKiLMGjxmNMyqocZySSVIIwc5oA9jorxbwh8VLi01HXovFf225tT4pm0WyuooYhHbjP7uN8FWPRvm2seOT0rqbX4raFcajbwrb6ithc6idJh1NokFtJdD/lmPn389AxQKfXg0AegUV418OvijPN4fsIdcF7rXiHUb68itbayhiWRooSSSclEAA7kgn3roY/i3oN1baO+k22palcanHNLHa28aLJEsWfMMnmOqrggj7xz2zQB6JRXlmm/GDSNRu9Ku1kns9Hu9LudSYXNmN6rDIyMTIsxxyhwoRs8cjpW/bePFn8NvrzeH9Xt9M8pJ4prqazgEsbdGG+4G0YIPz7ePfigDtKK8W8R/FldX0XRLzwfczWkh8TWulXySpDITG4fcoZS6FWwMMjHpwa9poAKKKKAPjj9sf/kp2mf9geL/ANHT0Uftj/8AJTtM/wCwPF/6OnooA+n/AIWf8kx8If8AYHs//RKV0d1AtzazQSEhJUKMV64IxxXOfCz/AJJj4Q/7A9n/AOiUrqKAPPfDvwp0jRbfRbV9S1fUdP0aU3FjZ3kkXlRSli28hI1LsCzEbicZ4q9oHw+s/D8pj0bV9ZtNKNy12NMSWPyA7dQDs8zbnnbvx7V1OrTPbaVezxS28MkULusty22JCFJDOeyjqT6V8wa/4p13xR8NvGOl6vqN9f31nZx3MstjJZXOnyDz0yqvDEGU4OdpYnCkk+oB7Tb/AAp0ODwPpnhVLrUzp+n3q30Uhkj81nDs+GOzG3LHoAfemXvwl0K8/tHzbvUx9u1hNbk2yR8TrnCr8n3PmPByfeuJ0TW/EeqeNvDnhrw140UaS3h6O/e5NpbXRkdZ2R0BVVAIA8v228gtk1n6V8S/Esl54f0+61dTqUniuTTr22aCJZPs2V2IV25UHnDDBPPPFAHpY+FWgjUTMJ9Q/s86l/a50vzE+zG6x/rMbN//AAHft9qil+EmgXuuzatrM13ql3LBNbsZo7eEFZVKuT5MUZY4Y4LEkZ45rgYfEGpeMPhp4qXWvFEtr4nktL9H8MwpbI0QRWxGI2jMzAqOTu6NxgjNU/BnjO70Gx+GNtF4jWTw/eWFxFeGUQFIrhLcGO33qgKlWK4Uncc4JNAHqM3wysLrw1FoOoa1rV5p9r5TWKyvAHsmj+40brEGJA4+csMdq57xd8InvILJ9E1KRtUfXrfV9Q1C/dfOlWNXUBAkezK7vlXYF9a4rwt438c+KIfh1Y2/iZbC812DUWurttPhmyYXk2HZhRkBQOCB3Oe+lD438Zy+N7+yutd0jS2sNWS2XTb5hG95a52ho4hA0jl/vB1kAHdQOaAO/g+FGhxm0le71Oa7h1lddkupJI/MuLlem/CBdn+yoWtbwt4Jt/C1zINF1TU4NLeeS4OlnyWtwz9cEx+YBnkAPjPtkV5/8O/HOtah8SJNF1rVP7TErTyQvo1xaXFhHGudok2p50Z443PySOOte2UAFcvqH/JTtA/7A+o/+jrGuorl9Q/5KdoH/YH1H/0dY0AbuqWf9oWMtqbi5tt+P3ttJ5ci4IPDdun5V5tP4P8ABPiK5uZNa8SDxBfazbtpsU095bh2SJxIyQrCqKWVgrHgkY544q18Wb+az8U/DyKJLZluNZEbma2jlYDb/AXUlD/tLg+9eMeBzML/AOG5tc/aBquu+XgA/N5a46+9AHvV38PINQOiHV9f1vUTo97FfWhnNupDx9FYpCu5T3zz7iqMfwj0KEvLbXmqQXw1aXWYbyOWPzbeaQKHVMoVKEKPlZW+tea+Evij4i1KTwBbTa9Zm8u4NU/tdbmKJESWFZGi87CgxhQFJxt45OaxNf8AFOu+KPht4x0vV9Rvr++s7OO5llsZLK50+QeemVV4YgynBztLE4Ukn1APdZfh5ZXOs6VquoavrF9f6ct0scs8sfzidNj7gsYAAH3QoUD0NZmn/B7w9ZW+gwLc6pJFo9rd2kIeVP3iXIcSbyEByPMbBGMcda43RNb8R6p428OeGvDXjRRpLeHo797k2ltdGR1nZHQFVUAgDy/bbyC2TWfpHxO1vU/iDo1nY6rcLpepX9zYS2l41s91BtHyv5aQKYsEnbveTdtORxyAd7pfwa0GxaLzNQ1e7ii0ybSI4p5IQq28u7cPkjU5+ZjuJzzzmrtj8K9Ht20D7Vf6pfx6Jbz2dtFctFtME0XltG+yNSwC5wcg88k14b4Nv5NK+HugWyahDcXg8ZW8Fxp91b20xtAzy/MFaMujtg/MTkbfl2857LTPiF4qm8RadE9/5mrT+In0658OfZ4x5FiB/r/u+aMDneW2nPTg0Aet+DvCa+FLWOystY1S40uGMx29ldeS0cILZG1ljEhxyBuc8H6YZ8Rv+RftP+wxpX/pwt68e8EfEHxXdy+B7rUNZa6j1fVruwurd7aFUKJjYQVQMGGfXBwOOufYfiN/yL9p/wBhjSv/AE4W9AHUUUUUAFFFFABRRRQAUUUUAFFFFABXjmqa54mv/iX430qw8RzabaaNp0N5axLa28kZcxhmEm9CxUnPRgRnrXsdclrHw78M6xq99qd/Yzvd3yJFdGO+uIknRQAquiOFZcAcEYNAHnul/G+6vdK0lLLwzc6lrU2mf2hc28AmwMOUAQRxSHLEZG7aoBALZqhrXi/XLv4k6hO8eoWenad4UbWI7EX8lpJC+3cWePyyryhjs2SBkAG7n7p9Y1TwN4d1K6s7mWwa3ubOD7LBNY3Eto8cP/PMNCynZ/s9KT/hA/Df2i4n/s0CW40z+x5CJ5PmtMY8vG7A6feHze9AHndv8Yr2KwCQ6H9uktvDcevzTXOoLG7odoZfkg2luc5AUH0FV/FfxP1OSPU5fD3n27nwlHrsHnSxGKEu6jO3ySxcBu77DjG0fer0SP4ceFI1lVNKwJdMGjv/AKRLzaDH7v73sPm+971LH8P/AAxGWK6Up3aWNFIaaRgbMYxFgtjsPm+970AcDZfErUdNHhKbxMJdt14fl1W5NpNG6TLHCH3shgVg7cnarqqk4+Yc1PJ8ZprTTo7rUvDqwm70Z9asFiv/ADPNjXnZIfLHltjB43jnrXbWXw+8M2ctjImnyStY28lnbi5u5pwkLrtaPEjsCuOMHIA6Yqvb/DHwjBb3MCaUzRT2psmEt1NJsgJJMcZZyY1yScJtoAzvBHxHl8ReKYNFvdHSxkudFh1uCSO788NFIVG1gUXawLe44r0Suf0rwdoWlavbanp9j5V9baemlxS+dI222QgrHgsQcYHJGfeugoAKKKKACiiigAooooAKKKKACiiigDl/hZ/yTHwh/wBgez/9EpXUVy/ws/5Jj4Q/7A9n/wCiUrqKACuf8XeFLHxT/Y/9oS3Mf9l6jFqcPkMo3Sx52hsg5Xk5AwfeugooA4LxF8LtF1+bxVJeXWoo3iNLVLvypEAQQFdnl5Q4ztGc59sU7VvhlpOseItP1fVLy9uZLC4S5t4jHboEZMbQZEiErKMDguQcDPQV3dFAHnX/AAqTQxp1zYrfaqtq+of2rbKJIs2VznPmRN5efbDlh7Z5rH8W/CN7uysF0HUXOoHxBDrOoX99IvnS7AwO0LHs3DcNq7QvrVbRPGWrXmp+Kf7U177DrlheXEOm+GcW8f2tETMX30Msm890Ye1cpY/ErxU+mGa11v8AtO5fQL6+1GP7NCP7HuY1cxjCoCPmAXbJuJ696APSP+FP6IJ7a8TUdXXVodQk1P8AtHzImmkmcAEsDGY8cDACDHaiz+EGiWOmaNa2OpaxbzaReS3tpdq8LSq8n3gQ0ZQjgdV7VwbeIfHyaF8P5v8AhMIzc+KbiJS/9lQ4tkaIcY/jOTuzlefQcUeIvGXjfTvE+p6NP4l0nSptLhtvIn1MJAmp/KPNkEYgkaQscjZG6Fc4w2DQB28Hw28KamNStbTV7q4dPEP9uXSQ3MTtDd8/umAU7V5+6fm96vWvwp0K31G3mW41FrC21E6tDpjSobaO6P8Ay0Hyb+OoUuVHpya8rg8Uy+GdQ8dSRTXVpPe+KktRcQywxRRFkPMsk0UionqdmePrWJP4l1fxPa+D9W8R64bdNN8UzWD6jCIFjjVVRlmLNGE3fMRkqFIGduaAPabH4SaJp0OnHTb/AFa0v9PnuJ7a/jkiMyed/rEO6MoVPYFSR61l658KlsLHRU8Dxi3vdPhuIBdz6h5TMJR828G3lEm4sxP3CONpHGONn8Y63pX/AAmEuky20MH/AAlENnc6nDZQ7ra1ZTunfagDnp87huv0qR/iD4qkvtNs7PWmn0yfxXHpUGrLbwE3lq33sEJ5ZKnjeigGgDs/Cnwa0nTtE0a21q4mvbiz0yfTJUQhYJEmdnfjG7ILkA5HQHFad78LbK/8NW2g3+va7c6baPC9mkjW+bYxfc2sIcsMHGH3cfnTPgp4i1XX9L8RR65dm9n0vW7nT47ho0jZ4027dwQBc/MeQBXotAHnCfCLRR5jTajq88susxa7JLJJEGe4QNgHEYG07iSAB7EV6PRRQAUUUUAfHH7Y/wDyU7TP+wPF/wCjp6KP2x/+SnaZ/wBgeL/0dPRQB9P/AAs/5Jj4Q/7A9n/6JSuoryD4e/A34dav4B8NalqHh7zr280y2uJ5Pttyu+R4lZjgSADJJ4AAroP+GfPhh/0LP/k/df8AxygDv6K4D/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygDv6K4D/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygDv6K4D/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygDv6K4D/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygDv6K4D/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygDv65fUP8Akp2gf9gfUf8A0dY1kf8ADPnww/6Fn/yfuv8A45XP3vwN+HUXj7RtNTw7iyuNMvriWP7bc/NJHLaKhz5mRgSycA4O7noMAHr9FcB/wz58MP8AoWf/ACfuv/jlH/DPnww/6Fn/AMn7r/45QB39FcB/wz58MP8AoWf/ACfuv/jlRz/AP4WQRmSfw6kcY6s+o3IA/HzaAPQ6K8cPwx+CoujCNEJIOC4vLvYPx8zp710EHwD+FlxEskHh1JI25DJqNyQf/ItRGpGXwu5UoSjuj0OiuA/4Z8+GH/Qs/wDk/df/AByj/hnz4Yf9Cz/5P3X/AMcqyTv65f4jf8i/af8AYY0r/wBOFvWR/wAM+fDD/oWf/J+6/wDjlc/44+Bvw60zRbaex8O+VK+p6dbs3225bMct5DHIOZD1R2GeozkYPNAHr9FcB/wz58MP+hZ/8n7r/wCOUf8ADPnww/6Fn/yfuv8A45QB39FcB/wz58MP+hZ/8n7r/wCOUf8ADPnww/6Fn/yfuv8A45QB39FedL8CPhQ169mugwm7SNZmgGpXPmKjEhWK+bkAlWAPQlT6VN/wz58MP+hZ/wDJ+6/+OUAd/RXnVt8B/hRdGYW2gRTGGQxSiPUrlvLcAEq2JeDgjg+tTf8ADPnww/6Fn/yfuv8A45QB39FedXnwH+FFjayXN7oENvbxjLyzalcoij1JMuBU3/DPnww/6Fn/AMn7r/45QB39FcB/wz58MP8AoWf/ACfuv/jlH/DPnww/6Fn/AMn7r/45QB39FcB/wz58MP8AoWf/ACfuv/jlUv8AhSfwf+3fYv7Js/tnm+T5H9rXHmeZ5fmbNvm53bPnx1289OaAPTKK4D/hnz4Yf9Cz/wCT91/8co/4Z8+GH/Qs/wDk/df/ABygDv6K86uvgP8ACi0EZutAigEsixIZNSuV3uxwqjMvJJ6DvU3/AAz58MP+hZ/8n7r/AOOUAd/RXAf8M+fDD/oWf/J+6/8AjlH/AAz58MP+hZ/8n7r/AOOUAd/RXAf8M+fDD/oWf/J+6/8AjlH/AAz58MP+hZ/8n7r/AOOUAd/RXAf8M+fDD/oWf/J+6/8AjlH/AAz58MP+hZ/8n7r/AOOUAd/RXAf8M+fDD/oWf/J+6/8AjlQ23wH+FF0ZhbaBFMYZDFKI9SuW8twASrYl4OCOD60Aei0VwH/DPnww/wChZ/8AJ+6/+OUf8M+fDD/oWf8Ayfuv/jlAHf0VwH/DPnww/wChZ/8AJ+6/+OUf8M+fDD/oWf8Ayfuv/jlAGv8ACz/kmPhD/sD2f/olK6ivIPh78Dfh1q/gHw1qWoeHvOvbzTLa4nk+23K75HiVmOBIAMkngACug/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAO/orgP+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAPnf9sf/kp2mf8AYHi/9HT0VkftQeDtC8EeP9P03wxY/YbKXTI7h4/OklzIZZVJy7E9FXjOOKKAPsr4T/8AJLPBv/YFsv8A0QleWeKtT8YL43+INnot1qMmn3Bhs1kSRiulEWcMrTJz+73IZ+Rj955fc16n8J/+SWeDf+wLZf8AohK6qgD57g1y8vX8GLdySTSW76XcebJPK7SPJpV4zE5cgEkclQpPUknBFm1+Ll/ZyeDLKE2cn2y30pbu2mjJlH2lY8uksl15sgG/r5UnIIZ85Ne90UAed+MJtWlufC39s2VhabfEMAh+y3j3G9fLm5bdFHtPTgbvrXnngfxpeQa3bXsiQWq6to+jC51C6aWa3tMm6IDszmQs5O1Wd8Z+82cBvoeigDyf4Z/EbWfFPiuXT9QtNPt4RFM72yywLc2jJIFVXQXDyMCCckxRYOOCDWjJ4v1W68Ya5otrqnh3Tby0ZobDTL+F2ur5vIDrKp85P3e84wqtwjcg9PR6QjIIOcH0OKAPGb74paxJ4eOuWi6Pp2nfaYrP/iYlEl81Yma4CLJPCkm2QrHjepHlyH5+BVGDx3rNpe+J70eItC3va2N3Z2OqRtZ5SSKLdIiy3ICKCzZQnl8AuvWvaNG0uz0XTINP02HybSAEIhdnPJJJLMSSSSSSSSSau0Ac18OtffxN4Vt9Slninkd5EaSK38lCVcr8oEsqsOPvLIyt1BrpaKKACuV1L/kqfh7/ALAup/8Ao+wrqq5XUv8Akqfh7/sC6n/6PsKAOqooooAy/EOt2uh2JuLpst0SMH5nPtXj/iXxJe6/Kv2jbHbocpCnQH1Pqav/ABI1IX/iJ4kP7u1HlD69T/h+FctXi4vEynJwT0PUw1BRipPcdHLJGrqjlQ42sB3HXBqzp+pXtg3+hXc0GTzscgH6iq7eV5KbN/m8784x7YqVH32UkWIF2tv3MMOe2Ae/0rkV09GdLs1qj0nwt4puJdaj0y7uor1JEylwi7SGxnB9a70V896XMba9S4SYQyQ/vEJBOSO3HrXs3h/xRp2sRwrHOqXbDmBjhge+PWvWweI51yyep52JocrvFaG9XK/Ev/kXLP8A7DWk/wDpxt66quV+Jf8AyLln/wBhrSf/AE429d5xmf8AG7TLrWPhvf2Fjam7nmurICHyDOCou4SxZByyhQSRxwDyOtcRpdvr3hKGTSI4NS0m1fV5p7260HSPOhSJof3P2WHZKFjZkG9drMrE5IDBj7Br2s2Og6c19qkzRW4dIhsieV2d2CqqogLMxYgAAEnNcdf/ABM0/TvEgh1EXVtozaYL4Sy6ZdLNG3nPGxlUpmOMBQdzqo5znBFAHK6j4p8e2Gi3DXFlq739zocD2IttJMpW882QSGQKjCNjH5TFXO3qF5yK0ru+8e22oTXtpLf3ayarf2kWnTWMawLAkEzW8hcIHAMiRrvL7SGA68nrJvHuj2d1dwX8x8yO+axhjs7e4upJGWGOYgokWdwWTOF3DGDuzkK7/hYnhc/ZDHqTSx3UcMqzRWs0kUaynbGZXVCsW48DzCtAHKfC4apdeONR1LU5NdufN0Syie41XTfse2YSztJFGBFGCq7gf4j833iMUzW9f+INm2vWFjpktz5d61ra3/2XLbbgEwSxgDayQZVXJBz1J+Vs9Z4x8Xjw14i0G1uY3axvkuWmMNpNczAxqhXakQJx8xz8p4HaoNV+JPh620u7urK9S6aCzW+z5M5hETRl0d5I4n2KQp5weeMZIBAORt7PxRpGralc2MupSWl74imhmsnsUeKSBrXP2gny9331UZDBO2Oa5qwsfENppWpyS22sC/vfD2lmLThokb2jypDtkjZRAVQo2cRkrjOMEAAeuX/j3QoNRm02K6le/WV7VCLOdoDcLGZDEZgnl7wqkld2eK5ez+MOnf8ACB6bq88FxPq8lvYS3VnFZ3EQ/wBIkSNniJRt6KzNgruBIC5ywyAc/wCL7jxXqo8ZaS41rULWSKf7IIdOaO3iAlTYmHtkZ2x0ZJpQ2GJCjFek+DW1yHVPEdhrN1d39vaXEQsbu6gSJpkaFGYZjRVYBywyBkdDkiqmgeOre+8S6rpt8wtkF5FbacJLaWJ5N1lHcsJA4+RwGc4YKcLjGQav614tt4fAreItGxeR3CRix3qyLNJK6xxZBAIUu6846HIoA81tdf8AiE9g7RNrUmom0V7yO50ZUis7o3MS+XbkRjzk8tpsnL8KG3Anj0zxNFrGneCL1tL1SWfVrSM3CXFykQM2xt5jYBAgDKCmQoIBznPNZQ8X3lj4su9G1Q6eywJpkayqskW+W5edXwBv7xLtU4HJy/eq2iePtF1fwZHL4oe2aWa1Vr21itJJogJHKJGVAbLP0EZyzdgRQBx+t+JfH93p2l6rpRvLfTNWNxdw+VaGSS1j+QW0brHa3DYZMyHKA5YrvAABjaw8Uf8ACYnVotKlm1H+0ftSuLeRIHk/sHYDllBCGb5MnGDwcHivV4dYGseF7248HmJruFJIbeK7t5IRHOg4jkjbY6844ODg5rNtPF8ulwwW3jC3kt9ZuHmeG1020mvGeBXG1ysIkK4DorE8bs44IoA4i28QeOILCe+s11/V7ezFjPPBe6StrcTOzstxbwr5SblVSr7gDjbjewzVy9vvGupXzx6ppYSOw1TS4PLisRLDOTdh5biMurEKsJi+YH5GDnIKgjqNF+IdhqMWrvLp+sRf2ffS2ZEOl3c/mbXKhhsi5zjJUZ28Z6irKfETwvJFbyRajJIs9v8Aa12WkzFYQ7IXcBMoqsjBi2NuPmxQB5lK/i7XporK9n16fytXs5Uvhp3kwwqJjlkjltY2BVcE5aZAOS3avSPDFzrx8JayurT3J1G0ub2C2u57P95LGjsIpTHGoD5G0/Io3dhzW54e16y8QWrXOmre+QMYa5sZ7beCMgr5qLuGO4yK5yL4neHI7W1fULwxSzWyXbfZra5niiieRo1dpPKAVdyMMuFxjnjBIB5wsnifU7jwzqGsXXixE03VJBLewaYsjBXtJFDxwmxSTbuIQ7omA8w/McBh1dvqfi+w0fQNY1OfVrhJdVePUrOPTA7w2o+0KrCOOMynLeQSRngKQACxPWeMPGEHhjVfD9pc2d3cLq1xLBvtreWZogkLSZ2RoxYkqBjjgluimsXwl8TdLvrCf+3rlLG+hlv9+bWaOAxW87oSsjAozCNUZgrE5J4HQAHP6Br3iu8udMbxJN4k0qzlieSM2eiiWSWX7XMojnHkSeUohEODhchidxxWd4KvvEHhS00m3nPie6sYpdQiv7Z9GL+XKXLQGMxwAsjfMS4LKCwBIGAPW/D3iPTfEK3H9mSXBe3KiWK5tZbaRNwypKSqrYI6HGDXNax8RLNtOtLnw/5s8cmp2dm89zY3EUDRy3KRO0cjKqOQC2CrEZGTkUAczpeofEW80G8umkvo9QtfD1ldw2stjHELm+eObzUYsnYhCUXBB2jKgkNmQa949Phyeaa/1NZFuotgGk3LXToY33pu/s0Ko3BCG8hx1UsMg16gvjrw4YZJjqOyBLSa+814JER4IiBJIjFQHUbl5XOQQRkEVnnUPGt3qOpvY2WmQaULeSTT3uY2aSZ9sflhwJAVDHzScqCBs75oAyfiFb6nq3w28P3CLrUF3De6Ze3SxW8c15GqyxtIzRrGys6cuQiYyv3cZU43h2LxNpGpPqNlNrdzY3viFlms7jT0TzrdrUH7Q2Y1dGLqozlUB42ivRLLxdpkvgvT/E127Wmn3cMEvzKzGMylVVSAM53OF6fpUWpeOvD+nXktpcXdw13Hcm0aC3sp53MoiWUqFjQlvkdWyMjn1BoA8Xv77xz4k0fVbW+h8SrYILC9jEtgGuI3S9jaRB/ocQdlj+fagkGU4ZgSp+gtGfzNJs38+6uN0KnzbuHyZn4+86bU2se42rg9h0riPFPxP0mz0SO48P3I1C8mS2miCWk8sSxTSqoaVkXEWQWwHZTkdO1bE3xB8Mwy3yS38qLZRzySym0m8oiAEzBJNmyQoAcqhY8HjigDq6KpaPqlrrFmLuwMrW7HCvJA8W8f3l3gblOeGGQexNXaAOV+E/8AySzwb/2BbL/0QlcHrHiiTRfFfjqXRNUju9Qgk0qCK0u72W4hgM86xSnyfMAXG9emMHHrg958J/8Aklng3/sC2X/ohKn0bxXaX2oavaXZgsnstU/suHzZxm6fyIpflBA5xIRtGfu5+gB5vL4u8QN420eDVNd0bTYbTUr3S55Wt5I7a7YRwOg2GfAciQhQWbBBIznFGq/E3XtP8GaPrN1c6Nb3OrB2toPsWYx5YO4NLLdwqC3ykDOeoAfqPT7Xxd4bu45pLXxBo8yQyLFK0d7Gwjds4ViG4JwcA+hqF/G/hYPJHH4i0eWdLc3RhjvomkMXl+ZvC7s7dnzZ6Y56UAeXWfxf1291bQYY9P0y2ivrfT5jDczQxNc/aFUyGF5LlG+UsVAWKTJXBIzVVfiprGpaDcOZ9E1Avps13PFpvnRPprpNGipM6zFsuGYgDYw2nqOa9P0D4h+Hdc06zv7TULVbO4sjeySy3cA+zAeXujlAkLK481c8FVPBIJUHT8HS6AdDht/Cd3Z3Wl2pMKG0uRcKhHJUsGPPPQnPNAHkWueNb2/8f6Oxk06W50nVNUWLQ4I2+2/ubK6CPI+8jEgAKgIB84wxwaseGvip4i1e3TbFoUkkt3Y26ukkR8ozuyujxxXUrAjAIZtmfmBUYrrLH4n2d9qusW1rHp88NjNNbRmLVIjO7xRPIxaE4KofLcKVLsdpJUKCRe8P/ELTr60vLvWGtNFtLaOzcz3V2qoTcQLKF3MFAI3bffGeOlAHMzeLvGg1aa1iufDvlxa7FoRZtOmyWa1SZpsef0BbhO4/iHU8/wCJ/jNq+jeG7S6/4lf9qrHdvPbvbBYrjyLqSDMbvcowJ8onYqzMNw4I6+m+M/iBofhrQP7QOo6ZcTSxCaztvtqI14pIGY+pYc9QDXQ6zq+m6JZ/a9a1Gz0613BPOu51iTceg3MQM8HigDmPhk4kk8XOBgNrsxx9Yoq7Wsu38RaLcWoubfWNOltmlSESpdIyGRwGVMg43EMpA6kEetYGqfE7wdp5sS3iHSp4rq7+xmWC9hZIG8t33Snf8q/JjPqyjHNAHZ0Vl2HiLRNR1OfTdP1jTrrUbcFprWC6R5YwCASyA5GCQOR3FalABRRRQAUUUUAFFFFAHxX+2t/yVPSv+wLF/wCj56KP21v+Sp6V/wBgWL/0fPRQB9VfCf8A5JZ4N/7Atl/6ISuqrlfhP/ySzwb/ANgWy/8ARCV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFcrqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FAHVVyvxC1ptK0Yx28my7uDsQjqF/iP+fWuqryD4oyyP4jVXBEaRAJ+ZzXNi6jp0m0b4aCnUSZy88KrdCP7THIGxmUEkDPr9KkawlaW5FsUuI4BueSM/Lj15qnxQCR0NeFddUevZk1pbyXU6wwKGkboCQP51EylWIPBBwalt5Y4hIJIRJuUhSSRtPqKbAIjJidnVMHlRk57UWTS7hdjKltLiS0uYp4WKyRsGUj1FJOYSsXkLIGC/vNxBy3t7UW0DXEvloyK2CRuOAfahJp6A7W1PoHTLkXdhb3A/5aIG/MVz3xL/AORcs/8AsNaT/wCnG3rY8No0Wh2SSAhhEoIP0rH+Jf8AyLln/wBhrSf/AE429fSx2Vzwnua3ibRo/EGi3GmTzvBDOAHZIYZcjOcFZkdCDjuprl7b4X6NBot5pgu9SaG60uTSZGLxgiJ5HclQECqQZGAAAUAABQBWv8RptYg8KTN4beePU2ubSNXggEzpG1zGsrBCCDiMuSSOACeMZrhrvUvGNmXs76+19dOg1O5gbVLTSY7i8eIQxtB+7WFlKF2kUusePkAyOTTEdrY+B9Ns9dGrRT3huBeyX+1nXZ5j26W5GNuduyMEc5znnHFc5F8GPDUNzp88Lz+bZwxQbp7a0uTKsZJUkzQOVPOCY9meO4zWNFqPxElspNQuZNRtrm1i0thp8enxNHcNK4W5DHYzcLyQjjYe+K6D4gal4j0HRopp9aiRbnVba3STS9JYzxQu5DjYzTeY+MY2oOR0OcAA6PxT4WXX73T7yPVtT0q8sVmSKax8ncVlChgfMjcfwjBABHrWHY/D7w0+g69oOm3cws7qzh0i6SCdGa3EUWAOh2yFZAx3ZzkHHPPFT6/4+WxlaSTxDHEsNy+lyw6Kkk99KJiIUu4/KxCCm3nEWQSSVIxSateeLNGHiE6bYa1a3moa3JMJ7O33xjFlagZ/0W4ZkLhwGVQMoQXFAHRXPw91S48bw3K3S23huLUZtUNuLwSl5pIXjYrH9nUoSZGPMzjrhRu42bn4Z6RPpNlYfa9SjSz0220yGVJI96pbypLHJyhBcNGpORtP92uLvLrxzrfgXXZ7+O+S4j0C2mj05tKjdbq6kt382NkkjYth8EoOQcA8ZBs6zrvi/wDt7xP/AMI/c+IpPskM6WVjfaPiG4mHO+KZbdQI0G7ZukdpCBwRjeAdB4p+HA1PRtRtLe/uJr3VL60ubq9uZFSSMRRxxO8XlIoDtFGRjAGXboOK3td0q08S+BjZaFdWwgeOKbT7iFg8KvEyyQsCvVAyJ07dK800rXvHEi2y6re65FpT3LiS7s9IkmvosRApGVksYlKM+751hOOAWHWt/Q/7e0H4A6EunWl5DrNvY2kckQtS9xCu5FlKwkZZ1QuQpHJA4PQgG+vhfTNb1ifVri7J1VJrH7ZDaXKyRQT2u+RE5QNz55JzglSpwuecpfg54cTRJ9Iimv0sLgI00JaJ0kmRwyzlGjK+ZwAeNrAYZWrhIrvxlpVtqs2hjXmtL7Xp5Zr+605oruRBZ2wjbyls5CFLK4yIP4ACVOTXQXGofEGXw1r94Ly9S/stHt57OK000bbq6aF9+Flh3n5tp2bVYNgHAypAPRvBvhmz8J6QdP04hojK0pYW1vb5YgDlYI406Ac7c+pNUvHXgmy8Zpax6leXUENuSVWCK3Y5OPmV5IneNuOGjZCM9c4I5GUeOdO1+5C61rGo2Vrq2nQRpJp1vtuLeYxi4ZmSIHCbmIZSNuDuLVmQ6547kguc3OsQ3htJ2vFn0QmCxmEyCJbZkhLTBlLjIE2AAxxjBAOr1n4XadqsN5bz6tqy2VxfnUvshFtLCkxB3fLJC29Tuztk3gEAjGKu+Ffh5pfhi2WHS7q9G2xewRpPKO1Gmkl3BRGFyGkbAxtwAMHvxtjrvimZNLGr3Pi3TdNeOcvd22krd3EsyyKFVlFmCke3JUtAjHnJ4Ga2t+JvGthZ6/dmbVYrm1tdVmnhm0xFs7NIo5GtZIZjGPNYlYyQXfO5squMUAek+CPB1j4QgvI7Ceeb7XKJZDJHDEoIGPljhjjjX1JC5J6k1kr8MNFXSbzTxdaj5N1pkelO3mJuESSySBh8mN2ZWycYwBx3PIweJ/FVhpOpa7Je6te6Hpr2dyzahpqWk10jBhdRIhiQlV3RuhwCSNu5ga9C8Dahqs9n9i8Q294NVhgiubi4kgVIC0xdvJiYY3GIAIeAfuk5JoAt+JvDkWvS6ZP9uvdPvNNuDcW1zaeWXVmjaNgRIjqQVdhyPpiue1D4feGprGw0XUbqdo2bUPJglnRXnN0XkmAGATt3kjHQAZzXl/i3wf4rvIfiUum2t0NL1ee7knTawkcwW6PB5KYy/mudh29kxz0rSl07Xz5r/wBjT7ree+8kDTRh1OkRKpcbMSZk3Jl92SNnOAAAep+BPBOneDLe6i0x9/2gqXY2drbn5QQAfs8Me7qeWyea5u6+F3hn7VLFq+ozTyatcxSG3lW1gFy0L+fs8uKJBISEO4kM2wHkDmsKLxB40j8aaHZWdjrMGmia2t7qGWyH2fyjAN8ibLUBFDkdbjIII2AYxt+NNO8RveeGJL1rbVbi3ur2QyWGmvHHGp0+4VQ6NJLnLkDJIBLAY9QCbUvAtnqh0LSbbUzeWmh6h5l0Li68y4hh8vclp8q5KNmIkSHOwDlsiu71oX7aTdro/kDUWiYW5uGKxq5HBYgE4HXpzXjHgt/FmmeJJ/M0u+stMvWs3eWCx/1lwunWyiJ02Yig3K6s6L8rLtzGATXQfCDV/Gmo6lcL4uM6x/ZQ0kNxaSxmKfcMiNjaxIUwSMCSU8AhiMmgDrD4LsH+H1t4SlmuPscFtDbrPGQJQ0e0rIMgjduUNyCM9iKq6J8P7LS9ZXVZNT1S/wBQF5JfNNdPF88jwLAchI1AARBgADB9uKwzdeKL7U/ElqNV1nTdWSS4XS7caUraeY1XMMjXBhYEt/EDKDkkbRgZ5+98VeL9W8NWfiTTZ9TtbTUZ3kt9OsrAyzCBY1UfvVtrhVLOHcb1AIZQGUAmgDqIvhLpMFillaavrVvZGK3ingjkhK3PkPujZy0RIIOAdhUEAZFNHwd8NrdaxLC0sK6nFdRSKlrab4/tCsshSYwmYH52wC5AzjGOK5O2/wCEk0eTxlJbX3iOzv7vUY7yKKTSTPFJE0NuGZZYbSUCX5Wj4DhQuShOWr1bwLd3t94T0651SK/ivJEJkW/VVm+8QCwVIwMjBA2KcEZAOaANq2hW3t4oUJKxoEBPXAGKkoooA5X4T/8AJLPBv/YFsv8A0QlYv/CtdvirV9bi1d1fVJpRcQtBuUW8kMUbIh3fJJmIN5g65AZW2jG18J/+SWeDf+wLZf8AohK6qgDyXQ/g/wD2e1j9r1aK8+xyWvlu8Vy7tFA+8Rt5tzIgB/2EQAk4GDitDWPhtf6t4yg1i98TTy2cF6buG0eOU+WpiaPyl/feUB8xIbyt/YsQa9KooA8s/wCFVXc+h2em3+vW8q2eivocDxaeU/cl7dlZwZW3MBb4OMA7ugxz0y+A9GuNZ1u91my0/VIdQuIbmO3urNJFt2jhWLjdnJIXOcDriutooA4G5+HfnSRv/am3Zqd/qOPs+c/aYJYtn3v4fNznvtxgZyMe8+ETSwW5g16SG7tntZIZFjljUGG1+znd5UyP8wy3yupHTkZz6tRQB5NJ8JLmLTrmy0zW7SzhvrKKzvA1jLOT5cskgaJpLgumTIchmf2xXa+LvDt1rF7o2oaZfwWWo6XM8kLXNqbmJg6FGDIHQ5weCGGPfNdJRQB5xL4Ku7/4hyanfiM2KWMUkuYx9nu9Q2SReaIt5YBYmIwzc7kwSVJqvZfDbV7S1sxF4mh86wv4r2xiezmltbcJDLEYxHJcs+0iU8CQAbVwAM59PooA89sfA2uafd6zPpfieLTRexzC3htLKQw280kgfzjFLPIhYfNwixhi7Eg8Y9CoooAKKKKACiiigAooooA+K/21v+Sp6V/2BYv/AEfPRR+2t/yVPSv+wLF/6PnooA+qvhP/AMks8G/9gWy/9EJXVVyvwn/5JZ4N/wCwLZf+iErqqACiiigAooooAKKKKACiiigAooooAK5XUv8Akqfh7/sC6n/6PsK6quV1L/kqfh7/ALAup/8Ao+woA6qvO/i3HELeyk2jzi5APfGP/wBVeiV538XUJt7BsHaGYE/UVz4v+DI3w38VHnAhkaFpQjGJSFLY4BPSrEosVtv3TzvOQpyVAUHuPf61UDMFKgnaeozwaK8FNI9e1yWe3eCOF2aMiVdwCsCQPf0qKkopPyGiWaNEjiZZVdnGWUZynPQ10Pw+09NQ8QJ5oDJCvmYPr2rma9I+FOmyIbi/kBCuNie/PNdOFhz1VoYYiXLTZ6MqhVAHAFct8S/+Rcs/+w1pP/pxt66quV+Jf/IuWf8A2GtJ/wDTjb17x45L8RvEM3hbwpNq1ukbtFc2kTCRGcbJLmOJzhTkkK7EY744PSmDx3oTaTJqMbanJbRTPbzCPSrt5IXUAsJIhGXjwCDllAwR61qeJdEtvEOlHT715khM8FxuiIDbopklUcg8FkAPtnp1rk/EXwq0XXnna6ur5fPvZb502wSoXkjjjYbJYnXAESkHG5TnDDNAG3aeOfDl3EsltqSyq81tbptikJd7hFeHaNuSGVgdw4ADZI2nDdJ8T+G/Fd6lnaSC8liAvIPPs5FRwjACaF5ECyBWI+dCcZHPIqho/wANdD0rU9CvoXvJJdHsUsIVlkUpKqIyJJIoUBpFWSRQeOJG46YTwL8NND8FajJdaMCA0RhSN7S1UxoWBx5qQrM3QD53bPfJAIAGaP8AEC0fxNrej6y4tpbbVfsFm62s3lOpgikUPNgxhyzPgFlJAGB3NuH4j+F5YJJkv59iqjoGsbhWuFdtqmBSmZgWwAYw2c1DcfDrTrrWrm9utQ1Oa0udQXVJdNZovs7XCxrGr8R+ZgBFO3fjIzisG3+B3hWDTp7FQ7QOE8omysg8Oxgy/OLcNL0AIlMgI6gnmgDobj4l+FreGKSS+uyZEmk8tNOuXkjWFgspkjEZaPaSM7gMZz0p/wAQ/Fp8PeErfVNMC3Et7c21rauLeW4QedIqhykXzMApJCjBY4UHLCqNp8PdA0CwmnlvHt7aHTbuzmmMdraxpDMUeSRhFEiAr5Q+bAGM5z1GxqeiaRLoOhaZd3zRWtrc2b2bmZFaaSBlkjXJGGz5fIAyRnGKAI7Hxro39mWk15qSvK88li7rZzQhrmGNnlURsCyYEbnBJ6YyT1x3+KOlzeILTTdNttQuYrvT5L2G8Fhc+WSGjCj/AFWChEmTJuCrjDEEiprj4Z6bPqzXjapq625u7i+WxV4vISaeJ45HH7vfyJGOCxAJ4wMir8ngez83RJbXUdRtZNKsTpqtEYj9otz5e5JNyN18peV2nrgigDK8I/FDRdT8J2GoarctbagdPtru6hFlcIC0oC/uFZSZQZCVGwvzgZJrYj8feHZHtI0u7pri7aZIrYWFx55aIoJFMWzepXzEJBAODnoCRlaj8KtA1HR7LTbuS8kgs9Nt9LhLmNyEhZWRyGQqz5UZyCpGQVwau+Gfh9pXh28065spZTLYrcqgW3trdH8/yt5ZIIo1JHkpggA9c54wAa+s+J9M0fUbewu3u3vbhDIkNrZT3L7AQpdhEjbVyQMnA5rJ1zx3pVtoF5d6bdpLdgXsVqkkMm2S4tUkaRDwOAY25yAccHpTfFXhLSfH0en3cmpytZxfPE1kts4fnqsrRs6HjGY3U+9Ubj4W6XPfTTNqmsC1eW9mSyWSIQxPdo6TMv7vdz5jEBmIB6cZBAL2h/EXw7eaSLrUNVt9OlihhkuPt6PZKplB2lTMF3IxVtrAkHBwTUXinxroj6Tr1laAarPBYSvJGLGa5szmAyBJZVUxAMuPlZhkMPUVa8JeGtO0DWro/wBs3Wqay1nBCxvZIfNhtULiNQkaIAm4yckckHk44S88D2895rLwavqtpZ6wH+22MJhMMrvF5RcF42dW2hT8rAZUHHXIBEfFGgXFtpOm6/AUku0gZFn02b7IZdglVUlZDFkbcgbsgr6ipo/iJ4dk02K/SbUTaTyRxW7/ANlXeblnVmXyV8rMoKozZQMABk8YrG/4VFof/CS2mti91H7XazRTxblt3KtGgRQJGiMgTAzsDhMknbmoY/hhoMS3+lf2zObnUCl3PC1rpx3qhYbvs/2byuWk5k8vcTtG7AxQA/xj8RzpwS30mPF1PcWkKNLp13O8KzK7lpLdY0fO2M4QNuJ67cYOnb/EbRINKhuNWvFEp88yGytbmdESGZomkfEeYk3IclwFByAzAbiunfDjSLCayliutSke1e0kQyzK5Y28ciJuJXJyJGz+GMDisTU/hN4Uvr21tpLthqMSXEqiWGzuZHiluHmb5J4ZAFWSVgGVQcHBJoA19Y8f2ieJtE0fRW+1SXOq/YLyU2sxhjAt5ZCqzACPzAVT5dxOCeO43PEnirSvDZj/ALYe8hicAmdLGeWGMFto3yohROSPvEVgaZ4G0aTV4dQ03Wb2SzstUlvksIJIDbR3e14peke8HLPlN2A2eByKTx/8LtG8cakL3Vrq+jcW4ttkSwOoUMW3J5sTmNsnlkKkgAHOKAOi0rxRperard6fp73c01q8kUsgspxAHRtroJigjLA8EBicg+hqrfeONBsrvU7ee4u86YjyXs0dhcSQ24SLzWDyqhQMEwdu7PIAGSBUOleB7LTvGN14kW8upb64WRCnlW8SYdgfmMUSPJjaADIzkc9yTWf4k+GWl+IdZvtS1G/vxLd2s1mywx20RWOSFoiPMWISOAGJCu7KGwccDABKvxJ8I30v2KS5uj5zxwOlxpd0iDziFj8wvEFVX3AKWwrZ4J5ql4u8f6b4d8Oa1b6JE1vqulafPPaWd3p09vC6wAKfLLKiugyo+RuhGOK2L/wLpl6L/wA2e8H21rFpNrrwbSQSR4+XuVG7rkdMV5tqPgXwFa3Xiea81TXQ1tDNZX8qWAOz7UUJQTJbbp3G9NoLSMobpigD0PSPG1j9r1WDxBqOl6c8WrS6fZLNOsLThVjPAdvmbMnb1HFdjXG+GdU0Kw1A29o2rx3Gv3s13Gt9ptxADKE+ZQXiUL8sRIDHJAJGa7KgAooooA5X4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+K/21v+Sp6V/2BYv/AEfPRR+2t/yVPSv+wLF/6PnooA+qvhP/AMks8G/9gWy/9EJXVVyvwn/5JZ4N/wCwLZf+iErqqACiiigAooooAKKKKACiiigAooooAK5XUv8Akqfh7/sC6n/6PsK6quV1L/kqfh7/ALAup/8Ao+woA6qsvxFpEOs6e9vMOeqn0NalFJpNWY02ndHz/rGlXOlXr29whyDwwHDCqH1r6HuLK3uDmaJHPuK5fxB4Jsr5ZJbZfKuCOCOmfpXmVcv3cH8jvp43pNHkNSeaPs3leVHndu8zHzfTPpWheaDqFrfrayQMXdtqkDg16T4X8I2ltp8TX0CPdEZYnnmuajhKk5NPQ3q4iEEmtTnfAXhSLUITeajGTHn5EPQj1r062t4raJY4UCIvQCnQxJCgSJQqjsKfXsUqUaUeVHmVKjqSuwrlfiX/AMi5Z/8AYa0n/wBONvXVVyvxL/5Fyz/7DWk/+nG3rUzJfiJcana+FLqXRLmW2vg8ex4bR7lyN43KFSKUglcjd5bhc5KnFeYWFz4gi1+DX75fGXnyaHJGkKafFI9xLHNMRG7C1UR5BVk3rETlQRnK17pRQB4d4X1z4g6jLJbXDavBA+o2aJdXGnZkSCSObzuXtYB8rJH83l4UsOWBwd68uvFum6L4i1m41m+MeiXpaO3uLWCNbyziETyMzeWCWZRKFZCoyfYY9TqC+s7a/tJLW+t4bm2kGHhmQOjD0Kng0Acxo+oa1/wr661jUYrufUp4J76Gzt40E0SMGaKBQRguq7R8wOWz16V514b1r4hao8lpPNrdpBJqVmiXkmngyxwPHN5wzJaQr8rInzGIhSw5YEZ9zooA8B8XXvjW/wDCWraVqreIPLk03U7aFrHSBLJqEyzSxxpNiFhGrRCNgyiPdvJDDAr0Txja3bab4Na3s7m4e11O3mljijJZFWGQEn0GSBk4GSK7qigDwTS/E3xFuk1IRQ65GrJYtbtfadvkgdryNJkP+iwK2IWYsF3gAEiTuNXxHr3ifQ/FkFjPq+uCH+2NNs7QnTImt722leMTNLOINofLSLtVkICqQDkmvZqzJvD+jTa1HrE2kadJq0Ywl61shnUYxgSY3DgnvQB5j4D1X4h6lr93Bq8y2TmGbdFeafPJBBIJBsMZW3hRl25GPtEhOQQeCK27u98RQeNLay1rUtUt7AQQGGbRdGMlvdzGRxIsxKTtCoAjH3l4Zju9PRqKAPBNIu/Gmi+HtNsbSHWrOSCwhNhaQaX5sV1cGaTzUuXaMmEBdmPmj4YnLdBujxL42XUU06Kx1Ka/hvtV8xpdNZLWSBY5msx52wIQT5QyrZ4w3JwfXqKAPBbC88RWl9rnigXeuyyWejWE91Nq2mLZiQRTTyXNsgMSDARmwRkgsPnIxXoK3/iRvhRrGrAznxBPY3V9Y26W6tJblkZreEIAd7KNgIIJLZ69K7K+s7a/tJLW+t4bm2kGHhmQOjD0Kng1PQB5BO3j2wubyVNZ1m+js5tMaKGTTbfbcrNKi3KkpCCVjXcflIK87iaw2sfEJRrn+xZftAt7uIJ/Za7CDrIZf3ezaSYhvzjJ+/kn5q97ooA8g0bX/G198RpbOKHVLXSZftif8TOxMkVs6/6lspbwgocHAFxISpGSppfG+n+I11kXElvHql2ulLE01rph8hmN/A20RuZRuCAnliflLDGOPXqKAPD9IuvGuj/8JTBZaZewg3Or3WkotpvjvJmuZWHnMVzGNpVowMK+fvHha6/4Saj4l1C01NvEks8wRo/s/wBqtpYZQSp3hi9pbgjIGNqNjJyTxXoNFAHjtt4i8R2XhCbXNT1LXF1XTfLvNV0280pLe1WJWPnxQSmEb/lyVIlckqvPJpb/AFXxvbP4dluLnVpJLxRPdWFhYDdEZJcrGZTayxYRCEIZ4j8pbccivWr2ztr+2a3vreG5t2ILRTIHUkEEZB44IB+oqegDwLTX8T+G/CMtpY6h4mW9g1W8ae1OjsS0bTzupglSylU79yuSQ65O0GMHFdroOk6tqWneJrLUtISEarPBepNrNtDeQSA21urJJDHIhLhonzwq5wRnpXpFFAHmui+Eb3w9e+EtNtoHu7Sy1C71G5vIUit7W3EsM6iKOEyF1UNKoCgMAMkmu70DUv7Y0a01D7Fe2H2hA/2a+i8qeL2dcnB9s1fooAKKKKAOV+E//JLPBv8A2BbL/wBEJXVVyvwn/wCSWeDf+wLZf+iErqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPiv9tb/kqelf9gWL/wBHz0Uftrf8lT0r/sCxf+j56KAPoX4ZeNNLtfht4Tt5bXxA0kWk2kbGLQL+RCRCgO11hKsPQgkHqCa6X/hPNI/58/En/hOaj/8AGKPhP/ySzwb/ANgWy/8ARCU3UvGsdtqd/Z6fomtax/Z5Vb2awijZIGZQwT55FZ2CsrFYwxAI7kCgB3/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MVpnxPoAu760OuaWLqxjaW7hN3Hvt0UZZpFzlQByScYqra+N/Cl5cQW9p4n0KeeeTyYo4tQiZpJOPkUBsluRwOeRQBW/4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYrUi8S6FNe3tlDrWmPeWSs91At1GZLdV+8XXOVA7k4xWHpXxG8PX82uSnVdJi0jTJoYRqRv4zBM0kYbG/7oIJ24yen4UAWP8AhPNI/wCfPxJ/4Tmo/wDxij/hPNI/58/En/hOaj/8YrbutUgTQp9UtHiu7dLdriNopAVlUKWGGGRg4681y9v4/inXw7sscSarcW9vIPtUZ8jzrSS5BwuWOAm3DKmc5HHUAu/8J5pH/Pn4k/8ACc1H/wCMUf8ACeaR/wA+fiT/AMJzUf8A4xWh/wAJZ4c86xh/t/SPOvv+PRPtke64+Yr+7G75vmBHGeRitqgDlf8AhPNI/wCfPxJ/4Tmo/wDxij/hPNI/58/En/hOaj/8YrqqKAOV/wCE80j/AJ8/En/hOaj/APGK5q/8aaW3xJ0K4Fr4g8uPSdQjIOgX4clprIjCeTuI+U5IBA4BI3DPp9crqX/JU/D3/YF1P/0fYUAH/CeaR/z5+JP/AAnNR/8AjFH/AAnmkf8APn4k/wDCc1H/AOMV1VNd1jQu7BVAySTgAUAcv/wnmkf8+fiT/wAJzUf/AIxR/wAJ5pH/AD5+JP8AwnNR/wDjFYnjj4l2uiSQQaOLbUZn+aRllyiD0yO5rJj+M1v5GZNHm8/j5VnG0+vOM/pXPLFUovlbN1hqkldI61/GuiO4ZrDxGWHQ/wDCN6h/8YqT/hPNI/58/En/AITmo/8AxiuP/wCFzW/ngf2NN5OOW88bvyx/WsyL4x363c7SabbyWzE+Um8qyjtk85/IVLxlFdSlhKr6Hof/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFM8G+OdN8RWHmSyw2V2rbXt5JRn6jOMiusDAgEEEHuK6ITjNXizCUHB2kjlv+E80j/nz8Sf8AhOaj/wDGK5r4g+NNLudBtUjtfEAYatpkmZNAv4xhb+Bjy0IGcA4HUnAAJIB9PrlfiX/yLln/ANhrSf8A0429USH/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFaviXUL3S9NFzp2mtqU3nRRtAjlGCM4VnGFbO0HcRjoDXIXPxRgsYj/aHhzXI5raxtr7UVjWEiyExZQrB5FdyGRh8iHOOByKANr/hPNI/58/En/hOaj/8Yo/4TzSP+fPxJ/4Tmo//ABimQeO9Him1tddvbDRotO1I6ckt5eJGs7CCKXI3bcH97jbz93OeeLuteMNC0qLbNq+mfbZbc3FtateRrJcrtJXYM5YHHBANAFX/AITzSP8Anz8Sf+E5qP8A8Yo/4TzSP+fPxJ/4Tmo//GKp33xD02y0DRdSnezR742ZuIHvFU2cdwARI5I+6OeSADjqK2p/F/hq3sLS+n8Q6PFZXhK21w97Esc5BwQjFsNg+lAFH/hPNI/58/En/hOaj/8AGKP+E80j/nz8Sf8AhOaj/wDGK1E8SaG+tnRk1nTG1gdbEXSGcfLu/wBXnd93np05rmbr4jWlxq1/p3heK28QT2ttDL/oN4JB5kk/leW+xW2BfvMxzgZOOM0AaX/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MVYj8QXSeBJvEN/pUlncR2Ul6bCSQh1CqWVWJUFWKgZBHykkc4rOi8dwy6rolitmA2oT+RK5uYyID9ia6zhSW6ALhwh53AEYJALP/CeaR/z5+JP/AAnNR/8AjFH/AAnmkf8APn4k/wDCc1H/AOMVoJ4r8OvdWVsmvaS1zegNaxC8jL3AJIBQZywyD0z0qbXPEWi6AIjrusadpgmDGP7ZdJDvC4zjcRnG5c49R60AZP8Awnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8JzUf/jFT6b4rs7vxDqelyvbwfZpoYbaRrhf9LaSHzcIOMkLngE5AJqbUPGHhrToYZtQ8RaNawzlxE899FGshVirBSW5wQQcdCMUAUv8AhPNI/wCfPxJ/4Tmo/wDxij/hPNI/58/En/hOaj/8YrWg8Q6LPrMmkQaxp0mrRgl7JLpDOoHXMYO4flS3Gv6NbavDpNxq2nxarMAYrOS5RZnBzgqhO49D0HagDI/4TzSP+fPxJ/4Tmo//ABij/hPNI/58/En/AITmo/8AxitTSPEuhazdTW2j61pl/cwrukitbqOV0HqwUkgfWuX8S/FLQdGn1i0W4tpdR0u5tIJ7eS6jjJWaSJDIvJO1BLlsgcjHHWgDU/4TzSP+fPxJ/wCE5qP/AMYo/wCE80j/AJ8/En/hOaj/APGKvP4v8NJpEeqv4h0ddLkcxJeG9iELOP4Q+7aTweM1evdX02w0z+0r7ULO207aH+1TTqkW09DvJxg5GOaAMP8A4TzSP+fPxJ/4Tmo//GKP+E80j/nz8Sf+E5qP/wAYrTh8TaDPayXMGt6XJbRwi5eVLuMosRJUSEg4Ckqw3dMqfSsPx18RNC8K6dI76lpU2o+eltHZy6hHCTIzqh3k5KKu8MxwdqgnFAFn/hPNI/58/En/AITmo/8Axij/AITzSP8Anz8Sf+E5qP8A8Yq3o/i3RNRlSzXWtEk1ZYRLPZ2moJOY/lBbHRioz94qOMHA6U0eN/ChsZL0eJ9C+xxyCF5/7Qi8tXIyFLbsBsDOOtAFb/hPNI/58/En/hOaj/8AGKP+E80j/nz8Sf8AhOaj/wDGK37nUrG10xtRub22h09YxKbqSVViCHo28nGOeua5PV/iJpcOteHNN0a90bUJNZZzHK+ppHEEUqp2Mqvvcs2FQAbiG5GKALv/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFU/FvxI0Xw7ea5p0ksUmsabpL6qtq9wkf2gBJW8pOS2/ERJ+U4VlPNa1l4z8OXWjSaouvaQLOHatxML2MxwOQPkd84U89DigCr/wnmkf8+fiT/wAJzUf/AIxR/wAJ5pH/AD5+JP8AwnNR/wDjFdHYXlrqFnDd2FzDdWky745oJA6OvqrDgj6VPQB5h8MvGml2vw28J28tr4gaSLSbSNjFoF/IhIhQHa6wlWHoQSD1BNdL/wAJ5pH/AD5+JP8AwnNR/wDjFHwn/wCSWeDf+wLZf+iEpt742jj1G/tdP0PW9WjsJFhu7mxijaOGQgHZhpFdyAwJCK2M880AO/4TzSP+fPxJ/wCE5qP/AMYo/wCE80j/AJ8/En/hOaj/APGK0f8AhKvD32i/g/t7SfP09We8j+2R7rZVOGMgzlAO5OMU2Pxb4ck0yfUo/EGkPp0D+VNdLexmKN/7rPuwDyOCaAKH/CeaR/z5+JP/AAnNR/8AjFH/AAnmkf8APn4k/wDCc1H/AOMVdi8ZeGJbu1tYvEeivc3Sh7eJb6IvMp6FF3ZYHBwR6VaPiDRhbxTnV9OEEtubuOQ3KbXgGMyg5wUG5fm6fMOeaAMj/hPNI/58/En/AITmo/8Axij/AITzSP8Anz8Sf+E5qP8A8Yrb07WdN1TTG1DSb+01CyG7E9rOkiEr1AYHb+tZ1p4y8PzDTo5dY0y2vL+KKWCzlvoTK3mKGUAK5DE54KlgexI5oAq/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFac/ibQYLOK7n1vTIrSaJpo5nu41R41IDOGJwVBZQSOBketQv4x8Mx6VFqkniPRl0yVzHHdtfRCF3HVQ+7BPtmgCl/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMVbfxhoUKzTXWq6fbWMaQyLeS3sAhlWVWZCp35wVUkEgAjlcgHDrrxj4ZtLWyubrxFo0Fvegm1lkvolScAgEoS2GwSOmetAFL/hPNI/58/En/AITmo/8Axij/AITzSP8Anz8Sf+E5qP8A8YqOy+IWgX2r3+l2t3C+oWWoLp8tubmBXLEJ+8VTICUDOF4G7crAKSK1IvFfh2b7d5WvaS/2D/j723kZ+z84/ec/JzxzigDP/wCE80j/AJ8/En/hOaj/APGKP+E80j/nz8Sf+E5qP/xirjeM/C66b/aLeJNFGn+b5P2o30XleYBnZv3Y3Y7ZzV681e2trayuFdJoLyaKKKRJowreYflYFmAYd8LknsDQBi/8J5pH/Pn4k/8ACc1H/wCMUf8ACeaR/wA+fiT/AMJzUf8A4xWppHiXQtZuprbR9a0y/uYV3SRWt1HK6D1YKSQPrXLa98U9B0x9ct4p7ea/0e7tbW4t5LqOMlZpIUaVeSdieeAxIHzKV460Aav/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFXX8Y+GY9Ki1STxHoy6ZK5jju2vohC7jqofdgn2zW3HIksaSROrxuAyspyGB6EGgD4d/a71e21n4k6bcWcd9HGukxRkXllNaPkTTHhJUViORyBjqM8GitD9tb/kqelf8AYFi/9Hz0UAfVXwn/AOSWeDf+wLZf+iEqtc+FdattZ1e78N+IodOttVkWe4hn0/7S0coRULwt5ihSVRchlcZGcdqs/Cf/AJJZ4N/7Atl/6ISuavfH2pQePJNHD6WipqcFgmlvG5vp4XRWa7Vg+BGu5v4CMI2WB4oAZffCqa8srvT31yNdNKal9kVbH99E96kiu0snmfvAvmsQAqE4GScZrU1H4cxXh1MrfJE142mEEWwPlizlV8fe537cdtvv0rgdK+MWv3PhltTiTQ9YlOkx30semxMBp0rTxRmOctMQflkeTBMZAjbJA+YbGg/EDxVrw022sZPD0c1zNer9r2rdRtHDFE6nZBdOEYmQqVMp4AbvigCX/hS0ZjvrZ9ZMlpIlytoZVuZJbYzPvPDXBhIzjIEK7gOoPNa3/CvNWbV21uXxBYtri3sd5E40thbJtt2typh84scqxIIcEH24rn9K+IOuaobGfTorC2u9W/slc3HnTxQ/aIJpHIj8xRwUGNu3P8RPBFTWPizrljo91LPceHtOurO0v5fNu4JGj1Ge2uJIRDAnmqVJEYY5ZyN44OCaAO/0n4daPY6FDbS21jdavFbzQpqr2UYmQymRm2Hqq5lfCg4AOK5+/wDg9BqNhDZXeszi3WW1kcwReW7CGye1wG3HG7fu5BHG0hgSaseH/Hl9ffEYaBd3Wk+U6looLNFnlwIgxMri43RHJPDQ46AMSa9NoA8qvfhTdX2qRX15rkE7SRW0V5D9nuYYZvIbKMscN1GinGOGDgMMgAfLXqtFFABRRRQAVyupf8lT8Pf9gXU//R9hXVVyupf8lT8Pf9gXU/8A0fYUAdVXj/xt8URsg0CzcmQMHuiOABjKp79cn8K9ekdY0Z3ICqCST2FfJOo3LXmoXNzI5dpZGcse+TmuHHVXCHKup2YKmpz5n0K1FRW9zBcbvs8scu04bY2cVjSeJraPWGsWjfh9hk6jP0ryo05S0SPTlUjHVs3qRiFUsxwAMk0pqG7h+0Wzxbtu4YzjP6VK31Le2gyzvYLwMYG3Aeo61tadrmp6dLE9pfXMflMCqiQ7ePbpXPabpos5GcuGYjHC4q1b3MNwXEEqSFDhtpzg1cvdd4bELVWmfV/hbXLbXtHtrq3mjeRo1MqKeUbHII7c5rN+Jf8AyLln/wBhrSf/AE429fOui39xpup211ayNHJHIrZU4zz0NfQ/xEfzPC9hIBjdrGkN+eoW1exhcR7ZO61R5OJoexemzOtrzLxv8Lj4m8Tahqwu9IU3llFZ/wCm6T9qmtdhkPmW8vmr5b/vOu04Kqe1bXxg/wCSf3//AF3tf/SmKuFt/ir4guNe1qyFtoVr9kF6Fgv7uC3e3MIby3lJuTIyttGf3KABgdxHzHqOY3tS+GOoTQXsOn+Kbm2hvL17qdGSYearW0MIV2imjdmHkls7sHeQVNS+HfhvqHh6xey03XrVrW60+2sb37RpzO7+TD5IaNhMuwFcHaQ4Bzjqa5NPijqk1vBqEAtdSuIbPU3PkRPFCGiFoRxFczRSqolZiwZiACo2HdnZt/H+u30lrZaTqHh3UGuNai01NXt7WVrR0e1lmbagmOXRowDiQjnsegBo6H8LW0jTbPTI9aE+nW97aahtntN0rSw7d4Mm/JRtowGBKdASAAKOr/B77ZeXF1ba15clxLemaKSO4WJ4riXzDGRBcRMcZIOWKsP4RXU+APGSa9Yafb6lJAmuzxXMzQwRuEZILgwNIuchQW2/KWJ+bvgmuxoA8p1D4T3eo63aXN54mnfTrWbzIbTZPmJPIaHy0zOYwBuJDeWX7Fm5rf8ABHgu+8P6nFd6hq9rfLBpkWlQR29gbYLHGxYM37x8sc84AHoBXb0UAc94j8I6Rrcd/M+n2Eer3NnLZpqRtUeeJXRk4fhsAMeMjqRXGap8H4NUlb7XrMywvcpcMsMOxvl08WYXO4jBI3kEEEZQggk16pRQB5bcfCy5u9fj1S+1qG4aVrWS8g8m6hile3xsZI4rpEU4VT86yAMMjj5a1PH3hvW9b8X+H7nRpbS2t4LDULa4urm3+0LH53kBQI/MQ7iEfnkDHI5Fd9RQB5jD8K209bJ9H1kQ3NhPZzWj3VqZ1XyLQ222QCRS+5WJ4K4OO1cl4n+GfiPT9Fn0vw9M+p3OqadLpt7dyWkKxKr3Ms27LXCvF/r2ztSQEKOAcV73RQBx2j+EL3TvGd3rKatHHYXDyyNp9tFMiSO+Pnk3zPGWGM7kjQknn0qlq3gCa+8R3d5Hq0UWm3uoWmp3Ns1nvmMtuECBJt42IfKTI2k/ewQGIrvqKAOJ8K+Ak0C78PTpfLL/AGTp9zYkC32ed50scm/7xxgxnjnO7OR3r+IvAN1q+paxJHq9vDp+qT2NzPbyWRkkD20kbDa/mAbWEWCCp65z2rvqKAPMtd+Fj6hfTX1rrb2t42pXF+hCzoirNDFG0beTPE5P7oEMHA5IINbl74MEngPT/DlnLZQGyWERSvFcMkbR4w0e24WVCCPlPmkj1NdjRQB5Rqvwr1W+sJ4P+Es3T32mJpt/cXNi0zyqkskishMoK48wp8xclQOc/Mehn8BpJFeqL5Ue51+31xnFvz+6kicRH5uc+Vjd23dOOe2ooA8p1f4T3mt+ILm+1jxTdXNnKL2NINkoeOO5ieLYuZjEuwOMFYlJ2/NnOaua58PdY1u20g3/AIhtEvdK3pbSWdnc2kZjdArK6xXSuT8owVdR1G0g16VRQBx154JSXwJpnh61uYrV9Oa2lt5VieSJZIHV1zG8jMyZX7pcnH8WRmq3h7wHLpniW21y71SO5vQ97LcLFaeTHI9z9nHyLvYoFFuOCWJLEk+vdUUAcP4w8EXWvanrNxaatDaQavojaLdRSWZmYLibZIjCRdpBmJIIbIGOOtZfiP4WDV72S8g1h7S4VrJ4PLjkRY2t45o+TFKjkMsx+6yEbRyRkV6ZRQBh+CtBXwz4btdKV4pDE0js8QlCszyM7ECWSR+SxJy55z06DcoooA5X4T/8ks8G/wDYFsv/AEQlVn8La3Z6pqs3h7xHFY2Wp3AupYZ9P+0SRS7VVjE/mKFDbRkMrgHOMZqz8J/+SWeDf+wLZf8AohK4rxJ8SNZ07xJ4j0yzfSLm4srS5nsrO3iFzI5igMg84pcB4zuGNphAPADkmgCxf/CSe90m40qXXoV09Le+t7IJp+JYvtTEsZX8z97tyeAEz1OSK2ta+H73euz6xp2pQ2l6Ly2vbZZLPzYo2hgeHDoHXeCshxgqVIGDxXPp8ULvVtZ+x+Gp9FvLd7nT7VLkB5EVriKdpMlXw20xLgDH8QJzyMCHWb/wi/irxBqd9or6tc65/Zi3h0nB+WJG2GSW7RUiwowrSAAg8sWAAB1/iD4c634g12y1DU/FYaK3urS7+yxW06RK8DqxCILnYA23+NXYE5DdqZN8IrWXTPEFk2rXAS/eP7DtQp/Z8KXBuFhXawLL5rEkgqdoUAjaDWT4Y+KOpa2mifb7/wAP+HxdWnnmW+jLLeyi5lhaK3/fqoIEak/M5/eLwRyb3wm+IuteMNfmtNTtNOt4havO0EcsK3FpIJFXy3jFxJIwwxyzRxYIxj5hgA6zwb4Rbw/oep2U13FcXN/M881wguDuZkVMt588zE4Uc7wMAcDqeftPhWlv4fl006qrs9ppVr532XBH2Eqc43/x7emflz/FUM/j3Vm8cS6NDPo8Un9pf2fHpkkEjXoi8neLskSAGLPONgGON+axvCFtqFj+zVqOo2EtrDrN9o8+oC5srVopnkaEtudg5Z5s5/eZHO35eMEA6L/hWMts3iCTSfEFxYzXxCWLJDj+z4mm86aJSrqxEjlskMhA2gEbc1zV38Ode8MW8d7oNzPrOsvcXrki2WRFW5jhVgftN2HBBhGH8xz8xBUis7TPE+s2er+IPEWmavoGsRQ6XpJu5YrdylyDPcptjYTNsZQWBYl/mH3RyB03h74ja1qfxOl8Pz2enwWaXlzatBJLCl0qRhikwBuPMcNtBwIAArZDEDJALXhv4Yy2dpoD32oR/aLGPS2khWHcu+0geMgNu7l8g4429Dnirr/wmv8AUtEn0m18Uy2thcG/MsAglCE3Mzyhtsc8e4oHK4fejDqoo8dfEbWdC8fJollaacluBbMn22WGE3gkch/LeS4jI2gYG2OXLcHGRXM618VdYl0TWNs+iXjrDqoksrLzoriwFs7rHJNIk25Q+1RxsOWBU+gB3Vt8ObqC7dRrcTac+p22rGI2R87zoY4oyBJ5uNrLCONuQT1OMVmp8JJm0gaZda7DJa22lvpNj5enhGSF5I3JmPmHzW/dKMgIOWOMk1h+KvGF7qHjfSLeSbTmk0vxFMkOiRRt9udY7O42zM+/Gx88AR/xL8xwRTPD3xa8SapZq4t9CklluNPgVRLEGga4uFieOSOO5lcYDcOwQ5BBTtQB2HiL4cT6hqmq3+m6rbWV1eXUdzHK1tN5lqVt1h/dvDPEckLk5JBBwQa6TVfDcmo6TodnPqMjy6bdWt09xJGGa4aEgnOCAC2OvbPSuF1Hxd40ttbv7GG58Oslpq1lpG9tOmBdp4I3Mv8Ax8cBWk+5zkDG4HmqJ+IGuC4neb+x49QsrLVI3mmnkt7R5La/hgDFHmCLlWJG5s54DqGOQDtPCvgJNAu/D06Xyy/2Tp9zYkC32ed50scm/wC8cYMZ45zuzkd62ueALnU9Q18rq8Eenaxd2V9LbvZF5Elt2t+A/mAFGW3wQVyC2c8YOt8NvEMvifwwmozzwzyGZ4y8NuIUO04+XbNMrD/aWRlPaupoA8t174TtqWqT6jba29vdSXtzdAbZ0j2Txwo8beTPE5P7gHO8A7iCp4r0Pw/psejaDp2mQ7BFZW8duoQMFwihRgMzMBxwCzH3PWr9FAHxX+2t/wAlT0r/ALAsX/o+eij9tb/kqelf9gWL/wBHz0UAfVXwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCV1VAFLRNKs9D0iz0vS4fIsbSJYYYtzNsQDAGWJJ/E1doooAKxfEfhnTPEaJHq63ksCqUaCO9nhilU4yskaOqyA46OCMZHc1tUUAIAFACgADgAdqWiigAooooAKKKKACuV1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsKAOZ+N3iGWwsLXTLKeWG4uCZJGjbH7sAjafqT+leHEAgg9DXuXxw0D7ZpEWsQhRLZ/LLk4zGTx+IJ/Wvn/WLt7S1LQjMrcKT0FeNi4ydaz+R6+EcVSuvmVdL0O30u7luIJZArA5QngVn6feaHc64/lQYuixKyt0Zs9ua3dOuTd2251wwO1vfiqNr4csbbUDdxq+/duVSeFNZKesvaN3LcPh9mlY0NSkMOn3MgJUpGxBHUcVw/wAML6e5l1E3lzPLtVSPMclQMnPWuu1fWbPTGSO7LkyDoq5496ellaXGmSR2iLFDcpkmNcZz3pQly02pLfqOS5qicXt0LuVliJicEMOGU5rJ8O6O+krc+ZOJWmYHIGPX/Gr2k2Q06xjtldnVM4Jq3WfNa8VszRR5rSktUbHhDT4tU8S6fZ3D7IpZQGPqPSvffiQoTw1ZKvAGs6SB/wCDC3rxf4XaZLqXjKxMakx27ec59AK9q+Jf/IuWf/YZ0n/0429epl8bQbPOxzvNI6qiiiu84QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+E/wDySzwb/wBgWy/9EJVDT/iHZ33jXUtDt1sHisrpbBpBqUQuGnKKxxA2MxjJUsGLb1ICHBIv/Cf/AJJZ4N/7Atl/6ISqp8DZ1Ge6/tH/AFuvpru3yOm23WHys7v9ndu98Y70AU/BvxMstdspbzVIrbRbOLTLHUXnubxfLX7SZQELMFA2+V177ugxzp+LfH+geHvCVxrn9q6VcIbSa5so/t0aC+ZFJCRNk7iSAvyg8noa4+L4NeVo9vaJr8guLa306KGZIZIgHtPPG5vLlV8MJzwrqQVB3GpJfhJdJpd3badrlpaTahptzpl7I1lNcB0mkdy8fm3LOj5c7iXcMecDjAB6bHqNsILB7maG3kvdqwxySAGRyhfYufvHAY4HZSe1VdX1/T9Knjgubm3E7NGGiNxFGyI7FVkIdl+XKt0yTggAkYrN8Y+Ej4i8MWulxahLYXVrJDLBexJl4mTglRnqULr143Z5xisLTvhhBp88zW2pMIjqltfW8RhyLeCBmdbZTu+6GkkwewYDHHIAtn8XfC95/Yk8Wo2EWnais5lubm9ij+yNGFwkgyQGbdwCw7dc103ivxHHofh1NXgiS9hee1hQJLhWWeeOIOGAOQPM3e+McZzXOeH/AIfXOmyaIt5q1td22jJdQ2qrYmNzHMAPnYyMCwweQBkHoKtXXgFbn4Xab4MfUnVLSKyiN5HGUZxbyRvkANlS3l4yGyuc84oA3b7xZ4csED32v6RbKZmtgZr2NAZVxuj5b7wyMr1GaL/xZ4c055l1DX9ItWhJEonvY0MZGzIbLcf6yPr/AH19RXn+ofCGe4trCGPXl2WVrLpyK8E8ayWjsGCSC3uIS7jkFidrA8rnk7H/AAru4tdG1m00fXG0+51G/huzPDDIpWOOGKLyCyyrIVPlk5EisN/XqSAakvxF8LprenaYmr2MsmoWr3VrMl1CYpgsixhFbfy7MTtA67H54pfDmu+EtMsNN0+y1LTLCS//ANLgsZdQieVmuGMpxiRtxZnYjaWU5+UkYrm/DXwvvfD81rPaeIIZJlF9FcGeykkEkV1MkrBS05ZXBjADsz5zkgmpbT4Vpb+H5dNOqq7PaaVa+d9lwR9hKnON/wDHt6Z+XP8AFQB6WxCgk9BXI+G/Hdrr0EN7HpWq2ejzwPcw6ndLCLZ415LFlkZo+Of3gXv6Gt/TbS/ggvEvtSN3JLPLJDIIFj8iNjlI8Dhto43Hk45rzib4RtffbDqGp6bFJPaSW7S6Xo62b3DMVIe5xIyzbSo+Xao5PTNAHc/8Jl4Y/soan/wkei/2a0vkC7+3ReSZMFtm/djdgE4znANP0/xb4c1J5007xBpF28EP2iVYL2OQxxYB3thuFwQcnjkVzVv4AupdYttW1bV7e4v01WLUpPs9h5MTCO2kgVFQyMQf3m4uWboBgDGM6++EdteaLZabJqjRx29pqFqXht9jObmaOUNw3Gwx4x/FnqtAHoWi6zpeuWputE1Ky1G2DFDNaTrMgYdRuUkZ5HFc74n+Ivh3RdC1a/t9W0q+uNOwklrHfxBlkLbVRzk7Pm6kjjB44qTwF4Rk8MRaibu8jvbq+dGknT7Tubau0bjPcTMSBxkMOMccVy0HwlnFha2Vxr0T22n2a2Fh5eniN0iFxFMTK3mHzX/cquQEHLHGSaAPSNDvW1HR7O8c2ZNxGsmbO4+0QkHkFJNq71I5BwKvUUUAfFf7a3/JU9K/7AsX/o+eij9tb/kqelf9gWL/ANHz0UAfVXwn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QldVQAUUUUAFFFFABRRRQAUUUUAFFFFABXK6l/wAlT8Pf9gXU/wD0fYV1VcrqX/JU/D3/AGBdT/8AR9hQBqeKdK/tvw9f6du2meMqrejdR+oFfLGo2MlvPLaX8BSWNtrxyDkGvr2vH/ih4H1bWPFIvtKgSWKeJQ53BdrKMc/UYrgxtFzSnHdHbg6yg3GWx43DFHCm2JFReuAKfWjrmi6hod0LfVLdoJWG5QSCGGcZFZ1eS007Pc9SLTV0U9U0+HUbVoJxwejAcj6VYgiSCBIoxhEUKB7VVNxctqgiSMC2AO5j1JxWNp39tJ4jdblnezJY5/g29se9aKDcbN+Zm5qMrpb6HT0AEkAcmiu0+Emnpf8AjO1M1uZoIQ0hJXKqQDgn8amnDnko9y5z5IuXY9Q+D+gtpPhsXFzCY7q7O87hhgv8I/rWn8S/+Rcs/wDsNaT/AOnG3rqQMDArlviX/wAi5Z/9hrSf/Tjb19BTgqcVFdDwZzc5OTOqoooqyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+E/wDySzwb/wBgWy/9EJXlPiTU9Xn1fxFpk2vadJcw+LtNey0+4iczQoZbPy5MGXPkZYghVGW3EMM7R6t8J/8Aklng3/sC2X/ohK1J/Emh2+rnSp9Z0yLVAhkNm90izBQpYtsJ3Y2gnOOgzQB5H4i+KniTR9lpLDo63Ed3e2sl/IiQ20rQlNiATXUQRmD5P7xyNpwrc4uz/FHWINcubZ4tKnkWwe7g0ywKXc8jraed5byR3G6M7wRnyGQjbhyXFekw+LvDc+ni+g8Q6PJYmQxfaEvYjHvClyu4NjIVWbHoCe1KfFvhwRzSHxBpAjhjM0jG9jwiBgpZju4XcQMnjJAoA5T4QeNtT8YDVP7SGmPHbLC0cllLASC4bcjxx3M5UjaMFipOT8o2muah8d+JE0i6fSv7LjWzstW1OX7ZHcXLSfZr2WMRqxmBXcq9SSF6BQoCj01/GXhhI7KR/EeirHe/8erG+iAn52/Id3zc8cZ5qa08U+H7y8uLSz13Sri6t1Z5oYryN3jVThiyg5ABBBz0IoA4VviFrC63LpctjbxyxxHVmlWCWVRpvkbgwAI3S+b+7wCAcE47Vy+jfGTVr+PUEabRFhinsUXVXiVbe2inMu6SZI7qUfKYgADKhy43BcV62PGfhc6Z/aI8SaKdP83yftQv4vK8zaW2b92N2ATjOcAmsb4ieLPDVj4Fu9RvNYtngktZLuyS21g2b3xjUsEiljYMdxAHy569D0oA4FPidrEltPqUR0u8nt9P1Rop4ROltP5F9BCj+V5pXDK27JywzgMASDpeI/iRrXh99S03UbrSV1O11CO2iuVstsEyNbLNtImu41jYbsZMp3Y4XJ47GbXPDXw/8PaJHcvHpthfTiKMzXAIV5A0jSSSSNluclnJJJbnrW/Y+ItE1DUpdPsNY025v4l3SW0N0jyoOOSgOQOR270AeCj4i61eadr+tXeqWFqLvwvbahbaTI08bSyBLjzPs7rOrLhlBdkBbbsGVK7j2d/8SNVt/Et5ZI2ks0V5c2o0nypPtscUcLOt27B8eUxUfwAYYYbPFdRe+PbC18eT+HHn0qGOys1vL64u9RWF4gwcgJGVO/AQMxLKFV1POQKr+KPiPp+l6el9pH2TWrR7C/vVmtbxShNrEHKBlDD5s4z29DQByU3xG8TWOm77+Xw2s82l2OqxSuv2aOJZ3dXjIlnVZGAXK5kjB6cV1M/jO8/4VBJ4qsWtrm8FuZY2ktmhidvM252CRzt9CHYHqCQRW5H4x0aKwnu9Vv7LSoIZ1tmku7yFUMhjSTGd/Bw4+VtrcZ24IJ0rfXdIuYxJb6pYSxtMtsGjuEYGVlDLHkH7xVlIXqQQe9AHnEXjHxbZeIbi01OXQri1stZtNKn+zWM0TyieFJN6kzMF2+YBght2DyKxNA+Leua3e6xFpMem6jHa6c2pwbbYRSMkcyLJEyLdSkOY2ON4jYNjKEcV6H4X+IOh6xo2gXF9qGm6Zqer2sVzDps16nnfvOgUHDNzkAhecVsG+0TxFDe6XDqNpeeZE6Tw2t2PMVCzRtyjbl+ZXXIxgqR1FAFXwJrlx4l0eXV3SJNPubiQ6dtRlZ7YHakj5J5chnGAPlZeM5roqhs7aGztILW1jWK3gRY4416KqjAA+gFTUAFFFFAHxX+2t/yVPSv+wLF/6Pnoo/bW/wCSp6V/2BYv/R89FAH1V8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJXVUAFFFFABRRRQAUUUUAFFFFABRRRQAVyupf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYUAdVRRRQB5L8cPD19etZ6rZQvNFBEY5lQZKjOQ2PTk14xX2CRmuE8Q/DDQ9XnkuIvOsriRi7NCRtJP+yePyrzsTg3OXPDc78Pi1CPJM+dpo1liaNs7WGDg1R0ywks5ZczO0ROUXPavfYfg1YiXM2rXTx/3VjVT+fP8q6iD4d+GY7aGFtNSQxjHmMTub3JHWsYYKtZp6G08XSumtT5uhikmlWOFGkkY4CqMk/hX094H0OHQfDtpbpAsVw0avOepZyOcmtPTtKsNNiWOws4LdB0EaAVdrsw2FVF3buzkxGJ9srJWQVyvxL/5Fyz/AOw1pP8A6cbeuqrlfiX/AMi5Z/8AYa0n/wBONvXWcp1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8J/+SWeDf8AsC2X/ohKytQ8AXd1H4n09NYt49D19pZbiE2JNykkkYQlZhIF2ggHa0Z4yue41fhP/wAks8G/9gWy/wDRCVzX/Cfal/wn50cy6SqjVBp40kxP9uMPlb/te7fjy88/6vGP4s8UAW4fh3cz67aaxrOrWt1fQ6hbXrrb6f5ELLBBNEihDIxDZnLFyT90AADGH6t8No7/AEDUrBNRaC5utYbWY7iON02Sb9yq2x1dgBxlXU9CCMV5/YfGbxBN4cj1GIaDqry6bFdz/wBnxMF0uRpo4ylwWn2n5XZ8Fo8bDkgfMNrTviJ4p1aDTo7FvD8Us0OpTvclFuo5EthAU2rBdMqE+cwIMjEYB9iAalp8Lb2zks5bHXLexuo5WkuLu1hvPPn3Sb2BaS8cEHuJBIMkkAZrO0z4WajrGiPaeJr6Oztkl1b7NbWtuBMv2qaXEkkvmMsg2MGChV6gNkrS2/jzW726tX0yOwt7nVP7JXNz508cIubeWRyI/MUcFBjbtz/ETwRnax8WdcsdHupZ7jw9p11Z2l/L5t3BI0eoz21xJCIYE81SpIjDHLORvHBwTQB2Vv8AD26l1201nV9Ytri/hv7e8cW1h5ELLDbzQogQyMQ378sWLH7oAAGMZd18J7saVdWem6/BA15p15pdzJNp5lzDPPJL+7AlXYw80gnLBsDgYGLPh/x5fX3xGGgXd1pPlOpaKCzRZ5cCIMTK4uN0RyTw0OOgDEmud8Xm8tfiD4m1pzp9x9gfRrW2EkEqzwJPcqjCOZJVKA7nLADD5AbIBDAHpPifw3carpWkQWF/FaXmmXUV1DNNbmaNmRSuGQOpIIY9GHasfw54AudK1nTri41eG4sdOubu7toEsvLl8y5LF/MlMjb1BdsAKD93JYjNeX6Tr934Yt5tX06zF3c29nqgWM42qG1tlLtll+VQxY5ZRheSoyRt/wDC0NXvdEhS9vfDemxXcl5CNUkaOeBxHHEyRBIbp1WZ/NfCmYnEeQDuAAB3niXwGNbvfEFz/aPkvqcVgsYMG9YZLSZ5UZgW/eKzOAV44B55yMa9+Fk+ox6pLf65Eb/U479biSCw8uINc20cAKR+YSAqxKSCxLEnJFSaNrdz4b+AnhXWbaOKSOz0nTZblZFLf6PsiEzDBHzCMsw68joayNY+Iuq36XMMekmwWyOnNdRyyShw1zeQCHbJGyceU0hZeRu+U5UMGAN2P4dXdjq/9raVrVvFqSX0t3EbmxM0IWS2hgZCglUk/uAwYMMbiMEZy4fD7UP7dN3/AG7bixl1eLW57YWB3vcLEkbBZDL8qHZkDaSM/eNefaDqWvanqHhK1bxFpV1rdr4i1KLZPbySSWf7u+H75fP3EFBmNcphQBlgM12PijW7nX/gBf6rfQxrdzWp81IAdpZZdp2gnIB25AJOM9e9AFOX4PajJpmjaYfFsx0/TobONYWgmC7rd1YsqLOsfz7RnekhXqpFeh+C/DyeGNFewSZZ2e7ubt5RF5ZYzTPJgjJyVDhc552jp0HmWu/FfWLTTbSeGHTrWae9nt7iO5RAdMMa5WGfzbiFDI/UMHVcD5Q4wTctPiLr02iazq19/ZGn2el2trLJ5UJvi7zQo2VZJ1QoHbO7dgr1K4LUAevUV8/6T8R9b17U9CurnWtH0i0t9YudPmuHTNrcg2qSR7tl00eTuYACRxu2kcgrWgPiB4kttBu7nTRpSw6dpNzq0yXcc9w83l3UyeWrmbK5WP7x3YPAGMAAHuFFZ2k61Y6rcX1vZzb7ixkWG6Taw8t2jWQLkgA/K6nIyOfWtGgD4r/bW/5KnpX/AGBYv/R89FH7a3/JU9K/7AsX/o+eigD6E+GXj7wdZ/Dbwna3nizw/BcwaTaRyxS6jCjxusKAqwLZBBBBBrpv+Fj+B/8AocvDf/g0g/8AiqPhP/ySzwb/ANgWy/8ARCVPL400aPX7nRlOpT39rJHFOttpd1NHEzqrqGkSMouVZTktwDzigCD/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq6W0nS6tYbiJZVjmRZFEsbRuARkbkYBlPqCAR0IFS0Acr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdG1zGt6lqVm8142lDCFzHgEAgvjaD8wwpOSMkAgHEN9qtnY32nWd1N5dzqErQ2ybWPmOsbSMMgYHyox5x09cUAYX/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVauu67baLPpMV1HO7ald/Y4vKQNtfypJMtznG2JumTkjimaN4htNX1O9srWK6SW0ht53M8JiysyllG1sMCApyGUEHj1oAzf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+KrqqKAOV/wCFj+B/+hy8N/8Ag0g/+Krmr/x94Ob4k6FdL4s8Pm2j0nUI3lGpQ7FdprIqpO7AJCOQO+0+hr0+uV1L/kqfh7/sC6n/AOj7CgA/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIquqooA5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8Aiq6qigDlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKrpbieO2geaZwkaDLE9qxbrxJb7xDZlGnPP8ApW63RR6lmXr7AUm0hpNlT/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qm6d4rM08y3Ue1YjtZYo9+eeCrbsuPotdWp3KCM4PPIxQmnsDTW5y3/AAsfwP8A9Dl4b/8ABpB/8VXNfEHx94OutBtY7XxZ4fmkXVtMkKx6jCxCJfwM7YDdAqliewBJ6V6fXK/Ev/kXLP8A7DWk/wDpxt6Yg/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+Kra8QazY+H9Jm1LVZXis4SiuyRPK2WYIoCoCxJZgMAHrVfw/wCJdK8QNdJpk8pntSFnt7i3kt5osjK7o5FVwDg4JGDjigDN/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4qtDUfElnp+vRaTPFdtcSWUt8GhgMo8uOSNGG1cuWzKuAFPAPStqgDlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+Krdu9Us7PULCxuJtl1fM626bSd5RSzcgYGACecVdoA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4qt3VNUs9LW2a+m8oXNxHaxfKW3SOcKvAOMnueKg0fXLbVTqn2eOdf7Ou3s5d6/edVViVAJJGGHv7UAZP/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXS2k6XVrDcRLKscyLIoljaNwCMjcjAMp9QQCOhArN1nX7XSNR06zuY7l5L7zvLMMRkx5cZkbIHzE4BwFBJPGKAMz/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8Aiq6iKQSxJIoYK4DAMpU8+oPIPsawNP8AF2l3fgm18VSPNa6TPbJdZmjy6I2MblTdzyOmaAK3/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VWt4l1u28PaUdQvUmeETwW+2IAtulmSJTyRwGcE+2evStSgDlf+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iq6qigDlf+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iq6qigDlf+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iq6qsvxTrdt4b8OajrV8k0lrYQPcSpCAXKqMkKCQM/UigDJ/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KrX0TWrfWJNSS2SVTYXj2UvmADc6qrErgnjDDrjvxRp2tW9/rGrabCkqz6a8aTMwG1i6Bxt5yeDzkDmgDI/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIquqooA5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8Aiq6l2CIzHOFGTgEn8h1qO0nS6tYbiJZVjmRZFEsbRuARkbkYBlPqCAR0IFAHNf8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FV1VFAHK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FV1VFAHl/wy8feDrP4beE7W88WeH4LmDSbSOWKXUYUeN1hQFWBbIIIIINdN/wALH8D/APQ5eG//AAaQf/FUfCf/AJJZ4N/7Atl/6ISrI8Y6Q2vT6PEdRmvreZLebyNMuZYopGVWAeZYzGvyupJLYAPOKAMjRPGXw70PSLPS9L8WeG4LG0iWGGL+1om2IBgDLOSfxNXv+Fj+B/8AocvDf/g0g/8Aiq6S8uUtLdppVmZFIBEUTytyQOFUEnr6cDk8CqWo61b2GsaTpsyStPqTyJCygbVKIXO7nI4HGAeaAMj/AIWP4H/6HLw3/wCDSD/4qsTxH4g+GniNEj1fxho0sCqVaCPxD5MUqnGVkjSVVkBx0cEYyO5r0WigDlB8RvA6gBfGPhoAcADVIOP/AB6l/wCFj+B/+hy8N/8Ag0g/+KrqqzNC1q31qO9a1SVBaXctlJ5gAy8bbWIwTxnp/KgDI/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+Kro2uY1vUtSs3mvG0oYQuY8AgEF8bQfmGFJyRkgEA4paVrdtqWq6zp8CTLNpU8dvOzgBWZ4UlBXB5G2RRzjkH60AZP/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQByv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQB8N/td61pWvfEnTbrQ9TsdStk0mKNpbO4SZFcTTEqSpIzgg49xRWh+2t/wAlT0r/ALAsX/o+eigD6q+E/wDySzwb/wBgWy/9EJWba+BH/wCEv8Wa5c3MwbUpYntI4L+4jjAW1SI+dEpEbHcpPIbjH0rS+E//ACSzwb/2BbL/ANEJXO+N/HmsaVea5ptvpUFk0VpO1je3c8q/aHW3aUGIC3aJiCG+QyBvkYlcdQDFtPhJeJpMPnjSn1m1s9Gt7S7yxa3e02+eUbZldwUgEcnocVzdp4K1XUPE15pdnZLZ3iW2qxXHiRbW5iluXmcCMyPLCgbGcDy3kGMkFRjPcwfEHX7aynS80GxuLqx0GPW7iSPUm2yI3nDav7gHefJzjG35jzwN1vUPiYLe7+yWumRz3Ulvp0kIa8CRmS8aQKjttOxVEed2CTuGF9QDnPDvwlvbaLT4dRi08WkWqxXtzaLcI8EkaW08TBY4rSBQWMqbgQQwHJ7GrpHw71G91zUbi10nTNHig1bUGS++dLq5heOSNIdnlACDLhsh2HyjCg81r+IfHnirw54g16bUtJ0yWw0zQYtRlsoNRZtrGW4Xcjm3BYt5aAg4CgZGSSK6DWPH72euXOl2Glpezx31rYI32sIrNPE8gY/KdoXYAepwcj0IBzWpfCe5fSba105dLt5D4fk0y6fLKZrlntT5hYLlhtt2G48/dGMdE1X4T7fEIvdN0jw5c6XBqYvLfSroGOHy2s/JkGBE4VjIFkwFIYqCSD007L4m6lda/c6dD4TvLhLaeazlltftEgWeOMsRvMCxeWXGwMZA3zKSgB46XwD4oufE1veG/sYdOvLZ1WS0EkzSx7lyPMWWGIqfTAZT1BNAGf4j8DNctpB0m5uP9G1M30/9oahcXHy/Zp4sR+Yz7fmlU4G0YB9AK5TQ/hjr2mX2i3Mtzpd5BY2em202nTO/kTPbwmNpc7M7lJ3R5BB5yFOGX2WigDyf4Z/DfVPC3iuXUtRuYrjMU0bXUVxGHut8gYGaNbVGY8dWmkKnIHBOPWKKKACuV1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsKAOqooPSuZ1fWJ4mZYG2OzAwoyGORjjldr4Egz6EH05pN2Glc6aoL64W0tJp3xiNS2C2M+2TXPf2xq01hEY7WOK9dVOxopTtY/wnIUcZ67vz6VmTSXOryTXFwXaCD5MW+VUtyAIyf4iXA3egzxkYly7FKPcgkvLq+Pn6jbaoJVcSJbW8JYx8ZBO4FQB6gbs88dAsdtqD+XfW87WseSbiVtoCnj5ixYMxx13D0wBioJrqxTUfKclYYbfzj+4hBkJwBjcgwvJ+Y4zx070TcRXqyxfbpTcTJiJIJmGMjsMngZ/urn0xyM7miR0+jahYC5EV7cSXV4W2+aSHibnggqAo7dRn6114rzZbK2t1WFLpN8Ay8aTHOR95mcBV47nDHsOcV32lXaXllHKjAsPlf2YcEHk4PtWkGZzXVFuuV+Jf/IuWf/Ya0n/0429dVXK/Ev8A5Fyz/wCw1pP/AKcberIJfiLot74g8I3Wn6WbcXjTW8sf2mRkjPlzxyEFlViMhCM4PWuL8W+AfEfiyPUr/ULjTbHUJ0tbeOxtZTLA8EMryMksskJDFi56wlRtHytk11XxWu7mx8HGeyuJreb+0NPTzInKNta9gVhkdipII7gkVykfxM1KHTJpLTRxqJtrbUtQne7v1iZYra7kiKrsgwxIUbQQOMBmJyxAM2H4UaymktaxTWUO7Tby0ET3XmJG81zbyjZ5dvEqx4if5QgwWAAI5GneeANXC+JFt9K8LXd/qM08sOs3/wC8uTHJIGEEkbQONgTMY+YqAFOw8irtv8UJr3xWdL03w3qF1Zxzw20tzHHOWRpI1cMcQmIIN6glpVPU4xgnc8BeLrzxK1/FqWlxaTfWqxubJ5pjOgfd/rFkgjAGVIDIZFJDYbjkA878PfCPVNNexnv9P8N6kLTVpryOyuHXyo4ZbdEIVktVQMJE37ViVTgHIPNW/Cnw98TeD9Q1PVrT7LqOqfZbiK3mN1Gv2yWRwyNcRi2jZgCASWncjBC/epmieKPGeoJ4LuZoLKe7uby/j8pdSeKK5VFlH73bAAuzaMYV84BOCTjRvfjIkOmaTqFvpKTwXVvbXF3Ck0zTWnnSbBu2QNEB1ILyR7sHA9QDqfiR4Vm8VeH9OtzaaVqF1Z3tveGC/UrBNsPzrna5UMpYdG64Oa5hfhfOt8NSt7bSLTUzrDXhlhLbktGtjF9nVwgONxB24C4GevFdH8Mdb13WbTW5dejtPLttVvLaCSCYu+2O4kTYUESgBQqgNklhyQDXD/8ACy9QbXbHxDPZLFo8/h+e7tLGLUS5mL3VrHG8y7AsTDeQSC+0F+eCCAWLT4SXiaTD540p9ZtbPRre0u8sWt3tNvnlG2ZXcFIBHJ6HFdn8RPC174laxNjLbR+RBexN5zMMma2eJcYB4DMCfb16VoeEfENxrM+r2eo2UFnqOl3C286W9z9oiO6NZFKuUQ9HGQVBB/A1xMXxbuotNhvtS8OxwQ3ljJe2Qh1DzGfZPFDtlzGojBaZDuBbC5JxjFAHN2vhW/sviLpFq+jw393BqkN3LrX2W58yGBbXb5IleEReWD02Sk5wNmc4twfBaeDwpHpkMOhpO/h/7BdkK2y5vFljdJX+TLAbGAYjcN3Arbm8deJbnxrpGi2um6ZBcxX09rqEH9ol4ZMWwmTZL5G7hWyRtU5UA8HI2/iT40k8H3kEy2811GmlahftAsyRpIYPIwGJjZs/vDgggDnIbjaAO8WeFLrWfhkNAsdM0awn8y2kFhHMy2arFcxytGHWIEAqhGfL6np3rn/Dfwukt/EFje6tZ6KulxS3839kW5MlvbGYWvlpGDGoZQYHc5VQGYEDPNGu+OvFK67pelWuladZ6gmsQ2tzE2ol4Z4pbSaVF8zyCy8pyQuQUABYMSFHxduGXW7mPwvevp2nQ37rcgXAVntVclZHMAiQOY2AKyOQcZUHgAGbD8JtVe2vIJDpFrMbG5h/tG3kdrjUrhpFkhmuQUABRkB6yHJOCBxVrXPhv4n1qz1aPU9ZtL2S50eeC3EzybYL24CCYj5TiEeWNgHIEjjHSuos/F2uX2vx6RbaDp63P2SLUJvP1RkCQSOyptxC26T5G3KPlHA3nNYM/wAW54NLGoy6DEbW6s573T1TUMyyrFIqMJl8seUTvB4LjscGgDrPB/hOLwxrevyadBZ2mk3zwSW9rbDaEZY9rsVwACxAORknGTzXl3hn4d6/caXJeWumaJo90bfUbctco0kuoGac7RdRtEAEVQcA+Z1Bxjg9k/xD1hdbTQh4cszrjaj9gMf9qN9nANobkP5nk7vuggjZwehNZlx8Yrgpp66d4Vvr66lsVv7i3gE8rIpleIpGYoHDNmN+XManjnOQADP8KfCPUbO/tRrS6TJo6aq989hG4ZPLayeAptjt4YzlyCVCKCuc5Oc5198IPE13fa5Osnh+1Ooaff2bG1CwpMZmUxMyR2ysMbfm3vKc8gjJFdX4p8c+IJfDGu6l4e0+wt7Wwv8A7BHcz3p85pEukhfMPksqqfnwSxOMHAzW38Q9a8Q6P4X0e60+Gxh1WfVbG2ni+0lotsk6oyCQxE4bIUtsBAYsBkAEA5Dxl8LNZ1q6nmjubGa2k1K7uzZSyIqSJNHCqsTJbzKHXy2/5Znh+GHOe2+H3he88OTai15Osy3EVnGhM5mk/c26xNvcom45U/NgZ64HSs+18f3j63Ha3Oj2sdl/aa6NJMmob5VuvKDnbEYxujB4DbgxHzbAKyPiB4i1HRvH8l3LC8+jaRo/27yItTltt8jylAWRV2ycqq4dtqqWbk8UAOsvh1qGjQeHNQ0mDSJde0y+ubi4M0rxJcxyrcKqmURs3yCfIG3GdwGM5rGb4P6hcaTcLff2NLqi6PFZ2U5Ln7NcrdXExkRimVGJUAYfNkHtyepl+IWpQX0elz6DaNrLanFppih1IvAvmW0k6v5piDcCPDLsyAcjdwDWT4ieIJtXt7C28L6cxudTuNKhkfV2UGaBGd2YfZzhNqNg8nI+7zmgCO7+Gk761Nq9uumpqcmuSXxu8sJfsjW7R+TuC5+8QSv3e+c1mWnwkvE0mHzxpT6za2ejW9pd5YtbvabfPKNsyu4KQCOT0OK7e28aRzfDeHxXJBDaeZbrJ5FxM2xZC20IXRGY5Y4BCEnI47UzwD42PijSdZurvTZNPn0u6e1nhHmkttjSTcokjjfkOOGRTx9DQBwHgPw/eWfxRtN2jRlrE6ibzXPstxFLemSQbPMeaFA5HQbHlXAJBUYz7jXk8XxYvRYJe3Ph63WG502LVLRINT8yR4pJ44lDgxBUb95nAZhwRnvV658dapYeILjS7jTIpNVmuLS0t7Y34FqjyxzyZMvkBx8sPOQ+WICjuQD0qiuE+EWtvfeEbJdXv4pNWuLvUWWJrrzXZI72VTsLYZkQFFBwMDbwOBXd0Acr8J/+SWeDf+wLZf8AohKwLXwfrFr8QtW1cQQzWF9qEN2rp4gvLUxosMUZDWsaeVKcxk/M3zAgHArf+E//ACSzwb/2BbL/ANEJXVUAfPnhX4Y63feH7GcafpehSi08qUBpBcXzfaopQ1yDEu0osRCjLn5+oFbUnws1mTVp5kOjWlwzamTrsMjm/nFykixbx5Yx5e9RgSEYUY24xXtNFAHifhr4R39lFDDfrYiD+0LW5uII7lGhmjijmVyI4rSABm8xQc7twGGbjnRl+EFhLq8V3LpehvGNdN26mHO6w+zNGtvjZjAfY3l/cwM9eK9booA8E8R/CPxNf6Npmm2cmgBLC3aO3nbastu/2h5F2yNbSPsCGMAI0RBB5IxXp+keHLuz0HxLZSyW5l1O8vLiEqx2qsxO0NxwRnnGfxrrKKAPIL/4VXn9m2cGlNptpMugtp926s6/abgyWrEuwXLIy27IWPzbWAA9MPV/At3oSS6jd+H9Cl02bVhcjw7ZQXNzZsPsaxAssNqxyroz5MW3LdQSK97ooA+edM+E+v6hpfhq7n8uEQ6dBEbWSaO2msHWRnJiLWs5UkMuQpjYFcEnjHY6L4K8RaD4h8Ratodr4dt57yKc2zXb/aJHmeUOPMlW3jlEfByheX+EKQFGfVaKACiiigAooooAKKKKACiiigD4r/bW/wCSp6V/2BYv/R89FH7a3/JU9K/7AsX/AKPnooA+qvhP/wAks8G/9gWy/wDRCVqDwzoI1abVRommf2pMpWW8+yR+c4I2kM+NxBHHJ6Vl/Cf/AJJZ4N/7Atl/6ISuqoAytJ8OaJo6uukaNptgrx+UwtbVIgyZY7TtAyMsxx6sfU1WtfBvhi1srqztfDmiw2l0qpcQR2MSpMqklQ6hcMASSM9Ca3qKAMJPB/hqNbVU8O6Mq2sbwwAWMQ8lH3b1T5flDbmyBwdxz1NS6d4X0DTI1TTdD0qzRJFmVbe0jjAdQQrgAD5gGbB6jJ9a2KKAMa58K+HrrVH1K60HSZtRdSjXUlnG0rKVKkFyMkFSVxnocVZ0XRNK0K2a30TTLHTbdm3tFZ26QqW9SFAGfetCigAooooAKKKKACuV1L/kqfh7/sC6n/6PsK6quV1L/kqfh7/sC6n/AOj7CgDqWOATzxWXdXyTwmOKwuLln48uSAov1JcAY/X2rVoNIDiLxHsrsSqLQ+Uf3n2eAARseFQMd3zc5JxwB0yRWdBLPILqwcyRwyyl5Fii5UlhzgZIA/Urjg8H0SGGKFNkUaouS2FGBknJP50RwxxvI8aKrSHc5A5Y4xk/gBUuBamcFOy7XuRLtd2fy4m2CZcE+Xu3kbVAx8ox7jJNMN3Hp9qk0mn2srSKCFkVT1/iLty5z6YHtXW6tb3jTq9tcXwUj7kPk7QffeMnP1rAfT721aWaS6i0+CRsvsVS8h9NqrnP0apasUmmZ8OrGETvNPaFpYx8kcQEcYU5GASCcZPbGcc9BWhBqk2lwRJE6zqcBnHKZ5JCDOCfVieSfQHGe1lDvkaC2nu5yQuJm+Ztxwd5P3c52heoUsetatt4Xe5lha8Bt4UUjYj5Y8g49AD6DoAPWkr9Bux0Ol3U96zztEYrUgCIPjc3XLfTpisX4l/8i5Z/9hrSf/Tjb108MYhiWNN21RgbmLH8zXMfEv8A5Fyz/wCw1pP/AKcbetUYs6S8tLa+g8i9t4biHcr+XKgddysGU4PcMAQexANU10LSFSRF0qwCSRyQuot0w0cjFpEIxyrMSzDoSSTWlRTAxp/Cvh641KHULjQdJlv4VVI7l7ONpUVRgBXIyAB0wam0Pw/o2gRyx6FpOn6ZHKQ0i2dskIcjoSFAzWnRQBlWXhzRLG9e8sdG022u3laZp4bVEdpGBDOWAzuIJBPU5NVp/Bvhi4e1e48OaLK1qgjgZ7GJjCoOQqZX5RkngVvUUAUbHR9MsL68vbDTrO2vLxg1zPDAqSTkZwXYDLHk9c9TVK18JeG7Sa6ltfD+kQy3aPHcPHZRq0yuQXVyF+YMQCQeuBmtuigClo+k6botmLTRtPs9PtAxYQ2kKxICep2qAM1F/YOjmGOH+yrDyo4Xt0T7Om1YnILxgY4VioyvQ4GelaVFAGGPCHhpdOh09fD2jiwhl8+K2FlF5Ucn99V24De45q/qWk6bqf8AyEtPtLz908P+kQrJ+7fG9OQflbauR0O0Z6VdooAy9T8O6LqqTpqmj6depcMjzLcWySCRkGFLbgckAkDPTNQP4R8NvfXN6/h7R2vLlGinnNlGZJUZdrKzbcsCvBB6jituigDK1Pw5omqy2suqaNpt7Jaf8e73Nqkhh6fcLA7eg6elRx+FvD8c19LHoWlJLfcXbrZxhrjnP7w4+bnnnPNbNFAFL+ydNN/9uOn2f23zPN+0eSvmb9nl7t2M52Ern+7x0qjfeEfDeoQ20N/4f0e6its+Qk1lG6xZOTtBX5cnnituigDEufCXhy6vrq9uvD+kTXl0hjnnkso2kmUjBV2K5YEAcH0q1JoWkS6KNHk0uwfSQoQWTW6GAKDkDy8bcA9sVo0UAZFt4Y0G11KHULbRNLh1CGNYY7mO0jWVEC7QiuBkKFAAAOMcVduNOsriWaW4s7aWSaE20jvErF4jn92xI5Xk8Hjk1aooAytP8N6HptvBBp2jaZaQQTfaIo4LWONY5dpXzFAGA20kZHOCRVhNJ05Jo5UsLRZY5nuUcQqGWVwQ8gOOGYMwJ6kE561dooAovo+mvpLaW+nWbaYyeWbMwKYSvXGzG3Htim6LomlaFbPb6Jpljp0DtvaO0t0hVmwBkhQATgAZ9AK0KKAOI8N/DPQdD1K/vvKW9mvEEciz2lrGgUPv+5DFGrHcFO5gzfKOeK6TUvD+jaolwmp6Tp94lzsM63Fskgl2Z2btwO7bk4z0zxWnRQBnWGh6Tp/2b7Bpdha/ZlkSDyLdE8pZG3OFwPlDMASB1PJrRoooA5X4T/8AJLPBv/YFsv8A0QldVXK/Cf8A5JZ4N/7Atl/6ISuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+K/wBtb/kqelf9gWL/ANHz0Uftrf8AJU9K/wCwLF/6PnooA+qvhP8A8ks8G/8AYFsv/RCV1VeYfDLw5qk/w28JyxeM/EFtHJpNo6wxQ2BSMGFCFXdbFsDoMkn1J610v/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyv8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVVyupf8lT8Pf9gXU/8A0fYUf8Ivq/8A0PfiT/vxp3/yLXNX/hzVB8SdChPjPxA0jaTqDiYw2G9AJrIFQPs23B3AnIJ+UYI5BAPT6K5X/hF9X/6HvxJ/3407/wCRaP8AhF9X/wCh78Sf9+NO/wDkWgDqqK5X/hF9X/6HvxL/AN+NO/8AkWo5vDmpwRNJN4+8RRxryzPDpwA/H7LQB1rAlTjg9q5hvC5fUXuZJoJNy/xRHOT16EEj6k/SoIPD2pXEYkt/H/iGWM9GSLTmB/EWtVF0+4fU/wCzl+IniI3mCfLFvp+eOTz9kxUu3Uautjp9O0eG02MzGRozmNQNiR8fwoOB1PPJ561p1yv/AAi+r/8AQ9+JP+/Gnf8AyLR/wi+r/wDQ9+JP+/Gnf/ItUlYV7nVVyvxL/wCRcs/+w1pP/pxt6P8AhF9X/wCh78Sf9+NO/wDkWua+IXhzVIdBtWk8Z+IJ1OraYmySGwABa/gAb5bYHKkhhzjIGQRkEA9Porlf+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgDqqK5X/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoA6qiuV/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaAOqorlf+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgDqqK5X/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoA6qiuV/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaAOqorlf+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgDqqK5X/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoA6qiuV/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaAOqorlf+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgDqqK5X/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoA6qiuV/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaAOqorlf+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgDqqK5X/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoA6qiuV/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaAD4T/8AJLPBv/YFsv8A0QldVXmHwy8OapP8NvCcsXjPxBbRyaTaOsMUNgUjBhQhV3WxbA6DJJ9SetdL/wAIvq//AEPfiT/vxp3/AMi0AdVRXK/8Ivq//Q9+JP8Avxp3/wAi0f8ACL6v/wBD34k/78ad/wDItAHVUVyv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLQB1VFcr/wi+r/9D34k/wC/Gnf/ACLR/wAIvq//AEPfiT/vxp3/AMi0AdVRXK/8Ivq//Q9+JP8Avxp3/wAi0f8ACL6v/wBD34k/78ad/wDItAHVUVyv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLQB1VFcr/wi+r/9D34k/wC/Gnf/ACLR/wAIvq//AEPfiT/vxp3/AMi0AdVRXK/8Ivq//Q9+JP8Avxp3/wAi0f8ACL6v/wBD34k/78ad/wDItAHVUVyv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLQB1VFcr/wi+r/9D34k/wC/Gnf/ACLR/wAIvq//AEPfiT/vxp3/AMi0AfKv7a3/ACVPSv8AsCxf+j56Kz/2u7C5074k6bFeatfarI2kxOJrxIVdR50w2gRRouOCeRnk89ACgD66+E//ACSzwb/2BbL/ANEJXmOvX+sQ/FHX71r6/t9E07WdPSa7XU5/Ks4TbQu6Naj90Y3JIaQ8qX3Y4yPTvhP/AMks8G/9gWy/9EJWevxI0hfF2taVd3+iWVjpARLi6utUSKTzGCnAiIxsG8KWLj5vlxQB534p8eXraDr+lve6VpdtN/bSi51AzT/avKuHiWCHdKMSFTnAJAyAqYGBftfiRqlhe6dpkU2jRiK5sdPTSpYna+uopIY2M6N5igLlio+RhkcnPFejRePvDUviOw0WHV7KS5v7X7VayJcxGOdd+wKh3ZZic4AByFb0rmfH2raFpHj/AEWO6jiutUkjfUPLvtde2ghSLaoaOB2MTTHc2wEKDscl1wTQByuifF7xFqOjaldyL4btpIYIpsXN1bRG1YyqrROhvCzMFY48zyMsuDtzXa3Piq+v/glqviKyuFe/XT7qRJ4bbyVVk3jeqeZICF25BV2VsZBwRXUw+LNAk1CDTjrWmJqkwUrYteRGclkDgbAxJO1geM8EEZHNNTxT4ZvZr6yTXdGuJbWJ3u4BeROYo14cyLn5VGQCTxzzQB5p498ayfDqwOk+HZ9C06x03RFvbMahE8h1F9zL5UW2RPmG0MzfMT5gOOprfvvGmvW/ifUtCWzsxc2IuNQeZon8trARZhI+b/WNKdh5x+6kIHTE89r8Pb7w7p4k1u0l0C1RoIVGvSfZXWPDFHAl2ShRjIfdgcdOK0J9Z0G0ufEmo+G5tO1fxDFAsl7Zw6grTFIcgJjLbMAtgYALHnBJNAGX4R1/WNR8VeHhq7WZGpaBNqQS1E0axfPagIVMhRzmRjuKhgMAYG7dWvfH2pQePJNHD6WipqcFgmlvG5vp4XRWa7Vg+BGu5v4CMI2WB4r0bS76DVNMtL+zfzLW6hSeJ/7yMoZT+RFWaAOT+GGs6v4j8G6XrmtNYK+oW0VwkNpC6CLK8gsztuz16DHT5utdZRRQAVyupf8AJU/D3/YF1P8A9H2FdVXK6l/yVPw9/wBgXU//AEfYUAdVRRVHVtVstKgEt/OsSk4UHqx9AKTdtWCVzL8bapNY6NPHpzx/2lIuIlYkd+TkdO/NeFX+t+ItajsrK3vYLK/86RbmJ5i7hkO5cBiTtIB5q98QtTPiO4lEl7f6fdWs4LRxjaWj5CleeV9/XrXNx2iXcratcXN9PqemtGksZ2ndC/cbVBI2sc8Z615latzy0O+jTUY3Z1n/AAlsosrT7NJPaXD38dncwrKRsJPP3Tg5HQ+9VNA1S20vWbzxCxaXVJL2SyhGQSEX5cAEjjGSTXM6npv2i0lnihW01ixiF/BJHKJIp4gQeuATjHQ+tM8O2zw/adSMqR3N+RJbo4+ZEYktz0GT+lZc7WpqqcbOx7nZeO5GVHkNlPG77FKEoS3p1PNdtpN+mpWSXMalAxIKnqCDivlnVtYj/tBNPum+xW9uZmEluCHaYRgDDeuWIwPavUPAviq80vTorG7kSe8hgSa7RxjaWH97scDpzXVRxDvabOWrQsro9irlfiX/AMi5Z/8AYa0n/wBONvXTwSLNCkikFWUMMHPWuY+Jf/IuWf8A2GtJ/wDTjb13nKM+Kd5qFj4Pmm0yS4h/0i3S6uLZS00Fs0qCaRAAfmWMsenHXtXn2k+K/wCzNQ12fwvdf2vpGnwW93NN/bs+rRtbGUrLjeMxTrGC5QOwxjjnNes+KdZi8PaBeanNG0wgUbIVOGlkYhUQE9CzMq5964nxN4z0+81m58H6za6dIhsYn1WH+2VgkHnEqIog2zzMYBYlo/ldeGLBSALoni3xJrWuaLaQR6XaW2qWV1qkbTW8rulslxCsQI3rl2jlyemCwPO3DVn1u7vf2erTVPMa3uLzTYPNlSWRzEkhVZGDyMzkhWY7mYnjOa7Q+L/C9vLd2x8Q6LFJYLm5iN7EptlBC/ON3yAEqOcckCll13w1q+j3W/VtJu9MktHlnYXUbxG3JZHdiDjZlXUt0yCOxoA4nxZrep6Rb+MtJ0OHTLTR/Dvh9LyNPLmWRt0VziNWjkQp/qVw6ncOcckMvPa34xvNV8UaLZT3OmRtYa7CsWkKjm+lAtmYTl2k+4xbA+Q9R82civVodd8NaNbCwOuadAllGUZLi/VnjVFUneXYtwroSWPRlJ6iifxn4Xt7C2vp/EmixWV0WEFw99EscpXqEYthsd8UAeTQfF/XG0u5u4X0LVZhpUd+9pYQuH0+RriONo52abBMayMzAiP7vO0ch0/xa1yLw9bahPdeGoIzdXET3Cy21w0saJEymO3S+wWy7BlWZ24TCneAPQvBlrplv4p8QwR2l1Hq9mY43mutRmvWktny8bI0rEopIcFBgBlPXg1n3Xxb8NR3FvHDfWRX+130q7aa8ij+yhY5W848n5CYcDO3OfbBANHx94oudBsdEkt7nT9Ph1C4EM2p6nE32e0XymcF13oQWKhBl1ALcnOAcfwP4z1/xPrlratHptrarpsN/M/kSM0264uIv3eXG1XWFHUnJAbkNnI6658YeGrWOye58RaPCl8u+1aS9iUXC5xmMlvmGfTNM8N+MNF8Rajq2n6ZewyXumXD21xB5qFwVwC4UMTsyduTjkEdqAPOvFV7NpfxK8WeIbuXTjDoWkWRtGn003MlsZmuFLIfOQLkg7z8uV2glQpJxNJ+I+t69qehXVzrWj6RaW+sXOnzXDpm1uQbVJI92y6aPJ3MABI43bSOQVr2WXxb4civ7ixk8QaQl9bkCa3a9jEkZLKo3LuyMs6jnuwHcUsHizw5PeWlpBr+kSXV4N1tCl7GXnHPKKGyw4PT0NAHAfEC213XtY8F6VrdnoNta3Wqy+ZauZNRguFS0mdfMVlh6FT8vzDdsbPy7TiQfETxJb+H2u7FdLFtp+hwatPHcxzzyTF7ieNo1kabK/LECGbeQexHT0bV/iR4T03Sr2/Gu6beR2bxpOlpeQyPGXcINw3ccnnPYH0rUh8WeHZ7uztYdf0mS6vUElrCl5GXnU5wUXOWHB5GelAHmk/xR1ZPFZsYjpE7i91G1OiRxOb9Ut4JpI5C/mYHmmJcDy8YcYJNVPDXxU8Ravbpti0KSSW7sbdXSSI+UZ3ZXR44rqVgRgEM2zPzAqMV6DrEfhDQPEltq+vatBZ6nKXNr/aeruEBICuYYpZNinBAJRRw2O9dHqmp2Gk2L3uq31rY2aY3T3MyxRrnplmIFAHnmmeLr6++IM3hDXbrQ7uF43ieCzt1lMoEQLmT/SWaEElvkeIjBA3sTVzwjrTaT8H5tSuZ5Gj01L2OGZoXnYwwzyxwsU3Bn+REP3hn1HWukl8TeGr37NYf8JBpbSanH/o0cWoIslwjZGYirBj3wV7jg1BaeIvB+h6THbW+t6HZadYokIX7bEqQr8yopJbjOxgM9SrehoA818PfFHxFrzxWVk2ifaZdZh09bwwCWIxSWs0xbZDdSKWDRY4mPHUKemD8Q/iLqWsfDzV9P1G60XS2n0e5ZjNC5OoSLPNA0dsDINpAiDHPmEeYOCBk+vw+PtFPiy50W5v9Otl+zWlxZzyXqD7b55lAWNTjdjywcgnO8dO+heeL9CtrlLcapp8s3nGKREvYA0OCwZnDODhWRlIGTkHjg4AMn4q+KLzwpotpeWFxpVv5lx5cr38kYOzYx/dpJNCrtkDjzBxkgHGK5R/itNBIbaaXThez3OkLYxSwPBLdQXXlCaURM5YYLSAckKQASx69J4P+Jmi65odvqmo6loWmQ3sxjs421VHkcDGFcELsl+ZcxgtjcOea6K+8WeHbCWWO+1/SbaSIkSJNeRoUIKg5BPGC6j6sPUUAeVeBvFtzp1vpGitquiaHaMk1wlxqsZc3rtezq0MP72MBlCqTyx/eL8uOvpPw31GXVfB9peTjEjy3CkeZJJ92eRR8zszdB3PHQYGALeleLfDer3kdppPiDSL66kQyJDbXscrso6sFViSBg81Pf+IdF07U7bTtQ1fTrXULogQWs9yiSzEnACITlsngYHWgDUorLPiLRRbxXB1jThBNE08chuU2vGpAZwc4KgsoJHALD1rlT8T9CfxlNo1tqmgmys7YXF9fTatHH5RJcbETBDspQb8su0OvUnFAHfUVhP4x8Mx6VFqkniPRl0yVzHHdtfRCF3HVQ+7BPtmrFv4j0O51UaXb6zpsuplPMFol0jTFcbt2wHOMHOcdKANWiiigDlfhP/ySzwb/ANgWy/8ARCV5/aaur/GDXbS/1W03xatbx21tdeK7mzkVDbwHbFZKDHMCzMcEjcSQa9A+E/8AySzwb/2BbL/0QldDHf2ckdzJHdW7x2zMk7LICImUZYMc/KQOSD0oA8Li+KmsanpcZM+iagZrcT3EWm+dE+muLuGNUmdZicuHYgfIflIIZc0uq+OtRvPFthfFtNub3SpdXMWgW0bfbIjDBKqec2858zYCAIxw3BbFd5B428H+Ejpehx3VtZafJN9mtZmvYWhAMAuA5YyllUhlALAEl1wNrKx0/B/jvR/EVtODe2FrqMEt0s1ibxHlijhneLzGXghSEDcjA3Dk9SAcB4a+J/iTWYoUjTQZJLjULW0SZHicRiWOYsHihupiCpjUgsy7skbVIzWjL4u8ZnV4rWK58OrFLrp0IM2nTEhltmmM2PP6fKRs9x81eiad4n0DU4oZNN1vS7uOeX7PE0F3HIJJdpbYpB5baCcDnAJrP/4Tvw4fFFpoI1Wza9uoGngIuIykmJPLMa/NkvuDcAfwt6UAeV+I/jPquk6Npk4/sz+0mt2mubV7YKkwW4eImJ3uUbny2O1EmK8Z4rvPBV09j4e8Z3cQUyQavqUqhhkEqxIz7cVuDxXaReJ9Z0q/MFlBp0FpN9rmnCrI1w0qhMEAAgxDHJzu7Y5tHxV4eFzf2517SRcWCNJdxfbI91sq/eaQZygHcnGKAPMtQ8deIdOisNUuotPnmuvDsmppHCJ0igzLaLl18wq4XzXcttDBRtBHzFsbR/G1zp2veIZotf8ADbQ6lrUcU2vyQsNPjCafCQFQTdWK7RmXGVJ7ha9i/wCEx8M/2hFYf8JHo326ZzHHb/bovMdgxQqF3ZJ3Ky4HcEdq5uHxf4U8dafbRQ6lN5TXk0Ti11cWksJiE3zSeVMrlGWJ2UDdlcMQACVAOFb4xeIsaHiy0hGu7KG6JneK3S8ZpWVkiaa6jKYCjoJTlhkDjPa+B/G97rfjnV9EvrvSpBaiZo4tPRZgqpKFUvMs7kNgjKPFGck4yFOeo8IX/hubTU0/wnqGmXNnp6JF5VjcpMIVx8obaSRnB5PJ5NczY/E+zvtV1i2tY9PnhsZpraMxapEZ3eKJ5GLQnBVD5bhSpdjtJKhQSADP8SfE++8PXvie1u9HNydJbeJoA20RSxp9myvJZnlZ4zgrjYTXP674m1618a2q3WtadosNprKW17cXBme0Zn0lZMOrTqqp5jMFUEDcUblgd3eeHPiDBqsqJc2QtA5tFVjdR4zPa/aP4yhO0AjC7mOM4ABI27Txh4avLW7ubTxFo09taIJLmWK9iZIVPRnIbCg+poA89+FGs6vYv4e0m5awl0rUxqcsIjhdJoWhuf4nLlXDeYeAq4wOTWh4q8falpPjObS4X0uNYZ7OGHT543a71JZiA8kDBwAEyc/I/wBxslRg13Nt4j0a90W51fT9Usb3TbZXaW5trhJI12Dc2WBwMDnk1yWnfFvwxfXWjMNS0+20zUdOkvftdzfRR+RIrQj7O4yVEmJskbsjb0Oc0AbPw71jVvEGi/2pqrWCQzPJHDDbQurLslkQszM5zkKvAAxg8nOB1VZbeIdFXWI9JbV9OGqyqHSzNynnOpGQQmdxGOc4rUoAKKKKAPiv9tb/AJKnpX/YFi/9Hz0Uftrf8lT0r/sCxf8Ao+eigD6q+E//ACSzwb/2BbL/ANEJWdrnga/vJdem0vxBLp02q6hBesY45AAkdukJiYxyo5DbN2VZCOBzjnR+E/8AySzwb/2BbL/0QlchrPxNurP4p2nh20azntJL+KxnhkgWOePfHu3qxuN7jJX5hAE5xvyOQC74T+GM/h3+zlGr2t9bxwXdpew3Vi0i3MM9wZio3SkqRkrlzJkdRmtXUPh5pz3Mh0dbTSbRtHvNKFra2ioim4aNjLhSBx5fTHOeoxXDWfxR8TQ+HbHUtTi0WT+0dGi1SNobeWNLMNcQxO0uZGLoqzGQ42kBCPcdL8HLuXUbfxvcw6np2oTS665S9tISLeQ/ZLYBlTzGJX/gZzjgjNAFmP4bKjTMdTBaXU9O1EkW+CBaRQx7M7v4vKJz/Du6HHPE6P8ADPXNSaTRtWM9joNjo8mlWNw0MUUzE3MMqMfJuJN/+oG5j5ROegJJGZ4F1vUfC/g6wvLb+wkvb3Qhqr3M+61jkke4hQtOXnEcsuGY72KFjtXKjNdAPirqJTQJBqOim3vWZJWFohnkcTmPEcAvcsnGBJE04JyQMCgDpvDfw2/svVrDUbzUIbq6tryW8kZY7hjOzQCFctPcTMGUAcg9ABgYzS2fhPW/Daa7eaZepe/aIJEs9Itkkgt0md93mHzp5FXBPOwIMFjtYkCuau/i5fQ6RKqDSTrtrBrMl5ZbXLW5tBKYN678rvCKTk/MCSuOyeNPiT4p8NalZWbw6IXnskvkkn8u2hmZnI+zrJPdR4ZQBlwHJ3A+Wo6gHq3hXSRoPhjR9HWTzF0+zhtA/wDe8tAuf0rUrzjwn44vdV+ImqaDe3OlmOAzmGCyVJ3VI3CgyypcMUbBGUeFOSQrNtOfR6ACiiigArldS/5Kn4e/7Aup/wDo+wrqq5XUv+Sp+Hv+wLqf/o+woA3tWv4tMsJbqfJSMdB1JJxXhnjbV4fFs0dvcoz28zqoljJAiIPAT3B5969T+I4c6LERC8sSy5kVBnOVYAH2yRzXgOq+HdU1KC0gmg/s14Xe5E6yh4lOBtU9CD8o55rgxcpN8q2OvDRjuyn4in+0SxKNakS+gTyxLLp8ySlM8qxHBH4VXsdb8/WdOku4Ln7TaRuXntIPKMqKMlWVvvDA9vpVXw99pvpZr8+IJo9TkYxzoke6QpkYIOcAdOQK07K+1S/g/sxBaw6hbuwivfPYtG2cMrMQQxIJHWuO52NW0KMkzweZrdnZSWlqUmh+xyuWGxkG0heqqT17VeGoadDZ2tjcXQiudNtglwGGNxH8Kf3jzjFXkjln0bybu4MOoLm3meJQ52xnacA8cgck1l6rZadr919j0y6j1DWZ3EguUj8tI41GCHOcHj070txpq+pSuru1u9btJtAgkuJXCzvFdP8Au4ZASu9x9AO/f8K6TQ9GgW8vF1iaW6u5laWeTzmSGQ9cYGAy49ayvt1vDa3STPp1peRDBs7c4Eu3gYbGCSQeMmqs+pT6hfmymKyzPCE4BkFqG6qiKMsQAAST37ULcGm1oe8fBC7ubrw8JLowxgqNkMR+XGTggduMV0PxL/5Fyz/7DWk/+nG3rk/hRpurXjRalf8Ak2trbExR26wFHbA+9944BB6V1nxL/wCRcs/+w1pP/pxt69bD35Fc8ytbndiz4+0m51rwrd2un7TfI8N1bqxwrywypMik9gWjAz2zWNq3gt9ek1q9munsZNZttPRreSJXa2NtK8pBKvhid+3g4GM5bNdH4r06HUtDuI55r2ERK0qtaXk1q4YKcfNEysRz0Jx044ryDRbXU0tfhffaTqLtq9/o815Pc6xPcX6l2toGYhWlBXJPRWUDOcHGK2Mjqbj4a38s+qbNZsY7K7cyxWK2l0IIpTMsomCi7ykgIJDQmL5mLEHgCvqvwu1e90ye3HiwNc3mlSaRe3N1YtOzxNI7rszNuUr5jLl2kJGMnPNYFn8X9evdW0GFNP0y2jvrfT5jDcTQxNci4VTIYXluI2+XcVAWKTJXBIzSyfFvW4dO1iQHR725tZokP2GOOW3tY3lKeY84uyrAAfdk8g5OTgUAdhqvwziv9H8RWn9pNFcarqUOppcRxshiaJIVRGKOrMuYieGUjecEEZrNPwsvo7OBbDXLax1FZppZNRghvTcEybM7Xe9Yn/VqSshkQkA7eDnT0PxXf6z8KdZ1u8WyN1BBdlHsrhGjlCKxVswTSbCRjIWUkEHDdKxLXx14iGpAINK/sqDUtM0xongled/tVvA5fzTLj5WlPVSSByQeSAdt4d0y9Txd4j1m/iMKXS29lbIzqzPDAJD5h28Dc80mB1wBkA8DIj8A3S61BcSavbvp1vrj65Fb/Yj5okeOVGQyeZgjMu4HYCNuOc5HNP8AE/WI9L1WW9htLGXRlSz1CU2byR/b2n2KqBpo1EXlrvLPIABNGS3BByrX4wavdaPBNNc+H9KOb/N/eRGSC5aAp5cUSx3BXzHD54lcfKdu7sAbWv8Awg1DU/Do0SDxZLb6e0VzHJD5EwQtLPJLvCxzoCQJNuH3qQoOBXdeFvD13oOp6zIdQhuNP1C5N2sJtissUhVFbMm8hl+TgbARnqa8/svHOv3d5Zx6eNOgvNUvdPt2kuEnniiEunPcMVj80AYZAAFKgjrk/NWN4h+NOq6Vo2nzj+zDqPlSSXNq9sFSYJcyQkxO9yjDIiY7USYr34oA7aX4dXsmiXugnWbJtBnv11BIn04tOG+1pcsryebtcEhl5QHDDJOOTVfhkL3xzNr6amfs9zd217NZzfaSBLCEVWTy7hI8/IpG+N8H1HFcxpninVrXVbu0vNXs9TuU8USW409DLHcwxESsucTnMZAAVWXb9eMNt/irr0+kNNay6BeXckFnKywQS7dNlmu4YDbXA8wlpAsrH+A5jOVxigDRi+EOpSTX1xqfi6W+vLiyFok81vM5DCeOZXYPcMvWPBWMRrg8AVpS/DC4ufF39u3usQztPdWt7d2/lXccbTQBArRol0EX7ikeYsuD3I4rC1/4ma9otvPHe3fh6GWy1G5sri4MIDTLHHC6tDbSXUbMcSkMFkdsquFJbA7bx/4putBsNEkt7jT7CHULkQz6nqcTfZ7RfLZwXXehBYqFGXUAtyexAK3xP8Cah41iNvb+IpdNspLSW1mttkzI5fpJiOaPcQMja+9CD92tTxD4Wm1LS9Bis9Qjt7/RriO5t55rfzondY2jO+PepIKux4YEHBB454G/+K13a+N9G0ay1DSNUguLmztbh4bZYg/nhf3sLG7Z2T51IIidecF881t/D/xlr+sarokWtjSmttY065voltIJI3gMMsabWZpGD7hJngLjGOetACaj8MbnUvE/9s32sQTNcSWs17biK7jikkgI2tGkd2qr90EbxJhhn2p1/wDC7zdA0WystXa2vdLu7i6S5RJY1k84uWDCGaN8gOACJB05BBxXPf8ACUXmh/FrxNZ2F3pUz3uuafBJpboWvJI3tLdWmjIkG1UGWJKEHaeRWp8JviLrXjDX5rTU7TTreIWrztBHLCtxaSCRV8t4xcSSMMMcs0cWCMY+YYAAfCSZLeeyttYsrbTLyytLK7hjsJWk2QSySfuZHnYx7jIR83mEYGDmuitPASW0NuiXy7o/EM+vMwt8bzI8reWfm7CQDd/s9B24ewa8tviNrOrXH2CeafxTFpCyiCWO4jg+yRyBBKsvMfTMZUqXy5HIC8j4I8UXvhLw0l/p1vFLJJomgW7yzBTHbo32zMj7pI1wMAcyIMsOaAPSj8KrmHQLHTbHXYY9miDQbuWfT/N82AEnfGvmARvyeTvHTIOBWqPh1AunXNmt6Cs2t22rlntwxKwvEwib5vmyIsbv9rp6+a+MfiPqur/D7VLTULrw/paXmh38n2hmS4XUCDJGIrcxXDIsm0Akb5SpYcEAmvUvFviW48J+EdH1aO3FxZRywRXqhGeTynXYDGAfveY0Y5B4J+oAG2PgGO01qx1BL1d1trN5q5UW+DIbiKSPZnd28wHdznbjA7S694QvdQ8Y2et2GrR6asXkicQQzCa5SNy3luwmETKdzAb4mKhmwQTkctN461jVb5oRp8WnrZ6tY6ZNG7ysVunkfzPnRkEkYTyWAIw2/wCYdq5Xwnquv6o/ghoPEWj3us28WopK89vJM9sVVMxzr5+5pOOpKYB6HHIB1X/CoruSwj0+48RQvp9tp1xplnGunEPHHLNHJmRjKd7ARBeAoPXA5z02ueCrq8u/EN1pWtyaVcapa2VrG8MJzALd5GPKurEOJSvylCAOGz02vA+syeIvBuh6zPEkMuoWUNy8aElVZ0DEDPbmtugDyzw/8L9S0C5h1DT/ABFbvq8d1dT+bd2UtxEVuEhDrte4Mm4GBSHMpOGIOatad8MpLPxgdabVlniN7JqIgkW6zHPIhVmQC58kDLHGYmO0lST1r0migClolteWekWdvql//aN9FEqzXfkrD5zgcvsXhc+gq7RRQByvwn/5JZ4N/wCwLZf+iErnvFHwrTW9S168g1u5sH1La0IhiB+yuyLFcOPm+YyxIqdtvJ5JNdD8J/8Aklng3/sC2X/ohK5VfFGvSeLb3RtHfT4JJ9duLPz71J7lUSOxgmBCeauCSxGFKr3xkkkA07v4eTx+IW1nRtVt7S5TUUvreOayM0UaixFoYyBIpb5QWBBGDgYOOal98KLe+0KDTJ9TZURtTLyR24Vn+2O7f3j9zcBzndt7dKzdI+JOv36+Hbc6dZLe+Ibe3msGWORolIY/a9/P8CAOoyPvAHOMnCh+NOqS6hrEVnHp99bwWMt1A5gEDQMk8cZ85FuJXCqshZgyxNhDgc8AHYzfDnU59QTWZtesv7fiu7e5imj0wpbAQwyxBDD5245WZyT5g5C4wBirPhTwDf8Ahy90e5g1yC4ktYLm3u/NsT/pCTXJnJTEg8tgTjJ3j2FcpbfEXUbvWEjW+0bVorTU57eK+00TQwTqulvcZ2Cd1fD/AC/MWHGQA2CJLj4ma7pemGTW5tIjludLsdRtp4LFvLhNxIymOQSXCKR8v+sMkajPPuAdZrXgB77x0fFVpq32e/RbZIYpLfzYVEfnB967huLLMQGG1kxwSGIPNSfBYNaapZjWw1rcW93BatMlzJLa/aCSxANz5J687Ylzgcg81g+H/iFreueIdEv73V9L0y1mtNRtGgdW8m8miuolUR7bgqJWTG0q0m358bwwxoaP8TNWSz0CLdpcTyWelFNOnE0t3qIuI0MjwSNIWITcclhIfkYsw60AdP43+G974l1aKWLxFJZ6XG1q8eniKUpEYZA/yKkyRndtA+eNyMZUiiH4b3SpaW0mtwtY2V7fXlsi2JEg+1Jcq6u/mkNhrnIIVeFxjnIx7b4g+Jha291dHw95V/Z6nNbLIr2yQPayBV82VpCCrZ54XHrXQfDnx9Br9nbx6lf28uo3V1LbwC2tPLjcxxq7AMk08bYDZ3CTH8OAQaANTwv4NTQdVtb1LtZRBo1tpHliHZu8lmbzM5OM7vu9sdTWbc/DvzpI3/tTbs1O/wBRx9nzn7TBLFs+9/D5uc99uMDOR31FAHm1v8L/ACXsm/tfd9mntZv+PbG7ybF7TH3+M79/tjHPWs/Wfhg9t4f0sWNzJd3mj6XZWUEUNpGfPkt5kkDskkqKVJU5QuOpw2cV6zRQBxHw30bV7fQNaPiVFhvtVv57pkRVUorqqjKq8iqcLnAd8ZHJrO0r4bXNvZWNtqOsW10tjoVxoFuY7Ax4ikEIV2zK2XAiIOMBt38OOfSKKAPLNL+Ew07xFbX66v8AaLWOa2untphdDM0MaRh1CXKxD7gI3xuRkjJGAPU6KKACiiigD4r/AG1v+Sp6V/2BYv8A0fPRR+2t/wAlT0r/ALAsX/o+eigD6q+E/wDySzwb/wBgWy/9EJVk+J7dNe1a0mEFvp2kwRveX89wI0jkcbhHgjHCYYsSMblHOTit8J/+SWeDf+wLZf8AohKzdQ8L3t1qvi2z8m3bTtdEF2lzOpkjinREiZGRZEk+7FGysrDBzyCBkA6Sw8T6BqMfmafrml3UflPPugu43HloQHfIP3VJAJ6DIzWXa+OtI+1a9/ad5Yadp+mXUNsl7cXiLFcebbxzKQWwBxJgDJzjPtXNyfDTWDFFInivfqBsrvTpp7qzkuAbed0bam+cuCuwYZ3kPJz2qS3+GVzYajDqema3AmowTxTQtc2BliAWyjtWDIJFJJEe4MGGM456kA39U8bWlpZy31pFFeadbXVvDc3MV1E4WKZUZZlCFiVHmoSG2Erlhkbd3W15zr3g7VJdO163imjvLnxLeWhvJY4xBHaxpDDHK4DOxORCxUDJBdQcgFq9GoAKKKKACiiigAooooAK5XUv+Sp+Hv8AsC6n/wCj7CuqrldS/wCSp+Hv+wLqf/o+woA6O9t1u7Oa3k+5KhQ+2Rivm34i/D3XLDU7F7SG+1b7RdM8g8wtGRkELt7d/wAq+maMVlVoxqLU1pVnSd0eTaz4Wk0fR7nUxZRLIYgri2A80DoB0wcZrzuWSyhsI7l/tIsQxlkuYgFMjHgcYzuyAPWvo3XdPOqaTc2azvA0q4Ei4JU9R1rxG6+HF7oUn22acz3ch+WSTBgRh1cooGWwTgnvXHXocrvHY2o1Fb3jz3U/EF9HqtpbSWbJK0WVs4xy+4/IsjdTnq3rmtnUbLTItbsdQumW1iAFjLDFhItxjYnkds8flSaNo9nFoU+tX0kxe0vJpxcsoLzRj5f15x71VuCmpadbS28E76KLhUmknXYZPMIU4Geg4OfWuXU69OnoVbCJ7O8uIF0WDVLVX+W1Zw0tsMZIHqpzkHpWrHbjTryG/XRLm3mkw6RQRFSvzYAYjjpyRWp4f0OHUbZ7W4SRNT0q4a1guYgfMxwUPH3uCK9S8A6JqRd5/EUEW6MnyiqlQ3PBKk9cfhWtOm5uyMqlVROh8Exumi7pEZDJIzgMMccf4VV+Jf8AyLln/wBhrSf/AE429dUK5X4l/wDIuWf/AGGtJ/8ATjb16kY8qSPPbu7l/wAY67/wjehnUfs32nFzbW/l79n+unjh3ZwenmZxjnGOM5pb7xX4dsIvNvte0m2i89rbfNeRoPNX70eSfvDuvUVF478Nr4s8NTaO909oks9vKZYwdwEU6S4GCCCdmMg5Gc9sVw+ofCW4uLPSYIdfC/2ZDPZQboJ4le1kKnZILe4hLONuC2QGHVSeaoR3uoeLPDunSSx6hr+k2rxf6xZ7yNCnCtyCeOHQ/RlPcVmy/EPwums6NpyazYStq8cr2txFdRNC5RkTZu3cszPhQAclW9KyE+HU9ppmt2+j622nXGpSWbCaCFwY47eCKHyiwlEhVhEeRIrDecNnk1fDHw0vvD19pd7ba/DNdWt1eTTGe0lkWWO6aJpFBacuGBhGHZ3+8chqAOps/G/h2eLT/P1nTLO6vo45IbWe/gMrCT7gGx2DZwQCpIOOCa6SvLtM+EqWXh670xtXWVp9M0/TRMbTBT7K7vvxv/i3jjPG3qe3e6Hb6nFHfnWbtLh5rqV4EiACwQZxGgIVSTtAJJydzEAkAUAVl8Y+GWnuIR4i0YzW7bJkF9Fuibk4YbuD8rdfQ+lZmvXXg/xLNBpd/r9s8zQmZbS11p7dpoWTduZIpFMiFOfmBGMnoTWXpfw9vbXS9A0i71ixudH0O7iuLSMaaUmZYw4VZH80qx+YHcEXkZxzVS/+Fck3ia/1O11t4Ybq6a+SNxcs9tcGPYJI9twsOR1G6Fj2JI6AG3dfETwZpGkWc9trmkzad9ph09XtLyFo4GYHbuO7CqFUk+gBOOK0m8a+HYLeSfUNY0ywt1maFJbm+gVJcBTlSHPGHXg4bkZABGeG074TanaT3l9L4oW51SaWxnSae1nmQPau7AuJLl2YNvIKq6gY4A6V0Fh4AMGvpqt1qMU8ouby5ZFtdqlriKKMgZc4A8snvkNjtkgHRXfirw9ZXVpa3mvaTb3N2qtbxS3kaPMGOFKAnLAnpjrVnWtc0nQrdLjXNUsdNgdtiyXlwkKs3oCxAzXjdz8Odf0g2GhaGJLvTpv7JF/ey20Kp/obx8q32jzFysYOzynGTwwyxr03xR4cvdR1zSNZ0fUbay1HTo54V+12huYnSXZu+QSIQ2Y1wwbpkEHNAF9fFPh9ryK0XXdKN1M2yOEXke9244C5yT8y8D+8PWmX/i7w3pzbdQ8Q6PatvaPE97Gh3KQGXluoJAI7EiuY1vwZcQ+DvFkNoBqGr6lcnUbfyUWApcqIzFgsxGFkjDZJ6ZHPfHuvh5rMeo6Pa6Vd2kNumh3tlf6jc2ouPMnuJYXkZYxIhDuRI+47lHIIORQB11t8QvC8ura5p8us2FrPo7qtwbi6iRSpRG3r82dgMioSQMNkV0Wl6jZatYxXulXlte2UufLuLaVZI3wSDhlJBwQR9RXn5+Glxb2+qWen6rZHTr0WjLHe2UsksMtvFDEkiyx3EbA7YQQRhgxyG4xXSeFtC1nRxYx33iOXUraC2lililg5llaUMknmMzOAiZQKzMSCCWJGaAOmooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4T/8AJLPBv/YFsv8A0QldVXK/Cf8A5JZ4N/7Atl/6ISuqoAKgvbaO9tJraZpljlUoxhmeJwD/AHXQhlPuCDU9FAGX4f0HT9At54dMilXz5TPNJPcSTyyvgLueSRmZjhVHJOAAO1alFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8V/trf8lT0r/sCxf+j56KP21v8Akqelf9gWL/0fPRQB9VfCf/klng3/ALAtl/6ISuqry/4ZePvB1n8NvCdreeLPD8FzBpNpHLFLqMKPG6woCrAtkEEEEGum/wCFj+B/+hy8N/8Ag0g/+KoA6qiuV/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KoA6qiuV/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KoA6qiuV/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KoA6qiuV/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KoA6qiuV/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KoA6quV1L/kqfh7/sC6n/6PsKP+Fj+B/wDocvDf/g0g/wDiq5q/8feDm+JOhXS+LPD5to9J1CN5RqUOxXaayKqTuwCQjkDvtPoaAPT6K5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iqAOqqO5hS5t5IZRmORSjD1Brmf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOE+Inh2Lwx4QuLayHm20sTxRow53H6depP4VmzeGNW1fQtO0jRxG6RmIXMzHYAiYPHuSOlej3Pj7wDdRGK58W+GJYz1V9TgI/9CqRPiJ4GRQq+MfDQUcADVIP/AIquV4WLlfobKs0vMn8PeFLbSrprxyHu5DucgYXdjGfc44ya6WuV/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4quiMVFWRk23qzqq5X4l/8i5Z/9hrSf/Tjb0f8LH8D/wDQ5eG//BpB/wDFVzXxB8feDrrQbWO18WeH5pF1bTJCseowsQiX8DO2A3QKpYnsASelUI9Porlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqAD4T/8AJLPBv/YFsv8A0QldVXl/wy8feDrP4beE7W88WeH4LmDSbSOWKXUYUeN1hQFWBbIIIIINdN/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAfKv7a3/JU9K/7AsX/AKPnorP/AGu9a0rXviTpt1oep2OpWyaTFG0tncJMiuJpiVJUkZwQce4ooA+uvhP/AMks8G/9gWy/9EJU91428O2tz4gt7nU445tAiSfUkZHBgR03qenzZX+7nkgdeKg+E/8AySzwb/2BbL/0Qlcf4h+E82ueLvEOsT38cMd9MjpAmSLiJbaFRHNkfKBPBG/G7hSP4jQB6jpl9b6pptpf2Mnm2l1Ck8Mm0ruRgGU4OCMgjg81kQeLdLurjRY7N5bhNWknit5VTaoaEMX3bsEfcYDg8+3NecxfC3V0k0tZBos8sEGmRjUpJJPtGn/ZlQSpbjZ8yybW6sn3zuDdKl8P/CWO2bR7PVNE8NHTLC8uppvJXcb1JFkEZkjMQG5NyjBZgAOD0FAHsNFed6T8P7mDwDBpk+rX0Gux6U+nLc2+o3Jt42MbIriEsEbbuGCVzwMEEAjjLL4Ta/Z+H7yxhi0QtdXFs88E8lvLBIkayAui/wBnhI5SWTLNHKWAwSCAaAPahqlmdZbShN/p624ujFtPEZYqGzjHUEYzmrteGaP8IdWsbK0jlTQ5L8aRcaZ/aO8+fYu0szRTQHyRuKpIq4Hl428HGKd4e+Dt3A1jHq8GmSWUepW93dWpmjlgnSO3uIyRElpCoctMmd27cBy3yjIB7jRXOfD3Qrjw14TtNJunhZ7eSfZ5JJRY2mdo1GQMBUZVxjAxgcV0dABRRRQAVyupf8lT8Pf9gXU//R9hXVVyupf8lT8Pf9gXU/8A0fYUAdVRRRQAVzniXxbY6G6wtme5JG6JDyq9yT9O1TeNNU/snw9czI+ydx5URHXce4+gyfwrw52Z3Z3YszHJJOSTXDi8U6Xux3OvDYdVPelseu6r4/0u2tkexY3krEZjAZMDvkkVa0XxtpOqTJCGktrhyAqTDAY+gI4/PFeMUqMyOroSGU5BHY1xrH1Oa72Ol4OnayPo2isHw14lsNZghSOdRelAXhYYII649RW9XsQmpq8WebKLi7MK5X4l/wDIuWf/AGGtJ/8ATjb11Vcr8S/+Rcs/+w1pP/pxt6ok3tY1Sy0XTLjUNVuY7Wyt13SSyHAUZwPqSSAAOSSAKpeH/Eum6/JdR6e12s1tsMsV3ZTWsih87TtlRSQdrYIGODVfx3odzr+gfZtPnhgv4LmC8tmnUtGZYZVkUOBztJTBxyM5HSuY8TeHvFXiiOybWtN8MzW9ldLP/ZEl3LLb3Y8uRW82RoezMjKvlsMqc5yCoB6RRXi138Iby90SaC9OlXN8mhyWNjJIXIs7pppZEaMlSVVA6qrj5gF6CtKfwFrCS+JHh03wvfahqRneDWdQzLcIsigCB42hYGMDKffxt5KHkEA9XorxDRPhZ4l0jSr+XTLzSrHWU1Fb3TNj7oYVaAQzIwighUbhlhtjAyqk85NS3PwgvLfxVp11p9xHLploLNYWa4jhuLXycbtjNayud5BchZI9xZg3XNAHsklzHHeQ2zLMZJVd1KwuUAXGdzgbVPzDAJBPOM4OJq88+K/gnUvF+P7Nms4saRqOn/6Q7L+8uPI2HhT8o8ps9+RgHtnaj8NLuyuNUu/B39l6XdR3dte6SgVliikWIxTeYqrwJEZgSM54J5FAHqlQXtzHZWk1zMszRxKXYQwvK5A/uogLMfYAmvFtf+EmsyX2jJo0mkC20xbPybyUIl3ujl8yZnf7O8jFyWYbZYxljkEE1zk/gTVdY1fU9Gs9JtUvPsmqwT69NbXMLXbzOBGZpJIF3YzgeW8owCRgYyAfSdUtZ1Wy0ax+2alN5Nt5sUO/azfPJIsaDABPLOo9s88V56/w4uU8RNrloumRasdffUBdkN5n2Rrcx+USFyfnIJTO09c5rjbb4M689tqov4vDRNzDaEW0SolvLNDcrKzFI7WMIrJvTkSsA2CzDigD3uC5jmnuYkWYPAwRy8LopJUN8rEAOMEcqSAcg8ggTV4/efDXUpb6a7/svw5PZPexXI0GaZxZ7FsY7faSISMo6Ep+7IIP8J6VovhDetZXTXr6Xc6olhp9vYXTly1pLBNI8hRipZRtdFUgkkLzjuAe00jsERmcgKoySewrzrwP4Kv9B8c6vqz2ulW9jeCY7kdbi6dnlDjMv2eNwnByjvL/AAgEBRnM1X4bahf+Kr28kt9Fliub57o6nK7m8MDQeX9jKbMeVnj7+Nv8GeaAOz03xnp914Nm8U3lveaboqRG5Wa6RS0lvtDCZVjZ22kHgEBuOVHGdKz1u2uvEepaLGkwurCCC4ldgNhWYyBQpznI8ps5A6jr240/DpR8EG8Eww6Zb3smlJbSyRxYhe6Eagyn5QSS6htxG7oetYl58K5L5tUu/wCyPDmmXj2tlFpsVozMlhJDPLJI0beUhXcHU5VQc7geOSAew1mWOs295rup6TEkouNPSF5WYDYwlDFdpzk/dOcgfjXnPg34b6rofxDn1y9uYrmNp7qX7UlxGssyyklUlQWodwuQBmcgbQQAPlEnxB+HWr+ItS1S5sru0SG5uLKYW0rLtnWGOZWjk3wyoBmRWGUcZXkA4IAPVahs7lLu3WaJZlRiQBLE8TcEjlWAI6enI5HBrxu2+Fmq20/hmSC20t5dMCo0t/dx3ixJ9peUrHGbJRwrYVo2hI+UchBmLUfhRrU9gtvjQ7yVrOW1inupZA2lyNcyy/aLfEZzIVkXPKHMa/MRxQB7fWYutW7eJX0MJL9rS0W9L4GzYXKAZznOVPbp3rhNL+G8th4ns9cjXT1v11y7vrm6XImltJYpVWIttycMyMUJ28Egk9Yvih8P9R8Va7cXVnZaHcJPpX9nx3F/K6y2EvmM32iJVjbLqG4+ZDkdcUAep1U1jUItJ0i+1G4V2gs4HuJFjALFUUsQMkDOB615XP8ADPV3164uQ2lNI91cXB1l5H+3TRSQtGtq6hMCMFhzvIwowgPNV9c+E1xLo+nWtjpvh29ZdHexuEv2dUju2RF+2IRG+98JtywVsKuGHSgD2CwukvrG2u4gwjniWVQ3UBhkZ9+anrxqw+FusW3jyz1q4uoLiGGW2lWZLiOKaFY4lRohm1d2jJVvlE0YIY5AOSer+F3hO/8AB2k6fps0OkCGLTYYrm4tg5nnulJBLMQN0YXaFzyORwMCgDuqKKKAOV+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiEqxqPg/TdQvZbqe511JZTuZYNcvYEH0RJgq/QAUAdFRVLSNNg0myW1tXu5IlJIa6u5bl+f8AblZmP0zxV2gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPiv9tb/kqelf8AYFi/9Hz0Uftrf8lT0r/sCxf+j56KAPqr4T/8ks8G/wDYFsv/AEQlcmvi/VNF8feJori2+26M+uWGnK7XrCS2ae1twBFDsIK7mLNhl+8Tg811nwn/AOSWeDf+wLZf+iErUbw1oTa4dabRdMOsHB+3G1j8/hQo/eY3fdAHXoMUAeep8XJxplvfzaBF5F9ZDULBIdQEkkkXnxQ4lXYBE/75SBlhkMNwINQ+OvGWvSWt5p8NhbadJp+oaXFe3MOqPvUzXURCRKIgZFKEBiSg+ZwN2059Fg8K+Hrd7t4NB0mJ7xg9yyWcamdg24FyB8xDc89+afqHhrQtS1GK/wBR0XTLu/i2iO5ntY5JE2ncuGIyMHkehoA83b4x3BsdY1GLwrevplnb3c8VwROisYCRtkdoBGm7DY2PJjGCAa9T0uW9mtd+pWsVpMWOIo5/Nwufl3HauGx1AyAejN1rOk8IeGpLy7u5PD2jtd3islzO1lEXnVvvB225YHuD1rcoAKKKKACiiigAooooAK5XUv8Akqfh7/sC6n/6PsK6quV1L/kqfh7/ALAup/8Ao+woA6qiiigDxj4g6w2p69JEjn7NakxIM8Fh94/n/KuYrc8bWMen+Jr2GFiyFvM57FhuI/WsOvnK7k6kube57dJJQXKFFFFZGh2/ws062udSlu5pSLi2wYow2M5yCfcf416vXjPw50w6h4ijkLMsdqPNYrxk54H+fSvZq9vAfwtjysZ/E3CuV+Jf/IuWf/Ya0n/0429dVXK/Ev8A5Fyz/wCw1pP/AKcbeu05TqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+K/21v+Sp6V/2BYv/AEfPRR+2t/yVPSv+wLF/6PnooA+qvhP/AMks8G/9gWy/9EJXVVyvwn/5JZ4N/wCwLZf+iErqqACiiigAooooAKKKKACiiigAooooAK5XUv8Akqfh7/sC6n/6PsK6quV1L/kqfh7/ALAup/8Ao+woA6qiiigDi/iXptg2hzXsiRx3isuyQABpDwNp9eP5V5IK978RaLba7YG2ugQQcxyL1Q+orz7Wvh5d2sXmabOLoKCWRhtb8PWvKxmHnKfPBaHoYWtGMeWTOGrQ0DSpda1SKygdI2cElm6AAc11ul/Dx7vSEuJ7tobqRdyxlOF9m75rovCHg1NDujd3E4nudu1dq4VM9fqawpYOo5LmWhrUxUEnyvUn8F+Fz4ea7aSdZ3m2hSqlcKPb1ya6iiivZhCNOPLHY8yc3N80grlfiX/yLln/ANhrSf8A0429dVXK/Ev/AJFyz/7DWk/+nG3qyTqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4T/APJLPBv/AGBbL/0QldVXK/Cf/klng3/sC2X/AKISuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+K/21v8Akqelf9gWL/0fPRR+2t/yVPSv+wLF/wCj56KAPoX4ZeI9Ug+G3hOKLwZ4guY49JtEWaKawCSAQoAy7rkNg9RkA+oHSul/4SjV/wDoRPEn/f8A07/5Ko+E/wDySzwb/wBgWy/9EJXJeK/jDD4b13xVpt3ozH+yIN9rMbnC3sggjmeL7h8tgkmR97IVjxjFAHW/8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlVHq/xB0HTpb638+4mu7USjYlpOY5JY4zI0KyhChk2qfkBLcHjijw14/0TWtOtp5Z2064ktILuSG+iktwiynau1pVQOC4Kgr14x1GQCT/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+SqbffEPwxZAmfUJSqtMHaKznlEaxSGOR3KodsYcFfMbC8HB4qh4l+IVjaGCHRZlubldWtNPume2lMMSyTxRv+8wEDbZQV+bnrggGgDR/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqpB448PTwqtprFj9rnjd7SCaTynuQufmjRsNIhKnDLkHBwTXK6b8Sri50jwzcTjTYpr0ac9+cyBYVubaSViAwAUApwd78ZzjjIB03/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVTbv4h+GbSCCae9uFimhFyGFjcMEhLFRLJhP3cZIOHfCkAkEjmusoA5X/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKrqqKAOV/4SjV/+hE8Sf8Af/Tv/kquav8AxHqh+JOhTHwZ4gWRdJ1BBCZrDe4M1kSwP2nbgbQDkg/MMA8ken1yupf8lT8Pf9gXU/8A0fYUAH/CUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUGgDlf+Eo1f/oRPEn/AH/07/5Ko/4SjV/+hE8Sf9/9O/8Akql8QeOdE0WRoHuDdXikA21sN7j69h+Jrkbz41aZAZEj0m/aVcja5Reffk1lKvTi7NmkaU5K6R1v/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVXhmr/GTxLqOoSvp00en2yfKsSRq/4lmGT+lQ2fxP8AGFldxXU9808QPMU0QCOPTgD9DWH12nc2+pzse8/8JRq//QieJP8Av/p3/wAlVzXxC8R6pNoNqsngzxBAo1bTH3yTWBBK38BC/Lck5YgKOMZIyQMkdN8O/Fkfi7QFvRGsNyjFJogchW9vY0nxL/5Fyz/7DWk/+nG3rrjJSV0c0ouLsw/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSq0PF+vxeG9GN68El1M80Vrb20bBWmmlcJGgJ4GWYZJ6DJrnLD4iQQXd/b+Jm0Sxa0kihkOn6r9vMcsknlrHIgjR423EDJXb79aYjT/4SjV/+hE8Sf9/9O/8Akqj/AISjV/8AoRPEn/f/AE7/AOSqiPxA0aKS5F3JLGqSwwQwraXLXUjyReYFNv5QcNtBOAG4GTt6VT8JfECx1bw7aS32oaZb67dR3EsOntJ5UrokkiqRC7b+kZz9G6Y4ANH/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+Sq5nTfiVcXOkeGbicabFNejTnvzmQLCtzbSSsQGACgFODvfjOccZ6ST4h+Go/s++9uNs0azBxY3BVI3YqkkjbMRoxB2s5AYcgkc0AO/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kqtHxF4l0zw81omqSXAlu2ZIIre0muZJCq7mASJWbgAnp2qhJ498PRxadO11dG01ARNb3a2Nw1ufMbagaYJsQlsDazAgkZAzQA3/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5KrmtI+L1jqFxo8LaPq8bX93d2rFbC6cRiF5FVlIhw5bYCwH3Mnd9010X/CxvC4W6d9RkSK3iedpXtJ1jkjRwjtE5TbKAzKCULYyKAH/APCUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVRT/Efwzb3htp7u8ilURs+/TblVjWR2jRnYx4RWZSAzEA8HOCCbHinxfB4d17QNOuLO8nGqvKnmW9vLMYtibs7Y0bOTgdsDJ6A0AM/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSqzfBHxEsdbsFj1BpI9WC3UpghsZwsiQylT5RKkSsBsyqFjk9O1M1X4paNaTaclrb6ldNcaiLC4i/s66Se2JgeUMYTFvYkKuFwMhiwyFNAGr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lVo694l0zQmtE1CS5M93u8iC2tJrmaQKAWIjiVmwMjJxgZGetVJ/G2h2+qJp93LfWty6u8f2nTrmJJAkZkYJI0YRiFBOASeDxxQBD/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlVa8M+MNE8TSyRaPdTSSJDHcbZrWWAtE+dkiiRV3Idp+ZcjisXRfiFYya5q2l61MtpPBqctlbSfZpVhdVjVwGmIMYkxvO3cDgdPUA0P+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5Kq54c8W6N4inkh0q4meVIln2zWs0BeJiQsieYq70JB+Zcj3qpJ4+8OxjUHa7ufs9gzJPcixuDAHVwhRZQmx33kLsUlieAM0AJ/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lUxviH4bW3hl+1XhaWd7VbddOuWuBKih2QwiPzFIUhsFRwc1z//AAtGxn8XGK3vI08NW9la3Ul0dNuZTO1yzrGFkXCRAEJywbcSyjBViADo/wDhKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+Sqk1HxzoFhfTWUtzcy3sU5tmt7WxnuJPMEaSkBI0YkBJEJYDA3YznilPjnw8uqjT5L2SOff5ReS1mSFZNnmeW0xTy1fbzsLBh6ZoAi/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSqqeGvHEHiTxjNp+lB30pdNjvEnls5oGkZpGXKGQKHj2gEMoIPrWzJ4t0GOC9ll1OCJbNrhJlkyjgwLulwpGWCrgkqCMEHvQBR/4SjV/+hE8Sf9/9O/8Akqj/AISjV/8AoRPEn/f/AE7/AOSqyp/iXYw6/Z6cLSe4S5vZbPzLSC5maLZbxzDeghyGPmrlQSAPmLcMFn+G3j6z8V6fYxXL+VrUtu9w8ItZoo2VX2MYncbXAJUHazYJ5xQBe/4SjV/+hE8Sf9/9O/8Akqj/AISjV/8AoRPEn/f/AE7/AOSq6qigDzD4ZeI9Ug+G3hOKLwZ4guY49JtEWaKawCSAQoAy7rkNg9RkA+oHSul/4SjV/wDoRPEn/f8A07/5Ko+E/wDySzwb/wBgWy/9EJXPj4nMfHtz4cXTrF/I1GPTyqajm8YNGr+eLfy/9Uu7Bbfxg/SgDoP+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkqsPxJ8TrDTfB2p6hbOk2rxWt9NbW9vb3F0mbd5Iw0u2NSib0AZm2qDkBiBuO1b+P9BN/b6fPeSfbndLdzHaTNAk7Jv8ALMwUxq23naWyO9ADv+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5KqGP4keFpLaSdb+4EarGybrG4BnV3CI0KlMzBmIAMYYEkeorptLvotTsYru2S5SKTO1bm2kt5BgkcxyKrL07gZHPQ0Ac//wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lVbvfF+jWerXGmyTXT3Vsoa48iynmjgBXePMkRCiHbzhiDgj1FVLf4geGp4ZZl1CSOBLJ9Q82a0miR7dApeRGZAHA3rnbnrjrQAf8JRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lUg+IPhw6i9j9ru/tCSi3b/iX3G0SmMSLHv8vbvKsCEzuOcAZ4rM8K/FHR9c0PR7ya31O2vdQgEwsotOurhkHy5YFYvmjBdR5mNhPQ8GgDU/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kqtbxBrtnoFqtzqK3xhJOTa2M90VwMksIkYqMdzgVit8RvCy3EEQ1J385LeRZUtJniVZ8eSzyBCiBsgAsRzxQBJ/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lVSfx7aXfjXR9E0ZmuYp57mC7na0mEatFGxKxzECNmDLhgC2MEcVt3virSbPXF0iSW5kvyEZ0t7OadYVckK0rohWIHB5cqMAnpzQBR/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kqoB8S/ChsZ7w6jMttCkcu5rG4XzUkkWJHiBTMqF2UBk3Dkc07T/iP4Xv76O0ivrmKZ5Xg/0qwuLdFlRWdo2eSNVVwqs21iDgZxgigCX/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKqKL4j+F5LWacX86JGsTqsljcI8yyMVjaFGQNMGIIBjDZrJ0X4o6U9neTa3JNbsl5dpDFFp9yZFtoXC+bNGELRgZGWcKM+lAG3/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lVrWXiLRb7VH02y1fTrjUUjEz2kVyjTKhAIYoDuAwynOP4h61qUAfDf7Xd/c6j8SdNlvNJvtKkXSYkEN48LOw86Y7gYpHXHJHJzweOhJWh+2t/yVPSv+wLF/wCj56KAPqr4T/8AJLPBv/YFsv8A0QlZvi/4WeH/ABXZ+ILfVXvCNZuYLuV43QNBJFGkamIlTjKpg53febp20vhP/wAks8G/9gWy/wDRCVw3jafxTf8AiLxFo1tNrVxpt1Z3EUEdpY+VDCTanCu8tqVky/AZJ85ZRsGGNAHSj4VeHl8T3mtopE13LLNNEbW1bLyKVciVoTMuck4WQAH2yKUfC/R5odLj1K91LURp1nNYRfaGiG6CRAgVwkahtgztJGQWJOTjHL6G/jCfT7q20nVPECQWfh2KW0+3aVHbvJf5nUxHzIFyo2xcYyRtO7klln8V+L79buSwttetbCO10xZpm0VlnjdpJRdyQxvHmRgBGMbWA6hT3AOml+F+l/2bbWVrqms2iJYHTLmSGWMyXsBYswlZkPJZnJZNjfO2CKu3nw70O80a70m4Fw+n3WpR6lLCzKVLIYyI+V/1Z8tQQecE815vrq+JLbXtV1fw3qXiy6vbjw6qWE1zoyr9onjluSYplNqojKhlZQwTcWHLggV0s/iDxTrOszjRU1ix0uXU7OCKW40lo3SBoZDMwWWMEAOF+ZhgHHY4IB3mi6DFpOhHSUvL25tQrRxm5kDvFGeBGGwCQo4BbLepNcs3wl8OS6dbWF4by7s4Y7OIxTOhWRbWJ4ow2FHVXJOMcgEYrD0TVPHa/EldP1Ga5OlRXckOJrVzHPbCM7JfMjsxGshIDEmcLnK7BwK9doA851f4R6Jq1xZ3OoXl5dXltbi0Fxd29pdvJErMyq3nwOMjcRuADEfeJr0UAKAFAAHAA7UtFABRRRQAVyupf8lT8Pf9gXU//R9hXVVyupf8lT8Pf9gXU/8A0fYUAdVRRWbr+t6foFgbzVrgQW4YJuIJyx6AAcnpSbS1Y0r6I0q4r4t+IhoHhKcRsRd3mbeHDYIyDlvwH8xWZf8Axf8AD9vEzW0N9csB8u2IKD+JPH5V5zPqUnxO8Xxx37Czto4yIIkOdvI6k9Sa5quIi1ywd2zenRknzTVkilpMUMNoiQtGzYy7KQcmue8WGNbzKAeYEy+O/pUWvWT6DrFzaic5hOPMBxxisq2eTV7p7e03TTMpLOxwAOmSa8dx5XqeonzLQqeHdqXcUk6hkaQEhhwRXpd5DHNZyRyhTHtPXoK4q+0C6sLXzS0bxoBuKnpVOa/u5oxHLcSNGBjbu4xStfYq57H+zjqTi71fSyQYtizqcc5B2n+Yr0r4l/8AIuWf/YZ0n/0429eR/s4qT4p1IgcC05P/AAMV658S/wDkXLP/ALDOk/8Apxt69rCO9JHk4pWqM1/EmiWfiHSJdO1ESeS7I6vE5SSN0YMjow5DKygg+1cpD4F0u/1Wae+8Ranq+qWc1mJHlltw8P2eUXMUbLFEoGSwY5G4q3XpU3xnsLzUfAU8enm+86K8spytlCJZSiXUTMVQqxYqoLgAEkqOCMg8hplv4lsvFOq6tpd1rktnd61pkbxXOnIn2y3a1t45Z5AYVdSuDnbsClSCOCB0nOdxq3gOxv8AWZtXh1DUrDVHuUukubZot0LLCYcKHRlKshOQwPPIxWr4e8O2uheGY9Etp7ma2RZF82dlMjb2ZmJIAGcse1cD8M9Y8cX3iyWLxQJYrbypjNbS2sqpG4kATyZPskcZGMjBnlJBBHQ1bkufGS+KLu6S61FtPj8Qx2MVgbKPyXsmt42aXf5fmYEjN84bAKkHPQAFxvhL4cl062sLw3l3Zwx2cRimdCsi2sTxRhsKOquScY5AIxUN/wDCHQ7+/tb29vLy7vIIUtzNeW9ndtLGjEoGM0D4IBI3LhiMbiSAa86urn4ieIvDmr22vf2jEywRzzWkFhIzxypcxEiAmzVGUJvO0SzMcKQSM56+68T+NtLbV/7O03Utd0+CGO8tri6sDDczI8aRiJUCRjzFkEsjApkLgYG5cAHY+NPDN/r2s+Hrqw1SXTE0+Wd5Z7fYZsPEUAQSRunU85HTpzXK6h8HvCRvdJil1C7gkjWGO1gd7d3kMDeZlGkjaRScEv5bKGGcioH1LxxZ+IrayuLnVp7iK4sIUji0xHsruApH9qnlnEeI3DGbChkxtTCkNmsrUl8dtpvhDXFivtT10faXlt5bRIlsx5LrkKFX5yCMK7AMwAG0E0Ad1b/Dq2tZ7aSz13Wbf7JezX1qiG3YW7TGQyou6Ekoxkb724jjaRWZZfBnw1ZR6hDatNFb3cTw7EtbRXiVnDHbMIBKemPnduDznjGv4lvtUX4cpd6LfalHqBSErPPpsjXLDcNwaFIHKMRkZ8lguclSBXnWq+I/iP5GlGwj1W0hezLie7s3leW4E8gImSGxdgmwRlRst22tyd2QAD1LWfBWnatca3NczXatq8FrbziN1AVYHd0K5U4JMhznPGMYq34i8Ox61eaVeC+vbC802ZpYZrXyyTuQoysJEZSCD6Z9CK8vn134ijxRrkZW4hgh+3i3t1spZI3jWKQ2zRMLTZvJEZ+a4OcldgJAHZ+ApPEsWtXlp4gu76/tTp1ndx3F1aRw7J5DKJolMaKCF2odpyw3ck5oAdc/DXSLjTLSxa71NI7a3vbdHjmVH23TBpDuC9QR8uMe+azdL+EOj6VC39m6lqVpc/bYr9Li3itIjFLHE8QKxpAIsFJGByhz1681gxnxq13qVvp8uoaPbJ/bl4rWulwgTypdj7MDuiIJdGZsj5pBk5J+aus8Y6xrlr4A028s7bUxq1x5An+wQ5kgLLl2ZDBOwUHggRMwz25NAG34h8MprF/p+oQ6nqGmalYpJFFd2flFzHJt3oyyI6EEoh+7kFeCOa5dvhDokniZtdmv9SlvWlmlJZbfJaWJo3HmCHzCuHJCFtoOMADijQdX8W3HwU1PUL6G7XxZDaX/ANnDWhEzyIZRAwiMa7iQEIHljdn7ozisidvHthc3kqazrN9HZzaY0UMmm2+25WaVFuVJSEErGu4/KQV53E0AdzY+H9I8Lyrq8t68MVlpUOmtLdSosSQQlmDscDB+Y5OQPYVnXHw30y61a4ub6/1O5spr19QbTZGiFv57R+WXysYkOF6AuRnnFeXeIL34g63o3i7TtVt7t0lsL+L7AtlM4JyRD5DraKh4HQzylt3ABGK6HU/EnjdfiHLbadaa2NJEt1C8c1nviAWB2iljZbVRtLqmMzyE7sFRngA7XwF8O9I8ESzPpLs3mRrCN9paRsqg8AvFCjv25dm6Z681G/w7s2sb3T11jWE0qeY3UVkrQ7LSczCYSRN5XmAiQbgGZl5IwRxXHPqPj+wtbdJrvWbqG5sNOuru6XSo2nsneVhcLDGkWGZVCnYyuwyTg9Kli1vxYw04aneeJrPRWe8A1G00RZb6YK6CDzoPIfygVMhz5S52rnbnBAO10nwLY6fqlvqcl/qV7qMd3LeSXNy8e6eSSEQneFRVACKoAUKBgVn2nwt0S10S+0uO61Ew3dna2ZkaRN8Yt3eSJ1OzG8NIScgg7Rx1zyXi+fxZr0XjTwpbz3Msdpp97cedHDFvu454CLW1xs4O4yg4AbEac/MTUbXniW0cT6SNdltTpunxT6lNoarfRr9quBMETyFLsi7MJsYBW3hSWJYA6q++FOn39je299rWrXLX12b25muIbOV3kMSRgjdbkR4WMYKBSCTg9MKvwi8Npr8uqKrlpjulilt7abedmwnzniadSQM/LIOckYyau61e6rH8L7u68O3er3urCFjbz3mniO6ZvMx80BiToMgDyxkAHnqeN8T6n8QdJub2xsptTvrCHUUT+0/saicwtbK+FEVrKGUSllLLCxGMEjrQB3vhPwTB4c1EXi6tquoypZR6fEL1oiIoEJKqNka5IyeWyT3JrK8U/DbwxfNr+p6vPcW0d88V3dS+esccAiTa5BIwqugKyE9Vz061yq6749H2MXUup/bvs9mbaKy0dmtb52kInNw8kIeEgY4Pk46gHOKxrrWvFfiXwz4gtrefWNVS4s9dtbq3bSwlvEEM0duIJViUyyEhV2q798gEcgHqUvgWwm1M6rZanqNrePqLaos9u0TfM8CQMgDxspQog7E5JIIq1oXgrTtFuNFmtZrt20qznsYBI6kMkrxuxbCjJzGuMYGCeDXncviDxpB42sbOwtdbh0lJhbTxz2JlhWMWxPmpstR8u8L/AMvDNnI2DIwuh6p451KDT7N73xDC8mrQwXWonTkRfINvOzmNJbOIxrvWIEujgFlAducgHtVFeT+FtT8Z6bNp15r8us6tazWGoy3dr/ZsaNHJbyIIQgRFO+VN5CscMfugDp6nazfaLWGby5IvMQP5cq7XXIzhh2I7igDmvhP/AMks8G/9gWy/9EJVGfwp4dmk1u+TVJIrpNTGoz3kVxGH0+dYY1YAlSEBiVdyuDlXOeCMXvhP/wAks8G/9gWy/wDRCV5zruma1/aPipLfSbmSG81HUnV/sW8sraTEiMjlSQGcFAVI3EFeelAHWT/C7R73TJobHWNWtre9trm2uJLWWFvtMFxNJMyktGwwGmfaVwcHBJrPufhzqMnjC3a3uVi8Lx366hLbyXgkM0nkeWxEX2cFCSef3zLjJ25OBhyaz4+s/CcUcNnqFrqENzbwTQRWhaO3s/KOJIZBBK0jlggfMbFSSPLUDdXXW+o+LB8ImvfmufEoRsMlq6yFPOI3CKSKImQR84MahmHC4IFAEGkfB7QtI0++stOuJYYbqEW7f8S7T2YRBg2ws1sTIDtAPmF84z15re8LeDl8OT2KWmqX0unWdrJBFaSNhS8kpdpGCbUOOFVQgCDIHBwPPLzxR4jtrjTLefV/EcOk3WsSW0V+2iL/AGhPALN5Di3+zk8SrgN5IOASRgZNS48Q/E8SaOJYrm0D2kbhzZSOs0hlcEXCxWkxQ+WI8qGhwWOCeigHqF14Nhl1fU7211bU7KLVMG+s4PJMM7eWItx3xsynYFHysudo9853iPwFFqlv4Q0+Jl/s7RZk86SSQiaWBI8CLCjDB2WMvnAwvT05Vrjxw2mSzXkuo3q30WsxSWE+mRGOERtILUgCIMd4VcBywcMOD1M9rdeNo9SE8c2opZW+paZaR6cNPiWB7aS3g89yRFvAV2k5VgFKkHgYABu6f8P5H8T6rqer6ncPZy6yurWunwsnk70gijR5CY/M3hkJ2h9vCnGc1BL8JdMm0bTNKm1nVpdP004tY3isy8KDGESXyPMUDGNysH5OWPGOL03xX4xnu5LO41XWbfVn0Oe7uba50TEdpdLcwIBbhIDJKoV5AGHmjkMc4Irv/D2qeI5vhnqd6ttfzeIIork2kepIqvNIqny8KIYDtJAxujRj39aALPjnwhovjq4gstQv3W404GR7eHyJcLKCAZIpUdedh2ttBBU7SOahsvhlo1noculR3OoG3khsICzSJu22bBoznZjJwN3HPbFcDocetz+KLzURFr2opPcaGr3OraKIXASS5M2xDCgUJuHzgZXdnd0NVbqfxbrGmKurXPieb7Bqljdte2ulbFCCRw5igks0lyvysVxMAAvzH5gQD0/Svh/ZaZrlpqEGp6o0FlPc3NrYO8Rggefd5m3EYcglyQC5x2wOKn/4R2x1XWH1/StbvI4L+ONLqKzeCW2vkTIG7ejkcEqSjKcd8jNcnD/wlF7Da3l7NqF3EniKOCG2udLiXFoJgRcMDEGDbf4xtAB6AjNcj4bvPHGleFFs9AXXne10uaSe3vNI8lbWZZk8tLcvEpmLIZcjLjpgjIFAHo0Pwt0tbWK3uNU1i6jt4re3tBNLF/osMM8cyxJtjGQWhjBL7mIUDd3rSu/AWkXjN9pe7kRtUk1Z4y6hWkeBoGQ4XOzY54znPftXnniu813xDrEGoL/wk9lomneIIJLZ4NGbz44DYyK8qxPAzsBKxXlTjecjgbYLfxF8TfP1lmiuPtEUN0Vs3sJXVSH/AHbQEWqIzBcnaZ5N+RwDxQB0+ifCjwzYJc2Wk6lLFd2skDrJbQWMdxZuhDxktHAGYkdpd+4HPOc1fHwtsUWdoNe16G7uRcJd3UckAkuUnYO6N+62qNwJBQKwycGovhTFd/234tu7mXWrmG5ntjDd6tY/Y5ZwsCq2E8qMYBBH3R079a5UTeO4dBu201tR05rHSbm9htLbSYQtzdC6m2RlTEfvIEJVMMdwbOSSQD2qztorKzgtbZNkEEaxRr12qowB+QqauL+Jmq6tp3hq0k0eDVDeT3CRu+nxb2hBViWceRO2zjHyxMckdBk1b+F99rWo+BdMufFEc0esMJFnE0Jic7ZHVWKlVxlQp+6uc5wOlAHyp+2t/wAlT0r/ALAsX/o+eij9tb/kqelf9gWL/wBHz0UAfVXwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFcrqX/JU/D3/YF1P/ANH2FdVXK6l/yVPw9/2BdT/9H2FAHVV4b8f9XkOuaVpIdPs6wm5Ze+8kqM/gD+dHx68c6poetWulaZeT2UTQebI8Ywzkk4w3UAY7V4tqOuzatci41G+lupwoQSTMWbA6DJ+przsXiE06aO/C0GmqjNiX/VP/ALpqhoKPJqtupvLiE54eN9rZ+tS6XYX+rQu1o2+JflLF8DPpVS4hnsLsxyAxzxEdD0PUGvNjpseg9Ta8WaHAIGvTNcvIWAYSSFs+/NQ+Ebmw01ZhKfLkcgbiCeKrQNf61OLdpy/8RDnCjH0q3qXh57Ow89ZfMZeZABgAeoo8mIs+JNZguLP7PaPv3nLNgjAHasi2sQVDTZ5/hrPrRivgsQEgbePTvQ1ZWQ1bqehfAwzWnjiSKC5hjt5YD5iSMAZOeAo7nNex/Ev/AJFyz/7DOk/+nG3r5++GHiGw0XxhFeaxbCWJx5aPjJgYkYYCvoD4kkN4bsiOQdZ0kj/wY29evgn+7seXjF+8uWvH3iaPwh4XuNanhSaKCa3jdXlESqskyRFixBwFD7vw7daxLL4o+HrvVddiivbW403TEs9t7ZTfa/tEtw0iiJEiDEuDGOF3E7ugxXTeKdBtfEujPpl9JNHA80MxaFgG3RSpKvJBGNyAHjpnp1rI1nwHp2qarqOpNd39vf3hs3WaB0Bt3tmcxvGGUjP7xgQwYEdq7DkLFj458N3v+r1SOLEUkzi6R7fy1SQRvv8AMC7CHZQVbB+Ycc0zUfHvh2wkkjnvJ3kjllheO3sp52UxBfMJVEJ2LuUF/ugnGc1k2Xw98OakmmXrXtzq32a5ubhrl543F5JKQJBLsUKQGRCFUKAY144xVO7+DXhu40vSbMyXRfTRMI7meK2u5JBK/mP5gnidCd3O7aCOmcE5AOnh8b+HZlRotUiZXuvsSna3Mvlebjp93y/n3/d285xVOH4keFpYw/8AaE8YJi2CaxuIjKJSVjZAyAujEEBlyvvSQ/DzQo9d/tQpMznTxpzW+5UgK7dm/wAtAArlAEyuAF4AFZPh/wCEWgaE0Bs5p8QTwTx7bWziYGJtyq0kcCu4JxnezE4znPNAHW6r4m0vSdGttU1GS5gtLl444g1pN5rO/wB1fKC7wx6YK5zwayZfiP4Xjso7o31w0biZmSOwuHlhETbZGljWMvEFPBLhQK3Nd0W31qOyW6eVBaXcV7H5ZAy8bblByDxnr/OuE134VeFNR1aIXV20eqXEt3dRrNHaXDyLJIJJAsc8LrtVmXkLuG4Asc0Aa2i/EjSNQ1XVLKdLm1FpqSabBcG2maG4Z1iKES+WEUs0uAu45ADdGBrU1Hxz4bsAvnapHJvjEsf2aN7jzAZPKATyw25i/wAoUZYkHjg4yrr4babcWetWQ1HU4bDVWjlktoTCiwzxiILNERHuRwIEwM7RjhRxhp+F+gxy301jJfWU9xJayxSQSL/ojW+fL8kMpUAlmLBgwJY5FAGlH498OyfYVivLh5r0zLBAllO0zNCyrKpjCb1ZS65DAEDJ6AkZfhX4kaRd+HLG78Q6np+n3jwLLclmMUEJZmCK0jHarMFJCltxAJAxVzw34S0i11O21Oz1O61C9sZL2OaeSaNzJNO8Zl8zaoAZTCgCqFCjjHpJ4L8B6Z4Nc/2HcX0cEke2e3d1Mc0mf9cw28SY4JXAIAyDgGgDHl+IMketa5ZL/Z8kUFz5Fg4aTMo/s4XeflDK/O7qUG3oSQA2jo/xB0ibw7Z32oXJ+1NBbfaEtbWaUCeVAwijCqxZ+c7F3MByR3qTUPh/pV9rlzqstxfC4numu2VXQKHazNoQBtzjyznr97npxWFN8K/CsemQ+GjfXEdrIUurWwleCQLLCArzxxSRsCSHG8EFMvnaC2SAdnD4o0eXw1Pr4vAmkwJI800kbxmLyyQ4ZGAZWUqQVIzkdKwW+I2nnxPoukw6frBTUknYTS6XdwtG0ZiAGxoQSp83l+FXbyea19G8KWmj+E5NAsZ2igdZF86O1tY2G8nJ8tIhDnnHMeD3B5rnNG+Hei+HtU0hbDXL611KCS4uII1NrH50b+SJoxCsQQR/u4s+WikFs5y2SAbui+PPDutyWC6beyy/b4XntXa0mjSZEClyrMgBxuGRnIPHUEVWl+Ivh420UtlPeX5ms0vo1s9PuZ8ROCUaTZG3l7gDjfg+1Qn4dWEejeHtPsdT1WxbQ7drW2uoHi85onQI6tujK8hV5CgggYIqDw14F0qytrCfw3r+pLp4s7ezlFvLBLFfRQgopcmNuSuVJjKfgRmgCz4U+I2ja9othdy/abG6uNMOqyW09tMuyJVjMjKzRqJFUyKAy8N1XPOLUvxA8NRNMG1CQiCJJpWW1mZY0eMSIWITC7lI2g8knaMtxWP/AMKsshp1jaR6/r0Ys7GTS45Ua3D/AGNxGPs5Pk4Kjy1w2N/X5jWhL8OtFn0TV9KuGuprTU4beGYSMpK+RGqRlflxn5FJyCCe2OKAI4PHPhK2nlktVulv7yZlmt4NHuftckkaJkyQrF5vCPH8zLjDLz0rptY1e20myS6uor6SJmChbWxmuXyQTykSMwHHUjA/GuEl+DuiSaN/ZgvZ4rcytKxg03TYmLFVXIKWo2kbeHXa4z97hcdH408Faf4t0yxsb+4uo4rOQSptEUwchSuJEmSRJODn5lJBwRg80AMj+IfheUQmLUzIstmuoBktpWVLZi481yFwigxuCWxtxzjIzo+HPE+leImuU0uadpLYI0sdxay27qrglG2yqpKtg4YDBwcHisHRfhloWlaZc6cjXlxZ3GlDRpI5nXBgDzP/AAqMNmdxkdguAMZNzwH4F0zwUl2ultv+0BAxNnawEBM4GYIYy33ur7j6YycgGRqfxP0q38Q2sEE5bR4oL2a/vGsp9ii3C58qTbskwdwOzf07Vtt4o8M6HHcWsUqW4gaKRra1s5CzNcs7JsjRCXZyJGIUE5yTWR/wqzSXDw3Oo6tcad5F5bQ2MkkXlQR3OfNVCIw/fgsxx2qjq/wv8PDSdTm8Sa3f3Ub/AGaaW91JrUrbi2VwjbTEIsBZGB3qQep5yaAOg8QeObDT/h7qfizTo5NQtbKKR/J2SROzoxUowKbkIYEHcvy4JOAKdJ8QfDsVxDBPc3kMsgQsJtOuY/I3uUTzi0Y8ncwOPM256jgg0tv4G0uLwJd+EyXOnXUUsMrxQwW7kSZyQsMaRgjPUJ25zzVG5+HVvd3Dy3mva3N9pEIv0LQKt/5Tlk83bEMYBCny9mVABzySAdxRRRQByvwn/wCSWeDf+wLZf+iEqLUviP4Z07VJ9Oubu8+1w3AtHWLTrmVfPKB1iDJGVZypBCgknsKl+E//ACSzwb/2BbL/ANEJTz4K043st15135kmsLrRG9cecsKwhfu/c2qDjrnvjigCK5+IXhy30a21eS5vDpc4dhdJp1y8cQRyjeawjIiIYEEPtxg+lTxeOPD8uvf2Ol5L9t+0mz5tJhF54Tf5fmlPL3bRkDdkjpXKa/8ABXw9rdottdXupiILcLjFvJ/rp5JmK+ZE2xg0rAMm1sYBJxXTx+B9NSWKQT3m6PVv7ZGXX/XeUYtv3fubT06579qAM+2+IPgrVootR+1b1tIRfW89zp80Z2OfK3wF4wXJMgT93k5fb3xV5PiD4cdIdt3dedLLLAlt/Z9wLgyRhWdDD5fmBgro2CuSDkcc1k3Pwn8PXWh2WlXT3s1rZ6Yulx+Y0bExrLHKrkFMFw0SdRtIyCpBq94Y+Hek+HbmwuLOWQyWbzumy2tbZWMqorblghjU4EYwcZ9SRgAA1vEvizR/DbwR6rPOs06PJHFb2stzIUQAu+yJWYKMjLEYGRzVPTvHGj3mqJaC7hAuZIY7NgsuZTJB56ht0YVCUBIG45x2Py1l/EzwpquuyW914cmW11EWs9jLObwQDyZdpKlTby7xlQeNjDHDDPCf8Kx0ubw3c6VdXl+HuY7MPcQSCN4pLaNER4jg7ThOc56ntQBU0TxT4F0m51G+0i10yztphbMbnT7CQTXTzSTKm5EhBYFom2kFt2ScAbS23N8RvDEVlb3Jvbl1nMwWGKwuJJ18k4l3wrGZECHgllGMj1pG+H+j/wBox3cLXUHl/YBHDGyiNFszIYlAK5x+8IPPQDGO/KeP/BH9mWF1qWh6pHpkkhvTeX99qSWsccd06u6Nut5FZN4GOUYdnyc0Adf4r8a2eheG9K1uGCe/s9QurSCPyIpGbZO6gPtVGY4VshcAscKOSKzfDHxGsNQ1e/0/U3e1nGovaWe+yniR1ESyKru67VlxvOwlW4+7WkfC1nqvgTRtH/tCYw2kdpLbX9mybt8BR45U3BlIygPIIIqNfAOmtDGl1dX10y6n/azvK0YMsxhMRDBUA2lSSQAOemBxQBoeHfF+i+Irh4NJuZZZBEJ1821lhEsROBJGXVRImf4kyORzyK364rwF8N9G8EXUs2jljvi8hQ9paoyJkHHmxwpI/Qffds4ycnmuuvru2sLSa7vriG2tYVLyzTOERFHUsx4A9zQBPRRRQAUUUUAFFFFAHxX+2t/yVPSv+wLF/wCj56KP21v+Sp6V/wBgWL/0fPRQB9VfCf8A5JZ4N/7Atl/6ISuqrlfhP/ySzwb/ANgWy/8ARCV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFcrqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FAHLfGP4cTeNLuwvLO5SCS2ikSTcM5H3lwPrkfjXzrBCkMSoo4HrX2243Kw9RivjnUtOW21e+s4JxNHbzPEJcY34JGcc+leZjacYtTXU9DBzlJcj6F7whrdjpVjLZ38ggxIXjYqSHB+g6iuX8X6smq63JNaEiFVEaMMgvjv+tTajYeYUWRiMcgr3q5YWNpBEjpGpcDJduT/9avNas7o9BPoP+H14U1Ge0m+9Im5S3UEdvy/lXVeItSg07TpDOAzygpHHj75I6Vz954cupLP+2I7aTyOFMqkj8RisS4ty1wr3HnNIOQZGY/zquR7snmT2LGiNIwfzolU9Qc8/lWjNCJkKnAJ6H0qhbeYZR5SM7eijNbA0nW7iPEOj35Dd1t3P9KfI29A50lqXPF3g8eHdL069W7E7XOMoAOCRntXvHi92k8B6I8iFHbUtGJU9Qft9txXKfDT4cC6sIdS8XC6uZQQbezuHYCEDuV9/Q13HxKAHhuzA4A1nSf8A0429exhqfLeVrXPKxFTmtHexP8Q7jWLXwtJJ4bMo1M3VoiGODzyEa5iWQ7MHIEZcn0GTkYyOE12XxPpHii7ihn1gaVJNaR3WsWmkRXF4Y/JnJICQESfOI1J2NsDcAZJr1DXdYsdC0yS/1WfyLWMqpYIzszMwVVVVBZmJIAABJJ4rBvPiH4bsViN7c31sXj85lm0y6RoY95TzJVMeYkLAgM4UHBweK6jmPG7rW/FvhP4fHbP4g0iK10ue5tXj0lZTPdm6mytyWhYRDb5TAYQHecHoK62bW/H3/Ceajbu8tpp8c9wsKNYTzwm3ETGKRTHaEF87Wwbjk5XYCRXQ+IfFHw/uNfjTWrOO/wBVsbj7LDK2hzXTRzgb/LikETAvgbtqnPGa1f8AhY/hYx2siajK8VxGswdLOdliRnKBpiExCCysP3m3lT6GgCl8KNQ1y/0y/wD+EgbVJriKVVSa+g8hJflyTGptoHAz13IeejNXEQa78QpdNl8mTXDqLWateLPoypHY3RuYl2Wx8secnltNk5kGFVtwzXaah8R9Nj8U6dp9lOrWPmXa6hdy2sywxCCJnbZMQI2KspDAFsYPSryfEjww9uZReXm7zI4ltzptyLh2kVmTZCY/MYMqOQVUjCnng0AS+CzrfmeI7DWry9uUtL7ybG+uLeOOSWFoIn3DYio2HZ1yFx8uDnBryPwtoXiJU8LxW194ntLzS9N1SOaSXS40FvJutykSF7fY6uVJB+cnBAb09yv/ABBp2n6EusX0s1vZMEI823kWUlyAq+UV8zeSQAm3dk4xmsseP/DhjtmW8uGkuJJYo7dbGczmSPbvQw7N4YBlO0qDg5xigDzs+IfiLL4g0USxT2VvNBp8jIbKZopGdVNwsoS0lKMGLrzLFtwCQRmuo+K+p+IdNudMbw/NqpiKyeda6bZGSWU5XbiU208a/wAQ2v5YOc7wAa6vX/E+l6DcWtvqEly11dBmht7SzmupXVcbm2RIzBRuGSRjketU4/HXh6S/Fmt5MZftf2At9jm8tLjdt8ppNmxWJ4AJGcjHUUAeX3LeK7S18b2Y0q/isLn+157BItPF0L2dg5VJlZGwhGNoAKyEkFv4T0On3PjRdY+0vc6iLGPXILFdP/s+NYTZtbRl5dwjD4EjN8wYKCpBz0HSXfxL8KWrOJdQnZUWSR3isbiRERJGieRmWMhUDowLk7eOuKq2HxN0eWXVkvYb+2FjqLafGUsLmYXLYGPL2xfMxyfkXccDd0INAGr4FvbrVfDs1xcX1zcmS7ukhuZLaOBjGJXVCqqWBUAAKzcsACQM4rx7wtoXiJU8LxW194ntLzS9N1SOaSXS40FvJutykSF7fY6uVJB+cnBAb09/sLuO/s4rqBZ1ilXcqzwPC4H+0jgMp9iAa5G78TeI4fHEHh+LQdIdJ7ea8juW1aRT5EckaEsn2Y4c+apCgkcH5vUA4g+IfiLL4g0USxT2VvNBp8jIbKZopGdVNwsoS0lKMGLrzLFtwCQRmun+I+mave+NPD11otxqFk1rpmpk3dpbpLtc/ZikZ8xHUbipwMZO049aPA/xT0jV/CNjqGt3P2PUTYR3l1H9jnjjO5lT9zuU+aN7Ko2FzlgOpFdhoviLTdZ0+5vbCaUw20jRTrNbyQSROoDFXjkVXU4IOCOhB70AeYWWv+OZ9T0xrtNXgupX03bYx6UDZywyRxm6eaYoTE6sZht3qRsUbWzmuf06++IOi2Hh/TtOtruwso7KIxh7KaRXlMz+YswS0mZRt28bouGzk9vVbD4k+Fb6xmvINRlW3it47rdNZzwmSKRtqNGHQGQMxCjZnkgdTiqkvxN0c65pNhaQajcJevPFK40+5EltJEEO14vK3DIkBO7GAQx4INAFTwPqniG48c6vaavLqt1p6iZoJXsjbWsYEoCIBJbRuX2nAKyyqcMxxlaoavrHiuPU/FAt5daXVLfzv7I06PSw9hcIIco7XHlHLk5O0yp8wC4557aDxj4fuLGyu7fVIJYrz7N5Kx5aQi4OISYwNyhvcDGDnGDjOj+JXhOSGeb+1GSCGMTebJazIkkfmLH5kbMgEib2UbkLAZHOKAOQs9T8ZXl7Z2un3+vvpUupwQtqN9o6QXIha2uGmzGYVCqsiw7XKAbmx8w4Jrd34+tNC1C8s7zUp5YtXeyWL7HGrLZB+LhQtvIzvwBlY2XaxOwkZrptN8f2c/iTU7K7ZobRPsyWStaTJcSvIJC+Y2G7A2ZztAC/MTjmmaz8Q7CO40uXQdR0jU9Nl+1/ap4bjzVjMNu0wG+Pdt6DPyscHgdKAOOj13xysXh97m61W4MjMs0Fjpksckg88hWkeaw2AhMAgiDOCwOGFVtN8VeOb63u7jQp9S1W7U6sksFxpixWkPkyyJbeVL5aCVyVUFQ7Z5ztIru9D8f21zrmr2WqTW0KxXMEVkIUkdnR7SGd3fjIVTKcuVVQNu7B663hDxF4d1XzLPw7mIIn2ryTZSWodJHY+agdFDqzbjvXIJJOeaAODttQ8ZX13aWen6l4i/subU7eFtTu9Hit7oRG2naYGN4AqoJFhAcxjlsZbvzPjW98bat4I1HS9WTxDum0m4jhWx0fzGv5xcTR7ZyIW8oGJYWG3y928kHoK+h6KAPPPjBZXk48J3dpPq8MVjrAmuJNLtBdSxIbeZPMEflyE4LKvCkYckjoRS8Kat4suPGFvBqLas0bXN4t9bT6aIrS2gUt9neGfywZGYCPI3v95shMYr1CigAooooA5X4T/wDJLPBv/YFsv/RCVw2veJfGUHxGEOnW2spoyXbQTJNab4PKFuxEyOtqAF3heTcMc5BQA8dz8J/+SWeDf+wLZf8AohK6l1V0ZHUMjDBBGQRQB892vjbxf/wg0Wrpq2sywTafpks97c6Okfk3U11CkiWy+SvnKY3fkBxnbtPOBoarr3xDjsIfsD6u+nNfXSR6jNpxjvGhCRGEyQpZylQXM4/1C5CLkrn5vaTpennTodPNjamwhEYitjCvlRiMgxhUxgbSqkYHG0Y6VcoA8Tl8TeO/+Es8PQJbat5JksI9Q22T/ZJlkRPOkjzabkUFjnfMjKVOUwKi1rWPHtn4Q0e5WfxFJrN/FK8ggsI1itWThUdFs5pMvkHkKp2n5kHFe40UAeP2upePrgR6nLLqcPly6Qp00acgjkWZYftZYmPzPkLueGGwqc8DAgvNd8aLoOrzW02vN4jSZlfT30nZaW0P2gKXt5RbP5rCPkfNKSCx2NjA9nooA8+8Lal4sm+G+s3c6/bNfiW4OnrPBJC8hCZiWQSQW+Tu4yI1UjHPWuLvIvFHiWK1tWvfE02nw6npcy3l3pEdrcJJvczDy2gAMceImDFMA8ZYDn3WigDz34s6pr+labpsPhwaw9zKZA11ZwiQKVUbRKBazn5ieNqKMg5ZRS3+reKG+E2j6ikF3b6/PDZm/wDJs/MuLcOUE7pAQcuoLEJtPTocYr0Gq2pWFnqllLZanaW95ZyjEkFxGskbjOcFSCDyAaAPJvCWseKNf1GG0tta1n+zF1G/t5r6bTYY51jjSExBwYVWNtzSD5kBPIIyOOW8Xv4ruvAmo6NNaa3awT6Xcm3ttL0UMLq4a5nBjm2wt5Q8sRMMbC28ncTX0DpenWWk2UdnpdnbWVnHnZBbRLHGuTk4VQAOatUAUNP1L7be6jb/AGO9t/sUyxebPFsSfKK+6I5+ZRu2k8fMpHar9FFABRRRQAUUUUAfFf7a3/JU9K/7AsX/AKPnoo/bW/5KnpX/AGBYv/R89FAH1V8J/wDklng3/sC2X/ohK6quV+E//JLPBv8A2BbL/wBEJXVUAFFFFABRRRQAUUUUAFFFFABRRRQAVyupf8lT8Pf9gXU//R9hXVVyupf8lT8Pf9gXU/8A0fYUAdSeQa+Ob+GXTdavLe6R0kSV1YMOep5r7HqrcafZ3MvmXFpbyyAY3SRqxx9SK58RQ9skrm9Ct7Jt2Pjq6fzgDGrEL1OOlVGUOpVhkHqPWvtNLO2jUrHbwqp4IVAAa8k1z4Li/wBXu7y21dYIriVpfK+zfc3HOBhu1cc8FKK93U64YyMn72h5zZeOr5NFt9GuVjNhEc5Vfm46Vl+IdSt7+GFbfcWViTkY4xX0F4H+G2leGUmabZqN1LwZJ4Vwo9FU5x9a69NNsU+5ZWy/SJR/Sq+pznaU3qR9ajC6ijy/9nvRxBod5qkiDzLiXykJHO1ev6n9K9bpERUUKihVHQAUtd9OCpxUTjqT55OQVyvxL/5Fyz/7DWk/+nG3rqq5X4l/8i5Z/wDYa0n/ANONvVkGp4n0G28RaV9iupbiArLHcRT27BZIZY3Do6kgjIIHUEHoQRXOar8OYNWExv8AxBrskt1afYL+RWt4zfW4dmEcgWEAAb3XKBGwxBJrU+Ilxqdr4UupdEuZba+Dx7HhtHuXI3jcoVIpSCVyN3luFzkqcV5ZBN4m/tYa5JJ4sgv5vD80Vur6bHN5txHLMVSTbarsBBRl3LExyARnIoA9QTwTpqXcNws12Gi1dtaVdy484wtDt+79zaxOOucc9q5uf4M+Gpbu2ud03nRKUZprW0ufNHmvJg+dA+3BkYZTacYznANUNa1jxjoFtI8kutak95oE01v9n0oS+TqWF2JtjiyijJIEhIPIJJwKzdek8T69oPi3TNUuvEcGozafcQ2WnW2kqbS5Q2mV3TmBsOzFgV8xCD8oAOMgHXyfC3SJpWS5v9Vn0zN4Y9NeSIQRC6VxMFIjEmD5jEZc7T0wOKLn4Y2d3a3Ud/rWq309yIY5Li9hs7hjFCH2RbJLcx7QZHbOzcSeW61x9/4k8V6To13FpY8Tagsmiw/2ZLLobeat4JpBKJFEChMJ5eN6gFVBG4kk6XiG+8eQaRql/Yz37OusyWiWyWaqYrISHEyYgld24ABCONrE7SRuoA7LU/C+lQ+BrfSLy/urWw0tIpo9QkuFEtuYCHWYyOCuV25O4bcZyMcU3Q/BOn6fqFnqiX1/e3sctxctczyITcPOqKzMFQLwsaBQoUADpXPynX9Y+BXiOPVllvNYn0y/iiVLaVJZcpII1MbwxMXxgcRqGPIGCKzdJh8VvrR0+1e+0ayuNXlE11babCGMK6fAUYs8TKcyhl3sCTjbn5QAAd74g8MJq2q2eqW2qajpOpW0UlutzZeUS8TlSyMssbqRlFPTII4PJrL1/wAFmbwVr2j6RNuu9TuJLtJ7t8CCd5A/mKUXgow3KMdVAJ7155P4k+Jr/wBhF4bmzMmn28jsbCUpLcb2EonSO0mZOAvG6HG7IJ6L2Xw91TxDdeLNXtdak1W6tI1d4p5bI21sv7zCoqyW0b7tvcSSqQCcjIFAEd/8MEu9QjtYdSurHw6uiR6PJb2rIJblA7FlkLxsQrK3LKysSTzWle/DmxuINVtYtTv4NO1GcXMlkbeznhRwqqSqzQPwQq8EkDHGK4O8bxZoEniwaHJrsl1PrvnMjWGYktHVMzQyLayb3yAm0CQhQSUyCatRX/xDvNGaT+0dRhmt9HvbuNrfTObm4SX9zE4ntkbcV4KrGm7GVAzQB6JomhWHhU2CLq96IVto9Ngt7u6HlyMGZwwXABlOSOP4VAAAFaUuiW0nii211nm+129nLZKgI8spI8bsSMZzmJcc4wTx6eUXNz4l1nxdoo1ePXEa21uCVLKLSyLJLcQH98Z/LJ3bmIIMgweNvGa3PG8GsWnxKttU0p9V3HRJ4LaO3tBLby3IkDJFM/lMY1bgliyfd4Yc5AL1z8J/D11odlpV097Na2emLpcfmNGxMayxyq5BTBcNEnUbSMgqQa3fCfg+w8M6HdaXYtuhuHZ3dbW2tzllC/dgijQ8DqVJ98YAwfhlqWv3uoXaapNrF1YLaW7mbVdNFk8d0d3mxRgRpvQAKc4PJ++3biNd8Y+OLTUvEtxbw6za6Zb6fqky/bbMMttJFGzQOrfZUTBKkgebNkEbsHqAd9e/C7QL7RbbS7t7ya1t9Kg0lA7Ix8uF1dHIKYL7kUnI2nkFcHFJpHwz07SBpz6ZqN5Z3FlcSTpNa2tlBvEioro6R26oVIRedu//AGumOGm8VeKLe3id9X18aRc39jBHfy6KqXZ3xTNOkUH2fLKCsZVvLY5J5YA1DqfiH4mLZWBhF/BA8dw0N3Jp8hlmInYQm5his5imYgjFQsWcn5geAAd/pPws8O6XfaZdW32wvYXU91Grygq5lAUI428ogChB/DtHJ5zWf4Y6JZ6cVvtY1VtOsrXyLZbmeIR2FusscxVDsHGYYwWcsdqgZrmbvxN47/4TwwWlnrKadvuYZopLMyQrtt3aOSJhaKNpkVcZmcnOCoJ47I2us3Pwl1H+1bi8v9YvtId3he3SNo5Wt8GJURQfvZ4OTkkdMAAFm78DaTqPif8A4Sq2vLyDVpBCY7u1lTiNQRsGVIZHDfMDnOFIwQDWj4p8LWXiU25vpbmPyI7iJfJZRkTRNE2cg8hWJHv69K8x8P6j40EFrZ6bca4+nK+mwG51DRxBLAzM4uERGiQmJUEZ3sDg/wAR5rSOq+MbHxO9s02v37QX3lC2/syIW09kIM+ebgRKomLdg4G47fLA5oA6CP4X6HFrFxqkM+oR3tyEindJVHnQLAkBgcbcGNljUnuGyVK074ceBtA8JyXcnh66juRj7I+23s1aMoeUaSGFHZgevmMx4555rzvSPFHxClF+s8XiBLBls3+0y6YZbq1VpWWfYv2SESOq7MqI5QOSC3Sqy3njjSNOC6IutRWV3qOozvez6e4uZGLqYWkiSzlKqwLNxEmcY3L0IB9DUVw/giXxNf65q03iC7uIrS2a3W3tktBFDNvtIWlYM8YkZRKZMcqQdwbONq8rrXiPxknxJS20231qPRxeNbzLNZGaAReQxEyFLUfLvC/8vDNnI2AEYAPYqK4D4S6lr2oW2pJ4ibVZpYWjCXN5bfZ45SQd3lI1tA4A4yGD4yAHbBrv6ACiiigDlfhP/wAks8G/9gWy/wDRCV1Vcr8J/wDklng3/sC2X/ohK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4r/AG1v+Sp6V/2BYv8A0fPRR+2t/wAlT0r/ALAsX/o+eigD6q+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqACiiigAooooAKKKKACiiigAooooAK5XUv+Sp+Hv+wLqf/o+wrqq5XUv+Sp+Hv+wLqf8A6PsKAOqooooAKKKKACiiigAooooAK5X4l/8AIuWf/Ya0n/0429dVXK/Ev/kXLP8A7DWk/wDpxt6ANvXdYsdC0yS/1WfyLWMqpYIzszMwVVVVBZmJIAABJJ4rBvPiH4bsViN7c31sXj85lm0y6RoY95TzJVMeYkLAgM4UHBweK1/E+g23iLSvsV1LcQFZY7iKe3YLJDLG4dHUkEZBA6gg9CCK5XXvAmn3jquseKNXWfUoP7LuWaW2hbUosySCFgIgMhWl/wBWFYqWyTQBoX3xI8MWWpS2E13etdR3BtCsOm3UqtNt3eUrJGVZ9vO1STjnFMl+J/hKJIHbUpjHLbpd71sbhljhaRow8jCPEY3o6nftwRziraeCdNS7huFmuw0WrtrSruXHnGFodv3fubWJx1zjntXKv8Jo5NZuojq17H4cn02Oylto3j8y5P2m4mdZCYiQn74AbGVuoPY0Adde+NtDsNTmsL+a8tbiKOWXM+n3EccixLvkMchQJJhQThCTjpVS4+I/hiCBZpLy78lozNvXTrlgIhjMxIj4i5/1h+Q4PPBxzuo/CjwvaapqPiLUdTu7dXW7kmlma2RYknjdJMzGLzCiq52h3IXAxwMVqeJ/hboXiKfTp7tpEubK0WySVrW1ud8SnIBWeGRQQcnKgHk9uKAJNY8f2ieJtE0fRW+1SXOq/YLyU2sxhjAt5ZCqzACPzAVT5dxOCeO4uan45sNL8ZTaFqEFzDFFp4v3vfIlaJF3MDvYIVRQEJ3swHbrVe3+Hen2+tWt7BqOpx21tqDanFpymEW63DRsjMB5e/BDsdu7AJ4AqfWPCuk+Lbt9TXU7h7W6sZNMuY7SSJ4LuAswZGJViCGLcoykHvxQBp+G/FOk+I2uF0qeZpLcI0kU9rLbuquCUbZIqkq2DhgMHB5rhrb4tRXY0C4TT7y3tbvVLqwukbT7qV9sS3Gww4jBdmaFdyqrbNxU4IzXV+HtAsfDWpvNd63eahqmpJHaRSalNF5jpCrssUaoiA4DSMcAk/MSTUGleAbHTdRsbmPUtTlhsb+41C1tZGi8uGSdZhIARGHKkzufmYkEDBxkEAefiL4XEdpIuoySRXMSTrJHaTOkUbsVVpWCEQgsCP3m3kH0NaniLxNpfh5rRdUluFku2ZIIre1luHkZV3EBY1Y8AE9K4aH4R+EtSNjf2V0blYYzB5xgs7xZgsrtgmWFwCGZlym08YOSBjv9R0W3v9Y0nUpnlWfTXkeFVI2sXQod3GTweMEc0AY0nxD8MIlm41JpIrqCO5SWG1mkjjikO1HlZUIiBIIy5XofQ1T8MfEnSNZmnguluNNnS9u7SP7TbzJHKIGkywleNUzsjZiucryDyKyn+C/hpn011aYyWVtHabp7W0uTKiMSu7zoH2n5iMptyMZ6DGnd/DPSryK4gur/AFOWyk1Q6stsXiCRTOztKqsI9+yTzHVlZj8pIGKANW+8c+HrN2R79ppA0SKlrby3DSmVDIgjEasZMopb5c4Xk4FY/iTx94dn8O6lFZyx6nPLpUl4lq9lLNHJERKo80BcBC0bowYjHRsZGZYfhppNojNpl7qVheDUpNTiu4ZI2khkePyiih0ZfL8v5QrKcD3Gag0Lwh4YEV9aaZq8l099pJ0+bbdxyu0XnTl5uB98yTSgt93IxgYNAG54c1TSvEtlbAR29zcWIhlcLbkxW85QHCORt3qGxgEsoODjNQr498PNa3d0Lm8+y2zbGuP7PuPKkfzPL2RP5e2Vt/yhULEnoKseEPCdj4SgltdHmul099pSzd1aKFsfMyDbldx5IztzkgDJrjLf4beEPFSaxew6ydXjv38uWW2+xmOOVJFkyRFEEdwQo/ehzjg8E5AOnl+InhqK1jna7uzvaVTCmn3LTx+XjzDJCIy8YXcuSygDcPUU9fH/AIabWF0xL+R7lpYYA62kzQiSVFkiUzBPLBZXUjLc5x14rm7n4LeGp7OyhYlZbVpSky6bp/zCTbuDRfZvJP3Fw2zd/tY4rXufBWgaXZ3N1d3stpaJeWmpyyO8UMUTWscSJ0QKke2FcjjvjaMAAGr4h8W6d4f1HydVnhgtksJb+SQ+Y0ipHJGhIRUIIzKM/MGzjCkZK3PD3iLTfECXR0uWVmtZBFPFPbyW8kbFQw3JIqsMqwIOMEHis7xV4K07xNdvcX813G7WEunkQuoHlySRSE8qfmzCuD0wTx0xd0vT9O0/xJrM0F3u1LUzFdT27yKSiogiVlUDIU7Opzzn6UAZVh8SPCt9HNLDqbpFFbvdmSe0mhR4kYK7Rs6ASYYgEJk5IHWrFh488O312lql7LDdM0i+Td2k1s6lIxI25ZEUr8h3DOMgEjODjMuPhfoNzpNnpt097Na22nXGmqryL80czxuzHC8sGiXHbrkGqa/CHw+fDk+jPLcCCW4S4862t7WzlUhSpUG3hjBDIzqcgnDsARQB1HhrxPZeIrm5GmyRy28cFvcRviRXZJlZlLI6LtBAyMEk9wvGd6ubl8IWh1O4vrW91Gyknls5HW1mEalbYkrHwv3GBIZc8jjite31bTrnU7nTre/tJdQtlDT2qTK0sQPQsgOVB9xQBdooooAKKKKAOV+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPiv9tb/AJKnpX/YFi/9Hz0Uftrf8lT0r/sCxf8Ao+eigD6q+E//ACSzwb/2BbL/ANEJXVVyvwn/AOSWeDf+wLZf+iErqqACiiigAooooAKKKKACiiigAooooAK5XUv+Sp+Hv+wLqf8A6PsK6quV1L/kqfh7/sC6n/6PsKAOqooooAKKKKACiiigAooooAK5X4l/8i5Z/wDYa0n/ANONvXVVyvxL/wCRcs/+w1pP/pxt6AGfFO1vbzwbcRWEF1cjz7drq2tWKzT2wmQzRoQQctGGGAQT071wd/pmkSXmiy+CfCeoabFFq0ct0f7IltImAsrxQ3lOq9CyqzbACXQZbgD0fx74nj8IeHjqstrNdqLm3t/KiR2P72ZIyflVjwGJAx8xAUcsKwtG+I9lceK9X0nUvOtkS8trawZrC4j3edbRSqszMu2Ny0jAK2w8AYzQByWk3HjqDw9ZzwtqNp9g0/RQmmRaVEkUrybFukK+VuUIM5VCuzHYDFT29/4jtNReC+bXNF0d7/U5BcaPoazyyv8AbG8reogkwrRncJNmXJJLHv1Xif4m6Pomn6q6Q6hNqFhCbj7HNYXNu0qCRYyyF4vmUM65ZQwGQenNX/FXjW20Hw9p2sCyv7iC8vrezEZtJ0mQSyBCxi8syZAyQpUFjhRywoA8h8Wat441yDxVpn9m6/LpV3peootrc2RZo5VKiJUZLWMHcC20CSbcOpBHPrPxSvNYsvD9vJ4furi2uTdKJDb2clxI8e1sqNkE+znb8xiYcY4JBqj4e+I9hea9q2m6qz2jx6ktnYs1jPGrI1tFKoldl2pIS0nysVPygbc9eg8O+L9F8RXDwaTcyyyCITr5trLCJYicCSMuqiRM/wASZHI55FAHmUOq+LEkNzJba7pdnd3Fn9svItIinv0j+xkklUhIkPmhVY+W2zOAq9sG0vviFouhaLY6RDqFlai2llWWewldnuGu5iVnjjtJmA2eWcDyvvHDdh7Ivjrw82uNpH22VbxbhrQlrWZYhMqbzH5xTy920E43ZI6Vh6z8WNAs7O2n09b2/M11bQhFsrlC8U0oj86LMR81Rk4KZDHaoOWXIBJ8TbO+udT8KTWVnLcG3nvHk8uEyqmbC4VdwwRgsyryMEkDviuHbxJ4q0y60G2vZ9V0sNd6NZwWcOkotpNDKIRceZIYiEcMZV2KyFQowD1r1e28YaDcW88w1FIvIaRJI7hGhlVo4xK48twHyqMrEY4BrDTXPAd94rs7r7NZy665iihv30t9yPIm6OI3BjwjlGBEZYNhunNAHmOq6J4xT4c3Gj2p1ea21LT9WMlibJB9ndZt0SqfL3gyBnGGJ3A/LggEdN5/iaTV7o6Lca15N02lQf2rc6LHDdNGZroTlw0CfcXZ95MKCDj5yW6GT4naTNqGiT2F2h8P3ltcXE17PbTRDaioU8tmADcsQQAxzheDxVzxR490600S9l0PUNPudXtjA0ljK+JokkmjQmSHIkQgSD7wGCRn0oA4HxB4j8a6Vpt//aV/rtpa2MepeRqFtpEcsl1JFLiDz/3LJHGU53hEVuTuGK77xLquvWngXSdZ0eC4v76JrWe6tLeJWku4mwJUUYOD827jH3euK5/WfEvh7WfFltb+JtM0G80yzg1FlmuLVrqWKeC7hgCR70B3MWwVRWywUKzAAns7XxpoV1rUelRXU/2uSQwLvtJkiMoTeYvNKBPMCgkpu3DByODQBwt7feNdSvnj1TSwkdhqmlweXFYiWGcm7Dy3EZdWIVYTF8wPyMHOQVBEnwn0rUbHX4pL2wu7eMaVLGWmhZBuN/cOFyR12srY9CD0Nd5qHivSrHWxpErXs2obEkaK1sJ7kRq5IUu0aMqAlWxuI6H0rn/DfxQ0XVtE0y9u4r+yub8P5VobC5keQpjcI8RAyYBByoPf0OADmdf1DxldavqlhFJraNLcXdv9li0xfskdl5D+VOlwY+ZS2z5d7csRsAGawNK0nxT4YuornTZ/EFxqDeErWKygl0+MwG4jE5NtIyQDywm5SoZlZmOCzdK9cfx34ajsLa9k1RI7W5huJ4pHidQyQMFlPK8YJAweTnjNZj/EjTv+El0XS4rDVzFqUc7CeXS7uExmMxAfI0IJQ+bzJwq7eTzQBxug6l4/1KDT7ebUNTgjuNWhhluRpzfaIbc207SbvOsoYwvmLFhhG2CcFjkA7Oupr+s/ALXoNTtry512WyvLcR/Zts022SRIz5aqOWUKflABzkDBrqX+IHhhNPtb59UVbS5s11CKRoZADAZEjDn5ePmkQYODznGASD/hPvDwvIbV7m7jlkeOM+Zp9wixNI22MSsYwIix+6HK7gQRkEEgHEeJ7/x/o0ep2mnXGo6lDFf2oF+9mgmW3eFzJ5Yit3DASBBxFIQGOc/eHP6lqvizTNNfxBfTXUOonTrK0bUItPkJw2q7CvlywITJ5T8r5QyTlVwVr2Xw74o0vxEZf7Ia8liTJ897GeKF+SPkkdAj8g/dJrP1nxX4aF3NpWtrMrRK9xsvNMnEMnkYlZo3aPZIU2hxsJPy5HSgCp4HvvENx4d1yW7+2XksVzMulS6lbC0nuIhGpQyxhI9v7zev3VJABwOp4631vxK2l6S82reMl811/teX/hHQJrJ/KchII/sp3oZBhmAlxtX5huye4uPiP4YggWaS8u/JaMzb1065YCIYzMSI+Iuf9YfkODzwcb+sava6TZJd3KXk0LsFH2Ozmu2OQSDtiVmxx1xjpzyKAPJrzUviLLpst4kuq21xaaFbXiWsWnRMLu7M8wZHBjYhjGsRaNGBXdxjvFZaV4j0rVWu4BqV0Ztf1SbE+nwv5Ki1uPKlRhEGXe3lruzhhhRwxB9Eg8f+Hbl7JLG7ur1ryFLiMWdhcXBWNmKq0nlofLBIYfPt+6fQ1U8F/ETSvEun6XI8d1YXt/HLJHbT20ygiPBcq7RqrgBl5HHOOoNAHKXp8fNZ2DQ61rMc0nh641Kby9NtyBeqsPl2+DCcZLSHZ94/NgjA29R8P5fEi6vqdr4hur28thZWVzBPc2qQ7ZpBL50SlEUEKUTg5Zd3JORV9PHvh5hpTi5vBb6qITZ3J0+4EEnnY8seaY9is2QNrMDkgYrmvDPxJkubyH+3/strZyWwfzYopDiVr2S2QE5bap2pyeATyQOKAPTqKpaXqtnqouzYTecLW4e1lIVgFlT7ygkc4JxkZGcjqDV2gDlfhP8A8ks8G/8AYFsv/RCV1Vcr8J/+SWeDf+wLZf8AohK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4r/bW/wCSp6V/2BYv/R89FH7a3/JU9K/7AsX/AKPnooA+qvhP/wAks8G/9gWy/wDRCV1Vcr8J/wDklng3/sC2X/ohK6qgAooooAKKKKACiiigAooooAKKKKACuV1L/kqfh7/sC6n/AOj7CuqrldS/5Kn4e/7Aup/+j7CgDqqKKKACiiigAooooAKKKKACuV+Jf/IuWf8A2GtJ/wDTjb11Vcr8S/8AkXLP/sNaT/6cbegDU8VaFb+JNDm0y7muII5HilEtuVEkbxyLIjLuBGQyKeQR6isceA7FpJ5rm/1G5uJ9QtNTlmkaIM81ukaJkKgABESlgAOScYGALXxDuNYtfC0knhsyjUzdWiIY4PPIRrmJZDswcgRlyfQZORjI4TXZfE+keKLuKGfWBpUk1pHdaxaaRFcXhj8mckgJARJ84jUnY2wNwBkmgCxpHwe8KyLe3ljql9dx3trPYmeJ7Yna8isx8xIg0jq0YAaRnIwQc12+s+GE1nw9BpeoapqEk0E0Nyl+PJWcSxSCRHwI/LyGUcbMY7V4dda34t8J/D47Z/EGkRWulz3Nq8ekrKZ7s3U2VuS0LCIbfKYDCA7zg9BXWza34+/4TzUbd3ltNPjnuFhRrCeeE24iYxSKY7Qgvna2DccnK7ASKAO1HgHTXhmS6u766afU49WmeVowZJkhSLBCoBtKxgkADknGBgCHwF8N9G8EXUs2jljvi8hQ9paoyJkHHmxwpI/Qffds4ycnmovhPqGt3+m33/CQtqks0Uqqk97AIVkG3JMaG2t3Az13IeejNXdUAcrP4F0q4ctNJdOras2sMhZcNKYjEUPy/c2k8dc965zTPgz4e0u1eDT7m6tiGheCaG1s45oGilWVCJFgDvhkX/Wl845yea9NooA4HWvhVoWtyatLqdzqM1zqcUMU84lRGzGFVnXagCtIqKr4GCAAABV+XwFp7641+t7qMVq97HqMmmxvGLZ7mNVVZD8m8Y2IdocKSoOK6+igDhLj4XaDc6J4e0u4e+kg0K3aCyk81VkQkKBLuCjEilFIK4wex6V0Wr+H4dY8Of2PqN3dzRnyi9xlBK5jdXBOF25JUZwo79K2aKAOAuvhVoVzei8e41JbuOW7nt5klVXt5bi4WdpIyF4ZWXC5yNpIYNmpNL+GGiab4tPiGB3e9aZrmTzbOzcvKy4Z/NMHmqSfmwrqAegA4ru6KAOU8ReCLLXvEum6ze3l0stg6PDFFFbjBVt3+tMRmAJxlVkAI4IwTmPw94Ds9EudMli1LU7mPTPPWzhuDFthSXG5MrGrMBt43En1Jrr6KAPO3+EujSjyp9S1iWyjiuYra1aWIR2wncO2wrGGyGAKlmbGAORxWv8A8IW0l/pV/deI9aub/TmlEdxKtqDJFL5e+FwsIUofKXkAPyfm9OtooA85tPhJpFvEkLatrU9tDaLYW0MssO23gWeOZUXEYJw0SjLFjjgk8EXta+Geh6t4w/4SOYbL9mieUNaWs6yGPAX5poXdOAB8jL0B6813FFAHKeFPBFj4b1jUNTt7u5uLq+ULLvit4V+8TkrBFGGbn7zbmxxmsGX4PaDL4hvNYkvNRa5uTdFsi3yPtEbxuPM8rzWADnaGdguBgY4r0migDgvE/wALdC8RT6dPdtIlzZWi2SSta2tzviU5AKzwyKCDk5UA8ntxWr408Fad4t0yxsb6aeCCzkEkaxRwujEKVw8UsbxsMHgFDggEYIrqKKAOF8OfDay8NPZHQNY1exEEEdvMiGBlu40d3USB4jjHmOMpsOD14GGRfDO1gtbCC21/XYP7PaYWciNb74IpRh4QTCcocA5bLjAwwrvaKAPL1+Cvh5bzSbj7bqbHTBZiEOLdz/o23Z87RF0zsG4Iyq3PGTWhffDizg0DVbbSme4u7nTJtPiS+m2xfPLJKGZkTcCHkPI7Ad+a9AooAyvCuixeHvD1jpUDtKLePDSv96VySXkb3ZizH3JrVoooA5X4T/8AJLPBv/YFsv8A0QldVXK/Cf8A5JZ4N/7Atl/6ISuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+K/wBtb/kqelf9gWL/ANHz0Uftrf8AJU9K/wCwLF/6PnooA+hPhl4+8HWfw28J2t54s8PwXMGk2kcsUuowo8brCgKsC2QQQQQa6b/hY/gf/ocvDf8A4NIP/iqPhP8A8ks8G/8AYFsv/RCVu2eq2d7qGoWVtNvurB0juU2sPLZ0DqMkYOVYHjPWgDC/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIquqrF1HxDFaeI9P0SKyvLy9u42nYwBAlvCrKpkkLsvGXAwu5jzxxQBn/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FVoXXiOztdfk0mWK7a4S2jui0UDSja8piAwmWzuGScYA5JABxN4a1u28Q6UNQskmSEzz2+2UANuimeJjwTwWQke2OnSgDJ/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIquqooA5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8Aiq6qigDlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKrqqKAOV/4WP4H/6HLw3/AODSD/4quav/AB94Ob4k6FdL4s8Pm2j0nUI3lGpQ7FdprIqpO7AJCOQO+0+hr0+uV1L/AJKn4e/7Aup/+j7CgA/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKrqqKAOV/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKrqqKAOV/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKro7e7t7lpVtp4pWibbIEYEqfQ+lclH48t2bV1ezlRtPGdpcZkAYKfpyfyqJVIx3Y0my1/wsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVVW58dwW2iafqM1o6i7EmIw2cFeMZx3OK1PDniqw12UwW29blYhI6EcDOMgHvjNJVoN2TDlZV/wCFj+B/+hy8N/8Ag0g/+KrmviD4+8HXWg2sdr4s8PzSLq2mSFY9RhYhEv4GdsBugVSxPYAk9K9PrlfiX/yLln/2GtJ/9ONvWgg/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqtjxFrdh4c0ibU9XmeGyiZEZ0ieVtzuqKAqAsSWZRwD1qPw74h03xDDcy6XLM32aYwTxz28lvLFJtDbWjkVWXhlPI5BoA5fU/E3wu1W9trzVNb8FXt3anME9zd2sjxHOfkZiSvPPFan/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VUtL1Sz1RblrGbzRbXElrL8pXbIhwy8gZwe44oAwv+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiq6qigDlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiq6qigDlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiq0LHxJaXmm6texR3Ai0yee3mDKNzNDncV55BxxnH4Vf0fUItW0ix1G3V1gvIEuI1kADBXUMAcEjOD60AYH/Cx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVWX4h1u20G1tZ7xJnS5vLeyQRAEh5pVjUnJHALDPfHY9KAMn/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quks7lLu3WaJZlRiQBLE8TcEjlWAI6enI5HBqagDlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+Krp5pEhieWQ7Y0Usx64A5NV9J1C11fSrLUtPl86yvIUuIJNpXfG6hlOCARkEcEA0AYH/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVa+t61b6PJpqXKSsb+8Syi8sA7XZWYFskcYU9M9uK06AOV/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+Kp9t410648QnRkhuxdC/l0/cUXZ5kduk7HO7O3bIAOM5zxjmunoA5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq6qigDlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+KrqqKAOV/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4quqooA5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq6qigDy/4ZePvB1n8NvCdreeLPD8FzBpNpHLFLqMKPG6woCrAtkEEEEGum/wCFj+B/+hy8N/8Ag0g/+Ko+E/8AySzwb/2BbL/0Qlbun6rZ6hdahbWc3mTafMLe5Xaw8uQosgGSMH5XU5GRz65oAwv+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iq6qigDlf+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iq6qmyyCKJ5GDFUBYhVLHj0A5J9hQBy/8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXTW8q3FvFMgcJIocCRGRgCM8qwBB9iARUlAHK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FV1VUtZ1Sz0XTLjUdSm8mzgXdJJtLbRnHQAk9ewoAwv+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiq6qsu81u2tfEem6LIkxur+Ce4idQNgWExhgxznJ81cYB6Hp3AMn/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq19O1q3v8AWNW02FJVn0140mZgNrF0Djbzk8HnIHNadAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVWXout22r3WrwWyTK+mXhspjIAAz+VHJlcE5GJV64OQeO5AMn/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4quqrl9c8babo2vDSbqG8e5P2L5o0Up/pVw0EfJYHhkJbjgYxk8UAN/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKrqqKAPhv9rvWtK174k6bdaHqdjqVsmkxRtLZ3CTIriaYlSVJGcEHHuKK0P21v+Sp6V/2BYv8A0fPRQB9VfCf/AJJZ4N/7Atl/6ISse88P+J4tf8WtpiaYLDXzGFvGv5Iri0xbrCXWMQsrMCCwG9c8DI61sfCf/klng3/sC2X/AKISud8b+PNY0q81zTbfSoLJorSdrG9u55V+0Otu0oMQFu0TEEN8hkDfIxK46gHJ6b8JPEFhoF9ZRJorSXLWyzRTSW8sFwse/c+z7AFSXLAh3SYnoTwDWt4E+Eb6ZPpsniSPT7l7OxubVJraRlnhL3TSxmOVUjKbY2ZcpsxkhQAa0YPiDr9tZTpeaDY3F1Y6DHrdxJHqTbZEbzhtX9wDvPk5xjb8x54G63qHxMFvd/ZLXTI57qS306SENeBIzJeNIFR22nYqiPO7BJ3DC+oBF4n+Hl5e3rHSrlPsot7GFDfXc08uYb9bl9zvuY5UEDLHnA4HNc8fhV4hGl6taf2jYSNfC68mZnbfYeZdvNsi+QgpKrhZMjIOeXUBRoeIfHnirw54g16bUtJ0yWw0zQYtRlsoNRZtrGW4Xcjm3BYt5aAg4CgZGSSK6DWPH72euXOl2Glpezx31rYI32sIrNPE8gY/KdoXYAepwcj0IBL8KfCd14S0m/t7xYomuLnz1hguI5Ik+RVyix21uqZ28qE685yTXb15hZfE3UrrX7nTofCd5cJbTzWcstr9okCzxxliN5gWLyy42BjIG+ZSUAPHS+AfFFz4mt7w39jDp15bOqyWgkmaWPcuR5iywxFT6YDKeoJoA6qiiigAooooAK5XUv8Akqfh7/sC6n/6PsK6quV1L/kqfh7/ALAup/8Ao+woA6qiikJCjJIA9TQBDe3cFjayXF3KsUEYyzt0FUNC1/TtdikbTp95jOHQjaw98elcv4v8UaVJd3mg6tBcJAQAZ05AOAQcdeDXAaa9zo+uyS+HrpbryQTlR/rExk/L3rkniOWSUdV17lqN0dnEn/CK+NjJbSxTafqMohkUOC0Tk5GfTn+tU/GXg7VVvL3UrKVZ45FO9Rw5XHII71j6boU3iq2v7yylb7dFN8wc481TyCffg16z4aN4dGtotVQreRpskzzuxwDnvkYqacFVTTWm6G3Y8v1TTbib4aaPcLGxMEshIHUKzHn8wKX4U6beT679sjd4rWEHzMEgPkcL7+tewCGIReUI08vGNmOPyogght02QRJGvoigCrWFjzKV9hc7tYkrlfiX/wAi5Z/9hrSf/Tjb11Vcr8S/+Rcs/wDsNaT/AOnG3rqIE+KXh688VeCL3SNNaFbuWa2lXzpnhUiO4jkI3oCykhCAQMgkVxll8M9Snurc6otgum/2zHqUunPfz32UFrNDIWnlQPKztImVcbQqkZI4r0Xxdqt5omgz32naXLqlxGyAW0ZYEgsAWO1XYhQSxCozEDgE155a/EPXbjWrq7htNKn0i20OS/mto76QFJI5ZVbBe2V9+YwpRgu057jkAiT4UXEuuTrc2+jxadLPetLqEDP9subaeKSNLV02BRHGHUD5yMRJhV5qay+H3imdtNPiHW7a/WGzlaaEvI0aXvlSQxNECOE8uU7u+5AwGWJrWm+I11ZxXkmp6LBbCLQpddhC324uibQI2/dgKxLc4LAcdc1Q1rx9rt/4P8W6n4d0yxt4NJs7jN3Pfnz45kt/M3LD5LKwBYY3MN2OgBoA1Ph94Dbwjq0c9tHYW9q+jWtncx2uV867jZy8zDaA2QwG4/McciucufhddpPqH2bRvDE1vJrTamUldoxqELb/APR7gCE4VGcOvMgJUZUdte8+JN5oum6oda0m1F7pujW+qMIb4sk/myyRqisYlx9wHO3q20DjJXWPiXe6fbXdynh8S28eqvo0BW4kd5Z1cgMUihdgm1WOQGbdgBSDuoAlfwnqNj8GtS0B7qOG8MFy6i0E0kcKtI8ggjCjzGQKfLAUbiOgzgVxvg7wRNr13Lcv4c0/RNGj12C7bTxBLBFNEllJC4WOSGNmy8ozvjUN84+bv1f/AAsrVVg0ye68LTadbXBZLi41BrqGKFhLsAB+zFgGGGBlWIEMB1yBs+LNZ12y8d+FdO0eKzls75Lo3MdxcGLdsCEEEROcqGJABGScHHWgDhZPhPqF142n1HVIdEi0N/tkMyafEkcktrJEyRrsS2Dl1+Q/NK4yuVAOBXR/Dzwjc6h4aj1LxdNqa63qDRzTNBd3FjIqIgjiRxG6sPlG8o2cPI3esPwZ8RdS0vwrpsfiC1t2M2mzXlrfXGoSSGcxzpHtmAiZkJMybdvmE+gPFS6b8SfEHiDxBolrpmlW1ow1K6sL61uriWISbLZZVIMlsJF4fOCinK46HIAEk+GOrS+JLy9S30O08zUL29/tKGZ2u545o5ES3ceUAsYLhj87crwM80J8OvEtsqWds+jyWc82j3NzNJcSrJG1mIQ6ogjIYN5IIYsvXBHcdj468W6h4f1PT7DStIt9RmurO8vWM96bZY0txESMiN8lvN46dPfIwIvijdLazG+0aztLqSzs76xiN9LKLiO5d1RD5duziX92fkRHz696AK/gD4b6p4d8cS6xf3MVyCbnN3HcRrLcCV9wE0YtVdscY3Tvgjjg4DvE/wAPNU1Txy2rJbaJcxNqun38V9dyP9rs4oGjMkES+WQFbYzZDrkuQQetLafF8No0V/eaHJAZvtdvDGJ2zJewShFtgHjRgZM5UsoIwwKjFdh4q8R3mhxaCkOmRXV9qt6tiIjdeWkTmGWTcX2ElQYsH5c4OQCRtIB5/Y/DDV7TWtBvFh0V5bKXMt1PKLjan2mSX91FJbEo4WTh0lj+bBIbaMzaV8Mr2LSNP0680rw6s1te2013q0Mzm51NI5CzmYGIEMw5wZGGSRkCr9h8UdRvtYvbO18I39zFbSXdsZbYTsDPbqxKlmgWIK7oUU+YWyy5VcnFeb4tXcUFpAdASTWbieSI2MT3rtAEjWQ+aos/NViHGAIipHO7FAFCX4RXP/CbXF6BZNpDzFoQjxQvBAYfK+z+X9lZmiAyNgnVCD90Ec5N18GtYm0DQrAWuhQpYWTWc9ta3CIk8hWMG8DyWcm2ZthBIQMMKRIeRXU3vxS1aOGWe38J7YbeOwNzHe3zW08cl24jRPLMJ+65wSSOOQD0qvd+MvEF74n0ZLTTraG9tJ9StLuyfVXS1kMUcLBzL5WSAHyMx8EnoOaAOl8eeFLzXfDehWMNvYak9hdwXE9vqk7CO5VI2VldxG2SSw6pg85A6Vxi/DLxLY6TcQ6a+itLfaVf6ZJbyXEscFitxMZEWEiIl0QMUwQvQEY6Uyz+Kksd1c6xDY313Hq6aWljYO0rLA8sE0jcRxyNjEZ5RCWwOMcj0Kz8XO/w/k8Salp7aTLHFIz2uoGWEIysVGSY94ViAQfL3YYfLnigDhrn4Y6r50cs1j4f1mJdTe9ayv53WGRGsYbcbv3L5IeItjbjGOQekEPwo1qCOwikl0jUJorayhj1O5kkFxphhcs4thsOVIOB86f7WRxXd/DrxnJ4tGsR3WmNp13plytvLGTLht0auGAliikHDdGQdMjIINcB4X+KOoWOj6NpqaNqeu3aWUd1dzqLmaUrJK6jbshkDEBCf3jxjjAJ5wAXV+HHiD7PDplwmlT6RZnVfKZL+aGe4F20jKGIiIi278Egv647V2Xwt8N33hbQLix1CHS4C9y0scenxxqApVR87Rwwq75U8iNeNo5xk8X4u+LF3FD4gsdLsYCyafqMtjqUM05jL2yEscvbrGWHPEbyAMu0kZzXoHw+Ii8OW1lNcLJqNuim6jOpyX7xs43Lvkkw+WUhsEADOBwAaAOlooooAKKKKACiiigDlfhP/wAks8G/9gWy/wDRCVkronimw1jxadMtdDms9buftEVxc3kgeA/Zoofmh8kq4BjzjeMg44rW+E//ACSzwb/2BbL/ANEJVGTxvdGbxDcJY6bDoeiSSwXF5e6i0T+YkYb/AFawvhCzKNxbOMkKeAQDg/DPwj1yznuf7ROjRWdxeadcyWto6rH+4eQy4WK2hUbgygDaScYZjgGoL3wjNb/Eq2sdM0OAhNWS6j1eKynR7K1FttWBXaEQiNOAAkp5wNmc46bTfire3062S+HAuqNqkWmiKS4mhT95bSTrITNbpIAPLIIMfQ5G7gGzqHjrV5vDOvatFpdvbafp0s1q00Oo5ufOik8t9sb27IF3BsFjkjB2jPABX+EHw71PwZqVxcanLBIz2ot2lt7iMi5YOD5kka2sbb+vzPJI3zEZPWsPT/AGrap4i1W+TTdO0vZrGoy/2i7OLy7jkSSNIivlgCAlw2d7Z25AB5rpLr4nXNjfXD32hKujx317p63EN4ZJ3kt4pJSfJ8sAKyxMB85Oe2Oaim+J+o28Iin8P2h1KYafJaww6p5kbx3k3lIXk8oFGB5I2sCOjGgDir/wdqdj4r0KxfSbfVbtLzR5RqX2W4ZrCK2EQljjlMPlCM+U7cSKxLkFSSK34fgxbMLFrzT9DmlFrqSXrtGWM800itbucp83lqGGTyuflzWzY/EzUFvo49b0Ox0+0N3e2DXK6m0oSW2ikldiPJX90Vjb5vvf7Nanw68eyeLdU1bT7nTBYz2MUE6ujTlJo5d+1l86GFv4DztIORgmgDj4PhVri+L9K1a9vobxbf7A5lF0kctuYI0R1QtayOyMVZiBLEG3kMOSTBP8F5v+EehsraHRI7qTSbi0vXIbbdXDTxSwu52ZYLscbjyu4YBFb3g7x3rb6nb2PiGzs3iv9e1HToLqK75hWA3DbWTylGAIlRTuywO44Iwa998XL1NIbUrDw7b3FrBpT6tcl9SMZWJZni2piJt7HZuGdo7Z6ZAKN18LNUuPF1lqyW+mWNpG9q8drY3UcY07ymyyQM1kzFWI3EK0IYswPBzWl4F+Hmp6D4u03U7u20RRaW15BcahbyO13qLTSRskk2YxyAjcb2xu444GgfiFqqaodEm8P2aa+1+lnHEdTP2YhrY3G5pvJ3AhVYbQhyehI5Fjwn4/uvE+sW9jYaNEifY0vLmaS94jBuJ4GVAqHeQ0BKngMD1XAyAY/iT4d6lqvjq91WG20VI7i9sbqLVHlf7bZpBs3pEnlEfPsKk+YBhuQelc/ZfCbxF/amr3eoR6E8d/YTWs0NlOtotxI08ciuwjtBtwFbO/zjk4yQxruPEPjHUtK8Q67a6dpV1qrWUNg/kq52IJmuAz7YoXl48oZwJM5XCrhiectPiDcRa3repLJa3KT2Oli0shd3LwGWRrveItkDSFyI+QIQTswcYoAxvEPwl8Tan4WttJji8KxCKK5WPy4IImt5JCNjCQWZB4A3GNIGJAIPFem+CvDeoaNbeIkv7qIz6ne/aY5YGLMg+ywREncB826Jj34I9wOStvi5fX2irf6f4bicxadeajdxz37QmJbaYxOq5hJZjtyAwT0O2jVvHGo61q+if2TaC20mPXorKSX7cUuLh/IZzGYQu3Ydw5aTnAO3HNAGZN8KtWl8IWmkxaf4csru2ngkubu2lDNrIRZFP2nzbVwCS4f5hMN2fY1Y0r4WavZtp2Li0WK2/s3Mcl0ZSot9RmuXVWWCNduyQBAEUDG3gAE9t4A8XXfiV76HU9Mi0m9tljdrJpZmnQPu5dZIYwBlSAyF1JDYbjJ5WP4malDpk0lpo41E21tqWoTvd36xMsVtdyRFV2QYYkKNoIHGAzE5YgHrVFQWNyt5ZW9zGGVJo1kUN1AIzz+dT0AfFf7a3/ACVPSv8AsCxf+j56KP21v+Sp6V/2BYv/AEfPRQB9VfCf/klng3/sC2X/AKIStQeGdBGrTaqNE0z+1JlKy3n2SPznBG0hnxuII45PSsv4T/8AJLPBv/YFsv8A0QldVQBlaT4c0TR1ddI0bTbBXj8pha2qRBkyx2naBkZZjj1Y+pqta+DfDFrZXVna+HNFhtLpVS4gjsYlSZVJKh1C4YAkkZ6E1vUUAYSeD/DUa2qp4d0ZVtY3hgAsYh5KPu3qny/KG3NkDg7jnqal07wvoGmRqmm6HpVmiSLMq29pHGA6ghXAAHzAM2D1GT61sUUAY1z4V8PXWqPqV1oOkzai6lGupLONpWUqVILkZIKkrjPQ4qzouiaVoVs1vommWOm27NvaKzt0hUt6kKAM+9aFFABRRRQAUUUUAFcrqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FAHVVzHxJFy3hG7S1jLsxXfjqFyCT+ldPQQGBBGQexqZR5k0NOx4JomrWAs57fX7aS7VF3W5DYYHuufTv+FbXhjT/DuuagqWMl5pt7GQ8avIrbsf3a1/iToemQul/cNcxqw2CO3jXaCO5yRivOtPuorPVbe4iEipFKrglsMAD7V5sr0pKMrNGq95XR7X4W8Ptoepao0bK1rcsjxgdQRnP866So7eWOeFJYXDxuoZWU5BB71JXpRSirIyYUUUVQgrlfiX/wAi5Z/9hrSf/Tjb11Vcr8S/+Rcs/wDsNaT/AOnG3oA3tW0vT9ZsXs9XsbW/s3ILQXUKyxsQcjKsCDg1Qfwl4bdLRH8P6QyWcbRWymyjIgRs7lT5flBycgdc1t0UAZOq+GtC1dLZNV0XTL5LZSkC3NpHKIlIwQu4HaMADj0pj+FvD8mpf2hJoWlNf+X5P2lrOMy+Xs2bN+M7dpK4zjHHStmigDnn8EeFJILaF/DGhNDbBlgjOnxFYgxJYKNvy5JJOOua0bnQ9JurC5srrTLGayuZDLPbyW6NHK5OSzKRhiTzk960KKAMCPwX4WjezaPw1oiNZf8AHqVsIgYPmLfJ8vy/MSeMckmtDVdG0zV/s/8Aa2m2V99nkEsP2mBZfKcdGXcDg+45q/RQBlTeHNEmtUtptG02S2SF7dYntUKLExBZAMYCkqpI6EgelVk8GeF47JbOPw3oq2iTC4WBbGIIJQMCQLtxuwAM9cCt6igCtc2FndTpNc2lvNMkbxJJJGGZUfG9QSOA21cjocDPSqV54a0K9tzBeaLplxA0MduY5bSN1MUZJRMEY2qSSB0GTitaigDnZfBuik6OltZxWVnpd2b6GztIkihaYqyh2UL1G4sMY5wTnFbdzaW109u9zbwzPbyedC0iBjE+0ruXPQ4Zhkc4JHep6KAMW48J+HLnUZtQudA0ia/mRo5bmSzjaWRWUqysxXJBUkEHqDiov+EM8L/2X/Zn/CN6L/Zvmed9k+wxeV5mMb9m3G7HGcZrfooAzIvD+jRW5t4tJ09ICIVMa2yBcREGIYxj5CAV/u44xUGp+E/DurKV1TQNJvR5rT4ubOOT94wAZ/mB+YhVBPU4HpW1RQBl3fh3Rby3nt7zR9OuIJ1RJY5bVHWRU+4GBGCFzxnp2qSHRNKg0b+yINMsY9J2NH9iS3QQbSSSPLA24JJJGO9aFFAGdouhaRoUMkWh6XYabFIwZ0s7dIVYgYBIUDJxxVS78IeGrz7J9s8PaPP9jG2282yibyBnOEyvy888d63KKAMIeD/DQu7q6Hh3RvtV0rpcTfYYt8yuCHDttywYEg565Oa1baxtLSaeW1tYIZZ9pleOMK0m1Qq7iOuFAAz0AxViigAooooAKKKKACiiigDlfhP/AMks8G/9gWy/9EJWfrc/go6hc6ndaLYX+pJqMOh3Nx9gjaZZZxGgRncAlNk6ZwSNpI55FaHwn/5JZ4N/7Atl/wCiEri9U+Fst3rWusNM8PtaanrNrqb3bErcNCklu01syiLlW8qRvv4LNyBkmgD0XTfCvh7S1jGmaDpVmI5ROgt7OOPbIFZQ42gYba7DPXDEdzST+FPDtxqFxfz6DpMt9cLsmuHs42klXjhmIyRwOvpXk/iL4PandbIdPfTf7Kiu72SDTPMSKGGOYoUZPMtplR12sMKgxu+VhyD3/iXw1qN74W8P2unyQy6jpF1Z3QF7cNtnMONyvKseckZ+YJ152jpQB0o0jTQ6MNPs9yTtcqfJXKysCGkHHDEMwLdSCfWqth4W8P6fC8VhoWlWsTzJcMkNpGitKh3JIQB95SAQ3UHpXjur+Addn1jSLfUND0TV5LltbuphPJKbO2a4lgaPL+SxLj5sAqM7SQRineHvhxq//CXXAntbQtpt/pcg8QXJdbuVYLO3WRYR5eGRyjKzeZ3YEEigD2ltF0tiC2m2RIlkmBMCcSSKVd+n3mVmBPUgkHrUOh+HND0AynQtG03TDKAJPsdqkO8DOAdoGcZP5mvGtG+Det2dlqMFxeW0lxcQJA14t2qfaitzFKXlRLVH34RsM0sjAkjPJI9L8aeEhqHgv+w9At7C2gSeKb7E4MVtOiyiR4X2AkK/zAkA5zyDyCAJp+k+EfEc2u7vDWmSvHqBgvWubCFvtE0aghzwd2BIcFueTW4vh3RFtXtl0fTRbPAbZohapsaEksYyMYKZJO3pkmvHNR+EGs3dhHHHFodrbC/u7o6PbSILVUmSJV2tJaSLuTy2wfKH38gryDsz/Cme50PXYLj7Hcahd2dpbWVxdTNM8BjgSKQmTy15baQXVQWGMgdAAel6l4f0bVIrmPU9I068juWV50uLZJBKyjClgQdxA4BPSl0a00xYYbvTdPitd0CwIfsht5FiUkrGVKhlUFmIUgAbjgc151D8J7aw8Rz6lpFjo9kE1q0vbMwx7Ht7ZIkWaNcL8u9hIdo4bdkn0oad8MNXstT8LXIg0SSbTEhjnubiUXA2pKznyontiyNhjh0ljOcFgdoBAPUdV8OaHq/nf2to2m33nbPM+02qS79m7Zu3A5273xnpuOOpqO48K+Hrm0a1uNB0mW1ZI42hks42QrHny1KkYwu5to7bjjrVrRP7T/s5f7d+xfb/ADJN32Pd5Wze3l43c52bN3+1nHGKv0AZVt4b0O0tjbWujaZDbmF7cxR2saqYnO50wBjax5I6E9ajfwr4efUl1F9B0ltQUBRcmzjMoAGAN+M8Dgc9K2aKAMzQ/D+jaBHLHoWk6fpkcpDSLZ2yQhyOhIUDNKuhaQqSIulWASSOSF1FumGjkYtIhGOVZiWYdCSSa0qKAGxxpFGkcSKkaAKqqMBQOgAp1FFAHxX+2t/yVPSv+wLF/wCj56KP21v+Sp6V/wBgWL/0fPRQB9VfCf8A5JZ4N/7Atl/6ISuqry/4ZePvB1n8NvCdreeLPD8FzBpNpHLFLqMKPG6woCrAtkEEEEGum/4WP4H/AOhy8N/+DSD/AOKoA6qiuV/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKoA6qiuV/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKoA6qiuV/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKoA6qiuV/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKoA6qiuV/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKoA6quV1L/AJKn4e/7Aup/+j7Cj/hY/gf/AKHLw3/4NIP/AIquav8Ax94Ob4k6FdL4s8Pm2j0nUI3lGpQ7FdprIqpO7AJCOQO+0+hoA9Porlf+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iqAMvxloGpeIfFNlCysNIiQFnzgAknd+PAFcifB0uoyatPpSsILa5MEMZ5LgNgnPtXoX/Cx/A//Q5eG/8AwaQf/FVBaePfAVpEY7fxf4ZRCzOQNUg6k5J+96mueeHjJ3ZSk0a/hDS7jRtEisbqYStGzbWH90nIFbVcr/wsfwP/ANDl4b/8GkH/AMVR/wALH8D/APQ5eG//AAaQf/FVukoqyJOqorlf+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqYHVVyvxL/5Fyz/7DWk/+nG3o/4WP4H/AOhy8N/+DSD/AOKrmviD4+8HXWg2sdr4s8PzSLq2mSFY9RhYhEv4GdsBugVSxPYAk9KAPT6K5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqAOqorlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKoA6qiuV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqgDqqK5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqAOqorlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKoA6qiuV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqgDqqK5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqAOqorlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKoA6qiuV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqgDqqK5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqAOqorlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKoA6qiuV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqgDqqK5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqAOqorlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKoA6qiuV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqgA+E//JLPBv8A2BbL/wBEJXVV5f8ADLx94Os/ht4TtbzxZ4fguYNJtI5YpdRhR43WFAVYFsggggg103/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAfKv7a3/JU9K/7AsX/o+eis/9rvWtK174k6bdaHqdjqVsmkxRtLZ3CTIriaYlSVJGcEHHuKKAPrr4T/8AJLPBv/YFsv8A0QlTah430HT9Wl065urj7RC8cUzR2U8kULuAUWSVUKISGU4Zh94eoqH4T/8AJLPBv/YFsv8A0QlYGu+EdfuvFN1f6Qthp32i5hlOo22p3UUpRNoYS2oUwzttUqCzDgj0oA9JrL1rW7bSLrSILlJmfU7wWUJjAIV/Kkky2SMDETdMnJHHceLaD8Ntb1Wwu5obaz8Ozu+sRG+QyC9vPOnlEYlXy12xgEMCHYkbSNuTWnc/CvW7uFRp8mk+Fl+3w3KW+kSO8dsEtbiFpEzGmZHaZM4VflXO7dzQB7VRXh+s/CjWtR1HS7oJpVtFb2kNuLWyuliWydJGYyW7yWkrjfkMcGNsjBZ+CO18X+B5rrTA/hm/uLfWor6K9t59Qvri5jiYbkfars2weXLINqgAnaDwOADqNd1q30WOya6SVxd3cVlH5YBw8jbVJyRxnr/KtOvJpvhjqF7cXX9s3ltqkJ1Gz8k3jvI50+CR5PKkYg7nzK49GAXJzmsLXvg5q12iQW0unyaZFNfCDTvOSKO2imm3xmIyWs4Rwvy/IilcDa9AHuVzMtvbyzOCVjQuQOuAM1T8ParBr2gaZq9okqW2oWsV3EsoAdUkQMAwBIzgjOCa8ni+Fesp41bV57yO7QyiVLp7uNbhB5Pl+Ux+yGSROvAmRSDnaDXe+CPCS6DougJeT3T6lp+m29jKIr+4NqzRxKhKwlhH2OCUB79aAOrooooAK5XUv+Sp+Hv+wLqf/o+wrqq5XUv+Sp+Hv+wLqf8A6PsKAOqooooA47xt45t/C5aGS1lmuyoeNGOxZFPBIbnocZFanhHxHb+JdLF7bRSwoXMYWXGSQATjHUc4/CvN/wBoixuZbXT7uzifcivGZh91SSCAfTvTvgvpmrXBsb6+/dafYxSJCMY8x3PzHH9fYVx+1n7fk6HV7KHsVPqexE4Gaz9F1NNVhmmiGI0maNTn7wHesrxPNr8dwjaVaq9tH8zESDLjHKlT/SvNfBvjC6tr2/sbCELiUITdgqm7kZBz+dVVxHs5pNaE06PPFtPU9worN0cX8NoW1m5gkmZsgxjaqg9B71oK6tnawODg4PQ10p3MGh1cr8S/+Rcs/wDsNaT/AOnG3rqq5X4l/wDIuWf/AGGtJ/8ATjb0xG7q+q2ej20VxqM3kwyTxWyuVZh5kjhEBwDjLMoyeBnk1mw+MNBmllii1BXki1H+yXURuSLrGfL6enOfu8Hng1J420VvEXhLVdKidI7i4gYQSP0jmHzRufo4U/hXnln8LtWXULSebUraEHTpZLl4C5ZdVkWZTcRggZXFzJyTn5V46mgD0vXdat9FjsmuklcXd3FZR+WAcPI21SckcZ6/yo8Na1b+IdCs9WskmS3uk3oswAcDJHIBI7eteT+EPhTq+j+QZnsomjvbC4kEV0hjmEDszP5cdpDiQg9WLls4LcAnrdD8AyWng60sZ9RvLfWILGW0Se0v7gW6MwcB/J3KjEb85ZM5A9BgA7ie5jhntonWYvOxRCkLuoIUt8zAEIMA8sQCcAckAzV5FZfDnUEtNFhh0fwzo8lg0vnyafM7G8LWU0Akf9yp3b5AeSxwW+Ynq9/hi9p/wj7w6H4b1mO008W15Zak7JE1ziMG5VvKk3uQm3LKDtC4I6UAetUV43efDjxJLLJZRyaONLjutXuoZ2uJPOc3kUyorJ5e1djS4JDNkc4HQo3wbghN7Jp9jotvcG20wWUiKVaC4glLXEoITKs67BuHzNj5sdwD2WkdgiMxzhRk4BJ/Ida8YuPhfrEl74jks4tFtINRJkG+UTzXB+0pMYpJhbxyrE6qysrPNgMAOFwdyy+HqzatBd3mgeHNNtIdPlt47CxYywxzmVXSUDyYxkbc525BxjPWgDtNG8Q2mr6ne2VrFdJLaQ287meExZWZSyja2GBAU5DKCDx61sV4dB8JtZQadFJBoLSw2Wk2w1QzSG5smtQolaBfK534wDvTjqO1Vx8HteFzq7m/t3nulnAvPtSxtdrJKH8u4RLUSMpC7STO+3naOcUAey6VrdtqWq6zp8CTLNpU8dvOzgBWZ4UlBXB5G2RRzjkH60vhrWrfxDoVnq1kkyW90m9FmADgZI5AJHb1rm/hp4VufDU3iGWfT9H0yHUbxLiCx0pi0MCrBHGRzHHyWRm4XvXn9l8IdaTSZbQQ6Dps39mzWTz2c8jNqLySxurznylI2BCF++fm6gcUAe70V5N4i+GM0/iGafRbHQ47WX7Mbe6lLx3GlmOUvIYFVCGMhJYncmWJ3bqZffDbxBMNTsbbWoY9DutRYixLP5f2GaRpblSuMeaXchTyAq4yNzUAeuVSTVbN9am0lZs6hDbpdPFtbiJ2dVbOMcmNxjOePcV594e+HEuk+KrLW449Nju11fU7y7niBEs1tcGUxRltuW2l0JUnaCCRnunjn4eXet+LdT1XToNJjk1DR/7PW+lJW6sph5372PCHduWRUOHQhV6ngUAen0VxPw48LXXh241aaex0nSre88kRabpMjPbxFFIaTJRPmfIzhR90ck5NeQ2/gPVdXvtQ0ey0q1guV0jU7K41ya2uYDfTTSx+W0zywKWPyt9wygDOCAQCAfSlFeNeNvhbqepeJrW68PwaDZWVrLbTQShEiuUZJvMlLP8AZ3kct8xBWVOWO4Nk50/Cfgx5fE+vLfC8i0HT5prfSERpbWRPtBWa4ZHUq20OQiMpHAYDjqAd9FrdtJ4oudCVJvtdvZxXrOQPLKSPIigHOc5ibPGMEc+i6FrVvrUd61qkqC0u5bKTzABl422sRgnjPT+VeZ+O/hde6zrc0mmwabNbSaVBp8F9qV5NLd2EiTyyGeMsjl3xIMEyKcjripbzwB4ittUk1LSpNKnuJJdVQx3U8kaiK7aNlfKxtll8vlcAHPDCgD1qivD9M+EmtWniTQ9Qury2uY7JNPHmR3KRSW32eKNHSMtau7RsUY7RJEGDkEckn1/RdHttHiljtJb+RZG3sby+nuiD7GV2Kj2GBQBo0UUUAFFFFAHK/Cf/AJJZ4N/7Atl/6ISnXHj7wzb3et2s2qKtxouw38ZikzEHxtIG35h8y8rnGRnFN+E//JLPBv8A2BbL/wBEJXn/AI4+EWp682vXmn31na6pd6sLq3kLsFe1aGCOWGX5T1MO4YB5VeRzgA9qqld6pZ2eoWFjcTbLq+Z1t02k7yilm5AwMAE84ryP/hVWrDxfq+qXE8V5HdvfMky3y20zJPG6rC5W0aTau4AHziF2qyr8oWm6T8KtQtP7GlutG8J3S6dfyzpZyKigxPCqEtLHaoryB1Vh+6HCqCxIzQB7XUF/dw2FjcXl02y3t42lkbGcKoJJ/IVwPwy8E33hbWtVuZ7XSra0uV+QQOtxcM28sS84t4XK89HMhz/F2rndX+Fep6hqWps8Whn7TNqEx1N3c3d0k8UixW8y+XgRxl0wdzf6pMKpzQB6p4c1U63o9vqBsLywSdQ8cV35fmFCMqxCOwGQc4JyO4FadcTq3gyJ/hh/wi2n2Fii+TEht4pRaws4dWY7hE4wWBJBjYNkhhgmuL/4Vv4ottIkhsE8NrPdaPeaPLErG2igWWXejr5UAWRgCQ2EjBPIHYgHtVFeGaF8P9XuvFGozfYLHTmtdaimGtMXF28aWcKtHCpjwYmbILb8H5htyAah0T4OazZ6TeWdzcWZlm+xq86XaqtyIruKZpHSO1jcSFUfDNJI2WwW/ioA9YfxTbjxLPo8dhqUxt/JW4uoYQ8MLy/cRgDv5HJYKVUHLMBW3d3MdqiNKszB5EiHlQvIcswAJCgkDJ5Y8AckgDNeYXHwptoddv7/AEbTtCsfN1XTbyAwwCJo4IJInmT5U4LGMkAcE4JIqvpnw31K2srW1fTvDy3kGp2t7NraTObu/SK7WZvNHk5DFV6eYw3AdB0APSvEutW/h7QrzVr1Jnt7VN7rCAXIyBwCQO/rSarrdtpuq6Np86TNNqs8lvAyAFVZIXlJbJ4G2Nhxnkj614xD8JPFD6hrVzPLoEDahp81rJ9k2xJNI08ciuyR2yEcI2d7Stk8NgmvRPiX4WuvEk3h6W30/SdTh068e4nsdUlaOGdWgkjAyI5OjOGwVx8tAHb0V4Lqvwk8UXNnottHdaE7afDCsV0QqTW7LO0rIrtbySNGAQqBZIsAHIbJFak3w112O78US6ZZ+G4V1RZAv2zy7ySQvcJIwaRrQMFKh/lkM4DFMDCYIB6nfazb2eu6ZpMqSm41BJniZQNiiIKW3HOR94YwD+FadeTfDf4dax4b1DTp76bTxb2t3fTiG3kBEaTxwhVULDEnDRuSFRByMDk1q6v4LvbrxtqOrfYtHvkvI4ktr67kYXeklUKk26+UwPJ3jDxncTk9CADsdd1q30WOya6SVxd3cVlH5YBw8jbVJyRxnr/Kjw1rVv4h0Kz1aySZLe6TeizABwMkcgEjt615F4Q+Eus6NNZvPLZK8N1ZSyvFdJsuBDIWZzHHaRHzDk4Z3kJzgt3r1DwDotx4e8H6ZpN68UlxaxlHaEkoTuJ4JAPf0oA+S/21v+Sp6V/2BYv/AEfPRR+2t/yVPSv+wLF/6PnooA+qvhP/AMks8G/9gWy/9EJXD6t4m1Cx8Z+JbAXl8YptSe3hVZwFhC6MJ8AFSQN6lsIUO45JPIPcfCf/AJJZ4N/7Atl/6IStqXRdKmuXuZdMsXuHcyNK0CFmcx+UWJxkny/kz/d46cUAeU6H8WHh8E6Rcw6bNqMrPbaWrSSytNLcmDzHaSNIpJFXCkg7WZ8527TurvNP8T6heeAn15fD18morHI39lOrxysyMVwN6K2GxuBKAkEfLnitG58LeH7qOSO50LSpo5IkgdZLONg0afcQgjlV7DoO1WI9C0iPRTo0elWCaQVKGxW3QQbSckeXjbgkk4x1oA8503x34g1nxn4btLG10uO1njvVvrU3cysjRNbcnzbVJFdVlyEKqG38kYBrR8N/Ee61SPw1cX2iwWFprtjPfQv9v8xoliRGIceWBzuOCG6DJAOQOri8JeG4rezgi8P6QkFlL59rGtlGFgkzneg24VsgHIweKra7pvhWK00XStZ0rS3tJLlbXTrWWyWSJJRG7AIu0qmER+eBxjuBQBy+gfEPV/FOnSz6DollGIdOt7u4a71Fo2jeeDzVVFWFt4AIBY7cnOAcGqvhL4i6ovh3Rj4ksbVrqfwy+uG7ivOJ/LWHhl8pQjuZSSFyFxgbs8dtc+HvDVvdaXPJ4f09ri2KW1lLHpyyNbAA7QrKp8tBg88KPbIobwT4Ua2jtm8M6GbeOVp0iNhFtWRgAzgbcBiFXJ6nA9KAONuvipcwaXrGpDw+GstNNnG7C7ZnkkuYYHjVUWIkgNOAx64GVDE7QTfE3WYtHS9m8IXFsqTzR3M139sit4Y0RGEu77IZdjBz8zRKo8t8kYBPoS6JpS211bDTLEW90AtxELdNswCBAHGMMAqqoz2AHQVmHwJ4R+zQ258K6D9nhdpYov7Oh2o7Y3Mo24BO1ckddo9KAKvh2+n1zxfq99FcOdKsIo7CFI5CYpZiBLLJjo2A0SBscEOO5rrap6TplnpNo1tp8PlQtLJOw3FizyOXdiSSSSzE/jVygArldS/5Kn4e/wCwLqf/AKPsK6quV1L/AJKn4e/7Aup/+j7CgDqq8++JHjA6Nths5QhiAnllVs4UZ+Uj3xXoJGRivP8AxF8NbHULedbKVomlDbo5DuRge3qP1rDEKpKFqe5tRcFK89i34P8AEdr4002aC+hjcuPM2BTsaM4wee9bHjC8TTvDV6Y7qKzmMLpA7MEAfacAe9ZXw+8JS+GI5hNJEwZFjRI8kKB7mt3xBpdlrunTabelSJVyMY3L/tD3opqfs7T+IJuHtLx2PLvBXxMm86WPW5muXkclI40yy8HCqB1LEgDPYV2t/wCELXWbtNQJnshPHvkiAAYOehPUD3rlNA+DsOh+K21az1Nk+dJBmPczEZyCCcdO4r1wVFKnJx5aupVSpFS5qWhxvjsTab4LESSPNsaNWnc4YAHIY/iBXE6L4suLOK3jSZhCJGuJmHzNOxP3c9h0r0T4haPL4g8K3OlQ5zdMkbEHG1dwJP6V5noHgq4lWeztHg32DiJoZCy5A75HY4rHERqKqnTNaMoOm1M9c8O6hNqemrc3MUUMjE/IkgfA7ZI71k/Ev/kXLP8A7DWk/wDpxt62NC0e00e08mzhEW7DP8xbLY9TWP8AEv8A5Fyz/wCw1pP/AKcbeu6N7K+5xytfQrfF69vdP8DTXOlySR3i31gqeXKYi268hUruHIDAlT7E8Gsuw+Iep3urJo0Xh+1OsC7urOVf7RP2dGhjik3CXytzKVmA+5kMMY7jqPHVzpFr4blbxFp6ajpkk9vbyW0kKTK7STxxoSj/ACkB2U+2MjJAq7p+haRpqWqadpVhaJa7xAsFukYh3/e2YHy5wM464qhHnw+Kt1/Zxvz4fR7a4sLrUbFIr7fNLHbsBIJI/LHltg5ABfkbSQadrnxh062truXRrCTUDa2d1qDiSXyQ9vCAFlQgNlJHYKpOOjHBxz3lp4c0Szu7y6s9H02C5vQRdTRWqK84PUOwGWz75pzeH9GaAwtpGnGE2osjGbZCptx0hxj/AFf+z09qAM3wp4hvdV1LWNO1bTYbC+014tywXRuI3WRNykMUQgjkEYxxwTXLTfEu/wD7Ijv4dDs/395c2drbveXEk1wYJZUkZY4LaVsARqenGWzgKC3pEVpbw3M9xFbxJcT7fNlVAGk2jC7j1OBwM9Kzr3wzoN9Yx2V9oml3NnHK06QTWkbxrIxLM4UjAYlmJPUkk96APKdc+Jt94l8Hm48P2IsYhDp1zdXMmoGKaEzzLhIlVD5gwCCSyA5PXkVf1j4rzaHpeoXEdj/actpdakZbeSeTzkgt7ho9yiC1ZQny4BkKgcBnY5avQZPB3hmVrRpfDujO1mgjti1jETAgOQqfL8oB5wKpy6H4O13UL2xuND0e+utPlLTxz6ej+W8w8xjllwS+dxIzknnmgCn8NdUm1W68XzSzzywrrAFusrlvKjNnbOEUH7oyzHA4ySe9cvZfF+8bSLW/vvDcUQvdNj1S0it9R81mjaeKErJmJQjZmBHUHBGRXqllYWdgJRY2tvbCV/MkEMYTe20LuOBydqqM+igdq848KWfgnwx8J4tW07Q1bSBbRtKZbSA3VyEcBWlxhXfcAck9eaALV78QtR0/UbqC+0OzWHT7i1tr949SLOj3DAR+UhiHmgBkJyU53AbtuTiyfFPUtOdrE6Fcajq73d8GhjklmREgkVdsbQWpZuXAXcgwPvPkjPpeo+HdJ1C/j1C406ybVYV2wX7W0bzwdcFHZTggnI7e1ctYeG/DC6hJ4U1XTxrtyFfWpLjVreGcM80rBmHygK2QeFQADFAFC98d65qeieJrrQNGgtYtKtH8ya/u2huYp/somA+z+Sw+Xeo+ZlyQeMDmqPiDq2mCyGrWMUt/c6dZvFDDer9neW4uPKRncwKyZyCx5UDgKTye+fwt4ffUIr99C0pr6GMQx3Bs4zIiBSoQNjIXaSMDjBxTbfwl4ctrKWzt/D+kRWksZhkgjso1R0LbihULgrkk46Z5oA4ub4l6obwadaeHrKXU4jfrdI2qFYYzaiBm2SCEl9wnHVVIIII6kXdH+IdzqWu6RbPowsdL1OGCW2vLuaVTMZIBLsj2wmJmHK7WlVjtYgEAZ6+08P6NZRQRWekadbxQRyRQpFbIgjSTG9VAHAbauQOuBnpUNr4V8PWepx6jaaFpMGoRII0uorONZUQKEChwMgBQFAz0GOlAHL+OvH9/4b1jULWy0KC/ttP06DUbmWS/MD7JJpI9qJ5bBiPLzyyjnt3zNR+Kd9ptxLpl34cU69Hf/Yjb21xPcwkfZkuN++K3aQ/K4GBEeQecc16Pd6Tp15JO93YWk7zxLBM0sKsZI1JZUYkcqCzEA8Ak+tV9S8OaJqkVxHqejabeR3MizTrcWqSCWRVCq7Ag7mCgAE8gACgDz1fi1ey6ja2lv4P1ZphDbS3sDQXPnW5lYghVWBlO0AtmRosgcVR0L4geIINGs77X7eGXdcavs+zXa/vltjcHZIptxtC+WqqVbJxubup9Im8H+GZzZGbw7o0hsVCWhexiP2dQcgR5X5QDzgY5qRPC3h9Lq5uU0LSluLks08os4w8pZSrFjjLZDMDnqGI70AcSvxN1CINbXvh6CLVJVsGtIU1HdFILtnVPMkMQMZUxtnCv2xnNdL4b8VvqXhzVtT1O2tNPfTLi5t7gJdGWEeSSGbzDGp28H+HI9Kua/wCFdM1nSruye3gtvtMUUDzR2kEjeXG25E2yxuhUZbAZSBuOMHmk8I+FNN8LeHv7GsEMtozyPJ5qIPMLklsqiqgHONqqFAGMUAeZ3HxU13VJY7PSdKtbS/h1HTkYy3E6Q3MFwzgANNaq4BKY3BCMHKk4xXofjPxPN4b0uxlFtaz6ldSiJLMyzku2wswj8mCWR8YJ/wBWOMk4xirEHgnwrBZXNnB4Z0OO0udongSwiCS7SSu5QuGwSSM9Cau6noGj6rp8Vhqmk6fe2MOPLt7i2SSNMDAwrAgYHAoA5uHx/FL8LYPGQ0+QCWFHFmZACHaQRhS5AwNx5Yjgc47Vydt451nR9X8VrqFvaXOptqsUEGmx311cIiCxhdhCY7Z3PPzMPKUAsxJ4yfVo9J02PSjpcen2aaYUMZtFhUQ7T1XZjbg5PGO9Zn/CE+FfsQs/+EZ0P7GJBN5H2CLy94G0Nt243YAGeuKAPOdU+JWoeJfAXiOfQtMNkIvDI1Rrs3xSS3M0NxgIFTJdWhGDlQeTlSAGur8WHTSNOlsNHkvWvLlrK2DSTNIzRR5laWOKGWSM5A2rtZiDubYK9Gt/D2jW9pPa2+kadFazwC1lhS2RUkhAYCNlAwUAd8KePmPqahvvC3h/UFnW/wBC0q6W4KNMJrONxIUGELZHO0EgZ6DpQBz3hTxtqXiLWRYp4dksPKs7W8u/ts7RSQCYzAoIzHksDDxnaCCSdpADd1VHTNH03SgRpenWdkPLSH/R4Fj+RM7F+UD5V3NgdBuOOtXqAOV+E/8AySzwb/2BbL/0QlUZPG90ZvENwljpsOh6JJLBcXl7qLRP5iRhv9WsL4QsyjcWzjJCngG98J/+SWeDf+wLZf8AohK0rvwt4fvdTfUrzQtKuNRdDG91LaRvKyFdpUuRkgqSuM9DigDgtN+Kt7fTrZL4cC6o2qRaaIpLiaFP3ltJOshM1ukgA8sggx9DkbuAbOoeOtXm8M69q0Wl29tp+nSzWrTQ6jm586KTy32xvbsgXcGwWOSMHaM8dnpvhXw9paxjTNB0qzEconQW9nHHtkCsocbQMNtdhnrhiO5pJ/Cnh241C4v59B0mW+uF2TXD2cbSSrxwzEZI4HX0oA426+J1zY31w99oSro8d9e6etxDeGSd5LeKSUnyfLACssTAfOTntjmopvifqNvCIp/D9odSmGnyWsMOqeZG8d5N5SF5PKBRgeSNrAjoxr0MaRpodGGn2e5J2uVPkrlZWBDSDjhiGYFupBPrVWw8LeH9PheKw0LSrWJ5kuGSG0jRWlQ7kkIA+8pAIbqD0oA4mx+JmoLfRx63odjp9obu9sGuV1NpQkttFJK7EeSv7orG3zfe/wBmrngf4kw69e6ra6vawaQbFbV1meaURTicsse0zwwtksuB8pDbhgmuzbRdLYgtptkSJZJgTAnEkilXfp95lZgT1IJB61SsPB/hrT4ZIrDw7o1rFK0byJDYxIrsjbkJAXkq3IPY8igDcooooAKKKKACiiigAooooAKKKKACiiigD4r/AG1v+Sp6V/2BYv8A0fPRR+2t/wAlT0r/ALAsX/o+eigD6q+E/wDySzwb/wBgWy/9EJXM6v4B1G71/wAS3K2ujTS6qkgtNcmkYX+mbrfygkS+URtDAkbZE++3fk9N8J/+SWeDf+wLZf8AohK53xv481jSrzXNNt9KgsmitJ2sb27nlX7Q627SgxAW7RMQQ3yGQN8jErjqAYtj8KbqWaEX2meHLHTBd2Us2lWTvJbyrCkwkkYNGoLuZUBUrghBlies2nfDO/069snn0zw7rlhbG6jt7C/ldYrJHu3ljeEGFxuEbKhG0Y2ABsdb8HxB1+2sp0vNBsbi6sdBj1u4kj1JtsiN5w2r+4B3nyc4xt+Y88Ddb1D4mC3u/slrpkc91Jb6dJCGvAkZkvGkCo7bTsVRHndgk7hhfUA4uX4Oa6y+I1N5aS3OoWt7bx3zXSIZzOcr56LaCRscctM+3HAwcVta98JkfVHn0nR/Ds2nR6lb30OmXQMcMirbSRSq2InClmaN8hW3GMZ5wak8Q+PPFXhzxBr02paTpkthpmgxajLZQaizbWMtwu5HNuCxby0BBwFAyMkkV0GseP3s9cudLsNLS9njvrWwRvtYRWaeJ5Ax+U7QuwA9Tg5HoQDJt/hpPCkU0f8AZ8Op/wDCQ3Opvdx5Mi20kkzJGrFc5HmqdvC53H3Oz8LfCtx4V042t5o2hW1ysUccmpafKzzagy5zJOGiUhjndy78sefXJsvibqV1r9zp0PhO8uEtp5rOWW1+0SBZ44yxG8wLF5ZcbAxkDfMpKAHjpfAPii58TW94b+xh068tnVZLQSTNLHuXI8xZYYip9MBlPUE0AdVRRRQAUUUUAFcrqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FAHVUUUUAct8Sbu7svC081gzrNuUBlOMZ968j8Ja3qJurW7u5ZbKd3CylmL4UH9R7V77f2cF/aS213GJIJBhlPesCXwRoxnt5YIWt3hYN+7b72D3zXHXw8qk1OL2OqjXjCDjJbmN8TLHXb2O2m0me3SzgUTEyOEZZByGB+lc58LPiLqOraw2kanBJcMDtFxwMAAkkjv25r03xHoNj4h0/wCx6ijNEGDgo2CCPQ1geEfA1p4c1vUL6EBkcBLZcklEx8wOepJFXOnP2ilF6dSY1IezcZLXoTp4oebxmml2wSS1K4Zj1DYJ4/QVu22lQW+sXOoxlhLcIqOvbjv9a8ZkuL8ePpZwVsN8w2eamTGxJySD1GMV7pCGESB2DOAMsBjJ9aWHqOpzc3RhXgoWt1Q+uV+Jf/IuWf8A2GtJ/wDTjb11Vcr8S/8AkXLP/sNaT/6cbeuo5xfid4fuvFHgy60qxS0knkntpRHdyMkUixXEcrKzKrEZVCPunrXH6B8LpItTsptWs9GXSlu7y5fSLctJbQLLHCqRxqUUOu6JnIKqNzZAr1migDxez+E+otBfW13/AGVbebp93aSahayubnUpZXDRTXAKAKUIyOZDk8EDin698NfFWu6feR6vrVneSzaTcpGsrSbIdQuAFcodpKwKgKqAM/M3HNey0UAcp4P8JxeGNb1+TToLO00m+eCS3tbYbQjLHtdiuAAWIByMk4yea4O8+F+rT6Dq+nJaaDHf3MzSnXElJu9QT7QJfJuA8DYVlGD80i5VfkI4r2eigDxLTvg5M8Jj1e20yeBdPv4IbeaZZ0guJ2hMbxhLaFEVfLc4CAqWyM54nuvhZqEj6tiz0GS41GCxDak0rpcxyQ+UJVBERJV/LLbt4OSMjvXs1FAHjmr/AAw1ST4g6dqmj2/h+w0mwvra4g+zRRwTLChBlRsW5dixMnSZVOcFepron8FX7/BxvCTTWhv2tvIMm9vKzv3dducY9q9BooA8of4c6jpHildX8LQaPFa2up/bbTTWke3hCPZG3lzsjYI287+FO7uQTWDf/CXXLnS7a2ltfDl5cf2S+n/arieQGxmaeST7RAvlHcyiQY5Q5HXFe60UAZmhx6rEt3Hq8lpKiT7bR4N29oAiYMuePML787eMbe+a06KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4T/wDJLPBv/YFsv/RCV1Vcr8J/+SWeDf8AsC2X/ohK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4r/bW/5KnpX/AGBYv/R89FH7a3/JU9K/7AsX/o+eigD6E+GXj7wdZ/Dbwna3nizw/BcwaTaRyxS6jCjxusKAqwLZBBBBBq+PEPwqGrTaqNX8D/2pMpWW8+02nnOCNpDPncQRxyela/wn/wCSWeDf+wLZf+iErds9Vs73UNQsrabfdWDpHcptYeWzoHUZIwcqwPGetAHG6T4k+Fmjq66RrPgmwV4/KYWt1axBkyTtO0jIyzHHqx9TVa21X4QWtldWdrf+AYbS6VUuII5rNUmVSSodQcMASSM9Ca9IooA84TV/hFGtqqah4CVbWN4YAJrMCFH3b1Tn5Q25sgcHcc9TUuna/wDCjTI1TTdW8DWaJIsyrb3NpGA6ghXABHzAM2D1GT616FWRpuv2uoRavJDHOo0y5ktZt4A3MiqxK88jDDrigDkrnXPhNdao+pXWqeBZtRdSjXUlxaNKylSpBcnJBUlcZ6HFWdF8WfDLQrZrfRNf8G6bbs29orO8tYVLepCkDPvXV+HtVg17QNM1e0SVLbULWK7iWUAOqSIGAYAkZwRnBNaFAHK/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVdVRQByv/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVXVUUAcr/wsfwP/wBDl4b/APBpB/8AFVzV/wCPvBzfEnQrpfFnh820ek6hG8o1KHYrtNZFVJ3YBIRyB32n0Nen1yupf8lT8Pf9gXU//R9hQAf8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVdVRQByv/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXVE4GT0ri9Z+JGgaVetayTtJKpw3lrkD8aaTewm7blr/hY/gf/AKHLw3/4NIP/AIqj/hY/gj/ocvDf/g0g/wDiq6Oxu4r60iubdw8Ui7lI9KnpDPPNS8SfDfUr9bu68WeGmlCbDjVIBnkEE/N1GK2B8RvA4AH/AAmXhv8A8GkH/wAVXV0Ukkth3bOV/wCFj+B/+hy8N/8Ag0g/+KrmviD4+8HXWg2sdr4s8PzSLq2mSFY9RhYhEv4GdsBugVSxPYAk9K9PrlfiX/yLln/2GtJ/9ONvTEH/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVa3ibW7bw7o8mpXqTPAkkURWEAtmSRY16kDGXGeemaTWvEeiaFJbprms6bpr3GfJW8ukhMmMZ2hiM4yOnqKAMr/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qtO68T6BaSzxXeuaXBJAGMqS3camPaFLbgTxgOhOegZfUVXbxp4WXS11I+JdEGnNIYVujfxeUZAMlQ+7G7HOM5oAqf8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVdRHIksaSROrxuAyspyGB6EGqo1OwNjcXovrU2dsZBNP5y+XF5ZIk3NnC7SpBz0wc9KAMH/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiquX3i3RLeS7toNV0241SC3e5+wJdp5zKqb87ASwBHOcdDmqngjxb/wlDXY+xfZfIhtJf9bv3efAsuPujG3dj3xnjpQAn/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVVrWfGOg6VJe282q6e+o2kLTyWAvYI59qruJ2yOoXjnLEDHJIqxdeJ9AtJLiO71zS4HtgzTLLdxqYgpUMWBPABdAc9Nw9RQBm/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVaVt4p8P3VpJd22u6VNaxxCd5o7uNkWMsy7ywOAu5GGemVI7Gq13438KWV1Pa3nifQ7e5gJE0Ut/EjxkHB3KWyMHjmgCt/wsfwP/wBDl4b/APBpB/8AFUf8LH8D/wDQ5eG//BpB/wDFVoyeKvD0dxYW8mvaSs+oKjWcbXkYa5DHCmMZy4J6Yzmo18Y+GWnuIR4i0YzW7bJkF9Fuibk4YbuD8rdfQ+lAFL/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8Aiqp6h8R9GstQsEmubKPTbm5kt21GW/hEKbbdZlbKsRhg6gBip5BwQVJ328T6Ct5ZWja5pYu75FktYDdx77hW+60a5ywPYjOaAMz/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iqF8b6XceOLLw1pt1ZX9zJBczXJt7tHe0aJogEdBkgt5jdSMbDwe2vdeINGtNWi0q61fTodTlG6OzkuUWZxzyEJ3EcHt2oAyP8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+KrWbxDoq20dw2r6cLeS3N4kpuU2tAMZlBzgoNy5bp8w55qC38U6PdtZtYahZXlrdLKy3VvdwvEBGAW535OM87Qcd8cZAKH/Cx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVP8K+MtN8Ua1rNno1xZ3tppywEXlpdLMkpkDEr8vAK7fU9e1W4/F/huSa+hj8Q6O0tgrPdot7EWt1U4YyDd8gB4OcYoAo/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVX38XeG0uYLd/EOjrPPI0MUZvYg0jq21kUbslg3BA5B4p0Xirw9Le3lnFr2kvd2Su11At5GXgCcMXXOVA75xigDO/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+KrT0/xPoOo28Nxp+t6XdwTXH2SKSC7jkV5tu7y1IOC+3naOcc1r0Acr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VXVUUAcr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VXVUUAeX/DLx94Os/ht4TtbzxZ4fguYNJtI5YpdRhR43WFAVYFsggggg103/AAsfwP8A9Dl4b/8ABpB/8VR8J/8Aklng3/sC2X/ohK1NM1+z1C71u3jEkR0i4FtcPLhVLGJJdynP3dsg5OOQfrQBl/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FVesvF/hq+tZLmx8Q6Pc20cixPLDexOiu33VJDYBODgd6IfF3hua/trGHxDo8l7dKrwW6XsRklVhuUou7LAjkEdRQBR/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4qtfSdf0fWZrmHSNW0+/mtm2zpa3KStEckYYKTtPB6+lY/h7xzpGrahqenzXthaalZXdxB9ke8QzPHExBl2HBCkAnpgY60AL/wsfwP/wBDl4b/APBpB/8AFUf8LH8D/wDQ5eG//BpB/wDFVbh8aeFptOn1CHxLoklhAypNcpfxGKNj0DNuwCewNOXxh4Za5srdfEWjG4vVV7WIX0W6dWJClBuywJBAIzkg0AUv+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqu+E/EKa94ebVpYVs40uLqFg0u4KIJ5IixbAwD5e72zjnGajHjjwmdPN+PFGhfYRL5Juf7Qi8vzMZ2bt2N2OcdcUAVv+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iqp3Hj1I/FMekRWKyxyalBp63K3HBEtpJcCQDbzjy9uM85zntWjqHjjw/pvil9A1LU7WzvltBeZuJ441KZbI5YHcApYjH3ec0ARf8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FVq33iTQ9PjeS/1nTbWNI0lZprqNAqPnYxJPAba2D32nHSodN8XeG9Vufs+meINHvLjyzN5VvexSNsHV8KxO336UAUP+Fj+B/8AocvDf/g0g/8AiqP+Fj+B/wDocvDf/g0g/wDiqv23i7w3dWb3dr4g0ea0R/KaaO9jZFfaW2lg2M4BOPQE1rW1xDd20VxayxzW8yCSOWNgyupGQwI4IIOcigDmv+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKrqqKAOV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIquqooA+G/2u9a0rXviTpt1oep2OpWyaTFG0tncJMiuJpiVJUkZwQce4orQ/bW/5KnpX/YFi/8AR89FAH1V8J/+SWeDf+wLZf8AohKybnRPFNn4i8V3GkWuhz2mttEUmu7yRXgK26xEtCIWWQZUnbvGRxkVrfCf/klng3/sC2X/AKISsq++IFzBr1zaQaRBJp9vqkOjNO97smNzIisuIfLOY/nXLbs43EKQKAOK8M/CPXLOe5/tE6NFZ3F5p1zJa2jqsf7h5DLhYraFRuDKANpJxhmOAagvfCM1v8Srax0zQ4CE1ZLqPV4rKdHsrUW21YFdoRCI04ACSnnA2ZzjqYPiw17BCNP0MSXRNvaTpNeCNLa/llaM2zuEP3djksAT9zC5fiC5+KctreTPdadIs1pa3azWkF4kkDTxXVvAMSGMMRmYfPlQo3bkJAIAJfhB8O9T8GalcXGpywSM9qLdpbe4jIuWDg+ZJGtrG2/r8zySN8xGT1qtN8NtUm8Y3WpLbaJbrJqsuoLqaTObxomgMYtivlABCTk/OR/s5rovhzqGq33iLxumtmNJrfUYY0t4Lt7mGAfZIDtjZkTgkliNo+Zm69Tgx/Fy4g0kalq3h4W9rPplxqVoLa9M7yCKSOMq6+WuzJlUggtxnjPFAGfD8NPE1noqaXayaNLDcWWjQ3U0lxKrRPZbd/lqIzvVtowSVI7jniz4P+FuoaX4su77VrszwzfaVe9tb4W9xcLK+4eYI7dJSRxgm4baRxwcVcPxO1tdOe5k8G3MKxTFJbicXsdskflhhJk2nm4zuUnygo25LYIpmj+OfFDR+LLwaRaaxZWeprb2gtLqR3SNobdx8qW5ZowJGcsAz5JUKQAaAOa+NXhC4bzrTTNJk1/7XpP2CyS+W8vJLGYyuxmSYxyIGbeATJIhAjXDYGK6XxD8N768s9cktbbQrjUNQ1ZrkPexJJ/ojKmYw0kMqo25Fb/VuPlHfBHoPhTWBr3h+01IfZx54bIt5HkRSrFSAzojZBBByikEEY4rWoA8Jt/hvrGm6X4Y0J5N012bvT9VltgzwjTWmafYXCIFYDESjao/evtGBx7pGixoqRqFRQAqqMAAdhTqKACuV1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsKAOqooooA4/4qX99pvhKefTiVk3hWYdVU/5FfMsrvNMzyMWkY5JPUmvqXxf4h8P6dA9lr9zGizIcxsMkivBNZ8VaBp2pN/wj+mR3EQOfNnXqfYVvSbS2Mqlu512seKr/AMJfDrTraAsLyf7shHCLXC6d8UvE1nOjm885QclHHBrX1n4j6br+hR6fq2k4KH5XjI+X6Vz8Hge81aL7V4edLu1JxjdhkPoRVRSS95Ett/Ce3/D/AOJ9h4kMNpeAW2oucBB91vpXo1eEeA/hLe2t/aahqMwjaJg4RD3HvXuyjCgegrGfLf3TWN7ai1yvxL/5Fyz/AOw1pP8A6cbeuqrlfiX/AMi5Z/8AYa0n/wBONvUFFzxzoMnibwzc6XBdpZyySQypO8JlVWjlSQZQMuQdmPvDrXIeNfh/4l8YafJa6n4ut4Y5bea2kis7G4ghYOAA5RbsFmHzcOWQggbOMnY+Mf8AyIzf9hPTP/S+3rzjUfjTqkGo69HYDTbyC1sL+6t99sIpIpLdlAWVFuXfByQd6Qk4BAweADr9T+Hr2fhjW47OWS+1C51K11SLyraMsXgWBUjZZJUWRcwliC6/fOORk4dj8Mtb122/tTW746XrTX95ceWBKiGKdYlKsttcqVP7kHAmYYODu7TfEn4h+IPBz38Fxf8Ahu1ubbTDqMAurWUi+cu4FvCPOXLIFXc3JO8HYoqtP8VtfTxRrlgLHTIorH7eq208kKXAWCORo5dv2nzZFcoCQIVG1shyBkgHpPhLRdQ0TNpNdwHSLW0trOxtYFIVBGmHcl9z8nACl3wqjkkmuT1z4SwapqGq3A1ieCO9vVuFhWEFYYnGLqH73zCbJJJ6EJwdvOl4jvNfm+Dmv6ibq3i1aXSZrq3axikQw5g3BVO/cXBzhxt5IO3jnz2XxTrFjq+peJdK1jQdXFp4YsprmWK3do7lRdXQ2IRMdjDkFiX+YfdHQAHYS/CkP4kvtQGq77S5uri9WCYXTNDNLGyFkxcrDxuPWEnaSM9xq6H8N9Jtbe4g1yGx1y3kS0VYryyR1jaC3WHeAxYZIBPtnHPWuL1L4u6hB401LSrE6fdWsCagoWS3EUsMtvC8g3AXLSMpMZGWijBHKk12vgLxHrWpa1eabr506SRNOs9SjksoHiCicygxsGd9xUxfeBGc9BQBU1L4e39xpPinRrTWrSDRtda4ldH09nnhkmXBIkEqqyg8gFM44zwMWb/4f+fZ6kLfUI4r251lNahme1EiRyJs2o6bh5i/Kf4lPPGMVx+q/EXUbzXrnRHutFSOe51PT5dMETm9gjgt53SZn8zGHMakDy8bX4Ymo/Dnj/UtPXQNIjfSkSOPSrOLTZo3N7exTQxF7iJg4UIm9s/Iw/dNllOBQB0fir4daz4hN9LL4jsba51PTk07UGi0tijpHK8iNEpnJjOJCpyXz1G01qWngCKDWbDUDeo5tdau9YKfZx85nikjCZ3cbd4O7vtHA7eV+D/iJq2h+C4bXSZtF1dLPSp7uSK3idpNOMc6LtuCJCG3K8hAAQjYeCBmtzXfHX9s+ONPuNIFrqtno2pz/YjZNu+1H+yJ5Cu4EhiXJUEcfWgDo9L+GV5pdxoZ0/XY7RNPjihnktraaKa7jSRn2ORP5ZXDso3xuVDNtIJ4s6X8Pb210vQNIu9YsbnR9Du4ri0jGmlJmWMOFWR/NKsfmB3BF5Gcc1xemfFvxBeaBfXrSeGIjC1sfOkurVPL8zfvjMX245cbRt3yRZ+bgFcH1HwZ4rtNesrCJrpZdTmsUv2VbV4AYmdkDhSzgAlSMb26ZyQQaAMS9+H98Ndl1fStZtILxtUm1JBdaeZ0XzLWO3KYEqEkCMtuyPvYxxzh6d8FotNu7NrbWHms0+ytc29yLkCV4CCGUQ3EaLyAQHR9p6Z6V69RQB5/4T+H93oOs6PPJrMFzp+kW93a2dutkY5Ns8kbkySeYQ7DywMhVznPXOXat4AmvvEd3eR6tFFpt7qFpqdzbNZ75jLbhAgSbeNiHykyNpP3sEBiK76igDzJfhPAlnrkCaq/+lyxPp++3DJp8UdwblYQuf3ieaTkHGV2rxtBqK/+FD6quoSatravd6h9sa5e1s/Jj3TwxQjYhdtoUQqSCW3EnJ5r1KigDlvCHhu/0fVdW1LVtTtb661BLePFrZG1jjWJWUYUyOed3r+nA4jVfg9qOrXWoTan4tmuWubK9skaWCZ2RbgrgkNOUGwKBiNIw3fkZr2CigDzfxh8L49e8RNqNtqC21tNaw2lxZSC58p0iZioUQXEIH3jwwcDAIA5zSufhXf3viCbUtU8RpqaGO8ijt762nlTZcDG10+0BNqjaMRpGSF5Oea9VooA4LSfBusWMOkW93rMOpR22qG/kkuYWkaKMQsixQmdpnB3kEuZNwBcKQDgd7RRQAUUUUAFFFFAHK/Cf/klng3/ALAtl/6ISqR8J69b6v4in0nxBZWlnrU/nyK2mu9xA3kRw5jlEwUH92GGUOD61d+E/wDySzwb/wBgWy/9EJXB+JfiDqWgXGvNBcaTawwa3LbM17L5shRbS3ceVFLcxBjmQ5WNhjjCFmJIBe0b4SXNtqM17qviL+0Zpriwnk8yCZ9/2V3bBM08h+bf2IVccLzioNT8H67N47+zWdvKPDk2s/2vc3MkUKHcbcowSVZzI3JwAYVwf4sAZwZ/Hlx4Xj8S3FncW0V5f667p9rtF8uTbYWjFT5lzCIycjClmY8gAkVrWnxM8R3ulrrEEOkRWENrpFxPbPDI0shvGVXCyCQBducglWz39aAOl+G3w5Pgy8E0mpLqCxWgsbdmFz5iRBgQp8y4kj/hHCRoM9MDiq8vw2v5tTllPiCOGzGo3eq2y21jsuIriaN4wTKZCGCCQkAIMkDPAxXGXHjjUNT8V2Opfb/DyX1hbauY9MlLQtYsm1VF3K0nG7aDnYg64JHNeh/D7xZP4m8H6lqE9xbXM9vJJEXtoBDHxGrYDJcTK/X7ySe2AQaAOcsfhJqEDanPdeIoL2/vfsuJ7iC8YxNB5uHVvtnmq583+GRQOcLzxNrPws1nVxYx33jS7uILf7KzJPFMcvDIJCwVZ1Q7sAfvEkYYBDZ5rK0n4geI18PWd9Cml/YLOw0WWeGaOeWaY3exXAlaUkbc5DMHJ7knmuq+JeqX+leKfBklvrllpGnzXM8Vw96jGGRjESitiVBk4IUE/eIIzjBANGLwPF/wr3U/ClxfSPFfG8LXEcexlFxNJLwpJB2+ZjnrjtnFY3iP4eav4iGlz6l4gtF1DTlmhie0s7m1heGVUDKyRXavnMY5EgXBwVPFcb4T8Y+IfCvgfTo1tbHUoH0O71CzgghdJYzDNGuJGLkOCJdxwExtI969A+FHi/UPFlhqc2of2dMLaZUhmsJoGEgKAkMkVxOEYHPV+QQcCgCvpfw0j0+/0y4h1BEjsbu0ulgSBtuILJ7UIC0jMAd+4EliMYOfvVp+KPB0+ta3dXkWpRW9rfaW+k3kD2xkZ4mLHdG4ddjDeeqsPYV5A3xI1OXXYvE0LaVf6jD4fuN2m2kTB9OL3tmrJcFpfmZASzf6ofKc4B3DsvCvj/xL4hm0uzgOgrJeXF3H9sTZcRlIo4XVvLguZArZkZShlJ4DZGcEA0LL4Z37ajDeazr9teSRHTlVYdOMK7LN5GAIMrZLeYcnsRwOwmvPhZb3llJaTakywy3WqzuYoAjbb4SAqDu4KCQc4Odo4FYEPjnxrdCxkhm8ORR39rqV3Er2E7GJbSRU2sfPG4vvHIxt9GqG/wDiTqlraXmpQPpFkJHsWf7dc52rLZiUiKOa4ijZgxAwrpxk4Y9QDpbb4bXEuq22pazq9pdXUE9k4W304QRGO2WUIuzzG+YmYktnjaAAABXpFYHhPxLZa9BHDDc+dqEdlbXdyn2Z4NqzqSjbWztzsf5dzFcYJ7nfoAKKKKACiiigD4r/AG1v+Sp6V/2BYv8A0fPRR+2t/wAlT0r/ALAsX/o+eigD6q+E/wDySzwb/wBgWy/9EJWxJoGjya0mryaTp76si7VvWtkM6jpgSY3Y/Gsf4T/8ks8G/wDYFsv/AEQldVQBmzaFpE9ne2k+lWElrfSGW6he3QpcOcfNIpGGPyrycngelRxeGtChtUtodF0yO2SB7ZYltYwiwuQXjAxjYxAJXoSBmtaigDP0bRNK0OB4dE0yx06GRgzx2lukKsQAMkKBk4AH0FC6HpKRxxrpdiscUL2yKLdMJE+C8YGOFbAyvQ4GelaFFAHNDwD4OFusA8J+H/IVzIsf9nQ7Q5ABYDbjOAOfYVYv/B/hrUbiefUPDujXU86qksk9jE7SKuNoYlckDAwD0wK3aKAILCztdPs4bSwtobW0hXZHDBGERF9FUcAfSp6KKACiiigArldS/wCSp+Hv+wLqf/o+wrqq5XUv+Sp+Hv8AsC6n/wCj7CgDqqKKKAPK/jR4Fn8QwR6lp2Wu4FIaP+8vtXzhPDJBK8UylXU4INfcZAIweledeO/hhp3iL9/aYtLvuyjhvrW1Opy6MznC+qPl6us+HXiyfwtrccu5jZuQJo+xHrW74h+Eet6Yhe2xdIP7vWsLw74K1e/1uG1ks5UXeN5ZeAK2coyRlyyTPrKwuor2yhubc5ilQOp9jViq+nWqWVhBbRDCRIEA+gqxXGdIVyvxL/5Fyz/7DWk/+nG3rqq5X4l/8i5Z/wDYa0n/ANONvQB1VFFFAGL4h8MaX4haL+10u5okGDAt7NHDIM5xJEjhJBkdHBraoooAKKKKACiiigDFTwxpY8QLrTpdzaghYxtPezSxwlhtYxxM5SMkcZVRwT6mtqiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4T/APJLPBv/AGBbL/0QldVXK/Cf/klng3/sC2X/AKISuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+K/21v8Akqelf9gWL/0fPRR+2t/yVPSv+wLF/wCj56KAPoX4ZeI9Ug+G3hOKLwZ4guY49JtEWaKawCSAQoAy7rkNg9RkA+oHSul/4SjV/wDoRPEn/f8A07/5Ko+E/wDySzwb/wBgWy/9EJXN678WrbRte8YaVc6XI1xokUT2m2b/AJCDukR8sDb8hDTxL/Fw2e2KAOk/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kqo9H8f6Ne6BHqV3P8AZHW2sp7qHY8nkG6C+Uu4L82SwGQPc4rnfD3xS+1XaWWqWEi3DxX84nt7edoVEF5JAgYqj7QVjBZycA9vmAoA6b/hKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+SqhtfiL4ekltLee8dLqZbbcY7W4eCN51VolaYxhV3bht3bSc4wDxWf4c+JWmTaBpVxr84g1C6gWeZba1mkigVpGRWkZQwiUlSAXYA4PpQBrf8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlU3xn4rPhrWvD0EsTvZ6hLPHN5NrLcTDZEXXYkYLHkc/KeM9OtUNK+Ien3viW6tzdW50iSDTm0+eONy00t0042t6f6lcZAwc59gDR/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqlvvH3hyyDebezyMs08LJb2c87q0DbZSVRCQikgFyNvI55qeXxx4WigvJT4g0xxZwC5uEiuVkkjjOMMUUludy445LADqKAK//AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVUUfxG8NSM0f2m+W4Ext/s0mmXST+YIxLtERjDk7GDDjkHjNS3vj/wAPWF1eW+oXN7aS2kUk8n2nTrmINHGwV3RmjAkVdwJKEjBz05oAP+Eo1f8A6ETxJ/3/ANO/+Sq5q/8AEeqH4k6FMfBniBZF0nUEEJmsN7gzWRLA/aduBtAOSD8wwDyR6DYatZahe39rZziWaxdYrgKpwjMgcLuxgnayngnGRmsPUv8Akqfh7/sC6n/6PsKAD/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKrqqz/ABBqsGi6Nd6hdMqxQRl+TjJ7CgDF/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqvBNT+OfiW4kf7ILW2TPAWPccfjXqfwT8dXnizS7uPVHV722cZYLjcp6VpKm4q7IU03ZHUf8ACUav/wBCJ4k/7/6d/wDJVMXxJqituHgHxGD6ibTv/kqusU5ANLWZZyv/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVXVUUAcr/wAJRq//AEIniT/v/p3/AMlVzXxC8R6pNoNqsngzxBAo1bTH3yTWBBK38BC/Lck5YgKOMZIyQMken1yvxL/5Fyz/AOw1pP8A6cbegA/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSqm+Inif/AIQ7wjea39niufs8kEflzXHkJ+8mSLc0m1toG/JODwKxtA+JVhd6O97q0SwMb57G3GmmXUUvSqBy9uY4w8iAE5YJgFW570Aaf/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVP/AOE98NGzubtdUVre2so9RldYpCFgdmVX4XnlGG0cjHIFNTx/4abVpdOOoPHcRSzQO8trNHCJIlLSJ5zIIyyqpbAbOBnpQAn/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVVXwt42j8SeMr7T9OSQ6VDplteRTT2c1vJI8kkykjzAu6PaiEMowSTyeg1JfGXh6GxvbubVII4rP7T5yvlZB9nJE2IyNzbSOwOcjGcjIBV/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSqj1Lx7o0L3lpa3MjahEkqxiS0mELTJGZDF5pUJvABJTduGDxxWT4V+ItvPBd3Hiu+0jSbeOKxMUs0wgV5JrVZmXLtg8lsAc4HfrQBtf8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVRa14/0awttYa3lknk0yORp5Da3P2VGRdzK9wkToCARkDc3PQnip73x74ds5byOe9m3Wc32eby7OeQCXKgRgqhDOd64UZLckAgHAA3/hKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+Sqkbx14fjt72ae6ubZbK1W9uEubGeGSKFndFYo6BuWjbjGcDOMEE1Lr4leGLbUpLB7u+e6S4ktNkOl3UoeZOXjRljIdwOdqknHPTmgCf/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5Kp1j488P6hdWNvp11dXkl5DFPH9msLiVUjkJCNIyoRECVb75XG05xg1EnxF8NPAk63d2baSUQw3H9nXPlTud2Fik8vbJnacbCc9uooAf/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlViX/xJht9a0+FIi1jJfTWc4itLqa5XbapOo8kRh1f94MqFcAdSDuC7MPxD8MTy2iQak0y3QhKSx2szxJ5pxGJJAmyNmOAFcqeelADv+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5KqjZ+PbbVvHOk6PopNxYXFteyzXL2kyKzwvCq+TKwCSLl3DFd3ReR30dY8b6Vp1zqlmgvbq+06FpZ47exuJY0Ii80I8qRsisVwQCc8jg5GQBn/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVVXR/iRod/pumT3H221ur21W7Fq9hcllQ7QzD92CUBYfPjbj5s45q7P488NwWFveS6liC4sotQhIgkLSQysFjKqFyWZmUBAN2T0oAZ/wlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVWdJ8TdJh16WyubTVYLOPTjqL3U2mXabFVnDB0MQKACMnc2Aeg7Z173xv4espRHc6hscx28gHkSHK3BYQ9F/iKMMdRjnGRQBD/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lUR+P8Aw496lq15cRSMdhaaxnijSTy/M8tpGQKsm3kxsQw6EZ4rU8OeIdP8RWrXOl/bGtwFZZLiynt1kVhkMhkRd6kd1yOlAGX/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAeYfDLxHqkHw28JxReDPEFzHHpNoizRTWASQCFAGXdchsHqMgH1A6V0v/CUav/0IniT/AL/6d/8AJVHwn/5JZ4N/7Atl/wCiErKuPiBOvjSbQYbDTlMV1HbbLvVFtrucMqkywwMmJEAbqHBO1sDOAQDV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqqcnxS8JpO0P2y+eQPMi+XpV24kaFtsoQrEQ+w/e25wOTxzWjL440GKXTFe5uRFqQh+yXIsZzbS+djyx54TywWyMAsDyKAIv+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkqsnwB4z1HxFq0drew2iRtYPdEwowO5buWEDljxtjU/XP0qbRfiDZy67quk6uzQXMGpyWNqY7OcxyhY1cKZNpQykbjtBBIAwvqAaH/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVTV+IXhww3bvc3sUlq8MctvNptzFcbpSRGFhaMSNuKkDapzg1NdeN9EszZfbTqdql2UWOW40q7ijDO+xVd2jCxktgYcg8j1GQCP/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5Ko8KeKRfeC7jXtcktrSK3uL1JpFysaRwXEsYY5JP3YwT75xjpTZfiD4fitIbiV9UjExfyon0i8E0gVQzOsRi3lAGXLhdoyOaAHf8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlVgn4gXU/iq1stPFjPpdzqlraRThWJeCaxkud4O7GdyLg4xtJ4zzWxrPj3T9G8WXOjalb3kcFvpv9oyXkdrNKiKC+4NsjIACoTuLdeOtAE3/CUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVP1Px34d03P2u+kDCO3lCR2s0rMs5YQ4VUJJYowAAzxyBkVW0/4k+Fb+Vki1GaLaszs9zZT26DyQTKpeRFXcgBLLncMHIoAm/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSqji+I3heSAyfbriP95HCI5rG4ilZpFZo8RsgYhgjbSBgkYBJ4rqbaZbm2injEipKgdRJG0bAEZGVYBlPsQCO9AHNf8JRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQB8N/td39zqPxJ02W80m+0qRdJiQQ3jws7DzpjuBikdcckcnPB46ElaH7a3/JU9K/7AsX/AKPnooA+qvhP/wAks8G/9gWy/wDRCVFe/DzQL7WdS1W9hlnvbycXAd2H+jv9mFvmPA/uDPzbvm57DEvwn/5JZ4N/7Atl/wCiErm9VuvGUfi/UZ7S51E6ZBrdjaQWQsozBLayRQ+fIX8syEKzSHcGwpBByBgAF2b4V6U8MMEOq6xb2qwWUE0EUkW25FoR5LOTGTngZ2lQfTgVag+HGn2zwtZ6nqtvtju4ZAjQsJ47mdpnRt0ZwA7HBXaQOCTXCQa78QpdNl8mTXDqLWateLPoypHY3RuYl2Wx8secnltNk5kGFVtwzXb6AnjF31uxOrRn7FqIjtr3VtL8xrm3MET8CFoVOHZ13AEfLjGRQBQsfheq6vdi81S8bQg9g0NhG0e2f7LGioZyY92d8anCMAccjtTZvgx4akmsJg0xltIEtt09raXPmorMy7vOgfafmIym0kYz0GOYvfFPxC/4STVl0fTtYe2EF/5VvfWm5Y5EGYSrLbRqQ2DtHnS7gQCVNFt4p8SyXWo2lnq3iW70+3vLGO5vJdDVb62ikhlaRktxbgkF1iGTG+AxIyOaAPU/FHhldeudNuk1TUNMu9PeR4Z7Lyi3zoUYESxuOhPbNYMXwr0S2tRFY3WpWjolkIZo5EZ4ntXkeOQb0ILEyvu3Ag56Cua8D614x8RWFhPFqN/JALS/mE0tlDGbmaK+dIY5G8sKhaNQGACnGSNp5GToviL4jSaVPJqEmpICbUXJXSpZLm0BkxM0CGziRwFONo88jGcsKAOuvvg34fvYbf7VdXs93DPcT/armG1uXczuHcMssLR/eGQQgI55wTXU+I/DkWoeCZtBgjVlW3SOBRILYK0e0xkMkbBMMqkYQgY+7jivIL7xl4yn8MyNoM3iO9uY7vUI4bz+z0BcRsFijmiSzkIf2Kwj7wZwcYlafxlpdz4v1DTl1wavqDWN2sB0/wDceWYLZJpEcW7/AL2PDoI/mOFyY3IyQDs/Bnga70vUbnxD4t1MzaqL2S+DLOjoqm2SD944hiDYVCeEQDgc4yU0P4WeH7LU5Nf065m1KS5t7lUWcweVcJcYYh5Ui8yRegDOzkAnGa5O51fxtd6DHb6tca2lnPDeqLjTdIkmuZZAIxDDMslmmwENJ84hRTtHzDnPrfgaGW28E+H4LiJ4p4tPt0kjkUqyMI1BBB5BB7UAVPhx4Zbwl4QsNLmm+0Xir5l1PuLebM3LHJ5IHQZ52qKj1L/kqfh7/sC6n/6PsK6quV1L/kqfh7/sC6n/AOj7CgDqqw/FulW/iDRbjTboboZhhhmtmU4Q1nXlzHaW8k87hY0GST2oA8ql+CmhmNABIpU8kOcmtK4g0f4Y6Dc3FhCqSyDHqWPbNcZ4z+J99LqkkWkSBLVDgMO9b+jgfEHwi8F+c3EZxurVqW8tjO6ekThB8bfEKXRZViMOeFI7V6V4I+Mmn6u62+rBbSY8bieDXjviT4b6rplw4t4zNFnggVJ4Z+Gmq6nIrTK0Kg+laSVNohOdz61tp47mFZYHDxsMhgeDUtYHg6xbSNEt7F3LmNcZJrfrmZuFcr8S/wDkXLP/ALDWk/8Apxt66quV+Jf/ACLln/2GtJ/9ONvQBqeKdBtfEujPpl9JNHA80MxaFgG3RSpKvJBGNyAHjpnp1rBu/h7YPqLX2m6nqmlXAuWu4vsbxbYJHUrKUWSN1xJkFgQRuG4YJJOh8Q7jWLXwtJJ4bMo1M3VoiGODzyEa5iWQ7MHIEZcn0GTkYyOB1rWvGen/ABC03TNOPiC702K9tYLma5tEaG4hfHmSAxWYUBd3JMykFT8mKAN3UfhLo93Yi0h1PWbKB7BNOuRBLGTdxLI0gMheNju3u5JXbncQcjir03gjw9qpubJ7uW5+z6lcXtzAsyErLcwOjRuAMqpjnJA4PKnJHXik1P4j2ei21z52qX13e6XPPNFLpkY+xTJPCqiNVjUl/KeVgjltxTgY4qpps/iGx1XWrm3ufFcekX+sI1xqp0TdfPGtjGqEQfZ8bPMUoWEPG0ZwSTQB6d4V8Gw+H9Um1D+1tU1K5ks4bANetEdkMTOUUeXGn/PRuTkn681j658OPC99rF1Lf3M8V5q19FeLELhVLPChDJEpGdrqXMgGSQx5HGOTa++JF5p11dfbNVsLm2sNOeG3j0yFhcSyzyLMXDRsdwjCMyKw2k9h1umx8V3viS1tbm61J5NP1O/t7PVprKNWWJ7BDHK22MRsBK7qDtwSuOSDQB0DfCnw/wD8JLe6zHujnvJJZpU+yWj/ADyKVZllaEzL1JwJAM9sZFbfhrQNJ8K3bW9reObm+ihjSK4lTc628KxgoAAT8oUt15PbpWZ8LNa1rxLYXer6wDb27FLWC12rgPEu2eUMBkhpd6jkjbGpGNxrzXXH8U6rcXV1d2+t3eqW+ma2hsptGBs4HKFYEiJixOHCjgvIG6YGcUAem6j8PLS9tddsRrGr2+laz5zXVhEYDEHlGHdGaIupJ+bG7bnPHard74H0+6sr6Bbu/gludSGrLcROgkt7gbcFMqVxhcYYN1Oa818WS+LdUj8TaEh1q4tbrSbqOCG20/yIIj9mOI2MlqA5Z/lBjnOd33VxmtLTm8TX+la/DHf69Nptpokb2kV/o8cUl3cMtyrxMjwLuUbYxtC5Pyc4Y7wDd1j4faZ4llvobnxRq8159lTTdTaCS1WSZAxmjWZVhwhAlyNoQlSM7ged628Fadb6lZ3qTXZltdSudVQF12mWeN43U/L90CRsDrnGSa8x0o+KNP8AGd9/Zq6zbz3uoaYXtv7JxZS2/wBjt0nkaYxYQptcBVdcMuNp6VU1jUvGfijwXLpN5aa+lzH4eL6gTpXlebfpPFlYy0eHJQScR5Ug/LkjgA9BX4W6Ss+hMb6/aPR9n2dDHbbvlcvzL5PmgEnBVXUEcEYJzJp3grTNOn0jSf8AhIdSmh06Rb3TtMmkt/3KRZQbcRiRo180LlmbGV59eRutc8cL4usrfTrnU30Yva+RPfabKhukLfvjOsdifLb7yjLwBQFYgjJqX4cSa/qfxD03U/EC6410uh3UV4t5pv2a2tLhri3Pkwv5a71wrEEs+QuQetAHYX3w+tJ9Tl1Gz1fVtOvnv5NR862MBKySQJAygSRMNuyMds5JOemMm2+DXhez1OxvbRHjktlhDCW2tbnzjF0Znmhd1JxyY2T1GDzUPiXxH430XWfEcen6PNq2n2yreWzrbku0bokYgi24DOsglkbOTswP4gRzPiTTPEf9r2M+oS6un9n6rYyXF/pmlRyzSf8AEvkSScBYGMmJG28KwUORgYG0A73wl4K0nTtUtNQ0vW76+g0tbqxtbVpoXgtQ8i+bGCiBsq0YXDMSMYPTixq/w+07VvFQ129u7szBSghjjt4xtMZjKmVYhMy4Yna0hXOOOAB55b2nizSrLVBZjU57PUdQ17zNPm06N4lU/aJIZMGPcd7hcbiVYOAF5FbFndeNo9TWZZtSjsbfUtMtE09dOiWFraS3g+0Pny9+FdpOVYBSpB4GAAdfofgmx0XyJZ9Sv79bXTm0xTeNEAttlTtPlonQIBk84znPWsHS/hdok+m2ctvr+sX1ulnbw6bcieBhbQxOssDQskYDYKrhm3bh1zTPHlhfD4maNqEc2sxWT6RdWebGzFxG0rTQsIpSInKK4ByxK42DDLznl9Hbx/4b8BWFppX9o3kq+HLGWOG5skQ2UodEliTbFkssRY7XEjZTOD90gHoV94Ht55XvNV8QatOTYS2F6832ZFurZizFZNsIChdxwU2HHUmqWjfDjS1lt9S/t3VtVYixkhnmlgKmO2LtCF8uNQVPmHJ6ng5zklng658Qap8P9fGvvNc3Z+0R22+2limaMxDCsr21vubcWwVjAIwOSDXH6JqXj6y1vw9pgiuLLSYIdNiSJ7OZ45YfJjE4kKWkmyQMXA3TRBSoyCMkgHcv8L9D/wCEun8RQM0N7PMbh1+yWkv70rtLLJJC0q9M4DgZ7ckHT8EeC7HwgdQaxubmd751eUyRwRKCoP3Y4Y40BOSSduT3JwK860TUvF1+8EOpxapqbxapYubi40vyrcIZW3mOOW0ikjKgAlsyBQVxJnNRQa78QpdNl8mTXDqLWateLPoypHY3RuYl2Wx8secnltNk5kGFVtwzQB7lRXEeGtT1rTLvUrDXE1fVo11hbKyvTZorGFrdJPNkKKieWr703qvXAPOa7egAooooAKKKKAOV+E//ACSzwb/2BbL/ANEJTNW8ER6tfNJf65rM2nNdR3h0x3iMHmIwZcEx+aqhlB2hwPwJFP8AhP8A8ks8G/8AYFsv/RCVwfiW/wDFWm3GvS6WuoWiNrcrLHYaUTLdwi0t9rCRbWdfv7xukX5sbd4CcAHaaR4Q0NHgSxv5530qa+RlWZGKSXbebIj4XgjzAVHBAIznOaw2+DHh9r7SLk3upM2mJZLAHFu5/wBFCCM72iLpkINwRlVueOa5bUL3xXo8GvNpVj4htrrUNZedZ4rYPwLG1A8wLaz5BcMMogXcjAstaFpqvxCutLXVJZNUtri3tdIkOnDTU2XEkrKLoMGjL/KCSQrAp34oA7vw94W0bwxq9sbe+l+2S2sltDDcSpmRPOeZiqgAkhpT04Ax9TQv/hpp1/f3kt3qusPaXN3JfGxWSJIkuHiMfmKyxiTIU5ALkA84rg3uPFd94it7+5m12HVbS31VWEuiO9nYOcCHyikW6fcFB4eTOOg6V3vw+v8AWdR8H6k+sx6o96kkiRtqEKqZR5akFF+zwMUySPniBJ3dRigDO0j4O6JpVlqttaX95jUo4IrhntLFgyxFyMx/Z/LYnecsyknA5zVeX4I+HZXsmkv9Vf7KIdnmfZ5GBjk8wFWaEtFknBWIopHGMVjaTceOoPD1nPC2o2n2DT9FCaZFpUSRSvJsW6Qr5W5QgzlUK7MdgMV1XxLtLtvFXgzUILnWLe0tbmdZ5NNsxcsm+EhSy+VIQCRtJxgBj0OCADY03wxod34FudDtrhr/AEXUDcu0qzKxbz5Xkfa6ADhnbBHTA6nmsnXfhfYeIYLEa/q+o6ndWTP9nury2spmRHChk2NbmNh8inJQsDnDc4rifD6+PfDXhGyg0ldQu5JdEu5ks7qyRVs7hJoxGqkIG3FHkO1yxYrwMcV3Xwo1DxFf2Gpt4immm2zL9mNzbywygbBuVi9rbhhu5BWM4zgk4oAktPA+gWWt6esd9Il/BLDqENsrQx7hBbm1DCJEACbZRnaAAxXGB8taWv8Ag601rWHv572+h86xfTrq3hMfl3MDbjtfchYcseUKnmvHDf8AjuXUF1u1t9duPEMWhTQ3Ed3pfkQWcr3lr5kduRD+8xGsjKcy52Ajdyp6vwre+OdVn0q1vtSv7e1muLsTXa6eVmSNY4TEHM9pCobcZAGEW0jjkgkAHQ6d8MrC1vI7u51jWr+4jayKPcvD8q2rO0SgJEox85z3PrnJNq5+HGiXds1vdPdzW73F/cPG0igObzf5qnCg4HmNtxgjjJNcXCfiFcCxkk1zXIPtdrqU8qLplti3khkUW8Y3QEjerE4bJbb8uKhv9T8YRWd5fRR3un3c72Ly/ZtHcyz5swZFDpbTkFZOMvG2NuzK9gDuLL4d2UOoQX97q2r6lfwzW8qXF3JFu2wLII48JGo2jzpCeNxJyTXa1geE9YuNQt47a807V7a6hsraaWa/hRRI8inK7kwpkUr84VQAWGBzgb9ABRRRQAUUUUAfFf7a3/JU9K/7AsX/AKPnoo/bW/5KnpX/AGBYv/R89FAH1V8J/wDklng3/sC2X/ohKlu/HGgWmvf2PLdzm+8+O1by7OaSJJpACkbyqhjViCDhmB5FRfCf/klng3/sC2X/AKISuW8Q+Dr0eOLa+j1GDTtAn1e21CWKW+XFxcqqqAsRgBDMVUcTEHGduaANLw78TNKl0DS7jxBcrb6hcwLPOtvazPFArSMitI6hhEpKkAuwzg+lN0D4m6ZKdWh1+f7Hc2d7qMSlbOcRPDaySZxJtKvII03MqsT1IUdKcPhVpCWgtINS1eCzkto7S8gjlj23sSOzKspMZIxvYZQoSDg5qUfDDSZLu5e+v9TvbOWe9uUsZmiEMMl1vErLtjVzxK4G5mwD680ATeKfF9iGsNOsjbXkl7PZR3MFxC5U2t07oG5wCSEfg5xjkc1kxaz8MBoV3YJp2mLoyBbtrb+xWW3uMyLGJIl8rbP87IoMYbll9RV/T/hjp9tdpc3WsazqE6Gz2tdPDwtqztEmEiUY+ds9z65yTT0j4PaBo1vewaXNJbxXMBtwP7PsHaOMurFd7WxaQfKB+8L8c9QCADs9GvNOTw6lxplnc2mm28beXb/2dLbuipn5VgKB+3AC88YByK5zV/GngzVNKltdZSS7tpLpLKTT7zR7h5HmKGZENu0W85VNwO3HAxzir9h4I0+y8D3PhaK6v/sNwkqNMsixyqJCSdmxVRAM4CqoUDjFZHhv4UaHoF1DcWlxeGSK/j1AAR28KGRIZIQNkMSKBtlbOACSAc9cgFDxH8RPDnhf4fXE/g9IDJDp8t3Y2Vvps3lRhWZcypGo8lfMVwd+zkN3Bro9R8Xwad4g1OK8kii0fTLeEXE3lvJI11M+I4kC5LHbg7QpJMiY9Di33wj0m40+6s4NX1qzgvLaW0uxbyQ/6TE80k2G3RNja00mCuDg4Oa2W8EW9xol9ZX17O13d6kdUN7bqI5I5xIGiZAdw+RUjQbsghORzigCUeP/AA4Y7ZlvLhpLiSWKO3WxnM5kj270MOzeGAZTtKg4OcYrqa5TRvA9jpmp2uo/bdQu7+Ga4nee4dC08kyorM4VFAwsaABQoAHSuroAK5XUv+Sp+Hv+wLqf/o+wrqq5XUv+Sp+Hv+wLqf8A6PsKAOpcZXFcj4/spb3wvfW8BIkZDjFdfVW5i3ggjIPWhaAfFlnZXhuJLZoJDIrEdK9X08X3hX4Z6lexI8d3KAqEDlc969c/4RfT1uGnW2TzDznbVm402Ge1a2liUxMMFSOK1lVv0M1TsfM/hj4pavp13CuqSfbrMH50kHzY9jX0F4F8S6Z4o017rSkaMRttdGXBBrkde+D+kX9ys0CmAlssE4BrvPDOgWfh+wFrYRLGnfA6n1pTlGS0Q4qS3NkHBqZJiODUFFZlmgpyM1y3xL/5Fyz/AOw1pP8A6cbeujt3zxXOfEv/AJFyz/7DWk/+nG3oA6qiiigAooooAKQgMCGAIPBB70tFAEFlaW1haRWtjbw21rCoSOGFAiIo7BRwB9KnoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfhP/AMks8G/9gWy/9EJXVVyvwn/5JZ4N/wCwLZf+iErqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPiv9tb/kqelf8AYFi/9Hz0Uftrf8lT0r/sCxf+j56KAPqr4T/8ks8G/wDYFsv/AEQlcL4rk8Q6j43htbka2YLTX7KS0tLfTt1k1qoRjO9wIidwcuCPMXGB8pHNavwy8R6pB8NvCcUXgzxBcxx6TaIs0U1gEkAhQBl3XIbB6jIB9QOldL/wlGr/APQieJP+/wDp3/yVQB5LrM/jfX/DVzaXr+IpJDaJc6jAdISJbW5S6hIitT5WZl2eaeDJnYp3fMRXX6Vq/iL/AIWBY2wvfEWo6HKEVfN0s2mweTkvcF7NFOW/uSoQSq+WcNXV/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVAHVUVyv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVQB1VFcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lUAdVRXK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVAHVUVyv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVQB1VcrqX/JU/D3/YF1P/ANH2FH/CUav/ANCJ4k/7/wCnf/JVc1f+I9UPxJ0KY+DPECyLpOoIITNYb3BmsiWB+07cDaAckH5hgHkgA9Porlf+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkqgDqsD0qOSMP9a5n/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5KoA3HQqaZWI3ibVmHPgTxJ/3/07/wCSqifxDqxPHgTxIP8Atvp3/wAlUAdBTgpPQVzg8QavnnwL4k/7/wCnf/JVTL4m1ZRgeA/En/f/AE7/AOSqAOlgiIOTXOfEv/kXLP8A7DWk/wDpxt6P+Eo1f/oRPEn/AH/07/5KrmviF4j1SbQbVZPBniCBRq2mPvkmsCCVv4CF+W5JyxAUcYyRkgZIAPT6K5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+SqAOqorlf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KoA6qiuV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqgDqqK5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+SqAOqorlf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KoA6qiuV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqgDqqK5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+SqAOqorlf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KoA6qiuV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqgDqqK5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+SqAOqorlf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KoA6qiuV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqgDqqK5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+SqAOqorlf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KoA6qiuV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqgA+E/wDySzwb/wBgWy/9EJXVV5h8MvEeqQfDbwnFF4M8QXMcek2iLNFNYBJAIUAZd1yGweoyAfUDpXS/8JRq/wD0IniT/v8A6d/8lUAdVRXK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVAHVUVyv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVQB1VFcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lUAdVRXK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVAHVUVyv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVQB1VFcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lUAdVRXK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVAHVUVyv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVQB1VFcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lUAfKv7a3/JU9K/7AsX/AKPnorP/AGu7+51H4k6bLeaTfaVIukxIIbx4Wdh50x3AxSOuOSOTng8dCSgD66+E/wDySzwb/wBgWy/9EJV3SvEAvtb8R6e1s0a6PLFGZFYuZd8Ky5CgZGN2MDOcfhVL4T/8ks8G/wDYFsv/AEQlQ6j4GW71bWL2DxBrVjHq+z7Za2xt/LkCxCLAZoWkXKrjKuD3BBoAevxD8NmK6Z7q8hltnijktp9OuYrgtLnywsLRiR921sbVOdp9Ksr430EwX8sl1cQCwihmuUuLOeGSJJmZYyUdA3JRuMZGMnAIrltH+DWhaR58ljqGpxXjvbyx3UaWsTwyQeZsdVSFUZiJXDF1bcDzWjq3w1tdVmnmu9e1wy3UEMF8yG3T7YIXZ4zIBDgEFyPk2gjqDQBq2Xjvw/e6xJpdtd3D3iyzwYNlOqPLASJY0kKbHZdp+VSTgZGRUSfELw40d0zXN7FLbPFHJbTabcxXBaXPlhYWjEj7trY2qfun0NRS/D3SpI0RrnUAEu7+8BWVVO+8EgkGQuQB5rbcYIwMk9+btvgb4Xhs7yB5ruY3LW7l5Le0AR4d+x/LWARuxEjBi6tu7880AejaHq9lrmmpfaZM0ts7MmWjaNlZWKsrIwDKwIIIIBGKv1j+E/D9r4Y0SHS7AgwxszbhbwQbixJ5SFEQenCjpzk81sUAFFFFABRRRQAVyupf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYUAdVRRRQAVVvb+2s0LXEqoB2JqeaRYo2dyAAM8189/F3Vr6SB5bWSRY2mw7oSCo7fTms6k+RHVhMN9Yla9kdn45+Jy6Hs+yp5hckIvdsdTnt1qPwf8WE1pJEmtTHNEAWXOcg9wa8S8T3cuoaTot1Od0jRyIx9SGAqXwrqMeh2r3ksTTPdSeSiqcYC4JP6iuf2sr7nt/wBn0fZ2tqe4z/F/RYL17aVyro2xso2Afriu50HXbPWrdZLSRWyNwwc5HqK+SPGVoLTX7gKSVlxLz23c4r2L4BTvLZQq3RN6D6Z/+vVwqycrM5cVgKUKXPA9rrlfiX/yLln/ANhrSf8A0429dVXK/Ev/AJFyz/7DWk/+nG3rpPEJviJ4n/4Q7wjea39niufs8kEflzXHkJ+8mSLc0m1toG/JODwKx/D/AMSLG90d73VYlgb7c9lbjTTLqKXpVA5e3McYeRACQWCYBVvrXR+L9Gste0Cex1WeS3sxJDcvKjqhXyZVlBJYEAZjGfbPTrXKav8ADDw14ljF1HcSm0mn/tC3WJbe4t0d1Id40ljkQiQEMcgjI3DBJJAHeKvidpVloqT6BcC/vZVtpYwlpPLEkcsqoDKyriIkbsBypyOnaui8U6xd2N7omnaYkJvtTuvKDzIWSKJEaSRyAQSdq7Rz95hngGuek+Fel+R5FvqmqWlrJHbpc29qltFFcmB98bMqw4Q56+XsBA5FdD4p0e7vr3RNR0x4RfaZdeaEmcqksTo0ciEgEg7W3Dj7yjPBNAEF9460DT7u9ttQuLy0ktIJ7lzcafcRI8cIzK0bNGFlCjn5C2QRjNRR/EPw1JZ3FwL24UQyRRNE9jcJM7S58oJEUDvvwdpVTnBx0NcvqHwk8LW11qWp6jql5AL6O5tJJZmtkI+2ZjYGYxCRzlwEEjtg7QBjitfxR4DW4Fxf6LJN/bJazeB3u1gWFrcOqureTKMlZXBDIwOcYHWgCwvxI8Ps6y/bFSxFvcSyPNDcRTq8M8cDJ5LRA53yBcEht2AFbJInk+IvhqO2imN1eFpbh7VYF025a4EqKHZGhEfmKQpDcqODnpXOaF8KITo8X/CR6hdS6uftTtNayriOSa8S6DqxjGXR4o8NtCn5spg4HSaT4FsdP1S31OS/1K91GO7lvJLm5ePdPJJCITvCoqgBFUAKFAwKAF0j4heHNYimk0y5vLkR24uwqadc7pYS23fEvl5lGePkDY71Xv8AxxA+nWWr6OwuNMTU49O1FJ7aWGeEyOsYO1wrKVd4yQy8qTjHWqdx8KtFm0G00n7ZqaQW2mppaOske4xLKkgLAoVYkxgEEbSCQV5qKy+GkGkaNb6Ho9wf7Kn1ePVb9phHGx8so6xxpDGiAM8UeeFwN2M5wAD0KaRIYnlkO2NFLMeuAOTXDR/Frwa8KzDULwQmBbrzG0u7VRAxwJiTFgR543/dB6mt21s49G0e+XW9YaUXlzK73FzLsVPOfCRIGJCqAVRVzyRnqax5vhro8uhtpTXOoC3bQ49ALCRN/wBnTOGzsxv55OMe1AGreeM9FstZ/su9lvLa7IkKGawuEil2IXYJKU2OQoJwrE8GqEvxK8Lx20M5vbtopYjOjJp1y+YQFJl4jOIxvXMh+XORnIIGXcfCPQp/FcuvyXeoG7kmnn27YPlMsbxsvmeV5pTDkhS5UHGBjipY/Cmg+I9Msm8P+JLsQ2didFkutLuoJPOhAUGKRijAMMA5Xaw3HBGaANz/AITfw/8A2ymmLfs9y8iQh0t5WgEjqGSMzBfLDspBClskEccik8LeONA8UzrFol3NM724uo/Ns5oBLFkDehkRQ4BIBK5wTzVCH4daXBqUc9teajDYLdQ3x0xJE+zNPEiqkhynmZARDgOFJUEjNXPDPgnTfD0ujyWU1450vTDpUPnOp3RFkbc2FGWyg5GB14oAn/4TPQv7f/sb7ZJ9u877Nn7NL5PnbN/ledt8vft52bt3tTtH8Vab4g0KbVNBmkubVYfOjme2ljjkBUkbS6ru6YOOh4ODxVH/AIQSxGvnURqGpC2N9/aR04SJ9mNzt2+Z9zzP9rbv255xWr4f8PWmh+FLLw/aSTvZ2tqLRHlYGQoFxkkADOPagDhLT4ppe+AdM1K1EY1+WHTJbm2ntJ4Y8XE8MUjRb8b0BkYBlZgCBknv1lx488PWl7d2t/d3NlNaxSzv9ssZ7dXjjIDtGzoFkALL9wtnIxnIrEsvhVpUFjBa3Oq6xfC2t7S0tXuHhDW8FvNHMka7IlBBaJNxYFiB1qknwV8ODULu7kutSkkuIriIk+QrgTMGJMixCR2VlBUyM2OnTigDSvviJZwa7pCnzbbRrm1vZp5b6xuLaYPCbcIESRVZg3nkcKdxwBzkVteJdfm04eHHso1KanqMVq4njZWWN0dshTgq3yjgjjnIrI1b4b2Wtvp82vazrOpXmniYWl3I0EUsDSGIh1MUSYZDCpU4/ibO4EAbPiLR7C9s9Hi1rUpka1u4pIZ2lSJ559rIoJAAy288KBzjGOlAFRviH4biS8NzdXdo9oiSSRXenXNvKVd9iFI3jDSbn+UbAcnimN8RvDK2qzm6vcmaWDyP7NuvPDRqrSZh8vzAFDqSxXA3DnmuOHwj0LR/tEOi380viCW3iktUnuLe1kAgnRxNujtyzsrbcyOkhO4Bs5rS8O/DW8jtGu9X12/tfEL3V1O17p00bOI5xGGjLPCFbPlIciNMEfLtoA6Z/H3hpbu1txqRc3CwsksdvK8Kib/Vb5VUohfIwGYE5HrVaP4l+FJBO39pSRxwxSzGSWznjR1iYLJsZkAkKsQCFJPPSqsfww0eDyYbO81O101VtBNYRSp5Nz9mCiIyEoX4CIDtZQ20ZzVg/DzTRZ6fBDeX0f2GK8hifEMhIuXDybleNlbBGACuMdQaAOl0bVLfV7P7TaR3kce4ri7s5rV8j/YlVWx74xV6sDwT4Ws/CGkPp2nzTzRPM05MqxphmwMKkaIiLwPlVQOp6kmt+gAooooA5X4T/wDJLPBv/YFsv/RCVj6r4+1Kwu/Es66BBPofh6cRXtyl+RcbPIjmeRITFtIVZOnmAnB+lbHwn/5JZ4N/7Atl/wCiEqpqHw8s7/UdWmn1fV/7P1adbi+0xHhW3nIjSPaxEfm7Ssa5UOAeexxQBG3jnf4ntLG3W3lsS96k7QJLNL+4jicbVCglj5h+VQ+eMEniodV+KWjWk2nJa2+pXTXGoiwuIv7OukntiYHlDGExb2JCrhcDIYsMhTVnUvhtpGoSXjyXWpRNdPduxhmVCpuI40faQuRgRrj6nORxWZpfwh0fSoW/s3UtStLn7bFfpcW8VpEYpY4niBWNIBFgpIwOUOevXmgDf/4WB4ZFxdRSai0QtlmZ5pbaWOA+V/rQsrKEcrg5CsSMH0NReDvF48TeIdetraKVLCxS2aBp7Oa2lYyK5YssoU4+UYIUD61ir8GvDC3epzbZPLv1nEkf2a1DIZgd5SYQ+eDliR+8wOmMcV1Hhfwumg3+o30mq6lql7frEs018Ys4jDBQBHGgHDHPHP1zkAbH420GWK3e3u5bhp0uJI4re0mllYQOEl/dqhYFWIXBGSTgZqovxF8NvEjR3F/JK08lt9mj0y6a4EiKrOpgEfmLhXU5KgYYetVb74Z6Jdy+JJDNqET66FE3lzDEGGDN5QKkDewDMCGDHqMcVkxfBrQ4dEuNKhv71LW4u2vJQLSxx5hjRPkX7PtjwEBBjCkEk56YAOiu/iF4cs11B57q8EGnqzXc66dctDAVUMytIIyocAjKZ3A8YzxR4j8WpY6xp2m6c8Ut02p29leJIj/ukljkcFTwCfkHrjuKpt8NtPOnatpY1TVhomppKLjTi8TRl5Fw0gdozKGz8338bucckUsHw5shcyXV7rGs395Jdw3jzzyRK5eKN41H7uNQBtc9ADkA565ALT/EPw1Cl213d3VkbQRNMl7p9xbOFllESMFkjUspchdwBA7kVqX/AIl0zT9Fh1W9e6htZnWKNXs5hM7s21VEOzzCxPQbc1xWkfBfw9pfn+Teai7TLbozFbdGIhnSdCxSFS7F4wGd9zEE5OcEdx4q0OLxHo02m3M7wwykbysEE24A9Cs0ciEfVaAMfUPiL4a06VI7+5vraRrdLpll0y6Uwws7Iry5j/dLuRhl9uMZPBGbN1440Cz1C5sr+6uLGa3jmmZryyngjZIseYySOgSQAEHKE8HNcgvwkj/tKS1Or36+HH0iDTZbdHj8272zzyuspMXyoRKAPLKdxgACpz8FvDT6reXtxNfztdJcxujCBTtnzuBlWMSvjPy73bbgAccUAdDL8QfD8VpDcSvqkYmL+VE+kXgmkCqGZ1iMW8oAy5cLtGRzVrTvGeh6nqiafptxcXkzJHJ5lvZTyQoHjEib5lQxplCrAMwOGHqKwdd+F9h4hgsRr+r6jqd1ZM/2e6vLaymZEcKGTY1uY2HyKclCwOcNzirNv8N9Mg1/TdVW8ull0+JIoI4be0gAVYvLALRQrJtwd2zdszjCgAAAHb0VS0TT/wCytIs7D7XeXv2aJYvtN5J5k0uB952wMse5q7QAUUUUAfFf7a3/ACVPSv8AsCxf+j56KP21v+Sp6V/2BYv/AEfPRQB9VfCf/klng3/sC2X/AKISuqrlfhP/AMks8G/9gWy/9EJXVUAFFFFABRRRQAUUUUAFFFFABRRRQAVyupf8lT8Pf9gXU/8A0fYV1VcrqX/JU/D3/YF1P/0fYUAdVRRTZGCIzMcADJoA8T+NXji402+GmadIVmKZY9kH9T1ryDT9W1O7uxbyyz3sc52PC7bgwPp6H3rrPipc6PN4xup53nuZSAhjhcKEx6kg+vSqNxeQWfhq1XRmFpcyNv2tIvmgZPX61wzbcmfVYaEadKKS3NxvCdk+kx2LyTFY3aRHyNwz1Fct4nsdPt9Vht21Boo4kRBGsRbyxgZOQcZPWtG28Vahp1oE1a0aW4cAwkYG8c5Jx+FY/iOWOQ213f6Y0V1cgu22QqCAcDIIPOKl2NYKSeo3WrWfV76W5tZ4LiNAqZEgBCgYBOcda9++C+gHSPDsbTFWmbLMV5HJr5vmu4rphGTJa25wNiHcgwOuOPz5r6c+El4knhi0txOs7Rxgb16NjjNaUbcxx5lzKhZHd1yvxL/5Fyz/AOw1pP8A6cbeuqrlfiX/AMi5Z/8AYa0n/wBONvXYfOEPxcz/AMIBqGc/ZvMt/teP+fXz4/Pz7eV5mfbNcn8RvEPi2w8W2sHhe11g2cTWm5Y7XzrW4jeUCTbttXIKoTndPHjAIB5z6zNFHNC8UyLJFIpV0cZDA8EEdxTba3htLeK3tYo4beJQkcUahVRQMAADgADtQB49LqPxFtdON/bSahfXdwNWUWE+nxrHB5Uji1YbUVssqjG5iHyMetVtM1vxBqWtSWlrcarrcdhqVgytq2kR28sW+CcyEr5KGNdwQbyMgHhsHn2u4hiubeWC4iSWCVSkkcihldSMEEHggjtVTRdF0vQrVrbRNNstOtmbeYrSBIULeuFAGfegDxDUrvxrrPhh7eW31rUpymn3NzBfaZ9kWC9W/t2aKFljBeIKJCX/AHgCqDuOTVnXfEPxEFnp/wBmGqWsrx3H2uQ6axEN2GULEFjtbgvAByrDG8E/vQRtHutFAHkt3qfjNNH8R6hcy6yZYL6K2srXT7JF/dvFblpgXt5JHRXaXpGzAbxtYgBeY0648Z32r+HNZ1b+3kurU6naQsmm5Em57doFmBtlKpIFKtIUiwEz+7Oc/QNFAHidtrXjqfQ7kWVz4gluWh0/zJ7zRUgktbiS6RbhIUMSiRFiLksQ4UAHee2lbXHjjTNUjmm1DWtVtI9amsGtpLCBfNtBbSSJMWSJSG8wKgcEIeARknPrVFAHhmha54g1PRPGcPjaHU/+Ee/sQzK+p2pjdHIkDx7vstuCwAXgK4BwQ5zx6X4J1qS8totKvIbo6lp9haG+ncDZ50ke4pnOS4wGIxgBl55rob2ztr6Dyb23huIdyv5cyB13KQVOD3BAI9CKnoA8b1HUPGV7q2pWBk1tDNNqEEtsmmKLWC0EUn2eWG4MfzysRF8u5uXYFV21zlnpXivwtNDc6VP4guNQbwnZxWkMmnRtD50fnFreRkg/d+WGDKGIZmOCX+7X0PRQB4v4ev8Ax7qs2l2lxqep21rcakyTXa6cRPDALSR8OZ7KFMGVUAYR/wAW0knr2FhfeIpPhQbq8mmtvEYtnBmewd3DhiquYEQkkgA4VT1yBjiu4ooA8Fv/ABJ8QzpWnGzj1yCJnuVlu57QvKzrs8v5E04uIjl/vQIxKn5xxuu6L4q8X3fiOaIXWp3l1batDbz6fb6ZtsltjaRSTMZ3hUq4d22qzhuVBXB49tqC2tLa1e4e2t4YXuJPOmaNAplfaF3NjqcKoyecADtQB4Xpfib4i3SakIodcjVksWt2vtO3yQO15GkyH/RYFbELMWC7wACRJ3Gvr2r+NLLx9YaVpkniK409Ly2t7i4ns43imhkx5kqmOz2Dbu5JmXBU/IR19kooA+ctNu/HOgeFtD0zSJfEEccSTx3bz6Y4NvOGHlxrssZS8RBZtwU5PHmLwDvahceKtX8QaTDrY1jzLfWNPljtLPS2+wNAEjaSdp2i3AiQuNpdCoAynU17fRQB5R8Uv7UtPG+nalpb65bNHol7DHPpemG8LzmWBo4XHlSKobYTk7fu/eHWp9M1fxg/jPT9Av5QjTxW+r3MyRxkW8Aj2S2vTvOowx52s2CSvHqFQR2drFezXkdtCl3OqpLOqAPIq52hm6kDc2AemT60AcB8RNT8Q2PijSU0ebVXsXVRNa6fZlmZjJjcZmtpYwMdVLxEAE7uRXB6l4t+Ithb+ILvUJprH7NFcnymsZHjiIkAiaFvsgjPy9jPLu3cAEYH0FUN5aW99ayW17BFcW8gw8UyB0YehB4NAHht+fEmoa7o2oXN94rbQ9N1hxb6gNGVb3y3sXVma3+zZ2iQ7AxiHDtnOFYE/in4jtrerjSNO1h4DaXrQ2+oWnEEqOvl7XFrGpypcqBJPuwMnPB94ooA81+HXiDxD9lk/wCEkh1O/Fxfx21s32GVJYFaMlmmL21sPLDL95YzjcASa9KoooA5X4T/APJLPBv/AGBbL/0QldVXK/Cf/klng3/sC2X/AKISuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+K/21v8Akqelf9gWL/0fPRR+2t/yVPSv+wLF/wCj56KAPqr4T/8AJLPBv/YFsv8A0QldVXK/Cf8A5JZ4N/7Atl/6ISuqoAKKKKACiiigAooooAKKKKACiiigArldS/5Kn4e/7Aup/wDo+wrqq5XUv+Sp+Hv+wLqf/o+woA6qqerxSTabcRw/6xkIFXKKBp2dz5J8e6JLomsz3V5iR7iVmSMjgdzu9evSuRVZbmdVUNJLI2AOpJNfWfjnwLY+K/K+1blKHOUODmsKD4W6fpsW+xjjEyDIZhlvzNckqMr6H0NHMqXIubc8X8R3s+iabp+k27stwkYeSYdRkn5R+P8AKp7i4iv/AAdBf3VmL25gPlSOzEFeeuR17fnWV8Q4Z4PFd5HcKw27VXPptHT8c13Hwu8NajfaHcRyWjiKWQkCRcBlKgd6zSbdjsnKMIKbZ53b6VJrAL6PatuU4li3g7fQgnsefyr3L4H6JqGjxSJfDG7LBQchfatHwD8PYdBvp5JIDsk5+dt30FelRQxxDEaKo9hit6VJrVnlY7HxknShqh9cr8S/+Rcs/wDsNaT/AOnG3rqq5X4l/wDIuWf/AGGtJ/8ATjb10HjHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHxX+2t/yVPSv+wLF/wCj56KP21v+Sp6V/wBgWL/0fPRQB9VfCf8A5JZ4N/7Atl/6ISuqoooAKKKKACiiigAooooAKKKKACiiigArldS/5Kn4e/7Aup/+j7CiigDqqKKKACg0UUAc9qXhWwv7lppQdzHJrY0+zisbZIYRhVGKKKSilqXKpOS5W9CzRRRTICuV+Jf/ACLln/2GtJ/9ONvRRQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8J/wDklng3/sC2X/ohK6qiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4r/bW/wCSp6V/2BYv/R89FFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.",
"       </li>",
"       <li>",
"        Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52:109.",
"       </li>",
"       <li>",
"        Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556.",
"       </li>",
"       <li>",
"        Scope A, Benvenuto-Andrade C, Agero AL, Marghoob AA. Nonmelanocytic lesions defying the two-step dermoscopy algorithm. Dermatol Surg 2006; 32:1398.",
"       </li>",
"       <li>",
"        Stricklin SM, Stoacker WV, Oliviero MC, et al. Cloudy and starry milia-like cysts: how well do they distinguish seborrheic keratoses from malignant melanomas? JEADV 2011.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39002=[""].join("\n");
var outline_f38_5_39002=null;
var title_f38_5_39003="Func out women rad cystect";
var content_f38_5_39003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Functional outcomes in women undergoing radical cystectomy and orthotopic reconstruction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of women",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median follow-up, months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Continence rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Catheterization",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day night required, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ali-el-Dein, B; 1999",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arai, Y; 1999",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hautmann, R; 2000",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        86*",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stenzl, A; 2001",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stein, J; 2002",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        75-78*&bull;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        44-58&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"     <br>",
"      * Percent of patients reporting continence both during the day and at night.",
"      <br>",
"       &bull; Range based on chart review and patient questionnaire.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39003=[""].join("\n");
var outline_f38_5_39003=null;
var title_f38_5_39004="Sources of latex";
var content_f38_5_39004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential sources of latex",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Home environment",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Latex dishwashing gloves",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Balloons",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Condoms, diaphragms",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bandages (adhesives)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pacifiers / baby bottle nipples / teething rings",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Spandex*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erasers",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Golf and tennis racquet grips*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rubber bands (minor source)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rubber cement",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Foam pillows and mattresses",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Medical settings",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gloves",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Blood pressure cuffs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tourniquets",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Catheters",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Equipment previously handled with latex gloves",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ostomy bags",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Emergency care settings",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oral and nasal airways",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oxygen masks and nasal cannulae",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Self-inflating bag",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Blood pressure monitor",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Emergency medications (latex seals?)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Dental office",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gutta Balota (used to seal root canals)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dental dams",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Some wedges",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Local anaesthetic cartridges",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Prophylaxis polishing cups",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Orthodontic rubber bands",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          General anesthesia / sedation equipment including tubing, face masks, props",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Endodontic stops",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amalgam carrier tips",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adhesives and dressings and their packaging",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *Sometimes contaminated with natural rubber latex, check with manufacturer",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39004=[""].join("\n");
var outline_f38_5_39004=null;
var title_f38_5_39005="Treatment summary I BCC";
var content_f38_5_39005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70043%7EONC%2F56173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70043%7EONC%2F56173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of treatment options for basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Treatment modality",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Five-year recurrence rate, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary BCC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Recurrent BCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Surgical excision",
"       </td>",
"       <td rowspan=\"4\">",
"        5-10",
"       </td>",
"       <td rowspan=\"4\">",
"        12-17",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Margin-controlled. Usually performed under local anesthesia. Area of tissue removed (including important structures) can be more precisely controlled than with cryosurgery, radiation therapy, or electrosurgery - therefore limiting unnecessary damage to critical structures. Resultant scar can be optimized both cosmetically and functionally.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Invasive. Occasionally performed under conscious sedation or general anesthesia with their inherent risks. Random margin results in both a poorer cure rate compared to Mohs and the unnecessary sacrifice of normal tissues, which in critical, or cosmetically sensitive areas, results in potentially unnecessary disfigurement.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Mohs surgery",
"       </td>",
"       <td rowspan=\"4\">",
"        1",
"       </td>",
"       <td rowspan=\"4\">",
"        6",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100 percent margin-control. Offers highest cure rate for both primary and recurrent BCCs while maximizing preservation of normal tissue. No sedation or general anesthesia required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arguably more costly than simple excision, cryosurgery or electrosurgery (not radiation). Invasive. Longer procedure compared to simple excision, cryosurgery or electrosurgery (not radiation). Requires special training in the technique.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Cryosurgery",
"       </td>",
"       <td rowspan=\"4\">",
"        8",
"       </td>",
"       <td rowspan=\"4\">",
"        13",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cost effective, relatively quick, requires a single visit, potential excellent cosmesis and cure rate in appropriately selected tumors, no sedation or general anesthesia required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not margin-controlled. Requires considerable experience on the part of the clinician, wound care, pigmentary changes, possible permanent damage to underlying nerves or other critical structures.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of treatment options for basal cell carcinoma (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Treatment modality",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Five-year recurrence rate, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary BCC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Recurrent BCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Curettage and electrodessication",
"       </td>",
"       <td rowspan=\"4\">",
"        8",
"       </td>",
"       <td rowspan=\"4\">",
"        18-40",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cost effective, relatively quick, requires a single visit, relatively easy wound care, well suited for multiple lesions, usually affords good to excellent cosmetic results, no sedation or general anesthesia required, and offers low recurrence rates in small primary BCCs that lack \"high risk\" features.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not margin-controlled. Recurrence rate unacceptably high with larger (&gt;5 mm) lesions located in high risk sites, requires special equipment, requires experience in its use to achieve higher cure rates. Poor choice in most BCCs of the head. Must be cautious in patients with pacemakers.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Radiation therapy",
"       </td>",
"       <td rowspan=\"4\">",
"        7-9",
"       </td>",
"       <td rowspan=\"4\">",
"        10",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noninvasive. High cure rate for selected lesions. Relative sparing of critical structures. Good for patients who are not otherwise candidates for surgery. Relatively painless.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-margin-controlled. Requires repeat office visits. Poorer long-term cosmetic results. Generally avoid in younger patients, in lesions located on the trunk or extremities, in deeply invasive lesions, or previously irradiated sites. Relatively expensive compared to simple excision, cryotherapy and electrosurgery.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Topical 5-fluorouracil and imiquimod",
"       </td>",
"       <td rowspan=\"4\">",
"        Variable, depending upon patient population",
"       </td>",
"       <td rowspan=\"4\">",
"        NA",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noninvasive. Rarely causes scarring. Avoids operative risks. Able to use in patients who are otherwise not candidates for surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limited role for superficial BCC's located in low-risk areas. Brisk inflammatory reaction that can be poorly tolerated. Requires prolonged application.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39005=[""].join("\n");
var outline_f38_5_39005=null;
var title_f38_5_39006="Tampon and balloon packs";
var content_f38_5_39006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tampon and balloon packs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    L-R: Merocel tampon, 6 cm; Storz T-3100 balloon packing, 12 cm; Rapid Rhino balloon pack with carboxymethylated cellulose mesh casing, 7.5 cm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39006=[""].join("\n");
var outline_f38_5_39006=null;
var title_f38_5_39007="Home O2 prescription form";
var content_f38_5_39007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Home Oxygen prescription",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 417px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_5_39007=[""].join("\n");
var outline_f38_5_39007=null;
               